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Smokeless tobacco (ST) products present a complex and widespread challenge to public health that has 
so far received limited attention from researchers and policymakers. In many regions and countries of 
the world, such as South-East Asia, ST use is the predominant form of tobacco use. Indeed, data from 
the Global Youth Tobacco Survey show that students aged 13–15 surveyed in 132 countries were more 
likely to report using non-cigarette tobacco products including ST products (11.2%) than to report 
smoking cigarettes (8.9%).1 Yet international tobacco control efforts have largely focused on cigarettes, 
devoting only limited attention to other types of products, including smokeless tobacco.  
The Global Challenge  
The serious health effects of ST have been documented. A 2004 International Agency for Research on 
Cancer (IARC) review found that there is sufficient evidence, based on epidemiologic and laboratory 
studies, to conclude that ST causes oral cancer, esophageal cancer, and pancreatic cancer in humans.2,3 
More than 30 carcinogens have been identified in ST products, including tobacco-specific nitrosamines 
(TSNAs), which cause tumors affecting the nasal cavity, lung, trachea, pancreas, liver, and esophagus in 
animal models.4 Smokeless tobacco use also causes adverse oral health outcomes including oral mucosal 
lesions, leukoplakia, and periodontal disease.5,6 Additionally, ST products contain nicotine, and users of 
ST products demonstrate signs of dependence similar to those of cigarette smokers, including tolerance 
with repeated use and symptoms of withdrawal upon cessation of use.7 
Although ST use, like tobacco smoking, causes serious health damage, ST use poses substantial 
challenges for science and public health that are distinct from those presented by tobacco smoking. 
Wide Range of Products in Use 
Understanding the use and impact of ST products is complicated by the diversity of products and related 
user behaviors. A wide range of ST products with different characteristics are in use around the world, 
including chewing tobacco, snuff, gutka, betel quid with tobacco, snus, toombak, iqmik, tobacco 
lozenges, and others. Yet limited data are available on the properties of these products, how they are 
used, and their prevalence within different population groups. This diversity makes it difficult to 
generalize about these products as a class. Additionally, the ways in which ST products are produced, 
sold, used, and regulated (such as through taxes or marketing restrictions) differ widely across countries 
and regions. (This report’s occasional use of the word “traditional” to describe ST products that are 
unique to specific groups or have been used historically by those groups should not be taken to imply 
that these products have a played a significant cultural role.) 
Complex and Limited Data 
In addition to the known biologic effects of ST, the overall public health impact of ST use depends on a 
range of health and environmental factors, including the prevalence and patterns of use of different 
products in the population, the impact of marketing messages, and the effectiveness of prevention and 
cessation efforts. While certain groups have been identified as being at increased risk for ST use, limited 
data are available on why particular populations begin to use ST and what factors are most important in 
preventing or promoting initiation of ST use.  
 




Novel Products and Marketing 
Tobacco manufacturers have introduced a new generation of ST products that may have broad consumer 
appeal due to use of attractive flavorings, such as mint or fruit flavors, and new delivery methods, such 
as lozenges or small pouches that eliminate the need to spit. Major multinational cigarette companies 
Philip Morris and R.J. Reynolds have introduced snus products carrying the well-known Marlboro and 
Camel brand names, thereby adding new product lines to these existing brand names and putting their 
marketing expertise and brand recognition to work for this new class of products. Tobacco control 
experts warn that increased marketing of these products may have an adverse impact on population 
health by appealing to young, new users or by helping current smokers maintain their nicotine 
dependence.8 Novel nicotine delivery devices, such as electronic cigarettes, which use heat (rather 
than combustion) to release nicotine, are also being marketed in many countries as an alternative to 
conventional cigarettes. These products are not addressed in this report, but they may also have an 
important impact on patterns of tobacco use behavior9 and therefore should be examined. 
Some tobacco companies have also responded to the tremendous growth in smoke-free indoor air laws 
by advertising ST products to smokers as a temporary alternative to cigarettes for situations where they 
cannot smoke. In addition to increasing ST use, this marketing strategy may impede smoking cessation 
efforts by making it easier for smokers to maintain their nicotine addiction between cigarettes and in 
situations where cigarette smoking is not permitted, thus reducing their motivation to quit. This is an 
example of how progress made in one area of tobacco control, such as through smoke-free indoor air 
laws, has been followed by tobacco manufacturers’ efforts to adapt, this time by introducing new 
products and marketing strategies.  
Impact on Youth and Development of Ongoing Tobacco Use Behaviors 
The potential for increased initiation of ST use among youth also poses a major ongoing public health 
challenge. This increased initiation may be caused by increased marketing and the introduction of new, 
flavored products. Indeed, ST use among teens and young adults rose substantially in the United States 
during the 1970s after the introduction of products that were more accessible to new users, in that these 
products had attractive flavorings and lower nicotine content.10 Evidence suggests that users who begin 
with low-nicotine “starter” products are more likely to subsequently “graduate” to products with higher 
nicotine content.11 Moreover, a number of studies suggest that ST use is associated with and reinforces 
use of other tobacco products, including cigarettes. Thus, adolescents who use ST products may also be 
more likely to move on to cigarette smoking.12,13  
Limited Treatment Options 
Intervention strategies for ST use cessation have had mixed success. Clinical trials have shown that 
behavioral interventions in particular settings, such as dental offices, may increase abstinence rates 
among ST users, although the available evidence is insufficient to support recommendations about the 
specific intervention components that should be applied.14,15 In contrast, trials of pharmacotherapies 
in ST users, including the nicotine patch, nicotine gum, and bupropion, have shown no impact on 
abstinence rates over the long term (>6 months).16 Some individual study results suggest that 
pharmacotherapies may help reduce symptoms associated with cessation, such as craving and 
weight gain, but such symptom reduction has not been shown to have any impact on cessation 






outcomes.17 Moreover, evidence suggests that people who use both cigarettes and ST demonstrate 
higher nicotine exposure levels and find cessation more difficult to achieve than those who only use 
ST or those who only smoke.18–20 
Tobacco “Harm Reduction” 
The response to the hazards of ST use is complicated by discussions about the possibility of using ST 
as a means of harm reduction for cigarette smokers. Some scientists have suggested that ST use may 
actually reduce harm to smokers by providing an alternative to cigarettes—that is, smokers who 
switch completely to ST, which does not carry the same risk of lung cancer and respiratory diseases 
as cigarette smoking, might reduce their overall risk. While smokeless tobacco also causes cancer and 
other diseases, the overall health risks for a lifetime ST user may be lower than those for a lifetime 
cigarette smoker.  
This inference requires a number of assumptions, however. Given the tremendous diversity of ST 
products and patterns of use around the world, it is difficult to support broad generalizations about the 
level of harm associated with ST products as a category. Little is known about the constituents of some 
ST products or the amount of exposure users receive from them. Will smokers who begin using ST 
products completely replace their cigarettes, or will they instead become dual product users, which may 
not yield any health benefit and could potentially increase their risk? Additionally, it is essential to 
consider the overall population-level impact of increased ST use. For example, will increased promotion 
of ST products lead to an increase in tobacco use initiation or have an adverse impact on smoking 
cessation efforts? Although the body of evidence on this topic is expanding, definitive studies to answer 
key questions are lacking. In short, there remain more questions than answers.  
Discussions regarding harm reduction have been limited primarily to high-income countries, such as in 
North America and Western Europe, where cigarette smoking is the predominant form of tobacco use 
and there is a long history of tobacco control measures. Because tobacco products, patterns of use, 
disease profiles, and policy structures vary so widely across regions, these discussions are of limited 
relevance for other regions and are not explored in this global report.  
Report Framework and Process 
With this information in mind, the goals for the report are as follows: 
1. Bring together experts and information on ST use from all regions of the globe. The aim of this 
report is not to provide a comprehensive review of all the science on the health effects of ST use, 
which has been covered elsewhere, but to provide a snapshot of current knowledge and data 
sources on ST use, characteristics of products, and related policy efforts.  
2. Summarize current survey information about the prevalence and characteristics of ST use and its 
health effects in different regions, as well as laboratory data on the contents of different products 
from around the world.  
3. Outline what is currently known about the changing ST product market, industry marketing 
efforts, and economic and policy factors.  
 




4. Provide an overview of the current state of scientific knowledge, public health information, and 
policy initiatives focused on ST in each major region.  
5. Identify gaps and needs related to monitoring and surveillance of ST products and other 
information collection, and make recommendations for strengthening international collaboration 
and building a scientific basis for ST product control and regulation.  
Thirty-two authors with expertise in ST, representing all six World Health Organization (WHO) regions, 
were involved in planning, researching, and writing this report. Two in-person author meetings were 
held to ensure coordination and consistency across chapters. Each chapter was reviewed by external 
expert peer reviewers not otherwise involved in the report, and the authors were charged with revising 
their chapters in response to the reviews. In all, 35 peer reviewers from 12 countries participated in this 
process. Additionally, information was compiled from a wide range of data sources, including data from 
the Global Tobacco Surveillance System, some of which are being reported for the first time. Given the 
wide variety and complexity of the ST product landscape, the report is also accompanied by a series of 
factsheets describing the characteristics and use of specific products (see Appendix B). These factsheets 
were developed and reviewed by individuals with expertise about the products. Each factsheet contains a 
description of the product, common and brand names, and geographic locations where the product is 
used, as well as information about mode of absorption, use patterns, main ingredients, processing/
manufacturing data, and when available, an illustration and chemical measurements. For additional 
explanation of key terms and definitions, please refer to the glossary. 
The report is divided into two parts:  
Part 1—An overview of information on the global impact of ST from a variety of perspectives. 
Individual chapters in Part 1 describe patterns of use, characteristics of different products, health 
consequences, economics, marketing trends, interventions, and policies related to smokeless tobacco. 
Additionally, these chapters describe available tools, such as existing surveillance infrastructure, as 
well as gaps and research needs.  
Part 2—Separate regional chapters providing information on all six WHO regions: Africa, the 
Americas, South-East Asia, Europe, the Eastern Mediterranean, and the Western Pacific. Because of the 
diversity of ST products and regional differences in tobacco and non-tobacco risk factors, conditions of 
use, and cultural and policy environments, it is essential to examine these regions independently. Each 
chapter describes patterns of use, types of products, known toxicity information, specific health effects, 
industry marketing practices, policies and interventions, and future needs and directions for the region.  
Report Background  
A series of meetings and reports dating back to 1991 have identified some crucial research and policy 
gaps related to smokeless tobacco.4 The 3rd International Conference on Smokeless Tobacco, held in 
Stockholm in 2002, defined research needs in a range of areas, including the chemistry and constituents 
of ST products, ST addiction and cessation, patterns of tobacco use, policy interventions, and harm 
reduction. One of the major outcomes of this conference was a set of factsheets profiling the range of ST 
products, traditional and manufactured, that are in use around the world. However, limited data were 






available about the characteristics and use of these products. The conference speakers discussed ST use 
as the predominant form of tobacco use in some countries (such as Bangladesh), and its association with 
serious adverse population effects. These experts also described the available data on the relationship of 
ST use to other tobacco use as unclear, and they urged placing a high priority on further research on this 
topic. The need for more research on innovative cessation treatments for ST users was also highlighted.  
In June 2006, the National Institutes of Health (United States) held its first ever State-of-the-Science 
Conference on tobacco control, “Tobacco Use: Prevention, Cessation, and Control.”21 One of the key 
questions posed to the panel was “What is the effect of smokeless tobacco product marketing and use on 
population harm from tobacco use?” The panel heard testimony from leading experts in tobacco research 
and identified some substantial research gaps. The panel concluded that ST products were of great 
concern for three reasons: (1) ST use is associated with health risks, (2) data about the effect of ST on 
public health are limited, and (3) new products and aggressive marketing may increase use of ST in the 
United States. The panel stressed that more research is needed to determine the overall effect of 
marketing and use of these products. In particular, they concluded that “the paucity of evidence about 
ST in the United States leaves many questions unanswered.”21,p.13 
The WHO Study Group on Tobacco Product Regulation has addressed research and regulatory needs 
related to ST products in two recent reports. A 2008 publication in this series urged that all ST products 
be subjected to comprehensive regulatory control by an independent scientific government agency. 
Moreover, the study group noted that “research on the health hazards and risks to individuals and 
populations of use of ST products is essential for governments and for implementation of the 
Framework Convention [on Tobacco Control].”22,p.12 This research should address how the design and 
manufacture of tobacco products could be modified to alter their health effects. A subsequent report in 
the series, published in 2009, proposed establishing upper limits for two tobacco-specific nitrosamines 
(TSNAs) [N’-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)] 
and one polycyclic aromatic hydrocarbon [benzo(a)pyrene (BaP)] in ST products. This report also 
recommended that regulation of the distribution and sale of ST products should include measures to 
limit increases in TSNAs, including storage requirements and expiration dates. Although the authors 
acknowledged that existing evidence is not sufficient to establish whether reducing the levels of 
individual constituents in tobacco products will have a measurable impact on cancer risks, they asserted 
that “it is difficult to justify allowing high levels of known carcinogenic constituents in a product that is 
known to cause cancer, when lower levels are readily achievable with existing technology.”9,p.41 
A second international conference focused on ST, the International Smokeless Tobacco Symposium, 
was held March 8, 2009, in Mumbai, India, in conjunction with the World Conference on Tobacco or 
Health. More than 150 participants representing dozens of countries from around the world attended the 
1-day meeting. Presentations highlighted a number of challenges related to ST products, including 
relatively low prices for these products (which makes them appealing), the targeting of products toward 
youth, and the lack of organized public health and policy efforts focused on smokeless tobacco. At the 
end of the conference, participants agreed on several key conclusions: 
 




 Smokeless tobacco use adversely affects all countries and regions.  
 Increasing use and industry promotion of ST represents an increasing threat to public health 
worldwide.  
 All forms of ST have an adverse impact on health.  
 Smokeless tobacco should not be promoted as a harm-reduction product.  
 Smokeless tobacco poses substantial challenges to regulatory and control efforts because of the 
wide variety of products and production methods in use, including individual point-of-use 
production, home- and village-based production, as well as manufacture by international 
corporations.  
 Smokeless tobacco has not received adequate attention from researchers and policymakers, 
including the WHO Framework Convention on Tobacco Control (FCTC).  
 Smokeless tobacco should receive increased attention (such as increased surveillance and 
monitoring) in all parts of the world.  
Another important conference was the 2010 International Smokeless Tobacco Meeting hosted by the 
Tobacco Harm Reduction Network (THRN), funded by the National Cancer Institute (United States), in 
collaboration with the Centers for Disease Control and Prevention and the American Cancer Society. 
This meeting brought together leading global ST researchers to develop a coordinated and collaborative 
process to better understand and address the public health burden of ST worldwide. The meeting agenda 
included presentations highlighting findings and recommendations from previous meetings and reports; 
regional ST trends among populations in Asia, Africa, Europe, North America, South America, and the 
Eastern Mediterranean; existing research surveillance tools, databases, and networks; and opportunities 
and implications for ST product regulation through the FCTC and the U.S. Food and Drug 
Administration’s new authority under the 2009 Family Smoking Prevention and Tobacco Control Act.  
Among other recommendations and conclusions, the meeting identified three critical action steps to 
expand efforts against the ST epidemic.  
 First, coordinate action to elevate the profile of ST within the broader tobacco control 
community. Specifically, it is urgent that reducing ST use be included as a priority in ongoing 
tobacco control efforts. These efforts should also focus on capacity building by attracting and 
supporting new researchers, especially those in low- and middle-income countries.  
 Second, develop and expand global ST product monitoring and surveillance systems. These 
systems must address the significant heterogeneity of ST products, both commercial and local or 
homegrown, and their toxic constituents and additives; systems should also monitor and assess 
product trends and prevalence across population groups.  
 Third, build the infrastructure needed to expand the evidence base critical for effective regulatory 
action. Strategies for developing this infrastructure should focus on building collaborations 
between scientists, tobacco control advocates, and policymakers. Research is urgently needed to 
address the diversity of ST products, changing patterns of ST use, and varied types of ST 
production. Timely and high-quality research is essential to the development and implementation 
of effective regulatory action.  






Presentations at the International Smokeless Tobacco Meeting provided the basis for organizing and 
structuring the current report, which is an effort to address these critical action steps by raising the 
profile of the global challenge posed by ST use, identifying sources of information and gaps, and 
identifying research and policy needs related to smokeless tobacco. 
Major Conclusions  
 Smokeless tobacco use is a global problem that is present in at least 70 low-, middle-, and 
high-income countries and affects more than 300 million people. The greatest burden from 
ST use is in the South-East Asia Region, which experiences the highest prevalence of ST use 
(including the majority [89%] of the world’s users), carries the highest attributable disease 
burden, and has the greatest diversity in product types and forms of use.23–29 Smokeless 
tobacco use is highly prevalent in India, where it exceeds cigarette smoking among both men 
and women.  
 The magnitude of disease risks directly associated with ST use appears to differ across countries 
and regions, likely due in part to differences between ST products and patterns of use. 
Laboratory analyses have shown widely varying levels of known carcinogens and nicotine in 
ST products from different regions, and epidemiologic studies of ST users in different regions 
have reached varying risk estimates for cancer and cardiovascular disease from country to 
country. Yet data to precisely quantify these differences in disease risk and to identify the factors 
that drive them are lacking.  
 Smokeless tobacco use and marketing present distinct public health challenges in different 
countries and regions. In particular, there is a divide between some high-income countries 
(such as in Scandinavia) with high prevalence of low-nitrosamine ST use, reductions in smoking 
prevalence, and strong tobacco control and regulatory frameworks, and low- or middle-income 
countries (such as India) where ST products are associated with very high levels of harmful 
constituents, where marketing of cigarettes is increasing, and a large unorganized business sector 
makes product control and regulation extremely challenging. Changes in product marketing, 
patterns of use, and tobacco control programs and interventions may have very different results 
in these different environments.  
 Changing tobacco industry marketing strategies may influence the future public health impact 
of ST use. In some high-income countries where restrictions on public smoking have increased 
and smoking prevalence has decreased, tobacco companies have marketed oral tobacco products 
to smokers. However, the impact of this trend on smoking behavior, and possible dual or 
poly-tobacco use, remains uncertain. At the same time, multinational tobacco companies have 
an increasing presence among low- and middle-income countries with both smoked and 
smokeless products.  
 In many regions, even those where ST use is highly prevalent, policies and programs aimed 
at ST use prevention and cessation are generally weaker than those that address smoked 
tobacco products. Prices are lower, warning labels are weaker, surveillance is less developed, 
fewer proven interventions are available, and fewer resources are devoted to prevention and 
control programs.  
 




 Significant challenges exist in monitoring the use and health effects of smokeless tobacco. 
These challenges include the diversity of ST products and their use; the lack of information to 
characterize products and manner of use; the informal, unorganized nature of the ST market in 
some regions; and the limited attention given to tailored educational and intervention programs. 
 A wide range of research gaps remain for ST products, including lack of surveillance data and 
data on: characteristics of diverse ST products; health consequences from use of different 
products, including fetal exposure and reproductive outcomes; economic policies concerning 
ST products and their use; and effective region-specific ST education, prevention, and 
treatment interventions.  
 A range of different policies have been proposed or implemented for ST products in some 
countries, but data are often lacking on their impact or effectiveness. Greater attention is needed 
to strengthen the use of evidence-based policies for control of ST use, which could include: 
having tobacco industries disclose the contents of ST products; establishing performance 
standards for toxicants and maximum pH levels; banning flavorants; establishing effective and 
relevant health warning labels; increasing taxes on ST products; banning or restricting ST 
promotions, sponsorship, or marketing; and raising public awareness of the toxicity and health 
effects of ST products. In sum, prevention and cessation of ST use should form an integral part 
of any comprehensive tobacco control effort.  
 Capacity for research and public health action around ST is limited in many countries, especially 
those where the public health burden is greatest. Development of international infrastructure for 
research and information sharing could enhance the ability of many countries to reduce the 
consequences of ST use. International collaboration and shared capacity building could include 
the following: (a) creating regional but globally accessible information clearinghouses for 
ST; (b) strengthening infrastructure for networking, communication, and collaboration; 
(c) building collaborations across disciplines and professions (e.g., scientists with policymakers 
and tobacco control advocates); and (d) developing ways to build research capacity by 
leveraging existing resources.  
Chapter Summaries and Key Findings 
Part 1—Overview  
Chapter 1. The Global Challenge of Smokeless Tobacco 
Chapter 1 introduces and provides a framework for this report, summarizes its chapters, and sets out its 
major conclusions. 
Chapter 2. Global Prevalence of Smokeless Tobacco Use Among Youth and Adults 
Chapter 2 describes available data on the prevalence of ST use by youth and adults in 114 countries of 
the 194 WHO member states. Data on ST use in many of these countries were available for the first 
time. Major data sources for ST prevalence included the 2007–2010 school-based Global Youth 
Tobacco Surveys (GYTS), the 2008–2010 Global Adult Tobacco Survey (GATS), and the 2005–2010 
Demographic and Health Surveys (DHS) on adults, along with other national and subnational surveys. 







 More than 300 million adults in 70 countries across all WHO regions use smokeless tobacco. 
The largest share, 89%, are in South-East Asia. More than 250 million adult ST users are in 
low- and middle-income countries.23–29 In a few countries, notably India and Bangladesh, ST 
use is very high and surpasses smoking.  
 Smokeless tobacco use prevalence varies significantly across individual countries and regions, 
between youth and adults, and between males and females.  
 Among youth and adults, males generally show higher prevalence of use than females. However, 
among adults, use by women is similar to or greater than use by men in some countries, 
including Bangladesh, Thailand, Cambodia, Malaysia, Vietnam, and some African countries, 
such as South Africa, Mauritania, and Sierra Leone.  
 Current ST use prevalence is especially high (>15%) among adults in Myanmar, Bangladesh, 
India, Bhutan, Nepal, Sweden, and Sri Lanka, and among youth in Congo and Namibia. All six 
WHO regions reported prevalence of greater than 10% among boys, men, or overall in at least 
one country.  
 Although data were available to measure overall prevalence for many countries, longitudinal 
data and data on patterns of use are lacking in most regions.  
Chapter 3. A Global View of Smokeless Tobacco Products 
Chapter 3 provides information on the contents of the various types of ST products that are used around 
the world, including their levels of toxicants, carcinogens, and nicotine. This chapter presents a method 
of classifying the variety of ST products based on the inclusion or exclusion of alkaline modifiers, areca 
nut, or other chemical and plant ingredients with biologic activity. This chapter also describes the factors 
and processes that lead to the presence or formation of toxic and carcinogenic agents in ST products, and 
discusses the use of species of tobacco that can contribute to extremely high nicotine levels (Nicotiana 
rustica) and toxicity (Nicotiana glauca). 
Key findings: 
 Globally, ST products vary greatly in chemical composition, with some products containing 
extremely high levels of nicotine, free nicotine, and carcinogens. Hence, the wide spectrum 
of ST products appears to represent differing levels of addictiveness, toxicity, carcinogenicity, 
and harmful health effects. For example, levels of certain carcinogenic TSNAs, such as NNN 
and NNK, can vary by several orders of magnitude among ST products distributed globally.30 
 Smokeless tobacco products may be premade (sold ready to use) or custom-made (assembled by 
the user or a vendor according to user preferences). Premade products range from manufactured 
products made in factories or large production facilities to cottage industry products made in 
market stalls or shops.  
 




 Levels of toxicity, carcinogens, and free nicotine in ST products are influenced by the tobacco 
species/type used, growing conditions (e.g., soil nitrate and metals concentrations), curing 
methods (air curing vs. fire curing), tobacco processing (fermentation vs. pasteurization), 
production methods, including the addition of certain ingredients (areca nut, tonka bean, alkaline 
agents), and product storage conditions.  
 The presence of microorganisms (e.g., bacteria, fungi) in tobacco or their formation 
during production can potentially increase the levels of some carcinogens or toxicants in 
tobacco products.  
 Reduction or elimination of fire-cured tobacco, microbial contamination, fermentation, and 
certain ingredients (areca nut, tonka bean) and improvements in storage conditions are potential 
means of reducing carcinogens or toxicants in ST products. 
 Elimination of nicotine-enriched tobacco species and greatly reduced use of alkaline agents are 
means of reducing users’ exposure to high nicotine levels and the addictive potential of some 
ST products.  
Future research requires more thorough characterization of contents and harmful chemicals, including 
those not previously studied, in the wide variety of ST products that are used worldwide. 
Chapter 4. Health Consequences of Smokeless Tobacco Use 
Chapter 4 summarizes the evidence on the adverse health consequences associated with ST products and 
their use, including addiction, oral conditions and precancerous lesions, cancer, cardiovascular disease, 
diabetes and insulin resistance, conditions of the nasal cavity, and reproductive outcomes. The chapter 
builds on previous reports and systematic reviews that have provided thorough assessments of the 
evidence. The chapter also provides estimates of the public health impact of ST product use in three 
countries where sufficient data are available—India, Sweden, and the United States.  
Key findings: 
 Compared with the vast amount of information linking adverse health effects to cigarette 
smoking, studies on ST use are not comprehensive. Epidemiologic studies of ST use have 
less information about what levels of use are associated with particular outcomes and, in some 
countries, fewer numbers of ST users on which to base conclusions. Also, because ST products 
contain varying levels of many known carcinogens as well as other plant materials, such as 
areca nut or tonka bean, comprehensive risk assessments must address complex mixtures 
of ingredients. 
 There is sufficient evidence that ST products cause addiction; precancerous oral lesions; cancer 
of the oral cavity, esophagus, and pancreas; and adverse reproductive and developmental effects 
including stillbirth, preterm birth, and low birth weight. Some, but not all, ST products are 
associated with increased risk of fatal ischemic heart disease, type 2 diabetes, and fatal stroke.  
 The extent of ST-related risks appears to vary by region, most likely due in part to differing 
levels of harmful constituents and ways in which these products are used.  






 The proportion of cases of cancers of the oral cavity, esophagus, and pancreas that can be 
attributed to ST use (i.e., the attributable fraction) is greater in countries where ST use is highly 
prevalent. A high burden of ST-related cancers is estimated to occur in India because of the large 
population, high prevalence of ST use, and high incidence of cancers known to be associated 
with ST use. 
 The public health impact of ST use can be estimated from the disease risk associated with the 
particular product, the prevalence and manner of use, and the population burden of disease 
known to be associated with ST use. The impact of ST use may be difficult to quantify where 
data specific to a product or region are lacking. 
Chapter 5. The Economics of Smokeless Tobacco 
Chapter 5 summarizes the literature and available data on the economics of smokeless tobacco. It 
provides the first systematic overview of ST excise tax rates and points out the vast gaps in both 
economic data and economic research related to ST use. 
Key findings: 
 Very limited data exist on ST prices, tax rates, and tax structures, which makes research into the 
impact of ST taxes and prices on ST use very difficult, if not impossible. Very little is known 
about the extent to which higher ST taxes translate into higher ST prices and how these prices 
affect the affordability of ST products. Little is known about the comparability of tax levels 
between smoked and smokeless products.  
 The best available estimates indicate that, by volume, 91% of ST products sold worldwide are 
sold through “traditional” markets (cottage industry and custom-made).31  
 The tax system that best suits public health goals is likely to be country-specific. The excise tax 
system that should be favored is that which most effectively raises the prices of ST products and 
makes ST products less affordable over time, because this will discourage ST consumption. The 
current best practice for cigarette taxation favors the use of a specific excise tax that is regularly 
adjusted for inflation. 
 The effectiveness of tax collection systems and the impact of higher taxes on ST use will also 
depend on the standardization of ST products. A standard unit may be based on dosage (average 
amount of a product used in a single session), the weight of the dry tobacco leaf used in a 
product, or the weight of a product (weight of the tobacco, water content, and all other additives). 
Lack of standardization complicates not only tax collection but also scientific research, as it 
hinders the use of econometric methods. 
 Data on ST prices, taxes, ST tax revenue, and ST trade (both licit and illicit) are needed. 
Currently WHO FCTC reporting standards do not require collection of data on all types of 
tobacco products. Attention should be dedicated to monitoring and regulating the ST supply 
chain (manufacturing, trade, distribution) in order to develop an effective ST tax regime.  
 




Chapter 6. Changing Smokeless Tobacco Products and Marketing Practices 
by Industry 
Chapter 6 describes novel ST products introduced over the past decade, how these products differ from 
more traditional ST products, and how they are being marketed. 
Key findings: 
 In some high-income countries, tobacco manufacturers have introduced novel ST products, using 
product innovations such as portion pouches, dissolvable tobacco, unique flavorings, and varying 
nicotine levels which may make novel products more attractive to consumers, including those 
who have not previously used ST products. Tobacco manufacturers, including cigarette 
manufacturers, have marketed new ST products to smokers for use in situations where they 
cannot smoke or do not want to smoke, such as at work, in airplanes, in smoke-free bars, or 
around family members. These marketing strategies may have an adverse public health impact if 
they encourage dual use or use of multiple tobacco products, discourage cessation, or encourage 
new tobacco use initiation.  
 In low- and middle-income countries, product innovations may also make sale and use of 
products more convenient. For example, in India the gutka industry has promoted a packaged 
ready-to-use product based on a traditional custom-made mixture.  
 Marketing encompasses more than advertising. Marketing practices of the ST industry should be 
thought of in terms of the “4 P’s”: product, price, placement, and promotion. Products are 
designed to appeal to targeted consumers, they are offered at a desirable price, and they are 
promoted effectively using multiple communication and placement channels. 
 Understanding consumer perceptions of and responses to novel products is essential to 
assessing the public health impact of changing product and marketing strategies. Research is 
needed into the perceptions of consumers and their attitudes toward marketing messages, 
product packaging, and product characterization in order to support evidence-based control 
and regulation of ST products. 
 Greater monitoring and research is needed regarding marketing practices in low- and 
middle-income countries. 
Chapter 7. Prevention and Cessation Interventions 
Chapter 7 describes evidence-based prevention and treatment programs that have been tested in a 
range of countries. The interventions vary from community, to organizational, to individual levels of 
treatment. This chapter also explores treatments that have been targeted to specific populations of 
ST users. 
Key findings: 
 School-based and community-based prevention programs lead to short-term reductions in 
prevalence. Involvement of youth in the planning and implementation of programs is an 
important contributor to their success. School programs that are supplemented by effective 
family-based and mass media programs improve success over school programs alone. 






 For adult ST users, dental office interventions and clinic interventions involving multiple 
sessions and counselor support have been shown to be effective treatments, although most 
studies have been conducted in high-income countries. Phone counseling and oral exam 
feedback appear to be key elements of an effective intervention. Training oral health 
professionals to intervene with ST users may also be an effective avenue for intervention. 
 For resource-constrained countries, mailed self-help materials with follow-up contact by 
telephone or using mobile technology may be a cost-effective intervention method. 
 Pharmacotherapies, with the possible exception of varenicline, have not been found effective in 
improving ST cessation rates. However, these medications may reduce withdrawal symptoms in 
individuals who stop using ST products. 
 Public awareness and understanding of the detrimental health effects of ST use is incomplete and 
in some countries, extremely limited. Educational efforts on these harmful effects through media 
or health care systems are essential to support implementation of large-scale interventions. 
 More research is necessary in order to develop country-specific ST intervention programs and to 
explore the best ways to make these interventions accessible to ST users, especially in countries 
were resources are limited.  
Chapter 8. Smokeless Tobacco Regulation and Policy 
Chapter 8 describes the different types of regulations that have been implemented in different countries 
and regions and those countries’ regulatory experiences. It also examines the challenges involved in 
regulating ST products and provides recommendations on how to address these challenges. 
Key findings: 
 Key provisions in the WHO Framework Convention on Tobacco Control as applied to ST have 
been implemented to varying degrees in some countries but not others. Almost all of the 
provisions in the FCTC have direct and distinct implications for ST products and, to be fully 
implemented, will require guidance specific to ST products. For example, demand-reduction 
measures—such as regulation of tobacco product contents, packaging and labeling, education 
and communication efforts, and dependence and cessation interventions—should be tailored to 
ST product users and to the context of their use. Additionally, WHO’s TobReg committee has 
published recommended upper limits for key tobacco carcinogens in ST products.  
 Countries and regions have had varied regulatory experiences, ranging from banning all or some 
ST products (Singapore, Brazil, Bahrain, United Arab Emirates, and the European Union except 
Sweden), following FCTC recommendations for ST products (Turkey), prohibiting ST sales to 
minors, restricting promotion, and requiring product reports by manufacturers (United States, 
Canada), requiring text-based warning labels on ST products (United States, Canada, India), to a 
total absence of regulation of ST (most countries in the Eastern Mediterranean Region).  
 Key challenges for effective ST regulation and policy include: (a) low cost, high social 
acceptance, and easy availability of ST products; (b) tax evasion due to illicit sales and 
production in traditional markets, and illicit trade and low levels of taxation in other markets; 
(c) lack of standards for testing ST products; (d) industry marketing strategies for ST; 
 




(e) heterogeneity of ST products in their composition and their manner of production, sale, and 
use; and (f) the introduction of newer tobacco products, which may impact efforts to quit tobacco 
use and may lead to dual use or use of multiple tobacco products. 
 To support product regulation and control, research is needed on regular surveillance and 
monitoring of ST products, including laboratory testing, sales and pricing data, marketing and 
packaging, and consumer response. Additionally, research is needed on the characteristics of 
diverse products, their manner of use, and the effectiveness of policies and interventions in a 
variety of environments. Capacity building will also be needed to support laboratory testing and 
regular data collection on smokeless tobacco products.  
 Overall, policies and regulation to control ST product use have been given less support by 
governments and public health leaders compared with efforts directed at cigarette smoking. 
Policies and interventions targeted to ST products should be an integral part of any 
comprehensive tobacco control policy and regulatory regime.  
Part 2—Regional Chapters 
Chapters 9 through 14 describe the types of ST products, their production and patterns of use, as well as 
the regulatory environment in countries of the World Health Organization Regions: the American, 
European, Eastern Mediterranean, African, South-East Asian, and Western Pacific Regions. 
Chapter 9. Smokeless Tobacco Use in the Region of the Americas 
Key findings: 
 Among youth, reported current ST use ranged from 1.8% in Canada to 9.8% in Barbados.32,33 
Smokeless tobacco use was more prevalent among boys than girls in nearly all countries and 
localities, with the greatest sex difference in the United States. The prevalence of ST use among 
boys ranged from 2.6% in Canada to 11.5% in Barbados, and among girls, from 0.8% in Canada 
to 8.5% in Jamaica.32,33 
 For adult men, the highest reported prevalence of use was in the United States (7.1%), while use 
by adult women was highest in Haiti (2.5%).24,29 However, detailed information on ST use for 
youth and adults is sparse or nonexistent for most countries in the region. 
 Two types of snuff are manufactured and used in the United States: moist snuff and dry snuff. 
Moist snuff is by far the most widely consumed type in the United States and Canada. Loose 
leaf, plug, and twist are the three types of chewing tobacco sold in North America. 
 In the United States, ST products have been marketed using flavorings and in pouches or 
lozenges, which may appeal to new ST users. Dissolvable forms of ST have been introduced in 
the U.S. market and a few other countries. Some of these products are compressed tobacco 
lozenges that resemble breath mints: Camel Orbs (R.J. Reynolds), Ariva (Star Scientific), and 
Stonewall (Star Scientific). (The latter two products were discontinued at the beginning of 2013.) 
Some of these products are produced by large cigarette companies and have been marketed to 
smokers to use in situations where they cannot smoke.  






 Other types of products in the region include iqmik, traditionally used by Alaskan natives; 
chimό, the main smokeless product in Venezuela; and rapé, a type of dry snuff used in Brazil. 
 Little is known about potential adverse health effects of many of the locally used products or the 
newer dissolvable products. More research is needed, including human and laboratory studies, to 
characterize the health effects of diverse products, including their use in combination with 
smoked tobacco products.  
 Regulation of ST products in the Americas is generally weak or absent. Brazil prohibits sale of 
ST products by law, but they are still available in some areas of the country. Compared with 
cigarettes, ST products are taxed at a lower rate, have weaker warning labels, and fewer 
cessation supports throughout the region.  
Chapter 10. Smokeless Tobacco Use in the European Region 
Key findings: 
 European regional data on tobacco use are largely focused on smoking; limited information is 
available on smokeless tobacco. WHO datasets report adult ST prevalence for less than one-third 
of the European Region’s countries. Additionally, limited data are available on youth ST use. 
 From the available national evidence, prevalence of ST use among adults varies from 0.1% in 
Latvia and Switzerland to 17% in Sweden.25 Men have higher rates of current use of these 
products than women, with 17% of Norwegian men, 22.5% of Uzbek men, and 26% of Swedish 
men reporting ST use.25 Subnational surveys show higher ST prevalence among specific 
groups—for example, Bangladeshi women residents of the UK. 
 Europeans use a variety of ST products. Moist snuff, or snus, originated in the Nordic countries 
of Sweden, Norway, Finland, and Iceland; a range of products are imported for use by 
communities of South Asian origin (India, Pakistan, Bangladesh, Sri Lanka) in the UK; and three 
national companies produce twisted tobacco for oral use primarily in Denmark. In Kyrgyzstan 
and Uzbekistan, nasway or nasvay is used, which is similar to the product known as nass or 
naswar in Iran, Pakistan, and surrounding countries. Snus and South-East Asian products have 
demonstrably different health risk profiles and negative health impacts. 
 In Western Europe, the European Union (EU) has provided a regulatory framework for tobacco 
products. This framework is less rigorous for ST products compared to smoked tobacco 
products, particularly with respect to health warnings. Sale of moist snuff, or snus, is allowed in 
Sweden but prohibited in all other EU member countries, and snus is acquired illicitly in Finland, 
particularly by its Swedish-speaking minority. The prohibition of snus sales within the EU has 
repeatedly been challenged by the Swedish Match Company and by the Swedish Ministries of 
Trade and of Health and Social Affairs. 
 The UK is home to the largest South Asian community within Europe. To varying degrees, 
members of these groups have brought their traditional ST use practices with them from their 
countries of origin, which have the highest global prevalence and negative health impacts.  
 




 With the exception of Scandinavia, there is limited research available on the health effects of ST 
use in the region. Studies of long-term snus use in Sweden have yielded sometimes mixed 
results, but overall have shown elevated risk for cancer risk and cardiovascular mortality. Studies 
of communities of South-East Asian origin in the United Kingdom have shown high rates of oral 
cancers linked to tobacco use. 
 The GothiaTek standard is a voluntary form of industry self-regulation of snus manufacturing 
and storage intended to reduce levels of carcinogens in the product. Because the GothiaTek 
standard was formally introduced by the Swedish tobacco industry in the late 1990s, the 
health effects of long-term exposure to modern snus manufactured under this standard are as 
yet largely unknown. 
Chapter 11. Smokeless Tobacco Use in the Eastern Mediterranean Region 
Key findings: 
 Data on ST use are not available for most countries in this region.  
 Where there is documented use of ST, adult prevalence varies widely across this region and 
between specific subgroups. Smokeless tobacco is widely consumed in a few countries, 
including Yemen,34 Pakistan,35–37 and Sudan (unpublished results, Sudan Toombak and Smoking 
Research Center, 2012). While ST use has been documented among women, prevalence is 
substantially higher among men than among women in the region.  
 The most frequently used products in the region include toombak (Sudan), shammah (Yemen), 
paan (Pakistan), and nass (Pakistan and Iran). Specific toxicity and nicotine profiles are only 
available for nass and toombak. Toombak has been reported to have the highest levels of nicotine 
and TSNAs ever measured in tobacco products.  
 Studies in several countries in the region have documented associations between precancerous 
abnormalities, oral cancers, and head and neck cancers and the use of toombak, shammah, nass, 
and paan.  
 In this region the production and marketing of ST products are primarily cottage industries, 
centered in tobacco farming areas and relying on locally available resources. Some ST products 
originating in South-East Asia are marketed to the large immigrant Asian labor force in the 
Gulf region.  
 Well-structured interventions to prevent ST use or promote cessation of ST use are lacking in the 
region. The price of ST products remains low, and countries have generally not made use of 
taxation as a tobacco control policy. In 2009 the government of Bahrain banned the importation 
of chewable tobacco products.  






Chapter 12. Smokeless Tobacco Use in the African Region 
Key findings: 
 Prevalence of ST use varies across countries and across geographic areas within countries. For 
example, the national prevalence was as high as 28.3% for women in Mauritania and 22.6% for 
men in Madagascar, and as low as 0.2% for men in Zambia and 0.5% for women in Nigeria and 
Zimbabwe.24,25 Data collected from a state in the northeastern geopolitical zone of Nigeria in 
2007 indicated high rates among people aged 15 years and older—10.8% for men and 4% for 
women.38 For some countries, however, prevalence data are lacking. 
 Smokeless tobacco products are sniffed, chewed, sucked, or applied to teeth and gums. Except in 
a few countries where imported premade manufactured products are marketed, most products are 
produced by small cottage industries or are handmade for personal use. These products are 
typically sold by street vendors, kiosks, convenience stores, or tobacconists.  
 Customs associated with ST use vary widely across different parts of the African Region. Data 
suggest that there is a widespread perception that snuff possesses medicinal properties, such as 
relief of headache, toothache, or sinus problems. 
 Based on limited existing data, the toxicity and nicotine levels of ST products appear to vary 
widely. Generally, commercially manufactured products tend to have lower levels of tobacco-
specific nitrosamines than custom-made products, although there are exceptions.  
 Very little data exist on the health effects of ST in this region, although existing data for some 
parts of Africa suggest oral ST use is associated with increased risk for oral pathologies and 
increased blood pressure. Nasal snuff use is associated with increased risk for nasopharyngeal 
cancer and respiratory disease. 
 In general, no organized public health education programs or cessation programs for ST exist in 
the African Region. Polices regarding ST use vary from a ban on the sale of ST in Tanzania (but 
with limited enforcement) to no regulations on the distribution and marketing of ST products in 
other countries. South Africa bans advertisement and promotion of ST and requires a warning 
label on manufactured products. Smokeless tobacco products tend to be cheaper than cigarettes 
throughout the region. 
Chapter 13. Smokeless Tobacco Use in the South-East Asia Region 
Key findings: 
 Prevalence of ST use among men is high across most of the region, varying between 25% and 
51% in five countries, but less than 2% in Thailand.25 Among women, ST use is high in India 
(18.4%), Bangladesh (28%), and Myanmar (16%).23,25 Prevalence is also high across the region, 
equivalent to cigarettes, among youth aged 13 to 15 years.23 
 This region is home to over 250 million ST users aged 15 and older. Rural users in India and 
Bangladesh make up 80% of total ST users in the world.39,40 Smoking remains more common 
than ST use in Indonesia, Thailand, Bangladesh, Sri Lanka, and Nepal, but ST use is 
predominant in India and Myanmar among men. 
 




 In India, the most common forms of ST used are tobacco with lime (khaini), gutka, and betel 
quid. Betel quid is typically freshly prepared by the user or a vendor. Pan masala and gutka have 
become increasingly popular as alternatives to traditional betel quid; they are manufactured on 
an industrial scale and sold in dried form.  
 High levels of TSNAs have been recorded in some products, including khaini and zarda. Areca 
nut used as an ingredient in betel quid contains additional harmful constituents. The fact that 
some products are produced and sold in cottage industries complicates efforts to characterize 
typical products in the region.  
 Incidence of oral and pharyngeal cancers is high in South-East Asia Region countries compared 
to most of the rest of the world, and this high rate has been attributed in large part to ST and 
areca nut use. Historically, only 10% to 15% of people with oral cancer in India are diagnosed 
when their cancers are in an early, localized stage, which results in poor survival rates.41 
 Most of the epidemiologic studies of specific health effects of ST use in the region come from 
India. Studies have documented associations between ST use and oral precancerous lesions, oral 
cancers, adverse reproductive outcomes, and cardiovascular diseases. 
 A number of intervention programs—including school-based interventions, community 
interventions, and mass media campaigns, primarily in India—have been evaluated and shown 
to have some impact in the region. However, resources and capacity for large-scale intervention 
programs are limited in some countries.  
 All member states in the region except Indonesia have ratified the FCTC. However, 
implementation of ST control policies in the region has been limited. In contrast to cigarettes, 
taxes on ST products are low or nonexistent. Unprocessed tobacco sold in loose form, including 
betel quid with tobacco, is often not taxed and does not display any package warning labels. 
Some countries have prohibited advertising of ST, including Bhutan, India, Maldives, Myanmar, 
Sri Lanka, and Thailand. Bhutan has banned the sale of all forms of tobacco, and several states in 
India have used national food safety regulations to ban gutka. 
Chapter 14. Smokeless Tobacco Use in the Western Pacific Region 
Key findings: 
 Prevalence data on ST use in this region are scant. Of the few countries that have ST use data, 
the rates vary from 22.4% among men aged 25–64 years in Micronesia, to 0.3% among males 
older than 15 years in Vietnam.23,25 In some countries (Cambodia, Malaysia, and Vietnam), the 
rates of ST use are higher in females than males.23,25  
 Forms of ST use involve areca nut/betel quid with or without tobacco, although in some 
countries tobacco is not traditionally added to areca nut/betel quid.  
 Areca nut contains an alkaloid, arecoline, which is carcinogenic. The lack of data on health 
effects and toxicity of using areca nut with tobacco represents a significant data gap for this 
region. Potential health consequences include oral pathologies (leukoplakia and oral submucous 
fibrosis), head and neck cancer, and low birth weight in infants of mothers who used ST products 
during pregnancy.  






 Current policies and interventions vary across countries in this region. Some countries have 
instituted bans on ST (Australia, New Zealand), bans on ST manufacturing (Taiwan), or bans on 
ST importation (Japan, Hong Kong, Singapore, Taiwan). However, these bans may not affect the 
use of areca nut/betel quit with tobacco, which sometimes is obtained from cigarettes. In 
addition, some of these bans remain weak because they do not prohibit importation of ST 
products for personal consumption.  
 Some of the challenges associated with policy implementation include the notion that chewing 
areca nut/betel quid is symbolic of cultural identity, the belief that it has medicinal properties, 
and the lack of awareness of its harmful effects. Educational efforts on ST will require also 
addressing areca nut/betel quid, because use of these two substances is closely linked with 
ST use.  
Chapter 15. Global Smokeless Tobacco Use: Future Research Needs and Policy 
Recommendations 
Chapter 15 summarizes the major conclusions of this report, discusses gaps in ST research, and 
describes needed policy changes. 
Key findings: 
 A wide range of research gaps remain in relation to understanding and addressing the global 
public health impact of ST products. Research needs include ongoing surveillance of patterns 
of use across product types, further characterization of diverse ST products and their 
constituents, assessment of the health consequences of using different products in different 
regions, evaluation of the economic impact of ST use and the impact of taxation policies across 
regions, as well as assessment of cost-effective, region-specific ST education, prevention, and 
treatment interventions.  
 Implementation of effective strategies for control of ST use and related health effects will require 
increased scientific and public health capacity, particularly in low- and middle-income countries 
affected by high burdens of ST use. International collaboration and shared capacity building 
could be applied to: (a) create regional but globally accessible information clearinghouses for 
ST; (b) strengthen infrastructure for networking, communication, and collaboration; and 
(c) develop ways to build research capacity by leveraging existing resources. Collaborations are 
needed across disciplines and professions, such as between scientists, policymakers, and tobacco 
control advocates. 
 Prevention and cessation of ST use should be fundamental to every comprehensive tobacco 
control effort. In all regions, greater awareness is needed about ST use and its health effects, 
including education of health professionals, consumers, policymakers, and community leaders. 
Effective interventions tailored specifically to ST users should be developed, evaluated, and 
implemented where appropriate. 
 




 Specific guidelines are needed to ensure that the WHO FCTC requirements can be and are 
appropriately applied to ST products as well as cigarettes. Such guidance must also take into 
account the diversity of product types, patterns of use, and local contexts that are found around 
the world.  
 A range of policies have been proposed or implemented for ST products in some countries, but 
data are often lacking on their impact or effectiveness. Greater attention should be directed 
toward strengthening the use of evidence-based policies for controlling ST use. These policies 
could include: requiring tobacco industries to disclose the contents of ST products; establishing 
performance standards for toxicants and maximum pH levels; banning flavorants; establishing 
effective and relevant health warning labels; increasing taxes on ST products; banning or 
restricting ST promotions, sponsorship, or marketing; and raising public awareness of the 
toxicity and health effects of ST products.  
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Smokeless tobacco (ST) is used in a wide variety of forms in many countries of the world. Used orally, 
tobacco can be chewed, sucked, applied to the teeth or gums (e.g., topical toothpaste or powder), 
dissolved in the mouth, gargled, or inserted in betel quid. It can also be applied directly to the skin. 
These products may be intentionally swallowed or the juices alone may be swallowed. Nasal use 
consists of inhaling a mixture of a small quantity of very fine tobacco powder and aromatic substances, 
called dry snuff.1  
Oral use of ST is widely prevalent in South-East Asia.2 Orally, ST may be used alone or in combination 
with products such as areca nut, ash, and slaked lime. In India, the most common ST products taken 
orally are betel quid with tobacco (a combination of betel leaf, areca nut, and slaked lime [calcium 
hydroxide]), khaini (sun-dried or fermented, coarsely crushed tobacco leaves), gutka (sun-dried finely 
chopped tobacco, areca nut, slaked lime, catechu, flavorings, and sweeteners), and products that are 
applied to teeth and gums such as gul (powdered tobacco, molasses, and other ingredients) and mishri 
(roasted, powdered tobacco).3 In Bangladesh, the most prevalent forms of ST are betel quid with 
tobacco, gul, khoini (similar to khaini in India), and sada pata (powdered or dried tobacco leaves).4 In 
Myanmar, oral or nasal snuff, chewing tobacco, and betel quid are most common.5 All three of these 
countries have high rates of consumption of oral products. 
In Europe and North America, chewing tobacco and snuff are the two major oral ST products. In North 
America, moist snuff is the most widely used product. In Scandinavia, Swedish snus, a particular type of 
moist snuff product, dominates.1 Since the mid-1990s, ST use has increased in Scandinavia and the 
United States,6–9 particularly among teenagers and young adults. Smokeless tobacco is also widely used 
in parts of Central and South-East Asia.10 Nass (also called naswar or niswar), a form of oral tobacco, is 
common in some countries of Central Asia,11 whereas nasal snuff is used among some specific 
populations in Nigeria,12 South Africa,13 and other African nations.  
This chapter attempts to delineate the magnitude of the problem of ST use among youth and adults 
globally by drawing on national or subnational data available for various countries. The chapter 
describes usage patterns taken from the available literature to delineate the burden of ST use and to 
characterize the prevalence of use among youth and adults in countries where usage rates are high. 
  
 




Sources of Data 
In this chapter, most of the estimates of ST use among youth come from a single survey, the school-
based Global Youth Tobacco Survey (GYTS), conducted during 2007−2010. This chapter also draws on 
the Youth Smoking Survey (YSS) (2008−2009) for Canada and the 2009 National Youth Tobacco 
Survey (NYTS) for the United States. (Information about these surveys and surveys of adults is shown 
in Table 2-1.) To report prevalence of ST use among adults, data from the Global Adult Tobacco Survey 
(GATS), conducted in 13 low- and middle-income countries during 2008−2010, were used. In countries 
where GATS was not implemented—mostly in Africa, Latin America, and Asia—national-level data 
from the 2005–2010 Demographic and Health Surveys (DHS) of adults were used. In addition, 
this chapter presents data from the following surveys in individual countries: for Australia, the 
2004 National Drug Strategy Household Survey (NDSHS); for Canada, the 2010 Canadian Tobacco Use 
Monitoring Survey (CTUMS); and for the United States, the 2012 National Survey on Drug Use and 
Health (NSDUH). These surveys are designed to be nationally representative for the countries in which 
they are implemented, but there may be differences across surveys in how smokeless tobacco use is 
measured (Table 2-1). Therefore, caution should be exercised in making comparisons among the 
different survey estimates. 
The World Health Organization (WHO) Report on the Global Tobacco Epidemic, 2011 was referred 
to for estimates on ST use from the WHO STEPwise Approach to Surveillance (WHO STEPS) survey 
and other national or subnational surveys in various countries (referred to in this report as individual 
country surveys, or ICS). Brief descriptions of the methodologies of these surveys are given below; they 
are described in detail elsewhere.6,14–22 Data on ST are available for some additional countries but were 
not reported in this chapter due to major differences in comparability resulting from the methodology 
of surveys.  
 
 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Global Youth Tobacco Survey, 2007–2010  
The Global Youth Tobacco Survey (GYTS) is a school-based survey designed to provide primarily 
cross-sectional, nationally representative estimates on tobacco use among youth, along with key tobacco 
control measures. The survey collects information on schoolchildren aged 13 to 15 years; however, in 
some countries the average level of education is below this age bracket so the data may not always be 
representative of all youth. In the GYTS, the area covered can be a country, a province, a city, or any 
other geographic entity. The methodology of the GYTS is standardized with respect to sample design, 
questionnaires, field procedures, and processing of data and analysis.14 Questions are included on 
tobacco use, knowledge and attitudes regarding tobacco, exposure to secondhand smoke, exposure to 
pro-tobacco and anti-tobacco media messages and advertising, interest in cessation, access to tobacco 
products, and having been taught in school about the harmful effects of tobacco use. As of 2012, the 
GYTS is active in more than 180 countries and has yielded data on ST use in 73 countries. The GYTS 
was this chapter’s primary source of data on the prevalence of ST use among youth, providing national 
estimates for 55 countries and 46 subnational estimates for 18 countries.  
Youth Smoking Survey, 2008–2009  
The Youth Smoking Survey (YSS)15 provides timely and accurate monitoring of tobacco use by 
Canadian school-aged children; its main objective is to collect data that will serve as a basis for 
sound, effective tobacco control policies and programs. The YSS is a classroom-based survey of a 
representative sample of schools in the 10 Canadian provinces, which reports current information on 
tobacco use behavior as well as correlates of smoking behavior and other policy-related initiatives 
for Canadian youth. Students in grades 6−12 are surveyed. (In the province of Quebec, students in 
primary/elementary grades 5 and 6 or secondary school grades 1–3 [U.S. school grades 7–9] are 
surveyed.) This report presents data on Canadian children only in grades 6–9.  
National Youth Tobacco Survey, 2009 
The National Youth Tobacco Survey (NYTS)16 provides estimates of the prevalence of tobacco use 
among a nationally representative sample of U.S. students in middle school (grades 6–8) and high 
school (grades 9–12). The survey obtains data on the use of various tobacco products (cigarettes, cigars, 
ST, tobacco pipes, bidis, and kreteks); exposure to secondhand smoke; smoking cessation; school 
curriculum on tobacco prevention; minors’ ability to purchase or obtain tobacco products; and 
knowledge and attitudes about tobacco and familiarity with pro-tobacco and anti-tobacco media 
messages. The NYTS provides data on tobacco use among students in grades 6–12, but this volume 
reports data for grades 6–8 only. 







Global Adult Tobacco Survey, 2008−2010  
The Global Adult Tobacco Survey (GATS)17,18,23 is the global standard for systematically monitoring 
tobacco use (smoking and smokeless) among adults and tracking key indicators of tobacco control. 
The GATS is a nationally representative face-to-face household survey of people aged 15 years and 
older (termed “adults” for this report). Using a globally standardized methodology, the survey elicits 
information on respondents’ background characteristics, tobacco use (smoking and smokeless), 
cessation, exposure to secondhand smoke, economic status, awareness of media related to smokeless 
tobacco, knowledge about tobacco, and attitudes toward and perceptions about tobacco use. In its first 
phase, the GATS was conducted in 14 low- and middle-income countries, which accounted for more 
than 60% of the world population during 2008−2010.The survey was designed to provide estimates at 
the national level and by residence (urban or rural) and gender. Survey information was collected using 
handheld devices. This chapter reports GATS data on ST use from 13 countries (one country, Turkey, 
did not include questions on ST use).  
Demographic and Health Surveys, 2005−2010  
The Demographic and Health Surveys (DHS)24 are nationally representative household surveys that 
provide data for a wide range of monitoring and impact evaluation indicators in the areas of population, 
health, and nutrition. Most DHS surveys also provide information on tobacco use behavior. The DHS 
surveys include a questionnaire for households, a questionnaire for women, and one for men. The 
household questionnaire is used to identify all usual household members and visitors in the selected 
households and to determine the members’ eligibility for the individual women’s and men’s surveys. 
For almost all of the countries, the estimates of tobacco use presented in this report are based on data 
collected from the individual women’s and men’s questionnaires. This chapter presents data on ST use 
from 19 countries that conducted DHS surveys between 2005 and 2010, representing both males and 
females aged 15–49 years. (In some countries, however, estimates on males were provided for ages  
15–54 or 15–59 years.) In countries where multiple DHS surveys have been conducted, the most recent 
data were used in order to ensure the most up-to-date estimates of tobacco use. 
WHO STEPwise Approach to Surveillance, 2002–2010  
The WHO STEPS assessments of risk factors for chronic disease provide an entry point for low- and 
middle-income countries to undertake public health surveillance.19 The WHO STEPS instrument covers 
three levels of “steps” for assessing risk factors: questionnaires, physical measurements, and 
biochemical measurements. The target population is, at minimum, all adults aged 25–64 years residing 
in the survey area; this age range may be expanded to include additional age groups if desired. WHO 
STEPS survey data reported in the WHO Report on the Global Tobacco Epidemic, 20116 were used here 
for reporting the prevalence of adult use of ST in 18 countries (13 national and 5 subnational estimates). 
 




WHO Report on the Global Tobacco Epidemic, 2011  
The WHO Report on the Global Tobacco Epidemic, 2011,6 known as the GTCR, provided information 
on ST use among adults. This information was compiled from various surveys (national or subnational), 
with GATS (13 countries) and WHO STEPS (17 countries) being the predominant sources. This chapter 
reports data on adult ST use taken from 18 additional surveys presented in the GTCR (16 national and 
2 subnational estimates), including the National Health and Morbidity Survey in Malaysia, Cambodia’s 
National Adult Tobacco Survey, the Family Health Survey in Yemen, Sweden’s National Survey on 
Public Health, the National Epidemiological Study of Tobacco Use Prevalence in Kyrgyzstan, and the 
Monitoring of Danish Smoking Habits in Denmark. 
National Drug Strategy Household Survey, 2004  
Data from the 2004 National Drug Strategy Household Survey (NDSHS),20 conducted by the Australian 
Institute of Health and Welfare, were used to report the prevalence of ST use in Australia. The NDSHS 
surveyed almost 30,000 Australians about their tobacco use, including any lifetime use and use of snuff 
and chewing tobacco within the last 12 months. The survey methodology has been reported in detail by 
the Australian Institute of Health and Welfare.20 
Canadian Tobacco Use Monitoring Survey, 2010  
The 2010 Canadian Tobacco Use Monitoring Survey (CTUMS)21 was developed to provide Health 
Canada, a national health agency located in Ottawa, and its partners with timely, reliable, and 
continuous data on tobacco use and related issues. The CTUMS is a telephone survey of all people 
aged 15 years and above living in Canada, the primary objective of which is to track changes in 
smoking status and amount smoked, especially for 15- to 24-year-olds, who are most at risk for taking 
up smoking.  
National Survey on Drug Use and Health, 2012  
The National Survey on Drug Use and Health (NSDUH)22 provides information on the use of illegal 
drugs, alcohol, and tobacco by the U.S. civilian, non-institutionalized population aged 18 years and 
older. Conducted by the U.S. federal government since 1971, the survey collects data by administering 
questionnaires to a representative sample of the population through face-to-face interviews at 
respondents’ homes. The 2012 NSDUH employed a state-based design to provide estimates for each 
of the 50 states and the District of Columbia.  
Smokeless Tobacco Use Prevalence 
Current ST use is the primary indicator used in this report for most countries, with the exception of data 
on adults in Canada and South Africa, where ever use of ST is reported, and data on Iceland and Saudi 
Arabia, where prevalence of daily use of ST is reported. For this chapter, current users of ST are defined 
as people who used any ST product either daily or occasionally in the 30 days preceding the survey. 
Ever users of ST are those who have tried ST at least once in their lifetimes, and daily users are those 
who use ST products on a daily basis. Table 2-1 displays the questions that define ST use in each survey 
system for youth and adults.  






As of 2013, WHO includes 194 member states. This chapter reports the prevalence of ST use among 
youth in 75 countries and adults in 70 countries. Prevalence data are reported by WHO regions.  
In only 16 countries were overall estimates—that is, for male and female respondents combined—
available for both youth and adults (the “Total” column in Tables 2-2 and 2-4). For the remaining 
countries, estimates were only available either for adults or youth, but not for both. For countries with 
national estimates, ST use was considered high if the prevalence in a country exceeded 10%, medium if 
the prevalence was between 5% and 10%, low if the prevalence was between 1% and 5%, and very low 
if the prevalence was below 1%. Using these categories, Maps 2-1–2-3 show the prevalence of ST use 
among youth, and Maps 2-4–2-6 show prevalence among adults in countries around the world. 
Smokeless Tobacco Use Among Youth 
Table 2-2 provides nationally representative prevalence data by gender. Table 2-3 displays subnational 
data within various countries, also by gender. These estimates were taken from different sources that 
together spanned the years 2007–2010. Of the countries with national youth estimates, 11 were in the 
African Region, 9 in the Eastern Mediterranean Region, 11 in the European Region, 14 in the Americas 
Region, 8 in the South-East Asia Region, and 4 in the Western Pacific Region.  
Of the 75 countries for which youth ST use prevalence was reported (Table 2-2), national-level 
estimates were available for 57 countries, and a total of 46 subnational estimates were reported for 
18 countries. Among the 57 national estimates, the prevalence of current use of ST ranged from 16.4% 
in Congo to 1.1% in Montenegro (Figure 2-1). For boys, national prevalence was highest at 18.3% in 
Congo and lowest at 1.1% in Montenegro (Figure 2-2); for girls, prevalence ranged from 15.8% in 
Namibia to 0.7% in Serbia (Figure 2-3). Total ST use prevalence was high (greater than 10%) in 
5 countries (Botswana, Djibouti, Lesotho, Namibia, and Congo). The prevalence exceeded 10% 
among boys in 12 countries and among girls in 4 countries (Table 2-2).  
In the 18 countries where subnational estimates were reported (Table 2-3), the prevalence among youth 
ranged from 22.7% in rural western Sierra Leone to 1.4% in the Mazovia province of Poland. Among 
boys, use ranged from 21.9% in Bangui in the Central Africa Republic to 1.3% in Warsaw, Poland. 
Among girls, the prevalence of use ranged from 24.5% in rural western Sierra Leone to 1.0% in the 
Mazovia province in Poland.  
Table 2-2 indicates that, among countries assessed in the African Region, overall prevalence ranged 
from 16.4% in Congo to 5.4% in Swaziland. Among countries assessed in the Eastern Mediterranean 
Region, overall prevalence ranged from 12.6% in Djibouti to 1.6% in Oman. In the European Region, 
the highest prevalence was reported in Estonia (6.9%) and the lowest in Montenegro (1.1%). In the 
Americas Region, the highest prevalence was in Barbados (9.8%) and the lowest in Canada (1.8%). In 
the South-East Asia Region, prevalence was highest in Bhutan (9.4%) and lowest in Indonesia (2.8%). 
In the Western Pacific Region, Cook Island had the highest prevalence (8.7%) and Macau the lowest 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2-2. Prevalence (national level, %) of current use of any form of smokeless tobacco among boys 
and girls, by World Health Organization region, 2007–2010 
Region* Country/year Source† 
Age group 
(years) 
  Prevalence (%)  
 Total Boys Girls 
AFR Botswana, 2008 GYTS 13–15  11.3 11.3 11.4 
 Congo, 2009 GYTS 13–15  16.4 18.3 14.1 
 Côte d’Ivoire, 2009 GYTS 13–15  5.6 6.2 4.9 
 Lesotho, 2008 GYTS 13–15  14.4 14.7 13.6 
 Madagascar, 2008 GYTS 13–15  5.7 6.2 5.4 
 Namibia, 2008 GYTS 13–15  16.0 15.6 15.8 
 Rwanda, 2008 GYTS 13–15  7.4 8.3 6.0 
 Seychelles, 2007 GYTS 13–15  5.5 5.2 5.4 
 Swaziland, 2009 GYTS 13–15  5.4 6.0 5.0 
 Togo, 2007 GYTS 13–15  6.2 6.9 4.8 
 Uganda, 2007 GYTS 13–15  9.4 8.6 9.6 
EMR Djibouti, 2009 GYTS 13–15  12.6 15.2 9.0 
 Iran, 2007 GYTS 13–15  5.1 5.4 4.8 
 Libya, 2010 GYTS 13–15  2.3 2.0 2.3 
 Oman, 2010 GYTS 13–15  1.6 2.5 0.9 
 Qatar, 2007 GYTS 13–15  7.0 7.6 6.1 
 Saudi Arabia, 2010 GYTS 13–15  3.4 4.8 1.8 
 Syrian Arab Republic, 2010 GYTS 13–15  5.7 7.9 3.5 
 Tunisia, 2010 GYTS 13–15  2.3 3.9 0.9 
 Yemen, 2008 GYTS 13–15  8.6 8.2 8.4 
EUR Albania, 2009 GYTS 13–15  2.0 2.3 1.7 
 Croatia, 2007 GYTS 13–15  1.9 2.7 1.1 
 Estonia, 2007 GYTS 13–15  6.9 9.4 4.5 
 Hungary, 2008 GYTS 13–15  1.7 2.1 0.9 
 Kyrgyzstan, 2008 GYTS 13–15  2.5 3.3 1.8 
 Macedonia, 2008 GYTS 13–15  3.0 3.2 2.8 
 Moldova, 2008 GYTS 13–15  3.8 5.2 2.6 
 Montenegro, 2008 GYTS 13–15  1.1 1.1 0.9 
 Serbia, 2008 GYTS 13–15  1.2 1.6 0.7 
 Slovenia, 2007 GYTS 13–15  2.2 2.0 1.8 
 Srpska, 2008 GYTS 13–15  1.4 1.8 1.1 






Region* Country/year Source† 
Age group 
(years) 
  Prevalence (%)  
 Total Boys Girls 
AMR Argentina, 2007 GYTS 13–15  4.3 5.5 3.2 
 Bahamas, 2009 GYTS 13–15  6.6 7.5 5.5 
 Barbados, 2007 GYTS 13–15  9.8 11.5 8.2 
 Canada, 2009 YSS Grades 6–9  1.8 2.6 0.8 
 Dominica, 2009 GYTS 13–15  8.4 10.2 6.4 
 El Salvador, 2009 GYTS 13–15  3.7 4.5 2.8 
 Grenada, 2009 GYTS 13–15  8.4 10.1 6.9 
 Guyana, 2010 GYTS 13–15  7.5 7.9 6.6 
 Jamaica, 2010 GYTS 13–15  8.5 8.5 8.5 
 Panama, 2008 GYTS 13–15  3.5 3.8 3.2 
 Peru, 2007 GYTS 13–15  4.7 4.3 4.8 
 Trinidad and Tobago, 2007 GYTS 13–15  5.5 5.4 5.5 
 United States, 2009 NYTS Grades 6–8  2.6 4.1 1.2 
 Venezuela, 2010 GYTS 13–15  5.1 6.9 2.6 
SEAR Bangladesh, 2007 GYTS 13–15  4.9 5.8 4.2 
 Bhutan, 2009 GYTS 13–15  9.4 14.1 5.3 
 India, 2009 GYTS 13–15  9.0 11.1 6.0 
 Indonesia, 2009 GYTS 13–16  2.8 3.3 2.3 
 Myanmar, 2007 GYTS 13–15  6.5 10.3 2.7 
 Nepal, 2007 GYTS 13–15  6.1 8.8 2.9 
 Sri Lanka, 2007 GYTS 13–15  6.8 9.6 3.9 
 Thailand, 2009 GYTS 13–15  5.7 7.3 4.1 
WPR Cook Island, 2008 GYTS 13–15  8.7 10.5 7.3 
 Macau, 2010 GYTS 13–15  2.1 2.2 2.1 
 Malaysia, 2009 GYTS 13–15  4.0 4.5 3.2 
 South Korea, 2008 GYTS 13–15  6.2 7.2 5.0 
* Regions: AFR = African Region; EMR = Eastern Mediterranean Region; EUR = European Region; AMR = Region of the Americas; 
SEAR = South-East Asia Region; WPR = Western Pacific Region. 
†GYTS = Global Youth Tobacco Survey, 2007–2010 (25); NYTS = National Youth Tobacco Survey, United States, 2009 (16); 
YSS = Youth Smoking Survey, Canada, 2008–2009 (15). 
  
 




Table 2-3. Prevalence (subnational level, %) of current use of any form of smokeless tobacco among 
youth, by World Health Organization region, GYTS, 2007–2009 
Region* Country/year Location 
Age group 
(years) 
 Prevalence (%)  
Total Boys Girls 
AFR Burkina Faso, 2009 Bobo Dioulasso 13–15  13.2 12.1 14.0 
  Ouagadougou 13–15  10.2 11.2 9.2 
 Cameroon, 2008 Yaounde 13–15  5.1 5.4 4.4 
  Outside Yaounde 13–15  10.9 12.0 9.4 
 Central African Republic, 2008 Bangui 13–15  15.4 21.9 8.0 
 Democratic Republic of the Congo, 2008 Kinshasa 13–15  20.8 20.6 20.1 
  Lubumbashi 13–15  17.8 18.3 16.4 
 Gambia, 2008 Banjul 13–15  21.9 20.1 23.3 
 Liberia, 2008 Monrovia 13–15  8.3 9.0 6.6 
 Malawi, 2009 Lilongwe 13–15  11.0 10.3 11.7 
  Rest of country 13–15  8.9 11.3 6.7 
 Sierra Leone, 2008 West urban 13–15  17.3 13.6 18.8 
  West rural 13–15  22.7 18.9 24.5 
 Tanzania, 2008 Arusha 13–15  6.2 6.9 5.5 
  Dar es Salaam 13–15  4.6 4.6 4.3 
  Kilimanjaro 13–15  5.7 5.6 5.7 
 Zambia, 2007 Lusaka 13–15  15.6 15.9 15.4 
  Kafue 13–15  16.7 17.0 16.5 
  Chongwe and Luangwa 13–15  14.1 15.3 13.2 
 Zimbabwe, 2008 Bulawayo 13–15  5.4 7.5 3.5 
  Harare 13–15  5.7 6.4 5.0 
  Manicarland 13–15  7.6 8.3 6.3 
EMR  Iraq, 2008 Baghdad 13–15  6.9 7.2 5.8 
 Lebanon, 2008 UNRWA 13–15  6.5 6.5 6.4 
 Pakistan, 2008 Karachi 13–15  10.8 13.8 7.4 
  Quetta 13–15  7.5 6.8 7.9 
  Lahore 13–15  4.2 5.8 3.1 
  Peshawar 13–15  6.0 8.0 2.6 
 Palestine, 2008 UNRWA Gaza 13–15  8.9 9.2 8.3 
  UNRWA West Bank 13–15  9.1 7.7 9.2 






Region* Country/year Location 
Age group 
(years) 
 Prevalence (%)  
Total Boys Girls 
EUR  Poland, 2009 Warsaw 13–15  1.8 1.3 2.2 
  Mazovia Province 13–15  1.4 1.5 1.0 
AMR  Brazil, 2009 Campo Grande 13–15  8.2 9.1 7.5 
  Vitoria 13–15  3.6 5.0 2.4 
  São Paulo 13–15  5.5 6.3 4.6 
 Mexico, 2008 Pachuca 13–15  5.3 6.6 4.1 
  Tlaxcala 13–15  5.3 7.9 3.0 
  Saltillo 13–15  4.5 4.9 3.9 
  Campeche 13–15  6.3 5.1 7.2 
  Villahermosa 13–15  5.0 5.8 4.4 
  Aguascalientes 13–15  2.8 3.3 2.2 
  Colima 13–15  8.4 8.7 8.0 
  Morelia 13–15  4.4 5.6 3.3 
  Queretaro 13–15  4.1 4.6 3.5 
  La Paz 13–15  7.3 7.7 5.3 
  San Luis Potosi 13–15  4.1 5.3 3.1 
* Regions: AFR = African Region; EMR = Eastern Mediterranean Region; EUR = European Region; AMR = Region of the Americas. 
Source: GYTS = Global Youth Tobacco Survey, 2007–2010 (25). 
  
 




Figure 2-1. Current smokeless tobacco use (%) among boys and girls, 2007–2010 
 
Sources: Global Youth Tobacco Survey, 2007–2010 (25); National Youth Tobacco Survey, United States, 2009 (16); Youth Smoking 
Survey, Canada, 2008–2009 (15). 






Figure 2-2. Current smokeless tobacco use (%) among boys, 2007–2010 
 
Sources: Global Youth Tobacco Survey, 2007–2010 (25); National Youth Tobacco Survey, United States, 2009 (16); Youth Smoking 
Survey, Canada, 2008–2009 (15). 
 




Figure 2-3. Current smokeless tobacco use (%) among girls, 2007–2010 
 
Sources: Global Youth Tobacco Survey, 2007–2010 (25); National Youth Tobacco Survey, United States, 2009 (16); Youth Smoking 
Survey, Canada, 2008–2009 (15). 






Smokeless Tobacco Use Among Adults 
Table 2-4 provides nationally representative estimates of ST use for 64 countries and subnational 
estimates for 7 countries, for various age groups and in most cases by gender. Countries are grouped 
by WHO region, and surveys span the years 2002 through 2010. Countries in the South-East Asia 
Region generally appear to have higher rates than those in other regions. Of the 64 countries with 
national estimates, 20 were in the African Region, 5 in the Eastern Mediterranean Region, 16 in the 
European Region, 8 in the Americas Region, 8 in the South-East Asia Region, and 7 in the Western 
Pacific Region.  
Subnational estimates were reported for 4 countries in the African Region and 1 each in the Americas, 
South-East Asia, and Western Pacific Regions. In the 49 countries included in Table 2-4 that had a total 
estimate, current use of ST among adults ranged from a high of 29.6% in Myanmar to 0.0% in Uruguay 
(Figure 2-4). Among men, prevalence ranged from 51.4% in Myanmar to 0.0% in Barbados and 
Uruguay (Figure 2-5), whereas among women the prevalence ranged from 28.3% in Mauritania to 
0.0% in six countries (Armenia, China, Moldova, Switzerland, Ukraine, and Uruguay) (Figure 2-6).  
Overall prevalence among adults was high—10.0% or greater—in 11 countries (Bangladesh, Bhutan, 
India, Micronesia, Myanmar, Nepal, Norway, Sri Lanka, Sweden, Yemen, and Uzbekistan). Six of these 
were located in the South-East Asia Region (only 7 countries in that region had reports on overall 
prevalence). Prevalence exceeded 10.0% among men in 15 countries and among women in 7 countries. 
A review of the prevalence of ST use among adults, by WHO region (Table 2-4), indicates that in the 
African Region the rate was highest in Benin (9.2%) and lowest in Gambia (1.1%). In the Eastern 
Mediterranean Region, it was highest in Yemen (10.7%) and lowest in Libya (1.2%). In the European 
Region, the highest prevalence was in Sweden (17.0%) and the lowest in Latvia and Switzerland (both 
0.1%). In the Americas Region, the highest prevalence of use among adults was in the United States 
(3.2%) and the lowest in Uruguay (0.0%), in contrast to findings for youth, where prevalence was lowest 
in Canada. In the South-East Asia Region, prevalence was highest in Myanmar (29.6%) and lowest in 
Thailand (3.9%). In the Western Pacific Region, Micronesia had the highest prevalence (11.4%) and 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2-4. Current smokeless tobacco use (%) among men and women, 2002–2012 
 
Note: Daily use of smokeless tobacco was reported in Iceland. 
Sources: Global Adult Tobacco Survey, 2008–2010 (23); Demographic and Health Surveys, 2005–2010 (24); WHO STEPS, 2002–2010, 
from: WHO Report on the Global Tobacco Epidemic, 2011 (6); National Drug Strategy Household Survey, Australia, 2004 (20); 
Canadian Tobacco Use Monitoring Survey, 2010 (21); National Survey on Drug Use and Health, United States, 2012 (22); Individual 
country surveys from: WHO Report on the Global Tobacco Epidemic, 2011 (6). 






Figure 2-5. Current smokeless tobacco use (%) among men, 2002–2012 
 
Note: Daily use of smokeless tobacco was reported in Iceland and Saudi Arabia, and ever use of smokeless tobacco was 
reported in South Africa. 
Sources: Global Adult Tobacco Survey, 2008–2010 (23); Demographic and Health Surveys, 2005–2010 (24); WHO STEPS, 2002–2010, 
from: WHO Report on the Global Tobacco Epidemic, 2011 (6); National Drug Strategy Household Survey, Australia, 2004 (20); 
Canadian Tobacco Use Monitoring Survey, 2010 (21); National Survey on Drug Use and Health, United States, 2012 (22); Individual 
country surveys from: WHO Report on the Global Tobacco Epidemic, 2011 (6). 
 




Figure 2-6. Current smokeless tobacco use (%) among women, 2002–2012 
 
Note: Ever use of smokeless tobacco was reported in South Africa, and daily use of smokeless tobacco was reported in 
Saudi Arabia. 
Sources: Global Adult Tobacco Survey, 2008–2010 (23); Demographic and Health Surveys, 2005–2010 (24); WHO STEPS, 2002–2010, 
from: WHO Report on the Global Tobacco Epidemic, 2011 (6); National Drug Strategy Household Survey, Australia, 2004 (20); 
Canadian Tobacco Use Monitoring Survey, 2010 (21); National Survey on Drug Use and Health, United States, 2012 (22); Individual 
country surveys from: WHO Report on the Global Tobacco Epidemic, 2011 (6). 
  






Number of Adult Smokeless Tobacco Users 
To translate prevalence rates into an estimate of the number of ST users among adults, the adult 
prevalence rate was multiplied by the total adult population in the age group on which the survey 
was conducted. Although the prevalence of ST use (either national or subnational) was available 
for 71 countries across all WHO regions, South Africa was excluded from the calculations because 
only ever users of ST were available; thus, prevalence rates for 70 countries were used. Estimated 
prevalence rates for males and for females were added together to get an overall estimate. The world’s 
total adult population was derived from the United Nations’ World Population Prospects, 2010 
revision.26 In 2010, these 70 countries represented about 70% of the world’s adult population, or 
more than 3.5 billion people.  
These calculations indicate that these 70 countries contain more than 300 million ST users 
(302.4 million, specifically) (Figure 2-7), with the number of users varying across countries. The 
largest number of ST users, more than 220 million, was in India. Other countries where the number 
of ST users exceeded 10 million were Bangladesh (28 million) and Myanmar (11.1 million). It is 
important to note that these three countries are in the South-East Asia Region. The number of ST users 
was less than 5 million in each country except the United States, which has 8.2 million ST users. By 
WHO region, the number of ST users varied greatly (Africa, 8.1 million; Eastern Mediterranean, 
3.1 million; Europe, 5.3 million; the Americas, 10.1 million; South-East Asia, 268.6 million; and the 
Western Pacific, 7.2 million) (Figure 2-7). According to these calculations, the South-East Asia Region 
alone accounts for almost 89% of the total users of ST in these 70 countries (Figure 2-7).27  
 




Figure 2-7. Number (in millions) and proportion (%) of smokeless tobacco users among adults in 
70 countries, by World Health Organization region 
  
*Because only ever use of smokeless tobacco was reported for South Africa, it was excluded from the calculations. 
†Daily use of smokeless tobacco was reported in Iceland and Saudi Arabia. 
Note: Percentages do not equal 100% because of rounding. 
Sources: Global Adult Tobacco Survey, 2008–2010 (23); Demographic and Health Surveys, 2005–2010 (24); WHO STEPS, 2002–2010, 
from: WHO Report on the Global Tobacco Epidemic, 2011 (6); National Drug Strategy Household Survey, Australia, 2004 (20); 
Canadian Tobacco Use Monitoring Survey, 2010 (21); National Survey on Drug Use and Health, United States, 2011 (22); Individual 
country surveys from: WHO Report on the Global Tobacco Epidemic, 2011 (6). 
  






Gender Differences in Smokeless Tobacco Use Across Countries 
Gender Differences Among Youth 
In several countries with available national data, the rate of ST use was more than 10.0% either among 
boys or girls (Table 2-2). Among boys, rates higher than 10.0% were found in: Botswana (11.3%), 
Congo (18.3%), Lesotho (14.7%), and Namibia (15.6%) in the African Region; Djibouti (15.2%) in 
the Eastern Mediterranean Region; Barbados (11.5%), Dominica (10.2%), and Grenada (10.1%) in 
the Americas Region; Bhutan (14.1%), India (11.1%), and Myanmar (10.3%) in the South-East Asia 
Region; and Cook Island (10.5%) in the Western Pacific Region. Among girls, the prevalence of ST 
exceeded 10.0% only in the African Region: Botswana (11.4%), Congo (14.1%), Lesotho (13.6%), and 
Namibia (15.8%). 
In 36 (63%) of the 57 countries that measured use nationally among youth, at least 5.0% of boys aged 
13−15 years were reported to be either daily or occasional users; use among girls of the same ages 
equaled or exceeded 5% in 23 (40%) of the 57 countries (Table 2-2). In general, prevalence among boys 
was higher in countries in the South-East Asia and African Regions than in other regions. In all 
11 countries in the African Region, the prevalence of use by gender was 5.0% or greater except for girls 
in Côte d’Ivoire (4.9%) and Togo (4.8%). In the South-East Asia Region, 5.0% or more of boys in 
7 countries were reported to be users, but among girls the prevalence reached 5.0% in only 2 countries 
(Bhutan and India). The sex ratio (boys to girls) of ST use (Figure 2-8) among youth in the countries 
with available national data ranged from 0.9 to 4.3; girls’ use of ST approximately equaled or exceeded 
that of boys in 10 countries (Botswana, Jamaica, Libya, Macau, Namibia, Peru, Seychelles, Trinidad and 
Tobago, Uganda, and Yemen). 
Subnational estimates showed a similar pattern (Table 2-3). Of 46 locations in 18 countries, the 
prevalence was 5.0% or greater among boys in 40 locations (87%) and among girls in 29 locations 
(63%). In the African Region, prevalence was 5.0% or higher among boys in every location except 
Dar es Salaam, Tanzania (4.6%). Prevalence among girls fell short of this threshold in the Yaounde 
section of Cameroon (4.4%), where data on ST use prevalence were available for the first time, and in 
Dar es Salaam (4.3%), and Bulawayo (3.5%) in Zimbabwe. In the Eastern Mediterranean Region, 
prevalence reached 5.0% in every location for boys and in most locations for girls (the two exceptions 
were both in Pakistan: 3.1% in Lahore, and 2.6% in Peshawar). 
 




Figure 2-8. Sex ratio (boys to girls) of smokeless tobacco use among youth, 2007–2010 
 
Sources: Global Youth Tobacco Survey, 2007–2010 (14); National Youth Tobacco Survey, United States, 2009 (16); Youth Smoking 
Survey, Canada, 2008–2009 (15). 
  






Gender Differences Among Adults 
High prevalence rates among adults, as among youth, were found more often for males than females. 
For men, the available data reveal that ST use prevalence was above 10.0% in the following countries: 
Algeria (10.4%), Benin (12.7%), and Madagascar (22.6%), in the African Region; Yemen (15.1%) in 
the Eastern Mediterranean Region; Norway (17.0%), Sweden (26.0%), and Uzbekistan (22.5%) in the 
European Region; Bangladesh (26.4%), Bhutan (21.1%), India (32.9%), Myanmar (51.4%), Nepal 
(31.2%), and Sri Lanka (24.9%) in the South-East Asia Region; and Micronesia (22.4%) in the Western 
Pacific Region. Among women, prevalence exceeded 10.0% in 8 countries: Madagascar (19.6%), 
Mauritania (28.3%), and South Africa (10.9%) in the African Region; Bangladesh (27.9%), Bhutan 
(17.3%), India (18.4%), and Myanmar (16.1%) in the South-East Asia Region; and Cambodia (12.7%) 
in the Western Pacific Region. The estimate for men reached 5.0% in only 22 of the 70 countries with 
available national or subnational data; the estimate for women reached 5.0% in only 16 of the 
67 countries with available data. The estimate was 1.0% or below for men in 22 countries (32%), and for 
women in 31 countries (47%).  
The sex ratio (male to female) of ST use among adults (either national or subnational) ranges between  
0 and 56.3 (Figure 2-9). In most of the countries with data available for both women and men, men 
were more likely to be current users of smokeless tobacco. However, ST use among females equals or 
exceeds that of males in 18 countries, and in 13 countries, women had an appreciably higher rate 
(prevalence for men shown first): Barbados (0.0%, 0.6%), Cape Verde (3.5%, 5.8%), Gambia (0.8%, 
1.4%), Lesotho (1.3%, 9.1%), Malawi (1.9%, 5.0%), Mauritania (5.7%, 28.3%), Sierra Leone (1.3%, 
4.7%), South Africa (2.4%, 10.9%), and Zambia (0.2%, 1.2%) in the African Region; Thailand (1.3%, 
6.3%) in the South-East Asia Region; and Cambodia (0.7%, 12.7%), Malaysia (0.5%, 3.1%), and 
Vietnam (0.3%, 2.3%) in the Western Pacific Region. In three countries in the African Region, one 
country in the Americas Region, and one country in the South-East Asia Region, differences were 
quite modest, but women (shown second) had a slightly higher rate: Bangladesh (26.4%, 27.9%), 
Guinea (1.4%, 1.5%), Liberia (2.3%, 2.4%), Mexico (0.3%, 0.3%), and Namibia (1.8%, 2.3%). 
Prevalence and Other Characteristics of Use 
Examining several characteristics associated with the use of ST products could be informative in 
understanding public health impact, developing programs, and establishing policies. These 
characteristics include type of ST product used; pattern of use, including dual product use; age of 
initiation; and cessation rates. 
  
 




Figure 2-9. Sex ratio (male to female) of smokeless tobacco use among adults, 2002–2011 
 
Note: Ever use of smokeless tobacco was reported in South Africa, and daily use of smokeless tobacco was reported in 
Saudi Arabia. 
Sources: Global Adult Tobacco Survey, 2008–2010 (23); Demographic and Health Surveys, 2005–2010 (24); WHO STEPS, 2002–2010, 
from: WHO Report on the Global Tobacco Epidemic, 2011 (6); National Drug Strategy Household Survey, Australia, 2004 (20); 
Canadian Tobacco Use Monitoring Survey, 2010 (21); National Survey on Drug Use and Health, United States, 2012 (22); Individual 
country surveys from: WHO Report on the Global Tobacco Epidemic, 2011 (6). 
  






Prevalence of Use, by Type of Smokeless Tobacco Product  
Understanding the use of various ST products is essential for characterizing the level of ST use 
worldwide. A number of manufactured and locally produced ST products are used in India and 
Bangladesh.3,4 In Bangladesh, betel quid with tobacco is chewed by more than 24% of adults (23.5% of 
men; 25.2% of women). Other products used in Bangladesh include gul (5.3% of adults) and khoini 
(1.5% of adults).4 In India, only 6.2% of adults chew betel quid with tobacco (7.5% of men, 5.0% of 
women); 11.6% of adults use khaini, 8.2% use gutka, and 4.7% use tobacco products that are applied to 
teeth and gums, such as gul, mishri, or gudahku. Men and adults from rural areas use these products at a 
higher rate than women and urban residents.3 
Daily Versus Occasional Use 
In countries with high use of ST (Bangladesh, India, and Myanmar), more than 65% of current users 
(both men and women) were daily users.3–5 In Bangladesh, prevalence of daily users among the 
general population was 23.7% (20.7% among men and 26.6% among women). In India, it was 
21.4% (27.4% among men and 14.9% among women), and in Myanmar, it was 22% (37.7% among 
men and 12.2% among women). The prevalence of occasional users among the general population was 
3.5% in Bangladesh (5.6% among men and 1.3% among women), 4.5% in India (5.4% among men and 
3.5% among women), and 7.6% in Myanmar (13.7% among men and 3.9% among women). In both 
Bangladesh and India3,4 2.3% of the population were former (daily or occasional) users of ST 
(Bangladesh: 3.1% among men and 1.5% among women; India: 2.6% among men and 1.8% among 
women). In Myanmar,5 the former daily ST use prevalence was 1.7% (3.9% among men and 0.3% 
among women). 
Dual Product Use 
Dual product use refers to the use of both smoked tobacco and ST products by the same person.28,29 
(These figures do not include use of more than one ST product.) Dual product use by adults was high in 
India (overall, 5.3%; among men, 9.3%; among women, 1.1%) and Bangladesh (overall, 6.8%; among 
men, 13.0%; among women, 0.7%).3,4 In the United States, seven states that had the highest prevalence 
of cigarette smoking also had the highest prevalence of ST use: Alabama, Alaska, Arkansas, Kentucky, 
Mississippi, Oklahoma, and West Virginia. At least one of every nine men in these states who smoked 
cigarettes also used ST (range: 11.8% in Kentucky to 20.8% in Arkansas).30 
Age at Initiation and Quit Ratio 
The available data indicate that the mean age at initiation of ST use among adults aged 20–34 years is 
25 years among Bangladeshi adults and 17.9 years among Indian adults. Bangladeshi men initiate use 
2 years earlier than women; in India, men begin ST use about a year after women (18.2 years old 
for men and 17.1 years old for women). These data were obtained by reanalyzing data in the 
WHO Report on the Global Tobacco Epidemic, 20116 specifically to look at the ST indicator. The 
WHO data can also be used to calculate the quit ratio—the number of former ST users divided by the 
number of people who have ever used ST daily. Quit ratios among adults (aged 15 years and older) 
were low in both Bangladesh and India, although slightly higher in Bangladesh than in India (5.5% vs. 
4.8%, respectively).3,4,6  
 




Prevalence Data for Adults and Sociodemographic Variables in 
Four Countries 
This section describes ST use prevalence in four countries in terms of demographic variables such 
as gender, age, location (rural/urban), and socioeconomic status, where data were available. These 
data demonstrate some similar patterns of use across countries and differences both within and across 
countries. Information in this section is derived from GATS data for Bangladesh and India because 
of their availability and because these two countries are home to more ST users than any other 
countries in the world. Additional information for the United States and Myanmar comes from the 
2009 U.S. Behavioral Risk Factor Surveillance System (BRFSS),30 the 2012 National Survey on Drug 
Use and Health,22 and from WHO STEPS conducted in Myanmar in 2009.5 
Bangladesh 
Current prevalence of any ST use among adults in Bangladesh was 27.2% and was similar for men and 
women (26.4% and 27.9%, respectively).4 Use increased steadily with age, rising from 6.6% in the 
15−24 age group to 56.4% among those aged 65 and older. Prevalence was higher in rural areas (28.8%) 
than in urban areas (22.5%), and was more than four times as high among adults with no formal 
education (42.3%) as among adults with a secondary school education or more (10.2%). A similar 
pattern was observed with respect to the wealth index, a proxy for socioeconomic status: Adults with the 
lowest wealth index had the highest prevalence of use (36.1%), and adults with the highest wealth index 
had the lowest prevalence (17.3%).  
India 
Data from India3 reveal a 25.9% prevalence of current ST use among adults, with use among men 
at 32.9%, compared with 18.4% among women. Although the absolute levels were different, the 
patterns in India were similar to those observed in Bangladesh. In India, prevalence was also 
lowest in the 15−24 age group (16.2%) and highest among those aged 65 years and older (33.7%). 
As in Bangladesh, prevalence in India was higher among adults in rural areas than in urban areas 
(29.3% vs. 17.7%), and more than twice as high among adults with no formal education as among adults 
with an education of secondary school or above (33.5% vs. 14.8%). Prevalence was 33.1% among 
retired and unemployed adults, 32.5% among employed adults, and 6.3% among students. By region of 
the country, prevalence was highest in the east (38.0%) and lowest in the north (7.0%). Among states in 
India, prevalence ranged from 49.0% in Bihar to only 5.0% in Goa. 
Myanmar 
Data from Myanmar5 indicate that the prevalence of current ST use for men and women combined was 
similar across age groups between ages 25 and 65 years (28.4%–31.5%), whereas young adults (aged 
15–24 years) had a somewhat lower prevalence of ST use (21.5%). The highest consumption was 
observed among men in the 25–34 age group (54.3%) and women in the 45–54 age group (21.1%).5 
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United States 
In 2012, prevalence of past-month ST use in the United States was 3.6%, and it was higher among 
young adults (5.5% among those aged 18–25 years) than among youth (2.1% of those aged 12–17 years) 
and older adults (3.3% of those aged 26 and older).22 Men also had a significantly higher prevalence of 
ST use (7.1%) than women (0.4%). In terms of education, the past-month prevalence of ST use was 
4.0% among adults (age 18 and older) with less than a high school education: 4.4% among high school 
graduates, 3.9% among adults with some college education, and 2.3% among college graduates.  
The 2009 BRFSS30 was the first surveillance system to present U.S. data on current ST use by state. 
Prevalence rates varied significantly from state to state; prevalence was highest in Wyoming (9.1%), 
West Virginia (8.5%), and Mississippi (7.5%), and lowest in California (1.3%), the District of 
Columbia (1.5%), Massachusetts (1.5%), and Rhode Island (1.5%).  
Gaps and Limitations of the Current Evidence Base 
The data used in this report are based on self-reports and thus may be subject to misclassification of ST 
use. Secondly, the surveys from which the prevalence estimates of ST use are available vary in terms of 
their methodologies, timeframes, and approaches (for example, in design, purpose, year of survey, 
questions used, and indicators measured). Therefore, comparisons among estimates should be made 
cautiously. Thirdly, due to the lack of available data and differences in methodology (e.g., definitions or 
questions used for reporting ST use), it was not possible to report on ST use in some countries, 
particularly among adults; these deficiencies might have some influence on reporting patterns and 
generalization across countries. Finally, due to the differences in coverage (age groups, countries, 
representativeness), the reported numbers of ST users are approximations and should be considered as 
interim results until more accurately weighted calculations become available. 
Summary and Conclusions 
This chapter has presented data on overall prevalence of ST use in 114 of the 194 WHO member states 
(almost 58% of countries in the world), at national and subnational levels, for youth and adults. For 
many of these countries, data on ST use were reported for the first time.  
From these data, it is clear that in the first decade of the 21st century, ST use occurs among youth and 
adults in almost every country of the world, but also that ST use is highly prevalent in some parts of the 
world and, in some cases, more prevalent than cigarette smoking. The GYTS and GATS, together with 
other surveys, document in detail the prevalence of ST use and reinforce the need for sustained 
monitoring of all forms of tobacco use.  
 




From the data reported in this chapter, a few general patterns of ST use prevalence can be readily seen:  
 Use rates appear to vary widely among youth and adults.  
 Among youth, boys generally report more use than girls.  
 Among adults, men generally have a higher prevalence than women, except in Bangladesh and 
Thailand in the South-East Asia Region; in a few African countries (such as South Africa and 
Sierra Leone); in Cambodia, Malaysia, and Vietnam in the Western Pacific Region; and in 
Barbados in the Americas Region.  
 Among youth, there is evidence of high prevalence (≥10%) either overall or by gender in the 
South-East Asia Region (boys in Bhutan, India, and Myanmar), the Eastern Mediterranean 
Region (Djibouti), the Americas Region (boys in Barbados, Dominica, and Grenada), the 
African Region (Botswana, Congo, Lesotho, and Namibia), and the Western Pacific Region 
(Cook Island boys).  
 Among adults, there is a high prevalence (≥10%) in the South-East Asia Region (Bangladesh, 
Bhutan, India, Myanmar, Nepal, and Sri Lanka), in the European Region (Norway, Sweden, 
Uzbekistan), the Eastern Mediterranean Region (Yemen), the African Region (in Madagascar 
overall; men in Algeria and Benin; and among women in Mauritania and South Africa), and 
the Western Pacific Region (in Micronesia overall and among men, and in Cambodia 
among women). 
The significant impact of ST use, particularly in some countries, is illustrated by data showing that 
more than 300 million adults in 70 countries across all WHO regions use smokeless tobacco. The 
South-East Asia Region has the largest share (89%) of ST users. GATS data from 13 low- and middle-
income countries included in this report account for more than 250 million users of smokeless tobacco.27 
In a few countries, most notably in Bangladesh and India, ST use is very high and surpasses tobacco 
smoking.  
Longitudinal data and continuous monitoring of tobacco use, particularly ST use, are needed to refine 
understanding of the extent of the problem. More extensive data on patterns of use, ages and groups at 
highest risk, and cessation success are important to informing tobacco control actions that would 
effectively reduce morbidity and mortality attributable to tobacco31 and prevent initiation of use by 
youth and young adults. 
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Global Diversity of Smokeless Tobacco Products 
Product Overview 
Unlike smoked tobacco, which is burnt or heated and then inhaled in products such as cigarettes (both 
manufactured and roll-your-own) and cigars, or via hookahs, smokeless tobacco (ST) is predominantly 
used orally (chewed, sucked, dipped, held in the mouth, etc.) or nasally, which results in absorption of 
nicotine and other chemicals across mucus membranes.1 Smokeless tobacco products are used 
worldwide2–4 in forms that vary greatly in appearance and toxicant emissions and in their composition 
of tobacco and non-tobacco constituents (Figure 3-1).2,5,6  
Worldwide, ST products range in complexity from simple cured tobacco to elaborate products with 
numerous chemical ingredients and, in some cases, non-tobacco plant material that may affect the 
attractiveness, addictiveness, and toxicity of the products2,5,6 (see chapters 9–14). For certain products, 
preparation, ingredient selection (including non-tobacco plant materials), and mode of use (oral, nasal, 
etc.) can vary based on geographic locality, ingredient availability, cultural/societal norms, and personal 
preferences1,2,5,6 (chapters 9–14).  
Production and Preparation 
In terms of production and preparation, ST can be broadly divided into premade and custom-made 
products (Table 3-1). Premade ST products, which are made for sale and generally consumed as 
purchased (i.e., “ready-to-use”), can be subdivided into: (1) commercial products (i.e., moist snuff, snus, 
khaini) that are made in traditional manufacturing settings such as factories or production facilities; and 
(2) cottage products (toombak, nasway, mainpuri, mawa) that are made in non-traditional production 
environments (market stalls, shops, houses, etc.) and often sold in non-commercial packaging (paper or 
plastic bags; wrapped in paper).2,5,6 
Premade manufactured ST products are available in a wide variety of physical forms, including, but 
not limited to, twisted tobacco leaves, loose tobacco, ground tobacco, dry tobacco (dry snuff), tars 
(chimó), pastes (kiwam), dentifrices (creamy snuff, toothpowder), tobacco-containing chewing gums, 
and mixtures of tobacco and other materials (zarda, gutka).2,5–7 Manufactured ST products, such as 
moist snuff and snus, are available as loose tobacco or tobacco sealed in porous teabag-like sachets 
(Figure 3-1), which are easily inserted and removed from the mouth. Release of nicotine and 
presumably other compounds is greater from loose tobacco than from sachets.8  
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Figure 3-1. Examples of global smokeless tobacco products 
 
Note: Products by country or region are: 
South-East Asia: kiwam, betel quid (paan), zarda, gutka 
United States: moist snuff, dry snuff, moist snuff (caffeinated), plug, twist tobaccos, dissolvables (Orbs, Strips, Sticks, 
tobacco-coated toothpicks) 




India: red toothpowder, mawa 
Saudi Arabia: shammah 
Brazil: rapé. 
Sources: All images except for betel quid (paan) courtesy of Clifford Watson, Centers for Disease Control and Prevention. Image 
of betel quid (paan) courtesy of World Health Organization South-East Asia Regional Office and Dhirendra N. Sinha. 






Table 3-1. Characteristics and product examples of premade and custom-made smokeless 
tobacco products 
Premade manufactured Premade cottage industry Custom-made vendor/individual 
 Made in advance for sale 
 Made in a manufacturing 
environment 
 Sealed in labeled commercial 
packaging 
 Made in advance for sale 
 Usually handmade in 
non-traditional environments 
 Often sold in non-commercial 
packaging 
 Made by a vendor or individual 
according to user preferences, 
generally for immediate 
consumption 
 Involves mixing two or more 
components (including premade 
products) together by hand to 
form a final product 
Product examples: 
 Chewing tobacco (plug/twist/
loose leaf) 
 Creamy snuff 
 Dissolvables 




 Moist snuff 
 Kiwam 
 Rapé 





















 Tobacco leaf 
 Tombol 
 Toombak 
Some premade ingredients are used 
to make custom-made products: 
twist, zarda, toombak, 
gudahku/gudahka, and kiwam. 
 
Increasingly, new varieties of manufactured smokeless products appear in a discrete, spit-less form that 
can be used where smoking is prohibited or socially inappropriate.9 Since 2001, several tobacco 
companies, including those that have traditionally marketed cigarettes, have been introducing 
dissolvable ST products, which are made from finely milled tobacco pressed into tablets, rods and sticks, 
or flat strips that fully dissolve in the mouth10–12 (Figure 3-2). Novel products introduced after about 
2010 include tobacco-coated toothpicks, which are sucked on to release nicotine,13 and an “energy-
enhanced” ST product called Revved Up, made by Southern Smokeless, which is essentially moist snuff 
augmented with energy drink constituents.14 A nicotine disk product called Verve, introduced by Altria 
in Virginia in 2012, is a chewable disc made of cellulose fibers and a polymer and impregnated with 
flavor and nicotine. The disk does not dissolve, but is chewed for about 15 minutes and then discarded.15 
Premade cottage products can be in the form of pressed cakes (mawa), pellets (nasway), or pulverized 
tobacco (toombak, shammah), among others. Some premade products are used as the tobacco ingredient 
in custom-made products; for example, manufactured products (zarda and kiwam) or cottage products 
(mainpuri and toombak) can be used as the tobacco ingredient in betel quid and tombol. The “tobacco 
ingredient” used to make a custom-made product (tombol, betel quid) may itself be a mixture of tobacco 
with other ingredients such as areca nut, alkaline agents, spices, and silver flakes.2,5 
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Figure 3-2. Dissolvable products and their packaging 
 
Source: Images courtesy of Clifford Watson, Centers for Disease Control and Prevention. 
  






Figure 3-3. Ingredients added to some smokeless products that may influence their addictiveness, 
carcinogenicity, or toxicity 
 
Abbreviation: IARC = International Agency for Research in Cancer. 
Notes: Samples taken from the Federal University of Paraiba (Brazil). Products may also contain chemical additives (sweeteners, 
moisteners, flavor chemicals, binders, whiteners, preservatives), plant extracts, essential oils, spices, and other plant materials.  
Source: Images for tobacco, areca nut, tonka bean, and Peruvian cocoa courtesy of Clifford Watson, Centers for Disease Control 
and Prevention.  
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Custom-made products, handmade by the user, a relative, or a vendor according to user preferences, are 
characteristic of countries in South Asia, Africa, the Middle East, North America (Alaska), and South 
America (Brazil) (see chapters 9–14). Custom-made products such as tombol and betel quid (also known 
as paan) are made by combining cured tobacco or a premade tobacco product (e.g., zarda) with one or 
more ingredients, such as ashes, alkaline agents, areca nut, spices, catechu, or other plant materials16 
(Figure 3-3).  
Product Packaging 
Approaches to the packaging of ST products are nearly as diverse as their formulations. Many 
manufactured ST products are packaged in tins, cylinders, or containers made of cardboard, plastic, or 
metal (e.g., snus, moist snuff, dry snuff); sealable pouches (zarda, chewing tobacco); tear packs (snuff, 
gutka, khaini); and toothpaste-like tubes (creamy snuff).2 Some novel dissolvable tobacco products are 
packaged in paper packs (tobacco rods and sticks) or foil press-out packs (tablets). Manufactured 
packaging serves not only to protect product integrity but also to display recognizable logos or images 
that can promote brand image and use. Alternatively, the hand-prepared cottage products (mawa, 
mainpuri, toombak) are often portioned into non-conventional packaging (unlabeled paper or plastic 
bags or cellophane paper wrapping). Custom-made products may not be stored in any packaging as they 
are frequently prepared at the time of use by the user, a family member (as in the case of iqmik),16 or a 
vendor (e.g., betel quid seller). Thus, cottage and custom-made products are likely to show substantial 
variation in product size, packaging, and composition as compared to manufactured products, which 
tend to be more consistent because of standardized production methods and quality control measures.2,17  
Smokeless Tobacco Product Ingredients  
Tobacco 
Tobacco Types 
Worldwide, approximately 70 species of tobacco (Nicotiana) occur in nature, although few are regularly 
used for smoked or smokeless tobacco products.2,18 The identity of different tobacco species in products 
can be determined by a chemical analysis of the levels of nicotine and other tobacco alkaloids19 and 
confirmed using infrared analysis.20 Most commercial tobacco products worldwide contain the species 
Nicotiana tabacum (cultivated tobacco), but N. rustica is also frequently grown and used in regions of 
South America, Africa, and Asia.2,18 In India, smoking tobacco tends to be made with N. tabacum, but 
most ST contains N. rustica, which has higher concentrations of nicotine and other alkaloids than 
N. tabacum.17,21,22 Some products, such as khaini and kiwam from South Asia, may contain both 
N. rustica and N. tabacum.2 N. rustica is also contained in some forms of naswar, Bangladeshi tobacco 
leaf, Indian chewing tobacco, maras, zarda, and toombak.2,17,20,23 Smokeless tobacco products such as 
toombak may contain N. glauca (tree tobacco),2,24 which has high levels of the alkaloid anabasine; 
ingestion of this form of tobacco has been linked to accidental poisoning and fatality in a few cases.24,25 
(Figure 3-3 includes images of different Nicotiana species.) 






Changes in Chemical Composition of Tobacco During Growth 
As tobacco grows, it absorbs metals, metalloids,26 and nitrate from the soil27,28 and synthesizes alkaloids, 
including nicotine and minor alkaloids (e.g., nornicotine, anabasine, and anatabine) in various 
concentrations, depending on species and variety.19 Alkaloids are key chemical precursors in the 
formation of tobacco-specific nitrosamines (TSNAs),29–31 some of which are potent carcinogens.2,32  
Tobacco nitrate content and the presence of certain microorganisms on tobacco leaves contribute to the 
formation of TSNAs from alkaloids.33 During cultivation, microorganisms (yeast, mold, fungi, and 
bacteria) and agricultural chemicals can be deposited on tobacco plants. On growing tobacco, bacteria 
are present at approximately 105 to 106 organisms per gram of leaf material. At harvest, tobacco is not 
generally washed, thus leaves with deposited microorganisms and agricultural chemicals will be 
processed, and the contaminants will be present in the final product. During the subsequent curing step, 
the tobacco leaves dry, and bacteria, which proliferate to levels 10 to 20 times higher than on the 
growing leaf,34 begin converting the nitrate (NO3-) present in the plant tissue to nitrite (NO2-), a process 
called nitrate reduction. Once nitrite is produced, a chemical process of nitrosation occurs in which 
nitrite reacts with tobacco alkaloids to generate TSNAs.35 (Figure 3-7 illustrates this process.) Amine 
compounds other than tobacco alkaloids can also react with nitrite to form nonvolatile N-nitrosamines, 
volatile nitrosamines, and N-nitrosamino acids.5,36 The International Agency for Research in Cancer 
(IARC) has classified various nitroso compounds as IARC Group 1 (carcinogenic to humans), 
2A (probably carcinogenic to humans), or 2B (possible carcinogenic) agents.37 The IARC has also 
classified nitrate and nitrite as Group 2A agents38 because of their potential to form nitroso compounds 
in the human body after ingestion. There are indications that additional amounts of nitrosamines can be 
formed in the mouth during ST use.39  
Curing 
Prior to use in products, tobacco is dried using sun, air, flue, or fire curing (Figure 3-3). Any given ST 
product can be produced using various tobacco-curing methods, depending on the manufacturer. The 
simplest method of tobacco processing is sun curing, the process of drying tobacco leaves in the sun, 
which is often used in making toombak, gutka, maras, khaini, and nass/naswar. Some tobaccos used in 
betel quid are also sun-cured.2 Air curing, which involves placing tobacco stalks on wooden staves that 
are hung in a well-ventilated barn, is usually used in loose leaf and twist chewing tobaccos and moist 
snuff.2,40 Iqmik can contain air- or fire-cured tobacco.41 Flue curing involves hanging tobacco in an 
enclosed structure connected to an external heat source without exposing the tobacco directly to 
smoke33,40; this method is often used in making chewing tobacco. During fire curing, tobacco is hung in 
a large enclosed barn and exposed to smoke from hardwood fires that are continuously burning or 
smoldering, in a process directly analogous to producing smoked meat.42 Fire-cured tobacco is used in 
the production of plug chewing tobacco, moist and dry snuff, and iqmik.2,40,41 Fire curing not only 
causes chemical changes in the tobacco leaf, it also contaminates the tobacco with smoke-related 
chemicals. As a result, the levels of polycyclic aromatic hydrocarbons (PAHs), phenols, and volatile 
aldehydes tend to be higher in fire-cured tobacco than air-cured tobacco.21,22,41,43 
 
3. A Global View of Smokeless Tobacco Products 




Fermentation and Aging  
Fermentation and aging of tobacco are common in the production of tobacco used in cigars44 and 
smokeless tobacco (e.g., moist and dry snuff, toombak, taaba).2,33,45 During fermentation or aging, the 
tobacco takes on a more agreeable flavor.45 For manufactured products, fermentation can occur in a 
partially insulated tank,33 which, because of increased microbial activity, can reach high temperatures 
(up to 65°C).44 Fermentation of toombak, a cottage industry product, occurs in a closed container at 
30 to 45ºC for a few weeks, then the tobacco is aged for a year.2 
Tobacco fermentation involves chemical and biochemical changes (bacteria-mediated reactions).2,33,44 
During fermentation, a portion of nitrate in fire-cured tobacco is converted to nitrite, which then reacts 
with alkaloids to produce TSNAs.33,44 
Chemical markers indicative of bacterial and fungal growth have been identified in tobacco of various 
types and at various stages of production.46,47 In tobacco or tobacco products, a number of bacteria 
including Bacillus, Enterobacter, Staphylococcus, Corynebacterium, Clostridium, Serratia, and 
Escherichia species have been identified that are capable of converting nitrate to nitrite (nitrate 
reduction).33,44,48–52 Additionally, several genera of fungi, such as Cladosporium, Alternaria, Candida, 
Fusarium, Aspergillus, and Acremonium are capable of nitrate reduction.44,47,52,53 Throughout 
production, the combined capacity of product microorganisms to generate nitrite is a key determinant of 
the levels of TSNAs and other nitrosamines in the final product.37,54 During one fermentation study, 
nitrite levels generated by bacteria resulted in an almost threefold increase in TSNA levels.44 
Pasteurization, or heat-treating of tobacco, is a very effective means of eliminating microorganisms 
during ST production, and thus preventing the reduction of nitrate to nitrite.55 Indeed, Swedish snus, a 
pasteurized product, generally has lower nitrite and TSNA levels than nonpasteurized products, such as 
moist snuff and khaini.56,57 It has been shown that a further increase in nitrite and TSNA levels can be 
prevented by cleaning fermentation equipment before use and “seeding” the fermentation process with 
non-nitrate-reducing bacteria.33 Together, these observations provide additional support for the idea that 
the levels of some carcinogenic and toxic agents in tobacco products can be substantially reduced by 
changing tobacco processing methods. 
Following fermentation, tobacco may still contain substantial amounts of nitrate, nitrite, and bacteria 
(including endospore-forming bacteria such as Bacillus spp.) that are active across a wide temperature 
and pH range.33,44,58 Moreover, moist snuff products, including South African smokeless tobacco, 
contain nitrate, nitrite, and viable nitrite-producing bacteria (e.g., Bacillus spp.).49,56,58 Bacteria capable 
of initiating various infections (Pseudomonas spp. and Staphylococcus spp.) and periodontal abscesses 
(Atopobium spp. and Klebsiella oxytoca) have also been isolated from tobacco used to make cigarettes.48 
Research on black South African nasal snuff users has found an association between the use of nasal 
snuff and chronic bronchitis, which can be caused by Staphylococcus spp.49 Although conditions in 
ST products are favorable for the presence of bacteria, it is not known which strains of bacteria are most 
common in ST products.  






Products from India, such as zarda, mishri, gutka, creamy snuff, and toothpowder, have elevated nitrate 
levels but lower levels of nitrite. In contrast, Indian khaini contains higher levels of nitrite and TSNAs.57 
Accumulated nitrite may contribute not only to the formation of TSNAs but also to other nitroso 
compounds, such as N–nitrosamino acids and volatile N–nitrosamines, in some ST products.5 The high 
levels of nicotine and other alkaloids in N. rustica19,21 may contribute to extreme levels of TSNAs such 
as are found in the Sudanese product toombak.20,23 
Other Tobacco Processing Methods 
Tobacco is processed differently during the manufacture of some forms of ST products. For example, 
Swedish snus, a snuff-like product, is made from pasteurized and air-cured tobacco that is not 
fermented. Pasteurization reduces or eliminates bacteria, including those that convert nitrate to nitrite, a 
key precursor for TSNAs.55 Similar processing is used in most novel “spitless” U.S. products that are 
also called “snus” but are slightly different from the traditional Swedish snus. Because bacterial activity 
is very low in snus products, it is not surprising that snus contains much lower levels of nitrite and 
TSNAs than moist snuff made with fermented fire-cured tobacco that is not pasteurized,56 and levels of 
nitrite and TSNAs do not increase during long-term storage of snus as they do with moist snuff.33,59,60 
Also, because snus does not contain fire-cured tobacco, the levels of total PAHs and volatile aldehydes 
are lower than those found in moist snuff.56,61  
The Swedish snus industry voluntarily complies with the GothiaTek industry standard, which sets 
maximum levels for nitrite, TSNAs, NDMA (a volatile nitrosamine), benzo[a]pyrene (a representative 
carcinogenic PAH compound), five metals (cadmium, lead, arsenic, nickel, and chromium), and various 
agrichemicals.55 The StarCured process, which may lower the levels of some carcinogens, was used to 
produce the dissolvables Stonewall and Ariva, which were discontinued by Star Scientific at the 
beginning of 2013. Although snus contains nicotine and toxicants at some level, maintenance of 
toxicants below certain thresholds demonstrates that the tobacco industry can use manufacturing 
controls to reduce the levels of certain toxicants in ST products.  
Additives 
After curing, aging, and fermentation, further steps for manufacturing smokeless products include 
cutting the tobacco to the proper width, adding other substances, and adjusting moisture and pH levels.62 
Manufactured ST products, particularly Western-style forms (e.g., moist snuff, snus) are known to 
contain flavoring agents, spices, fruit juices, sweeteners, salt, humectants, and alkaline agents.5,63–67 
Flavorings used include cocoa, licorice, rum, spice powders, extracts, oleoresins, individual flavor 
compounds (menthol, vanillin, etc.), and more than 60 different essential oils (such as wintergreen, 
cinnamon, ginger).5,63 The most common flavor chemicals detected in 85 brands of ST, primarily moist 
snuff, were methyl salicylate, ethyl salicylate, benzaldehyde, citronellol, menthol, nerol, menthone, and 
caryopyllene.68 Among many mint and wintergreen moist snuff brands, Chen and colleagues found high 
levels of methyl salicylate (18.5–29.7 milligrams per gram [mg/g]), ethyl salicylate (0.17–5.78 mg/g), 
and menthol (undetectable–5.25 mg/g).69 Sweeteners added to ST include honey, molasses, saccharin, 
brown sugar, sugar, and xylitol. Humectants, which are added to maintain product moisture, include 
agents such as glycerol, glycerin, and propylene glycol.5,63,64 Dissolvable tobacco products (Figure 3-2) 
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include ingredients such as flavorings, sweeteners, humectants, and alkaline agents, as well as fillers, 
coatings, binders, colorings, and preservatives.65–67  
Cottage ST products made in the Middle East, Africa, and South-East Asia may contain ingredients such 
as edible oils, metallic silver, potassium nitrate, and soil (chapters 11–13).  
Alkaline modifiers used in manufactured ST products are predominantly chemicals including sodium 
bicarbonate, ammonium bicarbonate, various metallic carbonates (calcium, sodium, and ammonium), 
and slaked lime (calcium hydroxide) (Figure 3-3).5,63 Chemical alkaline agents (mostly slaked lime or 
sodium bicarbonate) are also used in the preparation of cottage products (e.g., toombak, nass, shammah) 
or custom-made ST (iqmik). In some rural or tribal areas, custom-made or cottage industry ST products 
are prepared with ashes from the burning of certain woods, plants, or fungi (for example, wood: willow, 
mamón, paricá; plants: Aloe vera, Amaranthus, grapevine; fungi: punk fungi [Phellinus igniarius]), 
which significantly increases product pH.2,70,71 Unlike rapé products that are mildly acidic (lower pH), 
the type of rapé used by the Kaxinawás Indians, who live in eastern Peru and in the States of Amazonas 
and Acre in Brazil, includes ashes from the paricá tree (Schizolobium amazonicum).72 Products that 
contain alkaline ashes, such as iqmik41 and nass,73 have extremely high pH levels (pH 11). The effects 
of pH on nicotine levels are discussed later in this chapter. 
Non-Tobacco Plant Material 
In several regions of the world, especially South Asia, the Middle East, and South America, tobacco is 
commonly combined with substantial amounts of non-tobacco plant material. In those regions, several 
premade ST products (gutka, mawa, mainpuri, and some zarda products) and custom-made products 
(betel quid, dohra, tombol) contain areca nut, the seeds of the Areca palm (Areca catechu) 
(Figure 3-3)2,6,17,20 (see chapters 11–13). Products in South Asia often contain appreciable amounts of 
spices (cardamom, clove, camphor, mint, saffron, pepper) or other plant materials such as betel leaf 
(Piper betle) and catechu (Acacia catechu).2,6,17 Alternatively, packets containing non-tobacco 
condiments, such as supari or pan masala (a mixture of spices, flavorings, and other ingredients) can be 
purchased separately and combined with tobacco prior to use. In South Asian and Mediterranean 
countries, custom-made ST products, such as betel quid, dohra, or tombol, are often handmade from 
tobacco or premade ST (kiwam, zarda, toombak) combined with other ingredients, such as alkaline 
agents, areca nut, spices, condiments, or other plant material (such as coconut), and rolled in a betel 
leaf.2,5,6,17 Some forms of tombol, such as those used in Yemen, contain khat (Catha edulis) (Ghazi 
Zaatari, personal communication, 2012), a plant that has psychoactive properties.74 In South America, 
rapé and other indigenous forms of nasal ST used in Brazil and Peru contain tobacco mixed with 
ingredients such as tonka bean (Dipteryx odorata), cinnamon powder, clove buds, camphor, sunflower, 
Peruvian cocoa, and possibly cassava (Figure 3-3)75,76 (André Oliveira da Silva, personal 
communication, 2012). 






Product Categorization Based on Constituents 
Although ST products range from simple to highly complex mixtures of tobacco and other 
ingredients, all known products can be grouped by key product constituents (see Figure 3-4) 
into four broad categories: 
 Category 1 products contain tobacco with little or no alkaline modifiers. 
 Category 2 products contain tobacco and substantial amounts of alkaline agents.  
 Category 3 products contain tobacco, one or more alkaline agents, and areca nut.  
 Category 4 products contain tobacco mixed with other chemical or plant ingredients that exhibit 
additional bioactivity (such as stimulants). 
(A similar scheme of categorizing ST products was first presented in Smokeless Tobacco and Some 
Tobacco-specific N-Nitrosamines, International Agency for Research on Cancer monograph 89.2,p.34)  
To extend this categorization, ST products can be grouped in categories based on ingredients listed on 
packaging, but further analysis using gas chromatography–mass spectrometry, infrared spectroscopy, 
and pH measurements can be used for confirmation or when product ingredient information is 
unavailable.20 
Category 1 products can have a wide range of total nicotine, depending on the tobacco used, but because 
they have a pH of 7 or less, they generally have lower free nicotine. Category 2 products can have a 
wide range of total nicotine, depending on the tobacco used, but have an alkalinity greater than pH 7 and 
thus higher free nicotine values. Category 3 products generally contain an appreciable amount of areca 
nut, which decreases the tobacco content, thus the amounts of total nicotine are generally lower. These 
products also contain areca-related compounds, such as arecoline, and other compounds that can 
contribute to the formation of areca-specific nitrosamines; the pH of this category varies based on this 
composition.6,20 Category 4 products contain nicotine as well as other compounds like stimulants, 
flavoring agents, or spices. Some of these additives are toxicants, or carcinogens—for example, 
coumarin (a liver toxicant), which is found in tonka bean, cinnamon, and other substances. Products in 
category 4 have also been found to contain camphor, a cardiac toxicant. Figure 3-4 shows key 
ingredients and chemical markers for the four categories as well as products in each category. This 
categorization can help illuminate the relationship between ST product ingredients and the resulting 
levels of addiction, toxicity, and carcinogenicity associated with their use.  
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Figure 3-4. Smokeless tobacco product categorization by key constituents 
 
Notes: Tombol (Category 4) shown on betel leaf prior to addition of noura (alkaline agent), fofal (areca nut), and tobacco. 
This figure groups products with similar constituents for further investigation and research and highlights constituents of concern. 
This categorization, which is based on product knowledge at the time of publishing, does not reflect the safety or the addictive 
properties of a product or product type. The composition of products of a given type can vary such that seemingly similar 
products may fit into different categories. Detailed product information is given in Appendix A. 
Sources: All images except tombol with khat courtesy of Clifford Watson, Centers for Disease Control and Prevention. Image of 
tombol with khat courtesy of Dr. Mazen Abood Bin Thabit, University of Aden. 
  






Toxic and Carcinogenic Agents in Smokeless Tobacco Products 
In general, tobacco, and thus ST products, contains roughly 4,000 chemical constituents,77 including 
nicotine and other toxicants and carcinogens, which are believed to play a crucial role in causing the 
negative health effects associated with ST use.78–80 The U.S. Food and Drug Administration has also 
established a list of 93 harmful and potentially harmful constituents for regulatory purposes in the 
United States.81 Based on epidemiologic evidence and animal carcinogenicity data, the IARC has 
classified ST as a Group I carcinogen: carcinogenic to humans.2 Moreover, the IARC has classified two 
TSNAs present in ST, namely N’-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK), as Group 1 carcinogens. A list of carcinogens present in ST products based on the 
2012 IARC list37 is shown in Table 3-2. 
Among the carcinogens in ST, TSNAs are considered the most potent because of their concentration and 
carcinogenicity.32,82,83 The two main carcinogenic compounds in this group, NNK and NNN, are 
believed to be involved in the induction of oral cancer in ST users.32 Other carcinogens in ST include  
N–nitrosamino acids, volatile N–nitrosamines, PAHs, volatile aldehydes, inorganic compounds, metals, 
and metalloids.5,36,84,85 In addition, areca nut, a constituent of products such as mawa, betel quid, tamol 
(fermented areca nut), and mainpuri, is also classified as an IARC Group 1 carcinogen.6 Some ST 
products contain plant materials (tonka bean, cinnamon) that have high levels of coumarin, which is 
moderately toxic to the liver and kidneys.86,87 
The following sections of this chapter discuss some of the most important groups of ST constituents in 
greater detail: their origin, factors affecting their formation, and their reported levels in ST products used 
globally. 
Nicotine and Free Nicotine 
Nicotine in tobacco products leads to addiction and persistent use of tobacco products, and thus 
continuous exposure to numerous toxic and carcinogenic agents, which results in devastating health 
consequences and premature deaths worldwide.88 Additionally, nicotine is a major precursor of 
carcinogenic NNK and NNN.2 Nicotine has also been associated with fetal toxicity and an increase in 
cardiovascular risk factors.88  
In an ST product, the entire amount of nicotine present is referred to as total nicotine, which includes 
both free (also called un-ionized or un-protonated) and bound (also called ionized and mono-proponated 
or di-proponated) forms of nicotine (Table 3-3). Free nicotine is of importance because it is the 
uncharged form that crosses cell membranes most readily. The amount of free nicotine in a product can 
be calculated using the Henderson–Hasselbalch equation.89 The fraction of nicotine present as free 
nicotine depends on the pH of the ST product: A higher pH results in a greater proportion of nicotine 
being present as free nicotine, which is the most biologically available form.90–93  
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Table 3-2. Substances identified in smokeless tobacco products and their categorization as carcinogens  
Compound/substance IARC group* Source† 
Tobacco-specific nitrosamines   
N'-nitrosonornicotine + 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone {NNN+NNK} 
1 IARC 2007 (2) 
Volatile N-nitrosamines   
N-Nitrosodimethylamine (NDMA) 2A IARC 2007 (2) 
N-Nitrosopyrrolidine (NPYR) 2B IARC 2007 (2) 
N-Nitrosopiperidine (NPIP)  2B IARC 2007 (2) 
N-Nitrosomorpholine (NMOR) 2B IARC 2007 (2) 
N-Nitrosodiethanolamine (NDELA) 2B IARC 2007 (2) 
Nitrosamino acids   
N-Nitrososarcosine (NSAR) 2B IARC 2007 (2) 
Inorganic compounds   
Nitrate (under conditions resulting in endogenous 
nitrosation) 
2A Stepanov et al. 2008 (56) 
Nitrite (under conditions resulting in endogenous 
nitrosation) 
2A Stepanov et al. 2008 (56) 
Volatile aldehydes   
Formaldehyde 1 Stepanov et al. 2008 (56) 
Acetaldehyde 2B Stepanov et al. 2008 (56) 
Fermentation-related compound   
Ethyl carbamate (urethane) 2A Faizi et al. 2010 (157) 
Mycotoxins   
Aflatoxins (mixtures of) 1 Varma et al. 1991 (152) 
Aflatoxin M1 2B Varma et al. 1991 (152) 
Ochratoxin A 2B Varma et al. 1991 (152) 
Polycyclic aromatic hydrocarbons   
Benzo[a]pyrene (BaP) 1 Hearn et al. 2013 (41), Stepanov et al. 2010 (61) 
Dibenz[a,h]anthracene (DBahA) 2A Hearn et al. 2013 (41), Stepanov et al. 2010 (61) 
Benz[a]anthracene (BaA) 2B Hearn et al. 2013 (41), Stepanov et al. 2010 (61) 
Benzo[b]fluoranthene (BbF) 2B Hearn et al. 2013 (41), Stepanov et al. 2010 (61) 
Benzo[j]fluoranthene (BjF) 2B Hearn et al. 2013 (41), Stepanov et al. 2010 (61) 
Benzo[k]fluoranthene (BkF) 2B Hearn et al. 2013 (41), Stepanov et al. 2010 (61) 
Dibenzo[a,i]pyrene (DBaiP) 2B Hearn et al. 2013 (41) 
Indeno[1,2,3-cd]pyrene (IcdP) 2B Hearn et al. 2013 (41), Stepanov et al. 2010 (61) 
5-Methylchrysene (5MC) 2B Hearn et al. 2013 (41) 
Naphthalene (NAP) 2B Hearn et al. 2013 (41), Stepanov et al. 2010 (61) 
Plant material   
Areca nut 1 IARC 2004 (6) 
Betel quid (with or without tobacco) 1 IARC 2004 (6) 






Compound/substance IARC group* Source† 
Metals/metalloids    
Arsenic 1 Pappas et al. 2011 (26) 
Beryllium 1 Pappas et al. 2011 (26) 
Cadmium 1 Pappas et al. 2011 (26) 
Cobalt 2B Pappas et al. 2011 (26) 
Chromium VI 1 Pappas et al. 2011 (26) 
Lead/Inorganic lead compounds 2B/2A Pappas et al. 2011 (26) 
Nickel compounds 1 Pappas et al. 2011 (26) 
Polonium-210 1 Syed et al. 2009 (158) 
*IARC = International Agency for Research in Cancer, 2012 (37). 
†Numbers in parentheses correspond to full citations in the References at the end of this chapter. 
Notes: All carcinogen designations are current as of October 2012 (IARC [37]). Includes agents that are added or that can be 
absorbed from the soil, result from microbial contamination, or form chemically. Some smokeless products contain nutmeg, 
which contains methyleugenol (IARC Group 2B) and safrole (IARC Group 2B). The concentration of these compounds would 
depend on the chemical composition of the nutmeg and the amount of nutmeg used in the product. The compound  
3-(N-nitrosomethylamino) propionitrile (MNPN), which is an IARC 2B carcinogen, can be formed during the chewing of areca 
nut or products/preparations containing areca nut.  
Table 3-3. Forms of nicotine: Chemical structures, ionic charge, alternative names, and 
health implications 










I llust rat ion of chemical s t ruct ure of di-prot onat ed (+ + ). 
 
I llust rat ion of chemical s t ruct ure of mono-prot on at ed (+ ). 
 
I llust rat ion of chemical s t ruct ure of unprot onat ed (neut ral).  
 Ionized Ionized Un-ionized 
  Total nicotine is the combination of the ionic forms existing at a given pH.   






Health implications Doubly charged nicotine 
is not prevalent at pH 
levels typically found in 
smokeless tobacco 
products (generally 
greater than pH 5.5). 
For singly charged 
nicotine, absorption 
across cellular membranes 
is not efficient. This is the 
predominant form in 
unprocessed tobacco.  
Uncharged nicotine rapidly 
crosses cellular membranes and 
diffuses into the bloodstream. 
Smokeless tobacco products with 
higher levels of this form of 
nicotine may be more addictive. 
* A few smokeless tobacco products (plug, twist, zarda, and some forms of rapé) have a pH below pH 5.5 and would contain 
some di-protonated nicotine. 
Note: The fraction of nicotine present in a particular ionic form is pH-dependent. Di-protonated and mono-protonated nicotine is 
present at acidic conditions below pH 5.5. In the majority of smokeless tobacco products, a combination of mono-protonated 
and unprotonated nicotine is present. The fraction of nicotine in the unprotonated (free) form increases as pH increases above 
pH 5.5. 
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The pH of unprocessed tobacco is generally slightly acidic (pH approximately 5–6.5)43; thus, generally 
less than 5% of the nicotine is present as free nicotine. During ST production, various alkaline agents are 
added that boost pH and increase the amount of free nicotine that can be delivered to the user. Some 
products, such as iqmik or nass,41,73 are highly alkaline (pH 11–12; Figure 3-6); hence, greater than 99% 
of nicotine is present as free nicotine in these products. 
The common practice of adding alkaline agents to ST products increases pH and thus free nicotine 
levels, which increases nicotine emissions and exposure, subsequently resulting in adverse health 
effects. Products with similar total nicotine concentrations can contain a wide range of free nicotine 
concentrations, depending on pH2,94 (Figure 3-5).  
Figure 3-5. The effect of pH on free nicotine amounts (in products produced by the same manufacturer, 
with equivalent amounts of total nicotine and product moisture)  
 
Abbreviation: mg/g = milligram per gram. 
Notes: An increase of 1.2 pH units increases free nicotine by 433%. Each square or diamond symbol represents a different product. 
Percent moisture = 51.9–53.9%; trends remain the same when expressed on a dry weight basis. 
Source: Richter et al. 2008 (94). 
Clinical studies indicate that absorption of nicotine through cell membranes is more rapid for products 
with higher pH than for products with lower pH.90,92,95 Products with higher free nicotine concentrations 
generate faster spikes in blood nicotine concentrations and could cause such products to be more 
addictive.96,97 Addition of alkaline agents and the resulting pH increase in some products may play a 
decisive role in the targeted delivery of nicotine (Figure 3-5). The availability of products spanning a 






wide pH range may make it easier for ST users to move on to products with increasingly higher nicotine 
levels (i.e., the graduation strategy).96,98  
The wide ranges of pH, total nicotine, and free nicotine levels in various products have been clearly 
demonstrated in numerous studies.2,12,20,41,73,91,93,94,99–102 Combined, these studies include more than 
20 product types (such as zarda, chimó, gutka) from 12 countries. Products with the lowest pH include 
chewing tobacco2,73,101 and some forms of dry snuff, zarda, and snus20,101 (Figure 3-6). Toombak, khaini, 
chimó, naswar, tuiber (tobacco water), and some varieties of African snuff and gutka have pH values 
generally between pH 8 to pH 102,20,41,73,99,100,102; products such as iqmik and nass have the highest 
known values (pH 11.0 to pH 11.8).41,73 
Figure 3-6. pH values and % free nicotine in selected smokeless tobacco products from 11 countries in 
5 World Health Organization regions  
 
Country abbreviations: B = Bangladesh; I = India; P = Pakistan; S = Sudan; N = Nigeria; SA = South Africa; SW = Sweden; 
UZ = Uzbekistan; VZ = Venezuela; BZ = Brazil; US = United States. 
World Health Organization regions: SEAR = South-East Asia Region; EMR = Eastern Mediterranean Region; AFR = African Region; 
EUR = European Region; AMR = Region of the Americas. 
Note: Each diamond represents the pH value for a single product; the rectangles are added to aid in visualization.  
Sources: aGupta and Sreevidya 2004 (100); bBrunnemann et al. 1985 (73); cHearn et al. 2013 (41); dStanfill et al. 2011 (20); eStanfill, 
Oliveira da Silva, unpublished results, 2013: fRichter et al. 2008 (94); gStepanov et al. 2005 (57); hRainey et al. 2011 (11). 
In a 2010 study of 30 naswar products, reported pH values ranged from pH 8.10 to pH 8.96.102 Extensive 
surveys in the United States found pH values between pH 5.54 and pH 8.62 for moist snuff.2,91,93,94 
Among 74 brands of chewing tobacco sold in Massachusetts, the pH values ranged from pH 5.07 to 
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pH 6.91; for 33 brands of dry snuff the values ranged from pH 5.50 to pH 7.61. The pH for 106 brands 
of moist snuff ranged from pH 5.41 to pH 8.38,2,103 and a study of 40 moist snuff brands reported a 
similar range (pH 5.54 to pH 8.62).94 Several zarda products combined with supari mixes had pH values 
ranging from pH 8.56 to pH 8.90.100  
The content of nicotine and other alkaloids in growing tobacco plants is affected by numerous factors, 
including genetics, geographic location, climate, fertilization rates, stalk and leaf position, and maturity 
of the leaf. The wide variation of nicotine levels in various ST products used worldwide depends on the 
method of tobacco curing (air-cured, fire-cured, or flue-cured), variety within the type of tobacco, curing 
processes, manufacturing techniques, and tobacco blending approaches used.104,105 Because ST products 
differ in moisture content, which affects the amount of tobacco present in one gram of product, 
constituent levels are often reported per gram dry weight. This chapter presents nicotine values found in 
the product “as is” or per wet weight. While this approach could have limitations when applied to some 
products such as dry snuff, it makes it possible to compare the greatest number of values among 
published reports. All values are expressed on a wet weight basis unless noted otherwise.  
Most ST products have a total nicotine content of 20 mg/g or less, but products such as nass, gul 
powder, chewing tobacco (India), iqmik, zarda, toombak, chimó, and twist tend to have the highest total 
nicotine concentrations, as high as 95 mg/g.2,20,23,41,61,73,94,99,101 Products that contain a considerable 
amount of areca nut, such as gutka, mawa, and mainpuri, had the lowest total nicotine values due to 
tobacco dilution with other material based on weight (0.16–4.20 mg/g).2,20,73,101 Moist snuff, the most 
popular form of ST in the United States, had values that ranged from 7.06 to 24.3 mg/g in one study as 
reported by IARC2,103 and from 4.42 to 25.0 mg/g in another study.94 A 2010 study of 30 brands of 
naswar from a Pakistani market found total nicotine values ranging from 7.35 to 26.7 mg/g.102 The 
nicotine values for toombak varied widely (7.0–95 mg/g).23 The high nicotine concentrations found in 
many samples of toombak may be due to the use of N. rustica tobacco, which has higher concentrations 
of nicotine than N. tabacum.20,23 Other high total nicotine values were observed for dry snuff (U.S.) 
(4.70–24.8 mg/g), iqmik (38.3–38.9 mg/g), nass (11.8–28.7 mg/g), chimó (5.29–30.2 mg/g), gul powder 
(33.4–34.1 mg/g), twist tobacco (21.6–40.1 mg/g), and zarda (14.6–65.0 mg/g).20,41,73,101,102  
One global survey investigated N. rustica tobacco and its higher nicotine content.20 The presence of 
N. rustica was indicated by elevated nicotine concentrations and comparisons of infrared spectra of the 
product with known N. rustica samples. In one toombak sample containing N. rustica, nicotine 
concentrations were almost three times higher than in the toombak samples that contained N. tabacum 
(28.2 mg/g vs. 10.2 mg/g). Nicotine in several other N. rustica products, including gul, zarda, and 
tobacco leaf (Bangladesh), ranged between 19.7 and 33.4 mg/g. Some chimó samples had high nicotine 
values (27.5–30.1 mg/g), but the tobacco type could not be determined conclusively.20 Products that 
have high pH values (due to alkaline agents) and contain the nicotine-enriched N. rustica can deliver 
extremely high levels of free nicotine.20,23,41,73  
An analysis of ST products across several countries found that free nicotine amounts were generally less 
than 10 mg/g, with the exception of chimó (1.32–30.1 mg/g), gul powder (29.1–31.0 mg/g), and naswar 
(8.84–13.2 mg/g).20 Free nicotine concentrations in moist snuff products sold in the United States ranged 
from 0.01 to 7.81 mg/g91 (Table 3-4). Products that tended to have the lowest levels of free nicotine 






included gutka (handmade, cottage-made, and manufactured: 0.12–3.33 mg/g), tobacco leaf (0.15 mg/g), 
zarda (0.05–0.63 mg/g), mawa (0.11 mg/g), mainpuri (0.38 mg/g), and South African and Swedish snus 
(0.29–2.03 mg/g).20 
Table 3-4. Ranges of moisture content, pH, free nicotine, total nicotine, and 5 TSNAs in 39 top-selling 






Moisture, % 27.4 Hawken Rough Wintergreen 54.5 Rooster Long Cut Bold 
Wintergreen 
pH 5.54 Hawken Rough Wintergreen 8.62 Kodiak Ice Long Cut Regular 
Free nicotine, % 0.3 Hawken Rough Wintergreen 79.9 Kodiak Ice Long Cut Regular 
Total nicotine (mg/g wet)  4.42 Hawken Rough Wintergreen 25.0 W.B. Cut Regular 
Free nicotine (mg/g wet) 0.01 Hawken Rough Wintergreen 7.81 Kodiak Ice Long Cut Regular 
NNK (g/g wet) 0.382 Red Seal Long Cut Wintergreen 9.95 Skoal Key 
NNN (g/g wet) 2.20 Copenhagen LC Regular 42.6 Skoal Key 
NAT (g/g wet) 0.938 Hawken Rough Wintergreen 31.9 Skoal Key 
NAB (g/g wet) 0.123 Red Seal Fine Cut Wintergreen 4.24 Skoal Key 
NNAL (g/g wet) 0.021 Copenhagen LC Regular 1.41 Skoal Key 
Total TSNAs (g/g wet) 4.87 Red Seal Long Cut Wintergreen 90.0 Skoal Key 
Abbreviations: For nicotine values, mg/g = milligram per gram, and g/g = microgram per gram. For TSNAs (tobacco-specific 
nitrosamines): NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NAT = N’-nitrosoanatabine; 
NAB = N’-nitrosoanabasine; NNAL = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. 
Note: In the original report, one herbal brand (Oregon Mint Snuff) did not contain detectable levels of nicotine and was excluded 
from the data presented in this table.  
Source: Richter et al. 2008 (94). 
Several other reports published since 2000 have provided information on pH and nicotine content in ST 
products used in India, South Africa, and Pakistan. A report to the World Health Organization (WHO) 
South-East Asia Regional Office showed that 20 ST products used in India had pH values between pH 
5.2 and pH 10.1, and the total nicotine content ranged from 1.24 to 10.2 mg/g product, with free nicotine 
values ranging from 0.03 to 4.06 mg/g.100 A report on moist snuff products used in South Africa showed 
the pH of these products to range between pH 7.1 and pH 10.1, and total nicotine content to vary 
between 11.6 and 29.3 mg/g dry weight.106 In the 30 brands of naswar from the Pakistani market, total 
nicotine ranged from 7.35 to 26.7 mg/g, and free nicotine levels ranged from 5.52 to 21.4 mg/g. The pH 
averaged 8.56,102 resulting in an average 77% of total nicotine in these products being present in free 
form. 
Of the ST products available on the U.S. market, moist snuff contains the highest level of free nicotine. 
According to 2003 data from the Massachusetts Department of Public Health (MDPH) as reported by 
IARC, the average pH of moist snuff was pH 7.43, compared to pH 6.36 for dry snuff and pH 5.82 for 
chewing tobacco.2,103 The mean value for free nicotine in moist snuff was 3.52 mg/g, which is five times 
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higher than the proportion of free nicotine in dry snuff (0.71 mg/g) and 32 times higher than the free 
nicotine level in chewing tobacco (0.11 mg/g). In addition to the differences by the type of smokeless 
product, the MDPH report showed that pH and free nicotine in U.S. products vary by brand and over 
time. Thus, of the most popular brands of moist snuff, Kodiak has had the highest pH since 1999, and 
the free nicotine level in this brand has increased greatly, from 35.2% to 60.3% of total nicotine over a 
six-year period (1997–2003). In contrast, average nicotine levels in Copenhagen and Skoal decreased 
during this time.2,103 
A 2008 survey of 39 top-selling brands of U.S. moist snuff showed a more than fivefold variation in 
total nicotine levels and a more than 500-fold range in free nicotine.94 The ranges for moisture content, 
pH, total/free nicotine, and TSNA levels in this sample of U.S. moist snuff are summarized in Table 3-4. 
A 2003 study described nicotine levels for some of the brands that were later included in the 2008 
study.89 Comparing the data for the two time points shows the following ranking of differences in free 
nicotine content for the U.S. moist snuff brands: Hawken Wintergreen had the lowest free nicotine 
content in both studies (0.01 mg/g wet weight in 2003 and 2008), followed by Skoal Bandits Mint 
(0.97 mg/g in 2003 and 0.37 mg/g in 2008), Copenhagen Long Cut (2.04 mg/g in 2003 and 5.67 mg/g 
in 2008), and Kodiak Wintergreen (5.81 mg/g in 2003 and 7.14 mg/g in 2008). This observation 
supports the idea that moist snuff manufacturers target particular brands to specific consumers by 
controlling free nicotine levels in their products, most likely as a part of the continued use of the 
graduation strategy.98 
In 2012, nicotine levels were reported for a large sample of novel oral spit-less and dissolvable ST 
products being marketed to U.S. smokers as an alternative to smoking.12,107 A total of 117 samples were 
analyzed, including various flavors of Marlboro Snus (rich, mild, spearmint, peppermint) and Camel 
Snus (mellow, frost, robust, winterchill), as well as dissolvable products Camel Orbs (mellow, fresh), 
Camel Sticks (mellow), Camel Strips (fresh), Ariva (java, citrus, cinnamon, wintergreen), and Stonewall 
(java, wintergreen) (Table 3-5). Overall, the results of these analyses supported previous observations 
that, with the exception of Camel Snus, these products generally contain relatively low amounts of free 
nicotine compared with most traditional U.S. moist snuff brands.12 Although the dissolvable Camel 
products have very low total nicotine levels, they have a higher pH and thus a larger portion of free 
nicotine, exceeding the amount of free nicotine in Marlboro Snus and the dissolvable brands Ariva 
and Stonewall.12  
The varying levels of free nicotine across these novel products may affect how acceptable they are to 
current or new tobacco users. On one hand, smokeless products with higher nicotine content may be 
more effective at satisfying smokers’ cravings than products with less nicotine,108,109 and this may in 
part explain the greater popularity of Camel Snus compared to Marlboro Snus.110 On the other hand, 
products that are low in free nicotine could be more easily accepted by young people initiating 
tobacco use. 






Table 3-5. Moisture content, pH, total/free nicotine, and TSNA concentrations in novel U.S. smokeless 









  Free nicotine  





Marlboro Snus (71) 16.6 6.75 20.5  5.2 0.88 0.36 0.13 
Camel Snus (36) 29.6 7.42 11.6  21.4 2.47 0.62 0.31 
Camel Orbs (4) 13.0 8.10 3.0  54.5 1.65 0.21 0.28 
Camel Sticks (3) 13.1 7.76 3.9  35.8 1.44 0.26 0.31 
Camel Strips (3) 17.7 7.88 2.7  41.9 1.11 0.15 0.22 
Ariva (4) 2.5 6.92 5.0  7.3 0.37 0.09 0.07 
Stonewall (2) 3.8 7.10 6.9  10.6 0.73 0.12 0.06 
Abbreviations: TSNA = tobacco-specific nitrosamines; NNN = N’-nitrosonornicotine; NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone; mg/g = milligram per gram; µg/g = microgram per gram.  
Note: The dissolvables Ariva and Stonewall were discontinued at the beginning of 2013 by Star Scientific, Inc. 
Source: Stepanov et al. 2012 (12). 
Tobacco-Specific Nitrosamines  
TSNAs are commonly considered among the most potent carcinogens in ST products.2,32 A total of five 
TSNAs have been identified in tobacco products: N’-nitrosonornicotine (NNN), 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), 
N’-nitrosoanatabine (NAT), and N’-nitrosoanabasine (NAB). NNN, NNK, and NNAL are among the 
more common TSNAs and are the most carcinogenic.2,32,82 The carcinogenicity of NNN and NNK has 
been reviewed and established by the IARC,2 and the pulmonary and pancreatic carcinogenicity of 
NNAL has been demonstrated in a few animal studies (reviewed in Hecht 199832). NNN, NNK, and 
NAT generally occur in greater quantities than the other TSNAs.20,32,56,57,59,85,94,111,112 
Because of NNAL’s potential for carcinogenicity, the levels of NNAL present are also important, but 
these have been reported in smokeless products only occasionally.20,94,113,114 However, regardless of the 
sparse reporting, NNAL carcinogenicity should always be taken into consideration because it is 
metabolically formed from NNK in ST users. Moreover, NNAL is commonly utilized as a biomarker of 
exposure to carcinogenic NNK.115  
In the growing plant, TSNAs are not generally present at elevated levels,21,22,35 but they can accumulate 
to extremely high levels in certain products (e.g., toombak).23 The levels of TSNAs present in ST 
products are attributable to numerous factors, including plant genetics (tobacco species/varieties), 
growth factors (nitrate levels, climate), cultivation practices (fertilization rates, harvesting methods), 
processing (curing, fermentation), and storage conditions2,27,114,116–121 (Figure 3-7). Many studies have 
investigated techniques for reducing TSNA levels in tobacco.121–123 One study by Wiernik and 
colleagues proposed a method of quick-drying tobacco at 70C for 24 hours to remove excess water and 
reduce growth of microorganisms, which resulted in decreased nitrite and TSNA levels.34 Drying 
tobacco quickly at this stage of curing reduces the microbial activity but lowers tobacco leaf quality.  
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Figure 3-7. Plant-related absorption, microbiological, and chemical steps involved in the formation of 
tobacco-specific nitrosamines  
 
Abbreviations: NO3- = nitrate; NO2- = nitrite; NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. 
Note: Nitrosation is the chemical reaction of nitrite with various secondary and tertiary amines. This reaction produces 
nitrosamines, including tobacco-specific nitrosamines, nitrosoamino acids, volatile nitrosamines, and areca-specific nitrosamines.  
Nitrate, nitrite, and alkaloids are present in ST products at the time of purchase, and prolonged storage 
can lead to further accumulation of TSNAs, with larger amounts accumulating if storage occurs at 
elevated temperatures and humidity.121,124 Adding nitrate-containing agents could contribute to increased 
levels of TSNAs in ST products. One product, Ghana traditional snuff, contains tobacco mixed with 
potassium nitrate (saltpeter)125 (chapter 12).  
Worldwide, the use of different tobacco types, processing techniques, and tobacco blending approaches 
leads to wide variation of TSNA levels in various ST products. Several comparative international 
reports2,20,73,99 and individual studies on ST products used in different countries12,23,57,94,112 provide an 
informative view of the variations in TSNA levels among countries and product types. Concentration 
data in this section are expressed as microgram per gram (µg/g) wet weight, which allows for 
comparison of a larger global dataset of ST products.  
The highest levels of TSNAs ever observed in tobacco products have been found in Sudanese toombak. 
Calculations based on dry weight values and moisture content reported by Idris and colleagues23 reveal 
that NNN content in some samples of this product were as high as 2,860 µg/g, and NNK content as high 
as 7,300 μg/g. Lower levels of TSNAs were reported in 1985 by Brunnemann and colleagues for moist 
snuff samples purchased in Canada; total TSNA was up to 115 µg per gram of product.73 Some tobacco 
products sold in India also have very high TSNA levels, but Stepanov and colleagues57 reported a large 
variation in TSNA levels among Indian products. The largest quantities of TSNAs were found in khaini; 
amounts were also relatively high in zarda products, but the levels of these carcinogens in gutka were 






relatively low. Stepanov and colleagues found that, overall, total TSNA content varied from 0.04 to 
127.93 µg/g product.57 Such a wide range is not surprising given the variety of ST products and 
approaches to tobacco processing and product manufacturing used in India.  
TSNA levels also vary widely in moist snuff products sold in the United States, although they do not 
reach the levels seen in Indian products. A comprehensive survey of moist snuff conducted by the 
Centers for Disease Control and Prevention (CDC)94 showed an 18-fold variation in TSNA content 
among 39 top-selling U.S. brands of moist snuff (see Table 3-4 for a summary). The levels of NNN 
ranged from 2.2 to 42.6 µg/g; levels of NNK ranged from 0.38 to 9.9 µg/g. The survey also recorded 
information about NNAL levels in the studied brands, and an almost 70-fold difference was found in 
NNAL content among brands. Thus, even though TSNA levels had declined overall in some U.S. 
smokeless tobacco products since the 1980s,116 some U.S. moist snuff brands still contained high levels 
of these carcinogens as of 2008.  
TSNA levels in snus sold in Sweden are reported to have declined by about 85% over a 20-year period. 
In 2002, amounts of NNN in 27 samples of Swedish snus averaged 0.49 µg/g product, whereas the NNK 
amounts averaged 0.19 µg/g product.112,126 These levels are among the lowest seen in commercial ST 
products. The oral spit-less and dissolvable ST products marketed in the United States after about 2008 
also contain relatively low levels of TSNAs.12,56 According to an analysis of 117 samples of these 
products reported in 2012, total TSNAs (the sum of NNN, NNK, NAT, and NAB) ranged from 
0.53 µg/g in dissolvable Camel Strips to 1.19 µg/g in Camel Snus.12 Thus, considerable variation of 
TSNA levels has been observed even in this low-TSNA category.  
The most current and comprehensive analysis of international samples showed wide variation in TSNA 
levels in more than 53 products from 9 countries reported in 201120 (Table 3-6). The concentration of 
total TSNAs (that is, the sum of NNK, NNN, NAT, NAB, and NNAL) in the products ranged from 
0.084 to 992 µg/g. As mentioned earlier, the highest NNK concentrations were found in Sudanese 
toombak and dry zarda (Bangladesh) (3.84 µg/g). The highest NNN concentrations were observed also 
in toombak (Sudan), dry zarda (Bangladesh), khaini (India), and handmade gutka (India). Handmade 
gutka and mawa from Pakistan had the lowest NNK concentrations. The study found that NNAL levels 
ranged from 0.004 to 6.77 µg/g, with the highest NNAL concentrations in toombak, dry zarda, and 
khaini.20 Extremely high concentrations of TSNAs were found in saliva from toombak users.23,127,128 
Given the high carcinogenic potency of NNN and NNK, it is not surprising that over 50% of oral 
cancers in Sudanese men are attributed to the use of toombak or other oral products.5,128–130 
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value Brand or type 
Maximum 
value Brand or type 
pH 5.22 Baba Zarda120 10.1 Toombak, sample 2; Super Taxi 
Snuff 
Free nicotine, % 0.16 Baba Zarda120 99.1 Toombak, sample 2 
Total nicotine (mg/g wet) 0.16 Mawa 34.1 Mawa 
Free nicotine (mg/g wet) 0.11 Mawa 31.0 Eagle Gul Powder 
NNK (g/g wet) 0.004 Mawa 516 Toombak, sample 5 
NNN (g/g wet) 0.045 Gutka (handmade, Karachi) 368 Toombak, sample 5 
NAT (g/g wet) 0.014 Gutka (handmade, Karachi) 59.6 Toombak, sample 5 
NAB (g/g wet) 0.005 Gutka (handmade, Karachi) 41.5 Toombak, sample 5 
NNAL (g/g wet) 0.004 Mawa 6.77 Toombak, sample 5 
Total TSNAs (g/g wet) 0.084 Gutka (handmade, Karachi) 992 Toombak, sample 5 
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NAT = N’-nitrosoanatabine; 
NAB = N’-nitrosoanabasine; NNAL = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. 
Notes: Values for nicotine (total and free), mg/g wet = milligrams per gram as received (wet weight). Values for TSNAs (tobacco-
specific nitrosamines, NNN, NNK, NAT, NAB and NNAL), g/g wet = micrograms per gram as received (wet weight).  
Source: Stanfill et al. 2011 (20). 
Metals and Metalloids  
Metals and metalloids are naturally present in tobacco, and amounts of these substances in tobacco are 
influenced by soil pH, soil composition, and industrial contamination.131,132 Smokeless tobacco products 
have been reported to contain detectable levels of several metals that are classified as IARC Group 1 
carcinogens (arsenic, beryllium, chromium VI, cadmium, nickel compounds, polonium-210) or 
Group 2B carcinogens (e.g., cobalt, lead).133 A review of studies of ST products from Ghana, Canada, 
India, and the United States found detectable concentrations of arsenic (0.1–3.5 g/g), beryllium  
(0.01–0.038 g/g), chromium (0.71–21.9 g/g), cadmium (0.3–1.88 g/g), nickel (0.84–13.1 g/g), 
lead (0.23–13 g/g), and cobalt (0.056–1.22 g/g).26 A report of metals values in Pakistani naswar 
showed detectable levels of arsenic (0.15–14.04 g/g), chromium (0.8–54.05 g/g), cadmium  
(0.25–9.2 g/g), nickel (2.2–64.85 g/g), lead (12.4–111.15 g/g), and even higher levels of several 
other metals.102  
Some ST products also contain mercury, a systemic toxicant, and barium, a dermal irritant,26,125,134,135 
and metals such as aluminum and chromium, which may cause biologic sensitization.26,125,136 The 
potential for exposure to several of the toxic metals listed above (barium, beryllium, cadmium, cobalt, 
nickel, and lead) was demonstrated by determining how much of these metals transferred from tobacco 
to artificial saliva.136  






The amount of copper in ST products is also of interest. The copper content of areca nuts is higher than 
that found in other nuts.137 A study of seven ST product types from India (zarda, creamy snuff, khaini, 
etc.) revealed very high levels of copper in four gutka products (237–656 g/g) compared with other 
gutka products or other types of ST products (0.012–36.1 g/g).135 Areca nut use has been linked to oral 
submucous fibrosis (OSF), a condition that affects the mouth, pharynx, and esophagus. It has been 
suggested that copper upregulates lysyl oxidase, resulting in the excessive cross-linking and 
accumulation of collagen that occurs in OSF.137  
Among the previously mentioned GothiaTek standards set for the Swedish tobacco industry are 
guidelines for the allowable levels of metals in Swedish snus: cadmium (1.0 g/g), lead (2.0 g/g), 
arsenic (0.5 g/g), nickel (4.5 g/g), and chromium (3.0 g/g). The average levels of metals in Swedish 
snus in 2009 were low: cadmium (0.6 g/g), lead (0.3 g/g), arsenic (0.1 g/g), nickel (1.3 g/g), and 
chromium (0.8 g/g),55 which demonstrates that the levels of metals in ST can be monitored and held 
below certain limits.  
Polycyclic Aromatic Hydrocarbons 
Compounds such as polycyclic aromatic hydrocarbons (PAHs), phenols, and volatile aldehydes are 
formed from burning wood and sawdust.42,61 During fire curing, tobacco is exposed to this wood smoke, 
and these substances can be deposited on the curing leaf. Indeed, levels of PAHs and phenols tend to be 
higher in tobacco that is fire-cured rather than air-cured.21,22,41,43 Products made with fire-cured tobacco 
(e.g., moist snuff) have higher levels of PAHs, including PAHs that are IARC Group 1 or 2 carcinogens, 
than products such as snus, which do not contain fire-cured tobacco.56,61  
Ten PAH compounds have been designated as IARC carcinogens or potential carcinogens (see 
Table 3-2): in Group 1, benzo[a]pyrene (BaP); in Group 2A, dibenz[a,h]anthracene; and in Group 
2B, benzo[b]fluoranthene, benzo[j]fluoranthene, benzo[k]fluoranthene, dibenzo[a,i]pyrene, 
indeno[1,2,3-cd]pyrene, 5-methylchrysene, naphthalene, and benz[a]anthracene.37 All of these 
compounds have been found in smokeless tobacco.61  
Among U.S. products, total PAH levels (that is, the sum concentration of 23 PAH compounds) in moist 
snuff that contained fire-cured tobacco ranged between 921 and 9,070 nanograms per gram of product 
(ng/g), which was generally higher than levels found in snus that did not contain fire-cured tobacco 
(660–1,100 ng/g).61 Overall, among products with detectable levels of BaP, moist snuff had higher BaP 
levels (9.7–44.6 ng/g) than snus (3.0–12.3 ng/g); however, 41% of the snus brands had BaP levels below 
the detectable limit of 1.6 ng/g. The levels of naphthalene in moist snuff that contained fire-cured 
tobacco (409–1,110 ng/g) were comparable to naphthalene amounts in snus that was made with air-
cured tobacco (636–1,065 ng/g). When naphthalene was excluded from the total PAH concentration, the 
remaining PAHs in moist snuff (145–8,120 ng/g) were higher than those found in snus (21–213 ng/g). 
One brand of moist snuff, Hawken Long Cut Wintergreen, which could be viewed as a starter brand, 
contained only 145 ng/g of PAHs other than naphthalene (776 ng/g).61 It is clear that amounts of PAHs 
can be reduced by eliminating or reducing the use of fire-cured tobaccos.  
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Areca Nut  
Areca nut, an ingredient in some ST products, is an IARC Group 1 carcinogen.133 Areca nuts are 
seeds from the Areca palm (Areca catechu), which is native to South-East Asia and Eastern Africa 
(Figure 3-3). The seed can be used in the ripe or unripe form; can be dried, baked, or roasted; and 
then cut into slices, crushed, or consumed whole. Betel quid often contains areca nut, among other 
ingredients, such as tobacco, catechu (an extract of the Acacia plant), alkaline agents, and spices, 
wrapped in a piper betel leaf.6 
Areca nut contains compounds such as arecoline and guvacoline that can react with nitrite to form 
areca-specific nitrosamine compounds (ASNAs).6 These ASNAs are also formed in the mouth during 
use of products containing areca nut.39 The areca-derived N-nitrosoguvacoline (NGL) has been shown 
to induce pancreatic tumors in lab animals, and a mixture of NG and NNK has been shown to induce 
lung tumors.138 Another ASNA compound, 3-(N-nitrosomethylamino)propionaldehyde, is both highly 
cytotoxic and genotoxic to human buccal epithelial cells, a finding that is important to understanding 
tumor induction among users of areca nut–containing products.139 Areca nut is a carcinogen and a very 
harmful substance that should not be included in tobacco products.6  
Tonka Bean 
Tonka (Dipteryx odorata), a flowering tree in the pea family (Fabaceae), is native to Brazil and is 
cultivated in Central and South America. The tree produces seed pods containing black wrinkled seeds 
with a fragrance reminiscent of vanilla, which are known as tonka beans.140 
Coumarin, a benzopyrone compound, is present at high concentrations in tonka bean (35,000 µg/g), as 
well as in cassia (Cinnamomum aromaticum) (17,000–87,300 µg/g), cinnamon (900–40,600 µg/g), and 
Peru balsam (Myroxylon balsamum) (4000 µg/g).141 In the mid-1950s, Hazelton and others identified 
coumarin as a liver toxin in dogs and rats following oral administration of coumarin.142 Coumarin and 
tonka beans were banned as flavoring agents in the United States,143 and because of this ban, daily 
human exposure is thought to occur at very low levels (60 ng/g), primarily resulting from use of 
fragrances and foodstuffs made with flavor substances (cinnamon) containing low levels of naturally 
occurring coumarin.144 Detectable levels of coumarin have been found in the filler from several brands 
of Indonesian clove cigarettes145 due to the use of flavor materials containing tonka bean.146  
Tonka bean is widely used in a tobacco product called rapé (chapter 9). 
Other Harmful Agents  
Flavoring agents are added to ST products worldwide.63,64,147 
Diphenyl ether, a flavor compound with a harsh metallic aroma,148 and camphor have been identified as 
highly concentrated constituents of some tobacco products and certain spice condiment packs used to 
make betel quid.149 Diphenyl ether irritates mucus membranes and can damage the liver, kidney, spleen, 
or thyroid after prolonged exposure.149,150 Camphor can adversely affect the neurological, respiratory, 
cardiovascular, and gastrointestinal systems. Even small amounts of camphor have caused convulsions 






followed by depression.151 Ingestion of these substances is of note since betel quid can be swallowed 
during use.  
Brazilian rapé, a nasal product, contains tobacco mixed with tonka bean, cinnamon powder, or clove 
buds, but usually lacks alkaline agents. Varieties of rapé produced in the Minas Gerais State of Brazil 
are known to contain extremely high levels of coumarin, a liver toxicant, which is derived from tonka 
bean and cinnamon (André Oliveira da Silva, personal communication, 2013). 
Energy-enhanced smokeless products such as Revved Up contain stimulants (caffeine, ginseng), taurine, 
and vitamins B and C.  
Some forms of tombol contain khat (Catha edulis), a plant that contains cathinone, an alkaloid with 
amphetamine-like stimulant properties, which purportedly causes euphoria, excitement, and loss 
of appetite.74  
Gaps and Limitations of the Current Evidence Base 
Further research is required to better characterize the chemical contents of a wider range of products. 
Research is also needed into the role of microorganisms (bacteria and mold) in altering product 
chemistry (i.e., generating nitrite and nitrosamines, producing mycotoxins). The effects of bacteria and 
mold on TSNA levels in products and the conditions that increase TSNA levels are also subjects in need 
of further study.  
Because of the complexity of ST products—which can include a variety of tobacco types, chemical 
additives, non-tobacco plant ingredients, and microorganisms—ST products should not be viewed as a 
single homogenous product category for assessing composition or health effects. This wide variety of 
ST products worldwide differs in terms of addictiveness, toxicity, carcinogenicity, health effects, and 
impact on public health. Categorizing the products into groups with similar properties may provide a 
means of determining the health effects associated with particular product chemistries. However, 
drawing conclusions about the health consequences of different types of ST products (snuff, chimó, 
gutka) based on limited data from a small sample set from specific localities could be very misleading.  
Summary and Conclusions 
The widely diverse group of tobacco-containing products known as ST are distributed and used around 
the world. Smokeless tobacco products vary greatly in chemical composition and, in some cases, contain 
extremely high levels of total nicotine, free nicotine, and carcinogens. Most ST products contain tobacco 
and chemical/plant-derived additives, and may also contain microorganisms.  
From the growing process to the final product, ST undergoes numerous chemical changes. Many 
constituents in ST products are present at very low levels in the growing tobacco plant. Chemicals are 
formed or introduced at one or more stages in the process of transforming the harvested tobacco into the 
final ST product. During curing, nitrite, TSNAs, N–nitrosamino acids, and volatile N–nitrosamines can 
be formed. Fire curing can also lead to the formation of PAHs, aldehydes, and phenols.21,22,33,43,56,61 The 
fermentation stage may result in the formation of chemicals such as ethyl carbamate, nitrite, and 
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TSNAs.2,33,44 During production or preparation, compounds from areca nut may be added, and storage 
conditions may increase TSNA levels in ST products.114,121,124 Also, during use of products containing 
areca nut, areca-specific nitrosamines are formed endogenously in the mouth.39  
A number of studies have begun to address the presence of bacteria, fungi, and mold in tobacco.46,47 
Especially important are (1) bacteria and mold that convert nitrate to nitrite, which contribute to the 
formation of TSNAs and other nitrosamines,33,44,53 (2) bacteria and mold that are potentially 
pathogenic,48 and (3) fungi that produce mycotoxins, including aflatoxins (i.e., Aspergillus).152  
High nitrite concentrations in ST are a clear indication of past or ongoing conversion of nitrates to 
nitrites by microorganisms.33,44 Nitrite concentrations should be monitored and controlled in all ST 
products as they are a key precursor in the formation of carcinogenic nitrosamines, including 
TSNAs.2,38,54,133 Eliminating or decreasing the population size of nitrite-forming microorganisms (by 
pasteurization, cleaning fermentation equipment, seeding with non-nitrite-forming bacteria)33,55 or 
lowering nitrite levels by other means (use of nitrite scavengers, modifying production processes, etc.) 
generally results in lower TSNA levels in smokeless tobacco.33,44,53,55–57 
Among the means of controlling microorganism during ST production, pasteurization or heat-treating of 
tobacco is one of the most effective methods of preventing nitrate-to-nitrite conversion.55 Indeed, snus, a 
pasteurized product, generally has lower nitrite and TSNA levels than non-pasteurized products such as 
moist snuff and khaini.56,57 These observations suggest that changing tobacco processing methods shows 
promise as a means of reducing the levels of some carcinogenic and toxic agents in tobacco products. 
The user’s actual absorption of nicotine, toxicants, and carcinogens from a given ST product is affected 
by the product’s characteristics (product design, pH, moisture, cut width, additives content, 
pouched/non-pouched, buffering capacity),8,90,153 use parameters (dosage and frequency, duration, and 
intensity of use),154,155 mode of use (oral: chewing, sucking, dental application, etc.; nasal),1 and 
physiologic factors (salivary volume and pH).85,153  
Areas of concern regarding manufacturing smokeless products include, but are not limited to, fire curing 
(introduction of PAHs and other smoke-related chemicals), bacterial contamination (potential 
pathogenicity), fermentation (formation of nitrite and carcinogenic nitrosamines), the addition of areca 
nut (an IARC Group 1 carcinogen), nicotine-enriched tobacco species (high total nicotine levels), 
alkaline agents (which boost free nicotine levels), and storage methods that allow continued formation 
of nitrosamines. Another matter of concern is the addition of stimulants to tobacco products, such as the 
addition of caffeine to moist snuff products (e.g., Revved Up energy dip14), and the mixing of khat, a 
plant with amphetamine-like properties, with tobacco to form tombol in Middle Eastern countries such 
as Yemen74 (Ghazi Zaatari, personal communication, 2013). Maintenance of toxicants below certain 
feasible, but not necessarily safe, thresholds demonstrates that the tobacco industry has the ability to use 
manufacturing controls to reduce toxicants as recommended by the World Health Organization156; 
however, only one company has set its own voluntary toxicant reduction standards. 
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Introduction 
The health risks associated with smokeless tobacco (ST) can vary substantially by product 
characteristics and ingredients, manner of use, and potential interactions with other tobacco use 
behaviors, such as cigarette smoking. Based on epidemiologic studies of traditional ST products, such as 
snuff, chewing tobacco, and betel quid, the International Agency for Research on Cancer (IARC) 
concluded that these products are carcinogenic to humans1 and, specifically, that there is sufficient 
evidence that ST products cause precancerous oral lesions and cancers of the oral cavity, esophagus, and 
pancreas. Additionally, there is sufficient evidence that ST products cause addiction as well as 
reproductive and developmental toxicity. (IARC defines evidence as sufficient when “a causal 
relationship has been established and chance, bias, and confounding could be ruled out with reasonable 
confidence.”2,p.24) Given that over 300 million people use ST worldwide, the total burden of ST use is 
likely to be substantial. Moreover, ST use in some regions appears concurrently with cigarette smoking, 
thus contributing to the total health burden of tobacco use. 
Assessing the global magnitude or severity of the health effects of ST is complex primarily because of 
the variability of the products’ chemical composition and other characteristics and the different ways in 
which these products are used around the world. (See chapter 3 for descriptions of ST products.) 
Conclusions about a product’s use and risks in one country may not be transferable to similar products 
in other countries. Smokeless tobacco products differ considerably in their concentrations of nicotine 
and volatile and nonvolatile nitrosamines including the tobacco-specific nitrosamines (TSNAs), as well 
as polycyclic aromatic hydrocarbons (PAHs), toxic metals, and other compounds.3–5 For example, 
nitrosamines are formed when secondary and tertiary amines in tobacco, including the alkaloids 
(nicotine, nornicotine, anatabine, and anabasine), react with nitrosating agents such as sodium nitrite. 
TSNAs are carcinogenic to humans and are formed primarily during tobacco processing, curing, 
fermentation, and storage.2 PAHs, which are also carcinogenic to humans,6 are formed by incomplete 
combustion of organic matter such as wood; most PAHs in ST are formed during the fire-curing 
process.7 Toxic metals that have been detected in ST products include arsenic, beryllium, cadmium, 
chromium, cobalt, lead, nickel, mercury, and the radioactive metals polonium-210 and uranium.2,8 All 
ST products contain nicotine, and virtually all contain TSNAs. 
Some products also contain added plant materials such as tonka bean or flavoring agents that may 
contribute to adverse health consequences (see chapter 3). For example, additives such as the areca nut, 
a known carcinogen, are commonly used in products in India and other South-East Asian countries.9 
Areca nut, often used with tobacco or used prior to initiating tobacco use,9 is considered an IARC group 
1 carcinogen.1 It is estimated that 10–20% of the world’s population use areca or areca nut–containing 
products/preparations1 (in 2001, this was estimated at 600 million people9). Examples of these products 
are betel quid, tombol, mawa, and gutka, which often contain tobacco.1 Some users may intermittently 
switch between areca nut and areca nut plus tobacco.10 The health implications of using tobacco mixed 
with areca nut warrant consideration because areca nut has been linked to oral submucosal fibrosis 
(OSF) and oral squamous cell carcinomas.11 Areca nut–containing products are commonly used in 
South-East Asia (paan, mawa, mainpuri, gutka, etc.), the Middle East (tombol), and more recently in the 
United Kingdom,12 South Africa,11 and United States.10 
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The aim of this chapter is to provide a science-based summary of the association between the use of ST 
and a range of adverse health consequences. This chapter does not present an exhaustive review of the 
literature. Evidence was drawn from comprehensive reviews by authoritative bodies, particularly the 
IARC, the Office of the U.S. Surgeon General, and the Scientific Committee on Emerging and Newly 
Identified Health Risks (SCENIHR), and supplemented by reviews and original research reports in the 
peer-reviewed literature. These sources should be consulted for additional in-depth information, 
including strengths and limitations of individual studies. 
Adverse Health Consequences: Mechanisms 
Evidence supports plausible mechanisms by which ST use can cause disease. Disease pathways and 
biologic mechanisms specific to ST (Table 4-1) may be similar in some respects to the pathways and 
mechanisms that underlie the pathogenicity of tobacco smoke and nicotine.13 Higher concentrations of 
cotinine (a biomarker of exposure to nicotine uptake), nitrosamines, PAHs, and metals have been 
observed in the serum and urine of individuals who use ST products than in individuals who do not use 
tobacco.8,14,15 Concentrations of some TSNAs are higher in ST users than in individuals who smoke 
cigarettes.16 Constituents of ST cause local irritation and sensitization and are absorbed systemically 
through the oral or nasal mucosa and by swallowing saliva that contains tobacco particulates.17 
Smokeless tobacco carcinogens and other toxicants then circulate throughout the body and may damage 
multiple organs. 
Adverse Health Consequences: Cancer 
Conceptual Model 
An adaptation by Boffetta and colleagues18 of Hecht’s conceptual model of carcinogenesis associated 
with tobacco smoke19 is presented in Figure 4-1. The process begins with initiation of ST use and 
subsequent nicotine addiction (Box 1), leading to sustained use. Carcinogens present in ST are ingested 
and processed by the body (Box 2), which results in the metabolic activation of carcinogens and 
formation of DNA adducts, which are carcinogenic metabolites bound covalently to DNA (Box 3); and 
subsequent mutations (Box 4) which may ultimately lead to cancer (Box 5).  
Figure 4-1. Conceptual model of carcinogenesis of smokeless tobacco use 
Abbreviations: DNA = deoxyribonucleic acid; Hb = hemoglobin 
Sources: Boffetta et al. 2008 (18); Hecht 1999 (19). Reproduced with permission. 
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Table 4-1. Smokeless tobacco products: Constituents, biologic mechanisms, and biomarkers 
Product constituent 
Biologic mechanism related to 
health consequences 
Biomarker of human exposure (may not 




Increase DNA adduct levels, cause 
oxidative DNA damage, cause 
gene mutations, disrupt mechanisms 
for cell growth control; systemic 
carcinogens 
TSNAs and metabolites (NNAL) in urine 
TSNA–Hb adducts in red cells 
TSNA–DNA adducts in oral cells 
TSNAs in saliva 
Volatile nitrosamines† Form DNA adducts N/A 
Polycyclic aromatic hydrocarbons 
(PAH)‡
Form DNA adducts PAH biomarkers in urine 
Aldehydes§ Cause inflammation, increase cell 
proliferation 
Aldehyde–DNA adducts in white blood 
cells 
Metals¶ Cause inflammation and 
sensitization 
Metal levels in urine, saliva, blood, and 
hair 
Ethyl carbamate (urethane) Form DNA adducts N/A 
Nicotine Precursor to TSNAs Nicotine and metabolites (cotinine) in 
urine 
Arecoline Inhibits cellular growth, depletes 
cellular glutathione 
Arecoline in urine and blood 
Areca-nut-specific nitrosamines 
(e.g., MNPN) 
Form reactive oxygen species MNPNs in saliva 
Alkaline agents Increases the absorption of 
carcinogens and contributes to 
chronic inflammation and tumor 
promotion 
Sodium levels in urine 
Cardiovascular disease 
Polycyclic aromatic hydrocarbons  Accelerate atherosclerosis PAH biomarkers in urine 
Aldehydes Contribute to atherogenesis Aldehyde–DNA adducts 
Arsenic Causes vasoconstriction Arsenic levels in urine 
Barium Causes tachycardia, hypertension Barium levels in urine and saliva 
Cadmium Disrupts endothelial function, 
increases blood pressure 
Cadmium levels in urine, blood, and 
saliva 
Nicotine Acutely increases blood pressure 
and heart rate, may injure 
endothelial cells 
Urine thromboxane A2 metabolites, 
atherosclerosis, elevated blood pressure 
Arecoline Acutely increases blood pressure 
and heart rate 
Arecoline in urine and blood 
Alkaline agents Increase the fraction of nicotine and 
arecoline in free form that is most 
rapidly absorbed in the blood; 
increase blood pressure 
Sodium levels in urine 




Biologic mechanism related to 
health consequences 
Biomarker of human exposure (may not 
be specific to smokeless tobacco use) 
Addiction 
Nicotine Elevates dopamine; releases 
endorphins 
Nicotine and metabolites (cotinine) in 
urine 
Arecoline Elevates dopamine; releases 
endorphins 
Arecoline in urine and blood 
Acetaldehyde Enhances reinforcing effects of 
nicotine 
Aldehyde–DNA adducts in white blood 
cells 
Reproductive health outcomes (neurodevelopmental toxicity, pregnancy complications) 
PAHs (e.g., BaP) Causes anatomic and functional 
teratogenesis; prenatal, perinatal, 
and postnatal mortality; growth 
retardation; and developmental 
delay. 
PAH–DNA adducts in umbilical cord 
blood 
Cadmium Causes oxidative stress, interferes 
with placental transfer of essential 
elements. 
Placental cadmium levels 
Nicotine Binds nicotinic acetylcholine 
receptors in the developing lungs 
and impairs alveolar development 
and affects neurogenesis, migration, 
differentiation, and synaptogenesis 
in fetal developing neurites; also 
prune hippocampal and cortical 
neurons through effects of 
apoptosis. 
Cord blood cotinine 
Dental conditions 
Sugar Causes dental caries N/A 
Arsenic, barium, mercury, nickel, 
cobalt 
Cause dermal sensitization and 
irritation 
Metal levels in urine, saliva, blood, and 
hair 
Alkaline agents Cause irritation Sodium levels in urine 
Silica Wears down teeth N/A 
*Tobacco-specific nitrosamines (TSNAs): NNN (N’-nitrosonornicotine), NNK [4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone],
NAB (N’-nitrosoanabasine), NAT (N’-nitrosoanatabine). NNK is a metabolite of NNAL [4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol].
† Volatile nitrosamines: NDELA (N-nitrosodiethanolamine), NDMA (N-nitrosodimethylamine), NMOR (N-nitrosomorpholine), 
NPIP (N-nitrosopiperidine), NPYR (N-nitrosopyrrolidine). 
‡Polycyclic aromatic hydrocarbons (PAHs): Benz[a]anthracene, benzo[a]pyrene [BaP], benzo[b]fluoranthene 
benzo[j]fluoranthene, benzo[k]fluoranthene, 5-methylchrysene, dibenzo[a,h]anthracene, indeno[1,2,3-cd]pyrene, naphthalene. 
§Aldehydes: Formaldehyde, crotonaldehyde, acetaldehyde.
¶Metals: Arsenic, beryllium, cadmium, cobalt, chromium, lead, mercury, nickel, polonium, uranium.  
Abbreviations: N/A = information not available. DNA = deoxyribonucleic acid; Hb = hemoglobin; 
MNPN = 3-(methylnitrosamino)propionitrile. 
Sources: U.S. Department of Health and Human Services 2010 (13); International Agency for Research on Cancer (IARC) 2004 (9); 
IARC 2007 (2); Pappas 2011 (8). 
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In this model, metabolic activation and DNA changes and subsequent mutations occur that may 
ultimately lead to cancer. During the metabolic activation stage, shown after Box 2, NNK and NNN are 
metabolically activated by cytochrome P450 enzymes. This activation induces primary DNA lesions 
including pyridyloxo-butylations and nucleotide methylations.20 Permanent DNA mutations, such as in 
the RAS oncogene or the TP53 tumor suppressor gene, occur when DNA adducts persist unrepaired, 
leading to uncontrolled cell growth and cancer.13 This model represents a simplified version of the 
complex process of carcinogenesis. Other mechanisms that may contribute to tumor promotion and 
co-carcinogenesis include chronic local inflammation and irritation, oxidative stress, and reactive 
oxygen species.13 
Researchers have identified more than 30 carcinogens in various ST products, including volatile and 
nonvolatile nitrosamines, TSNAs, nitrosamino acids, PAHs, aldehydes, heavy metals, and radioactive 
metals (chapter 3, Table 3-2).  
The most potent and abundant TSNAs in tobacco products include 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK), the NNK metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), 
N’-nitrosonornicotine (NNN), N’-nitrosoanabasine (NAB), and N’-nitrosoanatabine (NAT).21,22 The 
level of TSNAs varies depending on the type of tobacco used (for example, Nicotiana rustica has more 
TSNAs than N. tabacum), the method of curing, fermentation, products added to the tobacco for 
processing or flavoring, and the method of storing the product.4 The TSNAs most strongly linked to 
cancer are NNN and NNK.21 Although some products such as Swedish snus contain relatively low levels 
of NNN and NNK, some U.S. brands of moist snuff contain very high concentrations, and toombak, a 
product used primarily in Sudan, has the highest concentration of TSNAs (NNN, NNK, and NAT) 
identified to date.14  
Some ST products have been found to contain PAHs, such as: BaP, classified by IARC as a Group 1 
agent (carcinogenic to humans); dibenz[a,h]anthracene, classified by IARC as Group 2A agent 
(probably carcinogenic to humans); as well as several PAHs classified by IARC as Group 2B agents 
(possibly carcinogenic to humans) including benz[a]anthracene, benzo[b]fluoranthene, 
benzo[j]fluoranthene, benzo[k]fluoranthene, 5-methylchrysene, indeno[1,2,3-cd]pyrene, 
dibenzo[a,i]pyrene, and naphthalene.7,23 Smokeless tobacco is consumed without combustion, but some 
products contain fire-cured tobaccos; these products have higher concentrations of volatile aldehydes 
and PAHs, including BaP, than products that contain air-cured tobacco.3,7 These PAHs may derive from 
the tobacco-curing process or from added ingredients such as punk ash.  
Other ingredients that are added to ST products also may have cancer-causing properties. Products 
commonly used in India and other parts of Asia often contain areca nut, which contains arecoline, a 
nicotine-like alkaloid, and the areca nut–derived nitrosamines 3-(N-nitrosomethylamino)
propionaldehyde, 3-methylnitrosamino propionitrile, N-nitrosoguvacine, and N-nitrosoguvacoline.9 
Areca nut use can lead to the production of reactive oxygen species and may cause precancerous lesions 
including oral submucous fibrosis and oral cancer, cancer of the pharynx, and esophageal cancer.9 Salts 
such as sodium chloride, added to ST as a flavor enhancer and antimicrobial agent, may damage the 
gastric epithelium, increase the absorption of carcinogens, and contribute to chronic inflammation and 
tumor promotion.3 




Users’ exposures to carcinogens in ST are most accurately measured by looking at biomarkers in the 
body. Biomarkers such as serum cotinine levels, total NNAL, total NNN, NNK–DNA adducts, or 
hemoglobin (Hb) adducts of nitroaromatic compounds may provide a realistic assessment of carcinogen 
and toxic dose in an individual.24 For example, studies suggest a dose–response relationship between 
total NNAL and serum cotinine (not a carcinogen itself, but a marker of tobacco exposure) and lung 
cancer24 and between total NNN and esophageal cancer risk25 in smokers. 
The metabolism of TSNAs can be measured in humans, as demonstrated by a study in which NNN, 
NAT, NAB, their pyridine-N-glucuronide metabolites, and NNAL were detected in the urine of ST 
users26 (Figure 4-2). These metabolites can be used as biomarkers to provide realistic and direct 
assessments of a person’s exposure to specific TSNAs.24 The concentrations of total NNAL detected in 
urine parallel the level of NNK measured in these products.14 A comparison of studies in the United 
States found that NNAL concentrations in the urine of users of moist snuff varied by brand used and, for 
some brands, were higher than levels seen in Marlboro cigarette smokers (Figure 4-3).14 
Figure 4-2. Mean NNN, NAT, NAB, their pyridine-N-glucuronide metabolites (NNN-N-Gluc, NAT-N-Gluc, 
and NAB-N-Gluc), and NNAL in the urine of 11 smokeless tobacco users 
Abbreviations: NNN = N’-nitrosonornicotine; NAT = N’-nitrosoanatabine; NAB = N’-nitrosoanabasine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; Gluc = glucuronide; pmol/mg = picomole per milligram.  
Note: Total NNAL = NNAL + NNAL Glucs. 
Source: Stepanov and Hecht 2005 (26). 
Smokeless Tobacco and Public Health: A Global Perspective 
125 
Figure 4-3. Total NNAL concentrations in the urine of users of Marlboro cigarettes, different brands of 
smokeless tobacco products, and medicinal nicotine 
Abbreviations: NNAL = [4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol]; pmol/mg = picomole per milligram. 
Note: Total NNAL = NNAL + NNAL glucuronides.  
Source: Adapted from Hatsukami et al. 2007 (14). Used with permission. 
A study15 using data from the U.S. National Health and Nutrition Examination Surveys from 1999 
through 2008 to evaluate biomarkers of chemical exposure found that mean levels of PAHs (measured 
in urine) were higher among ST users than among people who did not use tobacco (Figure 4-4). 
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Figure 4-4. Polycyclic aromatic hydrocarbons in the urine of smokeless tobacco users compared to that 
of non-users, NHANES, 1999–2008 
Abbreviations: NHANES = National Health and Nutrition Examination Survey; ng/g = nanogram per gram. 
Note: 95% confidence interval. 
Source: Naufal et al. 2011 (15).  
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Oral Cancer 
Available evidence from multiple epidemiologic studies in the United States, Asia, and Africa supports a 
causal association between oral cancer and use of ST, including snuff, chewing tobacco, naswar, 
shammah, and toombak,2,18,27 though observed relative risks (RR) vary substantially across products and 
regions, and with dosage and duration of use.2 Summary RRs (adjusted for smoking) comparing ST 
users to non-users in the United States range from 1.65 (95% confidence interval [CI]: 1.22–2.25) for 
oropharyngeal cancer27 to 2.6 (95% CI: 1.3–5.2) for oral cancer.18 The RRs associated with some ST 
products may be especially high; for example, the RR associated with toombak is 3.9,28 and relative 
risks ranged from 2 to as high as 14 for “tobacco chewers” (including users of pattiwala, naswar, khaini, 
and zarda) in India and Pakistan.2 In contrast, although increased risks were observed in some studies of 
Scandinavian snus,29 most evidence from Swedish studies does not support a causal association between 
snus use and oral cancer.2,18,27 
Relative risk (RR): The likelihood of an event happening in one group/
country/region, etc., compared to another group.  
RR = 1 (no difference between the groups) 
RR >1 (increased risk in one group compared to the other) 
RR <1 (decreased risk in one group compared to the other) 
A relative risk of 1 indicates no difference between the groups, whereas 
a relative risk greater than 1 indicates an increased risk, and a relative 
risk less than 1 indicates a decreased risk. 
Precancerous Lesions and Other Oral Conditions 
Many studies from the United States, Scandinavia, and Asia provide conclusive evidence that ST 
products, including snus, snuff, shammah, and betel quid (paan), are strongly associated with the 
prevalence of oral mucosal lesions such as leukoplakia, erythroplakia, and verrucous hyperplasia.2,18,30 
These lesions are important because studies show a high risk of cancers arising from leukoplakia and 
oral submucous fibrosis.9,31 Lesions tend to occur at the site of ST application and may vary depending 
on the product used. In comparison with use of chewing tobacco, use of snuff is associated with more 
frequent development of oral mucosal lesions and a greater variety of epithelial changes.31 Chewing 
areca nut or betel quid with or without tobacco is also strongly associated with leukoplakia and oral 
submucous fibrosis.9,32 Oral mucosal lesions are more severe in people who begin use at an earlier age, 
use ST for more hours per day, use greater dosages, or use on more days per month.2 The lesions usually 
resolve when people stop using smokeless tobacco.2 
Use of ST can lead to increased inflammation of the buccal and gingival mucosa.33 The combination of 
ingredients in gutka—tobacco, areca nut, and slaked lime (calcium hydroxide)—may cause greater 
inflammation than one of these ingredients used alone.34 Incidence of gingival recession, commonly 
adjacent to the area where the tobacco is held, is higher among individuals who use snus or snuff than 
among people who do not use smokeless tobacco.30,33,35 Gingival recession can be observed within one 
year of beginning to use smokeless tobacco.2 Prevalence of dental decay and caries is associated with 
the use of chewing tobacco.33  




Available epidemiologic evidence from Scandinavia and Asia supports a causal association between 
esophageal cancer and use of ST, including snus, snuff, and chewing tobacco.2,18,27 Summary RRs 
comparing ST users to non-users, based mainly on studies from Sweden, range from 1.13 (95% CI: 
0.95–1.36; adjusted for smoking)27 to 1.6 (95% CI: 1.1–2.3).18 Evidence of a dose–response trend with 
amount and duration of use was reported in two studies.2 
Pancreatic Cancer 
The pancreas is one of the target sites of TSNAs.2 Available epidemiologic evidence from Scandinavia 
and Asia supports a causal association between pancreatic cancer and use of ST, including snus and 
mishri.2,18,36,37 Evidence of a dose–response trend with amount and duration of use was reported in two 
studies.1 
Lung Cancer 
Although the lungs are also a target site of TSNAs,21 available evidence is inadequate to determine if ST 
use causes lung cancer.2 Epidemiologic cohort studies comparing ST users to non-users from the United 
States (summary RR = 1.8; 95% CI: 0.9–3.5) and India (hazard ratio [HR] = 1.6; 95% CI: 0.9–2.9) 
reported an increased risk, but findings from cohort studies from Scandinavia have suggested no 
association (summary RR = 0.8; 95% CI: 0.6–1.0).18,37 
Cervical Cancer 
The evidence that ST use is associated with increased risk of cervical cancer is limited but plausible.38 
Although numerous epidemiologic studies have confirmed that smoking is an independent risk factor for 
cervical squamous cell carcinoma,1 few epidemiologic studies have been conducted on the association 
between ST use and increased risk of cervical cancer. However, some research has shown that higher 
levels of carcinogen-DNA adducts have been measured in cervical cells of smokers than in those of 
non-smokers.13 Both NNK and BaP have been detected in human cervical cells and are metabolically 
activated in cervical tissue.2 Nicotine exposure alone can increase the expression of epidermal growth 
factor receptors (EGFRs) in cervical cancer cell lines; metabolites of BaP induce activation of EGFRs 
that promote cell proliferation.13 Increased risk of cervical cancer with use of chewing tobacco and snuff 
was observed in a case-control study in the United States (RR for moderate use = 4.7, and heavy 
use = 3.6, compared to no use).2 In a case-control study among non-smoking Indian women, women 
who had ever chewed tobacco (with or without areca nut) had a greater risk of cervical cancer mortality 
than women who did not chew tobacco; this association held true among women in both urban (OR 2.0, 
95% CI: 1.5–2.7) and rural (OR 2.2, 95% CI: 1.5–3.2) areas.38 Another case-control study in India 
observed a significant dose-response relationship between the number of betel quids with and without 
tobacco chewed per day and increased risk of invasive cervical cancer; ever use of betel quid was 
associated with a nonsignificant twofold increased risk.9 In a study in Côte d’Ivoire, high-grade cervical 
squamous intraepithelial lesions were more common among women who chewed tobacco.39 
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Adverse Health Consequences: Cardiovascular Effects 
Conceptual Model 
Much of the work on the cardiovascular effects of tobacco and nicotine has focused on cigarette 
smoking13; some, but not all, of these mechanisms also may be applicable to ST use. Several of the 
constituents in cigarette smoke that are implicated in cardiovascular effects are also present in ST, 
although in differing amounts. These include nicotine, PAHs, and heavy metals such as cadmium.40 
PAHs have been shown to accelerate atherosclerosis in experimental animals.13 Heavy metals such as 
cadmium catalyze the oxidation of cellular proteins, which may accumulate in the aortic wall and result 
in endothelial damage.13 Additionally, some substances added to ST, such as punk ash or licorice, are 
reported to have adverse effects on the cardiovascular system.13 Figure 4-5 presents a conceptual model 
of adverse cardiovascular effects associated with ST use (adapted from the conceptual model of adverse 
cardiovascular effects associated with cigarette smoking as described in Benowitz 200341). 
Figure 4-5. Conceptual model of adverse cardiovascular effects of smokeless tobacco 
Source: Adapted from Benowitz 2003 (41). Used with permission. 
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As illustrated in the model, nicotine has a range of cardiovascular effects. Its effects mimic those of the 
body’s sympathetic nervous system, acutely increasing blood pressure, heart rate, and the strength of the 
heart’s contractions, all of which increase the heart’s demand for oxygen and nutrients.18 Nicotine also 
can contribute to inflammation, thus potentially contributing to atherogenesis.41 Moreover, nicotine 
directly affects blood vessels and can contribute to the development of endothelial dysfunction.41 In 
addition, nicotine in tobacco products may contribute to insulin resistance and hyperinsulinemia, both of 
which are linked to mitogenesis (cell proliferation), vasoconstriction, and inflammation, potentially 
contributing to the development of endothelial dysfunction and atherosclerosis.42 Oral moist snuff users 
have shown decreased brachial artery flow–mediated dilation, a marker for endothelial dysfunction.43 
Because many of these studies have been conducted with individuals who use a range of tobacco 
products, the effects may be due to nicotine acting along with other tobacco constituents, rather than to 
nicotine alone. Additionally, safety studies have not shown any increased cardiovascular risk, even in 
people with existing cardiovascular disease who use nicotine replacement therapies.13  
Hypertension 
Several constituents of ST products, including nicotine, sodium, and licorice, can aggravate 
hypertension.40,44 Although some ST products clearly cause acute, transient increases in blood 
pressure,45 studies from the United States and Sweden do not provide evidence of increased prevalence 
of hypertension in ST users.40 In a study in South Africa, women who used snuff had a higher 
prevalence of hypertension than women who did not use snuff, but this association was attenuated 
after controlling for other cardiovascular risk factors.46 The prevalence of diastolic (but not systolic) 
hypertension was higher among Indian men who exclusively used ST products (mainly moist snuff, 
betel quid, and pan masala with tobacco) than among men who used no tobacco.47 In another study, the 
prevalence of both diastolic and systolic hypertension was higher among Indian men who exclusively 
chewed tobacco (mainly gutka, paan, and khaini) than among men who used no tobacco.48 One study 
from Sweden provides evidence that ST users may have a higher risk of developing hypertension.40 
Heart Disease and Stroke 
A substantial body of evidence from the United States, Sweden, and Asia indicates that ST use is 
associated with an increased risk of fatal ischemic heart disease and stroke, but is not associated with an 
increased risk of non-fatal myocardial infarction (MI) and non-fatal stroke.2,40,49,50 This finding suggests 
that thrombosis is a major mechanism by which ST increases cardiovascular risk44 and/or that ST use 
negatively affects survival after a cardiovascular event.40 Some studies suggest an increased risk of 
non-fatal cardiovascular disease associated with use of ST including snuff, chewing tobacco, betel quid 
with tobacco, and mishri, but evidence is limited.51–53 Data on dose–response trends are limited. 
Summary RRs for fatal ischemic heart disease range from 1.1 (95% CI: 1.04–1.19) in the United States 
and 1.1 (95% CI: 0.78–1.38) in Asia to 1.3 (95% CI: 1.07–1.52) in Sweden. Summary RRs for fatal 
stroke range from 1.3 (95% CI: 0.91–1.70) in Sweden and 1.3 in Asia (95% CI: 1.08–1.56) to 
1.4 (95% CI: 1.22–1.60) in the United States.49,50 






Adverse Health Consequences: Miscellaneous Other Diseases 
and Conditions 
Diabetes and Insulin Resistance 
Although nicotine increases circulating levels of insulin-antagonistic hormones and impairs insulin 
sensitivity,13 the few studies that have examined the association between ST use and the development 
of insulin resistance, metabolic syndrome, and diabetes have yielded conflicting results.2,40 Heavy use 
of Swedish snus appears to be associated with an increased risk of developing type 2 diabetes.40 
Conditions of the Nasal Cavity 
Some types of ST are inhaled nasally, including dry (powdered) snuff and Brazilian rapé54 and products 
used in India and South Africa. Limited information is available about the effects of ST on the nasal 
cavity. Nasal use of snuff has been associated with edema of the mucosa and submucous conjunctive 
tissue of the turbinates, atrophy of the middle and inferior turbinates, inhibition of nasal mucociliary 
clearance, and chronic rhinitis.54 Existing studies on nasal use of snuff have not provided conclusive 
evidence of a relationship with cancer.2 
Reproductive Outcomes 
Several constituents in ST have been shown to be reproductive or developmental toxicants, including 
nicotine, areca nut, PAHs, and several metals—particularly arsenic, cadmium, lead, and mercury.9,13 
Decreased perfusion from nicotine is not believed to be a major contributor to adverse fetal outcomes; 
rather, hypoxia is likely due to CO exposure. Metals may cause oxidative stress in cells and interfere 
with fetal nutrition.13 Evidence suggests that infants born to women who use ST (including snus, betel 
quid, and mishri) during pregnancy have a higher risk of several adverse outcomes such as gestational 
age/pre-term birth and fetal growth restriction.2,9,31,48,55–57 
Addiction 
Research evidence shows that ST products initiate and sustain dependence and addiction.2,58 Nicotine in 
tobacco causes addiction; other substances in ST products may reinforce nicotine’s addictive effects.13 
Physiologic manifestations of ST addiction include tolerance with repeated use, symptoms of 
withdrawal upon cessation of regular use, and pleasurable psychoactive effects.59 Smokeless tobacco 
users continue to crave and use ST despite harmful consequences, tend to switch to products with higher 
nicotine levels, and frequently relapse upon cessation.2 Addiction to ST is related to age at initiation, 
amount of nicotine ingested per day, and years of use.2  
Smokeless Tobacco Use as a Risk Factor for Cigarette Smoking 
One important question is whether ST use promotes smoking initiation, particularly among youth. 
Smokeless tobacco products contain nicotine, and development of nicotine addiction may increase the 
risk of transitioning to smoking.60 Some studies, but not others, have shown that young people in the 
United States who use ST are more likely to smoke cigarettes.35,61 However, studies in Sweden have not 
observed that snus use among youth leads to cigarette use among adults.31 Little evidence is available 
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about whether ST use precedes cigarette smoking in other countries, and transitioning from using ST to 
smoking is likely to depend heavily on social norms and tobacco industry marketing. 
A second important question is whether cigarette smokers who may otherwise have quit using tobacco 
prolong tobacco use or engage in dual use by using smokeless tobacco.1 For example, studies in the 
United States have found that smokers who may have otherwise quit using tobacco may switch to ST as 
a substitute for smoking or use both tobacco products concurrently (i.e., dual use).13,62,63 A major 
concern about novel products like dissolvables—which have not been marketed long enough for 
epidemiologic data on health risks associated with them to become available—is that these products are 
marketed to provide smokers with an alternative source of nicotine in settings where smoking is 
prohibited.64,65 People who both use ST and smoke cigarettes may have greater levels of toxicants, such 
as NNK, than people who use only one tobacco product, which suggests that a combination of ST use 
and smoking may have greater health risks than smoking alone.13,51,60 Dual use of cigarettes and ST 
products may prolong rather than shorten the duration of smoking, thereby increasing the risks from 
continued smoking. It is also possible that some individuals substantially reduce cigarette smoking when 
they begin using ST, but the extent to which cigarette smoking would have to be reduced to result in 
lower health risks is unknown, especially when cigarettes are used in conjunction with smokeless 
tobacco. Additionally, evidence on the effectiveness of ST as a smoking cessation aid is insufficient.66 
Abstaining from all forms of tobacco use is the most effective way to prevent its morbidity and 
mortality.13 
The Health Consequences and Disease Burden of Smokeless 
Tobacco Products 
Understanding the global disease burden of ST use is important for informing tobacco prevention 
and control efforts. This impact is a function of the number of ST users multiplied by the magnitude 
of the risk. However, given the variety of products and conditions of use, in addition to limited 
product-specific data, estimating this total burden is not straightforward.  
One way to measure the public health impact of an exposure to a risk factor is to calculate the 
proportion of cases of a given disease causally related to that risk factor, called the attributable 
fraction (AF). For example, the attributable fraction of lung cancer caused by cigarette smoking is 
over 90 percent.67 
The AF due to ST use can be estimated using the RR associated with ST use and the percentage of 
people in the population who use ST (p) according to the formula68: 
 






Then the attributable burden (AB), the number of cases (or deaths) attributed to ST use out of the total 
number of cases (or deaths) in the population, can be estimated by multiplying the AF by the total 
number of cases (or deaths) (D), according to the formula: 
 
Because RR varies by type of ST and underlying disease prevalence varies by country, the attributable 
burden should be calculated for each country separately. As an example, this chapter includes estimates 
of the AB due to ST use in Sweden, the United States, and India. These countries were chosen as 
examples because much of the evidence on the associations between ST use and health consequences 
comes from studies conducted in these countries,18,49 and because the ST products commonly used in 
these countries represent a wide range of products. (The prevalence of ST use was obtained from 
surveys reported between about 2008 and 2011; for descriptions of the ST products used and the 
prevalence of use in these three countries, see chapters 9, 10, and 13.) The RR estimates associated with 
ST use (Table 4-2) were obtained from reviews of studies in Scandinavia and the United States18,49 and 
from studies in India and surrounding regions.37,50 Cancer incidence data for 2008 were obtained from 
GLOBOCAN (http://globocan.iarc.fr/). These data were applied to the above formulas to estimate the 
attributable fraction and the annual attributable burden of disease due to ST use in Sweden, the United 
States, and India (Table 4-3). The estimated numbers of incident cancers of the oral cavity, esophagus, 
and pancreas attributed to ST use in 2008 ranged from about 130 in Sweden, to over 2,500 in the United 
States, and over 58,000 in India (Table 4-3). These estimates demonstrate the variability in public health 
impact caused by ST under different scenarios.  
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Table 4-2. Relative risks associated with smokeless tobacco use 
Outcome Country/region 
Type of smokeless 
tobacco Relative risk Source* 
Oral cancer United States Chew or snuff 2.6 (1.3–5.2) Boffetta et al. 2008 (18) 
 Scandinavia Snus 1.0 (0.7–1.3) Boffetta et al. 2008 (18) 
 India Smokeless tobacco† 5.1 (4.3–6.0) Boffetta et al. 2008 (18) 
Esophageal cancer United States Smokeless tobacco† 1.2 (0.1–2.3) Boffetta et al. 2008 (18) 
 Scandinavia Snus 1.6 (1.1–2.4) Boffetta et al. 2008 (18) 
 India Smokeless tobacco† 3.7 (1.6–8.4) Pednekar et al. 2011 (37) 
Pancreatic cancer United States Chew or snuff 1.4 (0.7–2.7) Boffetta et al. 2008 (18) 
 Scandinavia Snus 1.8 (1.3–2.5) Boffetta et al. 2008 (18) 
 India Mishri & other 2.0 (0.7–5.5) Pednekar et al. 2011 (37) 
Lung cancer United States Chew or snuff 1.8 (0.9–3.5) Boffetta et al. 2008 (18) 
 Scandinavia Snus 0.8 (0.6–1.0) Boffetta et al. 2008 (18) 
 India Mishri & other 1.6 (0.9–2.9) Pednekar et al. 2011 (37) 
Fatal ischemic heart disease United States Chew or snuff 1.1 (1.0–1.2) Boffetta & Straif 2009 (49) 
 Sweden Snuff 1.3 (1.1–1.5) Boffetta & Straif 2009 (49) 
 Asia Smokeless tobacco† 1.1 (0.8–1.4) Zhang et al. 2010 (50) 
Fatal stroke United States Chew or snuff 1.4 (1.2–1.6) Boffetta & Straif 2009 (49) 
 Sweden Snuff 1.3 (0.9–1.7) Boffetta & Straif 2009 (49) 
 Asia Smokeless tobacco† 1.3 (1.1–1.6) Zhang et al. 2010 (50) 
*Numbers in parentheses correspond to full citations in the References at the end of this chapter. 
†Type of smokeless tobacco not specified. 
Note: Relative risks associated with smokeless tobacco use are provided for the purposes of illustration, as some uncertainty still 
surrounds some of the values provided. Nevertheless, this table and Table 4-3 demonstrate the variability in public health impact 
from smokeless tobacco under different scenarios. 






Table 4-3. Annual burden of disease attributable to smokeless tobacco use in three countries: Sweden, 
United States, and India 
Country/disease Sex Relative risk 
Prevalence  





of disease (new 
cases per year) 
United States      
Oral cancer Men 2.6 6.9% 9.9% 1,566 
 Women 2.6 0.3% 0.48% 35 
Esophageal cancer Men 1.2 6.9% 1.4% 182 
 Women 1.2 0.3% 0.06% 2 
Pancreatic cancer  Men 1.4 6.9% 2.7% 507 
 Women 1.4 0.3% 0.12% 23 
Sweden      
Oral cancer Men 1.0* 26% 0% 0 
 Women 1.0* 7% 0% 0 
Esophageal cancer Men 1.6* 26% 13.5% 39 
 Women 1.6* 7% 4.0% 4 
Pancreatic cancer  Men 1.8* 26% 17.2% 67 
 Women 1.8* 7% 5.3% 23 
India      
Oral cancer Men 5.1 33% 57.5% 26,131 
 Women 5.1 18% 42.5% 10,359 
Esophageal cancer Men 3.7 33% 47.1% 13,569 
 Women 3.7 18% 32.7% 6,308 
Pancreatic cancer Men 2.0 33% 24.8% 1,260 
 Women 2.0 18% 15.3% 593 
* Relative risks for Sweden in these cases are not country-specific, but represent relative risks calculated for Scandinavia (see 
Table 4-2).  
Sources: Relative risk of disease associated with smokeless tobacco use from Table 4-2; Sweden: prevalence of ST use from the 
2012 National Survey on Public Health (70), Table 2-3; United States: prevalence of ST use from the 2009 National Survey on Drug 
Use and Health (71); India: prevalence of ST use from the 2009–2010 Global Adult Tobacco Survey (72); Cancer incidence data for 
2008 from GLOBOCAN (73).  
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The differences between attributable burden rates reflect both the different RRs seen in studies of ST use 
in these countries (likely due to differences in products and how they are used) as well as differences in 
the number of ST users, disease incidence, and the size of the overall country population. The 
attributable burden will be large if any of the factors is large (Figure 4-6). That is, the AB will be great if 
the RR is high, if the proportion of people who use ST is large, or if there is a high background risk of 
disease. For example, oral cancer is a relatively rare disease among men in the United States (15,800 
cases annually), and the association between ST use and oral cancer is moderate (RR = 2.6). With 6.9% 
of men using ST, the fraction of oral cancers attributed to ST use in men is 9.9%, and the attributable 
burden is about 1,600 cases. If more men began using ST, both the number of oral cancers would 
increase and the proportion attributable to ST use would increase. If future research determines that ST 
use is a cause of common diseases such as ischemic heart disease or stroke, even the relatively small RR 
associated with these diseases would result in a large number of deaths attributable to ST use. For 
example, the number of deaths from ischemic heart disease and stroke in 2008 potentially attributable to 
ST use would be approximately 1,000 in Sweden, 4,600 in the United States, and 300,800 in India.  
Figure 4-6. Attributable risk increases with relative risk and prevalence of exposure/use 






The health impact and disease burden of ST use may be influenced by other forms of tobacco use, 
particularly cigarette smoking, in at least three ways. First, some smokers who would otherwise have 
quit smoking because of restrictions on smoking may instead use ST as a situational substitute and 
continue to smoke. In such cases, ST products may prolong rather than shorten the duration of smoking, 
thereby increasing the risks from continued smoking.13 Second, some epidemiologic studies show that 
dual use of ST and cigarette smoking could have greater health risks than smoking alone.13,51 Third, 
although cigarette smokers who permanently switch to exclusive ST use may reduce their risks for some 
diseases specifically associated with smoke exposure, the single study that examined this issue found 
that smokers who quit all tobacco use had lower mortality rates from lung cancer, coronary heart 
disease, and stroke than those who switched to ST use.69  
Gaps and Limitations in the Current Evidence Base 
Compared with the vast amount of information linking adverse health effects to cigarette smoking, 
studies on ST use are not comprehensive. Epidemiologic studies of ST use have less information about 
what levels of use are associated with particular outcomes, and, in some countries, fewer numbers of ST 
users on which to base conclusions. Some, but not all, studies attempt to control for factors such as 
consumption of other tobacco products and alcohol, which may confound or modify the association with 
ST use. Also, given that the median time between smoking initiation and death from lung cancer may be 
as long as 50 years,67 data on novel products such as Swedish snus may not have accumulated for a long 
enough period of time to fully characterize the associated risk. 
Estimates of the proportion of the population using ST may not be available in all countries or may not 
reflect current prevalence. Prevalence may be difficult to estimate because of the variety of ST products 
and the possibility of multiple product use. Therefore, it may be necessary for countries to include 
measures of ST use in surveys, and to ensure that the information is product specific. Generic data on ST 
use will not provide the type of specificity necessary for accurate information on disease burden. Also, 
while reliable data on cancer incidence and mortality are available in many countries, there may be 
fewer resources for reliable data on incidence and prevalence of other conditions such as reproductive 
toxicity, cardiovascular disease, precancerous oral lesions, and diabetes. Current estimates of disease 
burden are critical for diseases that have an increasing trend (pancreatic cancer) or decreasing trend 
(heart disease). Chapters 9 to 14 in this report will help to fill in some of these data gaps. 
Summary and Conclusions  
Smokeless tobacco is used in various forms throughout the world. All ST products contain nicotine, and 
ST users exhibit characteristics of nicotine addiction similar to cigarette smokers. Smokeless tobacco 
products contain numerous known carcinogens, although in varying levels depending on product 
characteristics such as type of tobacco, additives, alkalinity, and processing methods. Many products 
also contain other plant materials (areca nut or tonka bean) or additives that may be carcinogenic or have 
other adverse health effects. For this reason, the assessment of health risks associated with ST products 
should include not only tobacco but also the more complex mixture of ingredients that may further 
increase risk. 
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Based on information from large, comprehensive reviews,1,2,9,31,40,58 the following conclusions can be 
reached:  
 The associations between ST use and adverse health consequences differ by type of product.  
 There is sufficient evidence that ST products cause addiction, precancerous oral lesions, and 
cancer of the oral cavity, esophagus, and pancreas, as well as adverse reproductive 
developmental effects including stillbirth, pre-term birth, and low birth weight.  
 The evidence suggests that some, but not all, ST products are associated with increased risk of 
fatal ischemic heart disease, fatal stroke, and type 2 diabetes; more studies are needed to clarify 
any causal associations.  
 There is insufficient evidence to assess whether ST products are associated with increased risks 
of lung cancer, cervical cancer, and hypertension. 
The public health impact of ST use depends on the disease risk associated with a given ST product, the 
prevalence and manner of ST use, and the background burden of disease in the target population. These 
elements may be difficult to quantify because of the lack of data specific to particular products and 
regions. Sample calculations of the attributable disease burden suggest wide disparities in the impact of 
ST across countries. Additionally, the role of ST use in shaping other tobacco use behaviors (such as 
smoking cessation or initiation) should be considered. Currently available data are insufficient to 
provide a robust estimate of the global disease burden due to ST use. In the long run, comprehensive 
monitoring of ST use and related health outcomes is needed, especially in those countries where use is 
high. Nevertheless, evidence is sufficient to conclude that on a global scale, the negative health effects 
of ST use are substantial and completely preventable.  
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Economic analysis of the smokeless tobacco (ST) market is relatively undeveloped compared to analysis 
of the cigarette market. Understanding economics of the ST market, such as the demand, pricing, and 
taxation structure for ST, is important for understanding tobacco control. This chapter summarizes the 
literature (written in or translated into English) and available economic data on ST in the context of two 
separate and distinct marketplaces: the modern market and the traditional market (defined below). The 
chapter also provides the first systematic overview of ST excise tax rates and points out the vast gaps in 
both economic data and economic research related to ST use.  
Smokeless Tobacco and Cigarette Markets  
The ST market is different from the cigarette market in several key aspects.  
First, the cigarette market offers, in most cases, a relatively homogenized and consistent product within 
and between countries. A pack of Marlboro cigarettes purchased in Cameroon is similar to a pack of 
Marlboro cigarettes purchased in Canada or Cambodia. On the other hand, ST purchased in Sweden is 
very different in terms of ingredients and types of products from ST purchased in India or Sudan.  
Second, although cigarettes are a legal product in every nation of the world (except Bhutan), the sale of 
ST has been effectively banned in nearly 40 countries,1 most of which are in Europe or the Western 
Pacific. As a result, and because ST is not widely used in many nations, the consumption of ST is 
largely concentrated in a few specific regions of the world. Cigarettes, in contrast, are consumed in 
almost all parts of the world. 
Third, ST markets in low- and middle-income countries are not yet dominated by multinational tobacco 
corporations; the products consumed in those countries are often homemade or manufactured within a 
fragmented network of small, locally owned businesses. The ST market in many high-income countries, 
however, has become more highly concentrated, with multinational tobacco corporations owning the 
largest share. This concentration among multinationals has implications for tobacco surveillance, the 
regulatory environment, and economies of scale.  
Fourth, ST markets are much less regulated than cigarette markets, particularly in low- and middle-
income countries, and this lack of regulation affects tax levels and the effectiveness of collecting taxes 
on smokeless tobacco.  
Given the diversity and complexity of the ST market, we define two separate, broad categories: modern 
markets and traditional markets. Modern markets, primarily located in Scandinavia and North America, 
are characterized by the presence of multinational corporations and the predominance of standardized, 
commercially manufactured ST products (defined in chapter 3 as one form of premade ST product). 
Traditional ST markets are much less concentrated, trading a large variety of products made under 
loosely defined standards (which would include cottage industry products, as defined in chapter 3, and 
custom-made products). These markets can be found in South Asia, Central Asia, South America, and 
Sub-Saharan Africa. The best available estimates indicate that, by volume, 91.3% (648.2 billion tons) of 
the ST products sold worldwide (710.2 billion tons) are sold in traditional markets.2 In contrast, the 
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monetary value of ST sales in modern markets (US$7.882 billion) is higher than in traditional markets 
(US$6.548 billion).2 Estimates of the size of traditional markets are conservative, however, as they do 
not include some important markets such as Bangladesh. 
Overall, ST sales represent approximately 2.2% of the value of the global tobacco products market.2 
Although this figure is projected to grow considerably, cigarettes have the majority share of the 
tobacco market.3  
Globalization of Smokeless Tobacco Markets 
The business outlook for ST markets was positive as of 2012. Growth was expected in both the modern 
and traditional ST markets, making ST a profitable investment for multinational tobacco companies, 
which have increased their presence in modern markets. For example, the leading U.S. cigarette 
manufacturers decided to expand into the ST market and acquired the two largest U.S. smokeless 
tobacco manufacturers: U.S. Smokeless Tobacco (acquired by Philip Morris USA in 2009) and 
Conwood (acquired by Reynolds American in 2006). In addition, the largest Swedish ST corporation, 
Swedish Match, entered the U.S. smokeless tobacco market in the early 2000s. By 2010, Altria (the 
American parent company of Philip Morris USA, which sold Philip Morris International in 2008) owned 
56% of the U.S. ST market by volume, whereas Reynolds had 30.3% of the market share.4,5  
In addition to capturing most modern markets, the multinational corporations have attempted to enter 
traditional markets. For example, Swedish Match, Phillip Morris, and British American Tobacco (BAT) 
have tried (thus far unsuccessfully) to capture a portion of the massive Indian ST market, and Japan 
Tobacco International made inroads into the rapidly growing Nigerian ST market.6 If these efforts 
continue, traditional markets can be expected to start selling more standardized ST products. 
It is difficult to accurately track the extent of the global ST trade because the United Nation’s 
commodities trade statistics database, Comtrade, does not disaggregate ST products from other tobacco 
products that are being traded.7 Table 5-1 summarizes imports and exports for several important ST 
markets using data obtained from multiple sources. The major ST-exporting countries are India, 
Sweden, and the United States. The primary ST importers are Canada and Norway. Because the United 
States is not a Party to the World Health Organization Framework Convention on Tobacco Control 
(WHO FCTC) and therefore does not have an obligation to provide an FCTC Party report, which is the 
primary source of these data, the United States is not included in this table. 
  






Table 5-1. Global smokeless tobacco trade in selected countries 
Country  Product Export (kg) Import (kg) Year Source* 
Sweden Chew and snuff  1,752,600 5,614 2009 Johansson 2010 (76) 
Canada Smokeless tobacco — 27,377,139 2008 Sabiston 2010 (16) 
Norway Swedish snus — 1,101,720 2009 Lindbak & Wilson 2010 (45) 
Norway Chew — 12,800 2009 Lindbak & Wilson 2010 (45) 
Italy Snuff — 10,000 2009 Galeone 2010 (77) 
Iceland Snuff — 19,953 2008 Guðmundsdottir & Jensson 
2009 (78) 
Singapore Snuff — 90 2009 Taylor & Ling 2010 (79) 
Singapore Other smokeless tobacco 
products 
— 10,400 2009 Taylor & Ling 2010 (79) 
India Chew 8,725,000 — 2007–2008 Tobacco Board 2011 (80) 
India Snuff 85,000 — 2007–2008 Tobacco Board 2011 (80) 
*Numbers in parentheses correspond to full citations in the References at the end of this chapter. 
Abbreviation: kg = kilogram. 
Smokeless tobacco may also be traded illegally across borders.2 Such illicit trade of ST may circumvent 
policies that ban the import and sale of ST products in certain nations and could be the source of the ST 
used in those nations. Although there are no estimates of the size of the illicit ST trade, customs 
authorities in several countries have reported confiscating illicit ST products. Data on ST seizures are 
compared with cigarette seizures in Table 5-2. Cigarettes are confiscated much more frequently than ST 
products in the few modern market countries for which data are available. There are also reports of 
illicitly traded counterfeit ST products, but evidence of the practice is scarce.8,9 
Although tax is most likely not collected on illicitly traded ST products, much larger tax leakage is 
assumed to occur in the domestic markets, primarily in traditional markets, due to weak tax 
administration and the challenges associated with collecting ST in a highly diversified market.10 
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seized Year Source* 
Modern markets     
Finland  54 kg 16,044 kg 2009 Hirvonen & Annala 2009 (81) 
Malta 4 kg 25,197,477 units 2010 Kingswell & Vincenti 2011 (82) 
Sweden 928 kg 56,900,000 units 2009 Euromonitor 2010 (2); Johansson 2010 (74) 
Traditional markets     
Algeria 4,000,000 kg — 2008 Euromonitor 2010 (2) 
Bhutan 1,823 kg 472,600 units 2010 Norbu 2010 (83) 
Brunei Darussalam 2 kg 58 kg 2009 Haji 2010 (84) 
India 21,109,000 kg 214,205,000 kg 2009 Desiraju 2010 (85) 
Nepal 147,504 kg — 2005 Government of Nepal 2007 (86) 
Oman 126,777 kg 17,743,000 units 2006 Al-Lawati 2007 (87) 
*Numbers in parentheses correspond to full citations in the References at the end of this chapter. 
Abbreviation: kg = kilogram. 
Modern Markets 
Geography and Characteristics 
Canada, the United States, and the Scandinavian countries of Northern Europe, represent the modern ST 
marketplace, each country having a sizeable, predominantly male population of ST users. 
Although the rate of ST use is much lower in the United States (3.6% of the adult population in 2012) 
than in Sweden (17.0% of adults in 2010) (see chapter 2), the population of the United States is more 
than 300 times larger than Sweden’s, thus the United States has significantly more ST users.11,12 
In contrast, 18.1% of American adults were current cigarette smokers in 2012, representing a market of 
more than 42 million cigarette users.13 However, ST is a growing segment of the U.S. tobacco market, 
for which marketing expenses more than doubled between 2005 and 2008.4,14 The most commonly used 
ST product in the United States is moist snuff, known as “dip.” Newer forms of ST, like snus and 
dissolvables are available in the United States, whereas sales of the oldest American ST product, 
chewing tobacco, continue to decline.15 Two cigarette multinational corporations, Altria and Reynolds 
American, dominate the U.S. market, and the Swedish multinational ST corporation Swedish Match 
maintains a significant presence. 
The Canadian ST market closely resembles the U.S. ST market in terms of its product selection and 
distribution system. About 2.4% of adult Canadian men aged 15–24 consumed some form of ST in 
2008.16 As in the United States, ST is consumed primarily in the form of moist snuff; chewing tobacco is 
much less popular. Canada does not manufacture ST products but imports most of them from the United 
States.17 The leading distributor is the National Tobacco Company, which supplied 82% of Canada’s ST 






market in 2009; Imperial Tobacco Canada supplies the remainder of the market.17 Because most ST 
imports come from the free-trade zone set up by the North American Free Trade Agreement, import 
duties are rarely levied.16 Similar to the United States, Canada was classified by business analysts as a 
growth market for ST products.18 
With few exceptions, ST is an illegal product in European Union (EU) countries. The EU’s Tobacco 
Products Directive19 on oral tobacco products prevents the marketing and sale of “oral tobacco,” which 
they define as “all products for oral use, except those intended to be smoked or chewed, made wholly 
or partly of tobacco, in powder, … sachet portions, … or in a form resembling a food product.”19,p.4 
This narrow definition of “oral tobacco” effectively bans snus and moist snuff, but chewing tobacco 
and nasally consumed ST (dry snuff) can be sold legally in all EU countries.20 
Sweden, the only EU country exempt from the Directive on oral tobacco products, is an important and 
well-defined modern market for ST. Approximately 17% of Swedes consume ST (26% of males and 7% 
of females) (chapter 2). Swedish Match has a dominant share of the market (85.8% of retail volume) 
followed by Fiedler & Lundgren/British American Tobacco (9.2%) and Skruf Snus (2.8%).21  
Norway, which is not an EU member, has about 10% ST use prevalence (17% of males and 5% of 
females use ST) (chapter 2). The Norwegian ST market is dominated by Swedish Match, which had an 
80% share of the market value in 2009. Other multinationals with a market presence are British 
American Tobacco and Imperial Tobacco.22  
Because the EU Directive does not ban chewing tobacco, there is still a market for chewing tobacco 
products in the United Kingdom, particularly “traditional” chewing tobacco products that are commonly 
used in South Asia.23 The vast majority of Britons who consume ST products are South Asian 
immigrants, who produce and distribute ST in a way that closely resembles traditional markets in their 
countries of origin.24–26 The general regulatory environment of the UK, however, is similar to that in 
other modern ST markets. 
A mixed ST market exists in South Africa, where major multinational cigarette corporations control the 
manufacture and distribution of ST products usually sold in a manner that resembles traditional markets. 
Corporate Influence 
The multinational tobacco companies British American Tobacco, Phillip Morris International, and 
Swedish Match have begun to consolidate the modern ST market, a process reminiscent of the 
consolidation of the tobacco industry into the American Tobacco Company (also known as the “Tobacco 
Trust”) at the turn of the 20th century.27,28 
Figure 5-1 illustrates developments since 2005 in the ownership of modern ST markets.29–33 Japan 
Tobacco International, British American Tobacco (a major stakeholder in Reynolds American), Imperial 
Tobacco, and Phillip Morris International have invested in both cigarette and ST markets, although 
cigarette sales are still their primary focus. Swedish Match has an international presence in the ST 
marketplace, but not in the cigarette marketplace. As a result of the consolidation process, the modern 
markets are dominated by five multinational tobacco corporations.34 
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Figure 5-1. Consolidation of the modern smokeless tobacco market, 2005–2010  
 
*In 2008, Skandinavisk Tobakskompagni changed its name to Scandinavian Tobacco Group. 
Figure 5-2 shows the change in these five multinational corporations’ combined market shares in ST in 
the United States between 2001 and 2010, and contrasts them with the combined cigarette market shares 
of the four multinationals, that sell both cigarettes and smokeless tobacco. By 2010, ownership of the ST 
market was more concentrated than ownership of the cigarette market.34 Consolidation accompanied by 
homogenization of ST products allows for economies of scale, improves efficiency, and reduces 
production costs.35 
Entities operating in the modern ST marketplace are trying to market novel nicotine delivery products as 
distinct from tobacco products, both as a response to increasing regulation of the tobacco market and in 
an attempt to broaden the appeal and user base of ST. 
Tobacco companies are also beginning to brand newly introduced ST products under the same names as 
popular cigarette brands.36–40 This trend is most notable in the United States, where moist snuff and 
dissolvable tobacco products with names like Marlboro (Altria Group) and Camel (Reynolds American) 
have been introduced. In addition to stimulating sales of products bearing the Marlboro or Camel brand, 
this branding is apparently intended to encourage Marlboro/Camel cigarette smokers to substitute or 
supplement their use by using Marlboro or Camel ST products (see chapter 6).  






Figure 5-2. Combined shares of the U.S. cigarette and smokeless tobacco markets held by multinational 
tobacco corporations, 2001–2010 
 
Source: Authors’ calculations based on data from Euromonitor International 2011 (15). 
Tax 
Several types of taxes are levied on ST products. An excise tax is the most important because it can be 
used by policymakers to achieve public health goals.41 Excise taxes, similar to sales taxes, are internal 
taxes that can change the price of ST products relative to other consumer goods and make ST less 
affordable for the consumer, thereby reducing the quantity of ST demanded. There are two types of 
excise taxes: specific and ad valorem. A specific tax is charged as a fixed monetary value per physical 
unit of product. In the case of ST, the physical unit is usually a kilogram (e.g., in Iceland) or a smaller 
unit such as a sachet (in Madagascar). An ad valorem tax is charged as a percentage of the value of a 
product. The value of the product can be defined as the retail price, the manufacturer’s price, or by some 
other measure. In addition to excise tax, most ST products also carry taxes that are levied on other 
consumer goods, such as sales, consumption, or value-added taxes, and customs duties, which are 
imposed on imports.  
Table 5-3 presents ST tax rates in selected modern markets. These taxes are imposed on a national level 
and do not include any subnational taxes.  
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Table 5-3. Smokeless tobacco tax rates in modern market countries (per year) 
Country 





product Year Source* 
Albania 15.21  Snuff & chew 2011 Tobacco Merchants Association 
(TMA) 2011 (46); General Directorate 
of Tax (Albania) 2002 (88) 
Armenia 4.01  Snuff & chew 2011 TMA 2011 (46); Tax Service (Armenia) 
2000 (89) 
Bulgaria 95.34  Chew 2011 TMA 2011 (46); National Revenue 
Agency (Bulgaria) 2011 (90) 
Canada 60.17  Snuff & chew 2011 Sabiston 2010 (16); TMA 2011 (46) 
Croatia 7.40  Snuff & chew 2011 TMA 2011 (46) 
Czech Republic 73.55  Snuff & chew 2011 Czech Tax Administration 2011 (91) 
Denmark 44.05  Chew 2011 TMA 2011 (46); Skatteministeriat 2010 
(92) 
Denmark 11.23  Chew, snuff 2010 Skatteministeriat 2010 (92); Falk 2010 
(93) 
Estonia 43.04  Chew 2011 Alcohol, Tobacco, Fuel and Electricity 
Excise Duty Act (Estonia) 2009 (94) 
Finland  60.00% All 2010 Hiroven & Annala 2009 (81); 
Colliander 2009 (95) 
France  32.17% Chew 2011 TMA 2011 (46) 
Georgia 11.93  Snuff & chew 2011 TMA 2011 (46); Ministry of Finance 
(Georgia) 2009 (96) 
Germany  None Chew 2011 TMA 2011 (46) 
Iceland 42.17  Snuff 2009 Ministry of Finance (Iceland) 2009 (97) 
Ireland  22.00% Chew 2011 TMA 2011 (46) 
Italy  24.78% Chew 2011 TMA 2011 (46); European Commission 
2002 (98) 
Macedonia 31.42  Snuff & chew 2011 TMA 2011 (46); Official Gazette of the 
Republic of Macedonia 2010 (99) 
Malta 45.97  Chew 2011 Justice Services (Malta) 2010 (100) 
Mexico  30.40% Snuff & chew 2010 Secretaria de Hacienda (Mexico) 
2010 (101); Avila & Ajenjo 2010 (102) 
Netherlands 34.48  Chew 2011 TMA 2011 (46); Government of the 
Netherlands 2002 (103) 
Norway 168.92  Snuff & chew 2011 TMA 2011 (46); Customs and Excise 
Special Taxes Department (Norway) 
2011 (44) 
Poland  60.00% Chew 2011 TMA 2011 (46) 
Romania 116.20  Chew 2011 TMA 2011 (46) 












product Year Source* 
Russian 
Federation 
18.08  Snuff & chew 2011 TMA 2011 (46) 
Serbia  35.00% Snuff & chew 2011 TMA 2011 (46); Lazarevi & Stankovic 
2011 (104) 
Slovakia 96.06  Chew 2011 TMA 2011 (46); Ministry of Finance of 
the Slovak Republic 2009 (105) 
Slovenia  0.00%  2008 Čakš et al. 2008 (106); Ministry of 
Finance (Slovenia) 2010 (107) 
Spain  26.00%  2010 Hurtado & Férnandez 2010 (108) 
Sweden 64.18  Chew 2011 Skatteverket 2008 (42); TMA 2011 (46) 
Sweden 52.78  Snuff 2011 Skatteverket 2008 (42) 
Switzerland  5.00% Snuff & chew 2010 Les autorités fédérales de la 
Confédération (Switzerland) 2010 
(109); Grundlagen 2011 (110) 
Ukraine 2.51  Snuff & chew 2011 TMA 2011 (46); Schlesinger & Dye 2010 
(111) 
United Kingdom 137.35  Chew 2011 HM Revenue and Customs 2011 (112) 
United States  1.11  Chew 2011 TMA 2011 (46); Internal Revenue Code 
2009 (113) 
United States  3.32  Snuff 2011 TMA 2011 (46); Internal Revenue Code 
2009 (113) 
*Numbers in parentheses correspond to full citations in the References at the end of this chapter. 
Abbreviations: kg = kilogram; TMA = Tobacco Merchants Association.  
Smokeless tobacco is generally taxed at significantly lower rates than cigarettes (Table 5-4, Table 5-5). 
For example, the taxes on a standard pack of 20 cigarettes in Sweden was Swedish krona (SEK) 25.80 
(US$3.57) in taxes in 2010, compared to SEK 11.42 (US$1.79) for a standard 34g pack of smokeless 
tobacco.42 This difference in tax policy is clearly illustrated by the share of excise tax in the retail price 
of a product: The excise tax on the most popular brand of cigarettes in Sweden represents 52% of its 
retail price, whereas the excise tax levied on the most popular brand of Swedish snus represents only 
22% of its retail price.43 A similar situation exists in Norway, where the excise tax on cigarettes reaches 
52% of the retail price, whereas the excise tax on Swedish snus represents only 33% of the retail snus 
price.43–46 The lower level of ST taxes likely results from many factors, such as a lower priority on 
controlling ST consumption than cigarette consumption, or preferential treatment for domestically 
produced ST products over cigarettes sold by the multinationals. This contrasts sharply with the bans 
imposed by the EU, Australia, and New Zealand on the import and sale of ST products. 
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Table 5-4. Relative tax incidences of cigarettes and smokeless tobacco 
Country Tobacco type Amount Excise tax, LCU (US$) 
Sweden Cigarettes 20 sticks ~ 20g 25.80 ($3.57) 
Sweden Swedish snus 1 can ~ 34g 11.42 ($1.79) 
Country Tobacco type Amount State tax (federal tax) 
U.S.–Washington Cigarettes 20 sticks ~ 20g 3.02 ($4.03) 
U.S.–Washington Moist snuff, loose 1 can ~ 34g 3.03 ($3.14) 
U.S.–New Jersey Cigarettes 20 sticks ~ 20g 2.70 ($3.71) 
U.S.–New Jersey Moist snuff, loose 1 can ~ 34g 0.90 ($0.99) 
Abbreviations: g = grams; LCU = Local Currency Unit. 
Note: Tax rates for Sweden are for 2008, and for the United States, 2010. 
Sources: World Health Organization 2011 (43); Skatteverket 2008 (42); Boonn 2011 (51). 

















Albania 23.83 0.0 15.21  Snuff & chew 
Armenia 13.47 0.0 4.01  Snuff & chew 
Bulgaria 67.17 23.0 95.34  Chew 
Canada 227.33 0.0 60.17  Snuff & chew 
Croatia 32.30 33.0 7.40  Snuff & chew 
Czech Republic 56.22 28.0 73.55  Snuff & chew 
Denmark 110.13 20.8 44.05  Chew 
Denmark 110.13 20.8 11.23  Snuff 
Estonia 43.76 33.0 43.04  Chew 
Finland 22.79 52.0  60.00 All 
France 22.01 58.0  32.17 Chew 
Georgia 16.38 0.0 11.93  Snuff & chew 
Germany 107.82 24.7  None Chew 
Iceland 134.93 0.0 42.17  Snuff 
Ireland 238.98 18.3  22.00 Chew 
Italy 9.05 54.7  24.78 Chew 
Italy 9.05 54.7   Snuff 
Macedonia 2.12 35.0 31.42  Snuff & chew 
Malta 28.66 50.0 45.97  Chew 






















Mexico 3.16 46.2  30.40 Snuff & chew 
Netherlands 120.03 20.5 34.48  Chew 
Norway 348.10 0.0 168.92  Snuff & chew 
Poland 47.84 31.4  60.00 Chew 
Romania 63.37 22.0 116.20  Chew 
Russian Federation 6.81 6.5 18.08  Snuff & chew 
Serbia 11.51 35.0  35.00 Snuff & chew 
Slovakia 68.23 24.0 96.06  Chew 
Slovenia 24.73 44.0  0.00  
Spain 13.29 57.0  26.00  
Sweden 42.84 39.2 64.18  Chew 
Sweden 42.84 39.2 52.78  Snuff 
Switzerland 105.32 25.0  5.00 Snuff & chew 
Ukraine 11.45 20.8 2.51  Snuff & chew 
United Kingdom 185.45 24.0 137.35  Chew 
United States 114.00 0.0 1.11  Chew 
United States 114.00 0.0 3.32  Snuff 
Abbreviation: kg = kilogram. 
Note: Compares cigarette and smokeless tobacco tax rates in all countries where a smokeless tobacco tax rate was available. 
Source: Compiled and calculated by the authors from multiple sources. 
Tax Revenue 
Tax administration of ST products in a modern market is relatively efficient at raising revenue, as taxes 
are collected on most products, but much less revenue is raised on smokeless tobacco than on cigarettes, 
due to lower consumption and lower tax rates. The largest share of ST tax in total tobacco excise tax 
revenue is in Sweden, but even there it reaches only 12.8%.47 In the United States, the federal ST excise 
tax revenue amounted to $165.5 million in 2010, or about 1% of the amount of federal excise tax 
revenue collected on cigarettes (based upon authors’ calculations using the following sources: 
Ekonomistyrningsverket 2011,47 Alcohol and Tobacco Tax and Trade Bureau 2012,48 U.S. Department 
of the Treasury 201149). Nevertheless, ST tax revenue in the United States is important, as it has been 
used to help fund the nationwide Children’s Health Insurance Program.50 In addition to the federal 
excise tax, each U.S. state (except Pennsylvania) also imposes a state-level excise tax on ST products.51  




The tobacco industry created tiered pricing schema in both the ST and the cigarette markets. In modern 
markets, premium-priced ST brands occupy a much larger market share than value-priced brands.52 
Table 5-6 compares prices of major ST product categories with the price of the premium cigarette brand, 
Marlboro. Generally, ST products are less expensive than cigarettes, but the price differences between 
ST products and cigarettes are country-specific. It is important to note that many of the ST prices come 
from WHO FCTC Party reports, which do not require use of standardized methods of data collection 
and reporting.53 
Table 5-6. Price in U.S. dollars of Marlboro cigarettes (per stick) and smokeless tobacco products 









snuff Chew Source* 
Canada 0.53 1.65 0.45 — 0.96 Economist Intelligence Unit 2011 (114); 
Euromonitor (Canada) 2010 (17) 
Denmark 0.35 — 0.09 — 0.78 Economist Intelligence Unit 2011 (114); 
Euromonitor (Denmark) 2011 (115) 
Germany 0.34 — — 0.59 0.30 Economist Intelligence Unit 2011 (114); 
Euromonitor (Germany) 2010 (116) 
Mexico 0.09 — 0.29 — — Economist Intelligence Unit 2011 (114); 
Euromonitor (Mexico) 2011 (117) 
Norway 0.71 0.47 0.26 0.63 1.06 Lindbak & Wilson 2010 (45); Economist 
Intelligence Unit 2011 (114) 
Sweden 0.39 0.16 0.21 — — Euromonitor (Sweden) 2011 (21); 
Economist Intelligence Unit 2011 (114) 
United States 0.32 0.18 0.18 0.40 0.07 Euromonitor 2010 (2); 
Economist Intelligence Unit 2011 (114) 
*Numbers in parentheses correspond to full citations in the References at the end of this chapter.






Sensitivity of Smokeless Tobacco Demand 
Data on the price and income sensitivity of ST demand are limited compared to that for cigarettes, and 
the vast majority of studies have used data from the United States. Research shows that the demand for 
ST, like the demand for cigarettes, responds to price and income changes.54 Economists measure the 
degree of responsiveness to price and income changes by calculating price, tax, and income elasticities. 
Various studies have estimated changes in ST demand (measured by changes in expenditures on ST or 
by the prevalence of ST use) in response to changes in ST prices (own-price elasticity), ST taxes (own-
tax elasticity), prices/taxes of other tobacco products (cross-price/cross-tax price elasticity), and income 
(income elasticity of ST demand). The magnitude of price elasticity will be greater than that of tax 
elasticity because taxes represent only a fraction of total price. For example, in order to achieve a 10% 
increase in price and a corresponding decline in demand, taxes must increase by substantially more than 
10%, yielding a lower estimate of tax elasticity than price elasticity. 
Price Elasticity – The proportional change in quantity consumed is larger than the 
proportional change in price. Absolute value of price elasticity is greater than 1. 
Price Inelasticity – The proportional change in quantity consumed is smaller than 
the proportional change in price. Absolute value of price elasticity is less than 1. 
Total Price Elasticity of Demand – A measurement of consumer price 
responsiveness; the change in quantity demanded or purchased in response to a 
change in price. 
Price Elasticity of Prevalence – A change in the percentage of people using a 
product in response to a change in price (captures the number of those who quit 
or do not initiate use). 
Price Elasticity of Conditional Demand – A change in the amount of product being 
used by those who continue to use after a price change (captures lower intensity 
or frequency of use).  
Price/Tax Elasticity – The sensitivity of consumers to price/tax changes; for 
example, an own-price elasticity of –0.4 means that consumption of a good will 
decline by 4% if the price increases by 10%. 
Cross-Price/Tax Elasticity – The sensitivity of consumers to price/tax changes of a 
related good (e.g., cigarettes, other smokeless tobacco products); for example, a 
0.8 cross-price elasticity between cigarettes and ST means that a 10% increase in 
the price of cigarettes will yield an 8% increase in consumption of ST. 
Price Elasticity of Prevalence + Price Elasticity of Conditional Demand = Total Price 
Elasticity of Demand 
Most studies evaluate the impact of price and income on all ST products combined and do not 
distinguish between various ST types. The analytic methods used to study the ST market are similar to 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5. The Economics of Smokeless Tobacco 




Generally, estimates of own-price elasticities of ST demand range between –0.25 and –0.5, similar to 
those for cigarettes.41 This means that ST is price-inelastic because the absolute value of its price 
elasticity is smaller than 1. Estimates of cross-price elasticity measure the degree to which ST products 
are substitutes for or complements to other tobacco products, primarily cigarettes. There is strong 
evidence that higher taxes on cigarettes lead to an increase in the use of ST products, especially when 
the relative prices of ST and cigarettes are changing (i.e., when the prices of the two products have 
evolved at different speeds).55 Despite this evidence that these products are substitutes, there is concern 
that tobacco company marketing efforts promoting dual use of ST and cigarettes may fundamentally 
change this relationship to a complementary one. The impact of higher ST taxes on cigarette use is less 
clear.56–60 Observations from Finland have linked the country’s 1995 ban of snus from the market to an 
11% increase in cigarette consumption by 2001.61 
Complementary products – Products that are consumed together, wherein 
increased consumption of one product increases consumption of the other (e.g., 
automobiles and gas).  
Substitute products – Products that are consumed in an either/or fashion, wherein 
increased consumption of one product decreases consumption of the other (e.g., 
margarine and butter).  
Demand for ST is also affected by income. Studies have tried to determine if ST is a normal good or an 
inferior good. The evidence from the modern marketplace suggests that ST is an inferior good, meaning 
that its consumption will decrease as the income of consumers rises (Table 5-8). However, the evidence 
that ST is an inferior good comes from the United States during the period of 1985 to 1994, which limits 
the generalizability of the findings to other places and periods of time.59,60 
Normal Good – A good that is consumed in larger quantities as a consumer’s 
income increases. 
Inferior Good – A good that is consumed less as a consumer’s income increases. 
  






Table 5-8. Income elasticity of smokeless tobacco demand in the modern market (United States) 
Income elasticity Type of good Dependent variable Year Source* 
(–0.0068† to –0.0069†) Inferior Participation in use of snuff‡ 1993 Ohsfeldt & Boyle 1999 (60) 
(–0.0001 to –0.0009†) Inferior Participation in use of snuff§ 1993 Ohsfeldt & Boyle 1999 (60) 
0.004 — Participation in use of any 
smokeless product  
1992–1994 Chaloupka et al. 1996 (71) 
0.004 — Frequency of use of any 
smokeless product (ordinal 
dependent variable) 
1992–1994 Chaloupka et al. 1996 (71) 
0.003 — Frequency of use of any 
smokeless product (continuous 
dependent variable) 
1992–1994 Chaloupka et al. 1996 (71) 
(–0.0015‡) Inferior Participation in use of snuff  1985 Ohsfeldt et al. 1997 (59) 
(–0.0021‡) Inferior Participation in use of chew  1985 Ohsfeldt et al. 1997 (59) 
(–0.0019‡) Inferior Participation in use of any 
smokeless product 
1985 Ohsfeldt et al. 1997 (59) 
*Numbers in parentheses correspond to full citations in the References at the end of this chapter. 
†Statistically significant (p <0.01). 
‡Model controls for tobacco control policies by an index. 
§Model controls for individual tobacco control policies. 
Note: Income inelasticity measures the sensitivity of consumers to income changes. For example, –0.007 income elasticity means 
that the consumption of the good is going to decline by 0.007% if the income increases by 1%. An income elasticity value of 0.5 
means that consumption of a good will increase by 5% if a consumer’s income increases by 10%. 
Traditional Markets 
Geography and Characteristics 
Traditional markets can be found primarily in South and Central Asia (Afghanistan, Bangladesh, 
Bhutan, India, Kyrgyzstan, Kazakhstan, Maldives, Nepal, Pakistan, Sri Lanka, Tajikistan, Turkmenistan, 
and Uzbekistan), Sub-Saharan Africa, the Western Pacific, and Latin America. The volume of ST 
products sold in these markets is much larger than in modern markets, as the vast majority of the world’s 
ST users live in traditional market countries (chapter 2). Traditional markets are competitive markets 
characterized by a high degree of product diversity, a lack of product standardization, low levels of 
market concentration, low barriers to product entry into the market, lack of mass commercialization, and 
the absence of multinational tobacco corporations. These markets are organized primarily as cottage 
industries, with informal production, distribution, and retail chains. Because of these characteristics, 
economic analyses of traditional ST markets are much more challenging compared to modern markets.  
Most of the data and research evidence on traditional ST markets come from India, the world’s largest 
ST market.62 However, researchers in this area struggle with severe data limitations because little is 
known about prevalence, intensity of use, product prices and taxes, product characteristics, distribution 
channels, labor practices, and tax collection. 
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Price, Tax, and Tax Revenue 
Information on ST prices in traditional markets is scarce. Smokeless tobacco price data (Table 5-9) were 
obtained from WHO FCTC Party reports and Euromonitor International country reports. Because the 
methods used to calculate these prices are not known, prices should not be compared across products or 
countries.  
Table 5-9. Smokeless tobacco prices in the traditional market 
Country Product US$/gram Year Source* 
Algeria Chemma 0.014 2010 Youcef 2011 (118) 
Bangladesh Hakimpuri Zarda 0.017 2009 Senior Assistant Secretary 2010 (119) 
Bangladesh Suravi 0.006 2009 Senior Assistant Secretary 2010 (119) 
Congo, Democratic 
Republic of 
Chew 0.15/scoop 2008 Muteba 2009 (120) 
Djibouti Angadda/Bouri 0.011 2009 Ali-Higo & Djibouti 2009 (121) 
Djibouti Kourkoura 0.017 2009 Ali-Higo & Djibouti 2009 (121) 
India Rajnigandha Pan Masala 0.086 2008 Euromonitor 2010 (2) 
India Sathi Khaini 0.006 2008 Euromonitor 2010 (2) 
India Unbranded khaini 0.001 2008 Euromonitor 2010 (2) 
India RMD Gutkha Mini 0.046 2008 Euromonitor 2010 (2) 
Lesotho Babaton 0.373 2010 Mosala 2010 (122) 
Marshall Islands Copenhagen 0.146 2005 Edwards & Langdrik 2010 (123) 
Panama Masticable Picadora Wolf 0.020 2010 Roa 2010 (124) 
Peru Longhorn Snuff 0.312 2010 Euromonitor 2010 (125) 
Peru Lotzbeck Snuff 0.347 2010 Euromonitor 2010 (125) 
South Africa Taxi Snuff 0.036 2010 Moodley and Phaka 2010 (126) 
Swaziland Snuff 0.043 2009 Dlamini 2009 (127) 
Tunisia Neffa 0.005 2010 Euromonitor (Tunisia) 2011 (128) 
*Numbers in parentheses correspond to full citations in the References at the end of this chapter. 
Traditional market excise tax structures for ST are very similar to those in modern markets. Just as in 
modern markets, the excise tax accounts for a smaller share of the retail price of ST products compared 
to cigarettes. For example, the excise tax on cigarettes in Algeria represents 40% of the retail price, 
whereas the excise tax on ST products reaches about 35% of retail prices.3,43,63 
Table 5-10 summarizes excise tax rates on ST products levied in various countries. The main difference 
between the traditional and modern markets is the efficiency and effectiveness of tax collection. 














product Year Source* 
Algeria 9.86/kg  Snuff & 
chew 
2011 Direction Generale des Impots (Algeria) 
2011 (63); TMA 2011 (46) 
Argentina  20.0 Snuff 2009 Fernandez 2009 (129); Ministerio de 
Economía y Produciόn (Argentina) 2011 
(130) 
Azerbaijan  12.5 Snuff & 
chew 
2011 TMA 2011 (46); Ministry of Taxes, no date 
(131) 
Bangladesh  30.0 Jarda, gul 2011 Barkat et al. 2012 (132) 
Barbados 23.56/kg  Snuff 2011 TMA 2011 (46) 
Benin  61.5  2011 Agossou et al. 2011 (133) 
Bolivia  50.0 Snuff & 
chew 




1.46/kg  Snuff & 
chew 
2011 TMA 2011 (46) 
Brazil  30.0 Snuff & 
chew 
2011 TMA 2011 (46); Receita Federal do Brasil, 
no date (135) 
Burkina Faso  17.0 Snuff & 
chew 
2011 TMA 2011 (46); Théodore 2009 (136) 
Burundi  41.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Cambodia  10.0  2008 Pheang 2008 (137) 
Cameroon  25.0  2009 Sibetchu 2008 (138) 
Chile  59.7 Snuff & 
chew 
2011 TMA 2011 (46); Servicio de Impuestos 
Internos (SII) (Chile) 2011 (139) 
China  30.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Costa Rica  60.0 Snuff & 
chew 
2011 Sistema Costarricense 2011 (140) 
Côte D’Ivoire 13.12/kg  Snuff & 
chew 
2011 TMA 2011 (46) 
Dominican Republic  65.0  2008 Direccion General de Impuestos Internales 
2004 (141) 
Ecuador  150.0  2008 Salazar 2008 (142); Servicio de Rentas 
Internas (SRI) (Ecuador) 2007 (143) 
Egypt 1.35/kg   2010 Ministry of Finance (Egypt) 2008 (144) 
El Salvador  39.0 Snuff & 
chew 
2011 TMA 2011 (46); La Asamblea Legislativa de 
la Republica de El Salvador 2004 (145) 
Ethiopia  75.0 Snuff 2011 Ethiopian Revenue & Customs 2008 (146) 
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product Year Source* 
Fiji 51.36/kg  Snuff & 
chew 
2011 TMA 2011 (46) 
Gabon  30.0 Snuff & 
chew 
2011 TMA 2011 (46); Direction Generale des 
Impots (Gabon) 2006 (147) 
Gambia    2009 Bah 2009 (147) 
Ghana  0.0 Snuff & 
chew 
2007 Ministry of Finance and Economic 
Planning (Ghana) 2007 (148) 
Guatemala  100.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Guyana  100.0 Snuff & 
chew 
2011 TMA 2011 (46) 
India  86.0 Snuff & 
chew 
2011 John et al. 2010 (64); TMA 2011 (46) 
Indonesia  30.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Iran, Islamic 
Republic of 
 5.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Jamaica  14.5 Snuff & 
chew 
2011 TMA 2011 (46) 
Kazakhstan 8.39/kg  Snuff & 
chew 
2011 TMA 2011 (46) 
Kenya  130.0 Snuff & 
chew 
2011 TMA 2011 (46); Kenya Revenue Authority 
2010 (149) 
Korea, Republic of 15.08/kg  Snuff 2011 TMA 2011 (46) 
Korea, Republic of 24.09/kg  Chew 2011 TMA 2011 (46) 
Kuwait  0.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Kyrgyzstan 0.03/kg  All 2008 Decree of the President 2006 (150) 
Lebanon  108.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Madagascar 0.0032/sachet 20.0 Chew 2011 TMA 2011 (46); Ministère des Finances 2010 
(151) 
Madagascar 0.0005/sachet 50.0 Snuff 2011 TMA 2011 (46); Ministère des Finances 2010 
(151) 
Malaysia 8.93/kg 5.0 Snuff & 
chew 
2011 TMA 2011 (46); JKDM HS Explorer 2011 
(152) 
Mali  78.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Marshall Islands 80.41/kg  Snuff 2010 Edwards & Langdrik 2010 (123) 













product Year Source* 
Mauritania  20.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Mauritius  230.0 Snuff & 
chew 
2011 TMA 2011 (46); Mauritius Revenue 
Authority 2004 (153) 
Micronesia  50.0  2010 Skilling 2010 (154) 
Morocco  59.4 Snuff & 
chew 
2011 TMA 2011 (46) 
Mozambique  75.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Myanmar  60.0 Chew 2011 TMA 2011 (46) 
Myanmar  25.0 Betel 2007 Kyaing 2007 (155) 
Nepal 2.32/kg  Chew 2011 TMA 2011 (46) 
Nicaragua  0.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Niger  10.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Nigeria  50.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Oman  0.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Pakistan  15.0 Chew 2011 Ministry of Finance (Pakistan) 2011 (156) 
Panama  50.0  2009 Roa & Vergara 2010 (124); Gaceta Oficial 
(Panama) 2009 (157) 
Papua New Guinea 20.35/kg  Snuff & 
chew 
2011 TMA 2011 (46) 
Paraguay  10.0 Snuff & 
chew 
2011 TMA 2011 (46); Subsecretaría de Estado 
de Tributación, no date (158) 
Peru  50.0 Snuff & 
chew 
2011 TMA 2011 (46); Alburqueque 2007 (159) 
Philippines 0.02/kg  Chew 2011 TMA 2011 (46); Thirteenth Congress of the 
Philippines 2004 (160) 
Rwanda  0.0  2009 Nzeyimana 2009 (161) 
Saint Lucia  10.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Saudi Arabia  0.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Senegal  40.0 Snuff & 
chew 
2011 TMA 2011 (46); Direction Général des 
Impôts et des Domaines (Senegal) 2011 
(162) 
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product Year Source* 
Singapore 280.48/kg  Snuff 2011 TMA 2011 (46); Ministry of Finance 
(Singapore) 2011 (163) 
Singapore 157.89/kg  Chew 2011 Ministry of Finance (Singapore) 2011 (163) 
South Africa  0.0 Snuff 2011 TMA 2011 (46); South African Revenue 
Service 2012 (164) 
Sri Lanka  0.0  2011 Sri Lanka Customs 2011 (165) 
Swaziland 21.93/kg  Snuff 2009 Dlamini 2009 (127); Swaziland Revenue 
Authority 2010 (166) 
Syria  15.0 Chew 2011 TMA 2011 (46); Syrian Ministry of Finance 
2004 (167) 
Tajikistan  10.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Thailand 2.73/kg 0.1 Chew 2008 Kingdom of Thailand 2010 (168); 
Termsirikulchai et al. 2008 (169) 
Tonga 75.10/kg   2009 Vivili 2009 (170) 
Trinidad and Tobago   All 2010 Ministry of Health 2010 (171) 
Tunisia  135.0 Snuff & 
chew 
2011 TMA 2011 (46); Ministère des Finances 
(Tunisia) 2010 (172) 
Turkey  63.0 Snuff 2010 Altan & Irmak 2011 (173); Council of 
Ministers (Turkey) 2011 (174) 
Turkmenistan 10.00/kg  Snuff & 
chew 
2011 TMA 2011 (46) 
Uganda  150.0 All 2009 Uganda Revenue Authority 2009 (175); 
TMA 2011 (46) 
Venezuela  70.0 Snuff & 
chew 
2011 TMA 2011 (46) 
Vietnam  65.0  2011 Ministry of Finance (Vietnam) 2011 (176) 
Yemen  90.0 Snuff & 
chew 
2011 Customs Authority (Yemen) 2010 (177); 
TMA 2011 (46) 
Zambia 24.36/kg  Snuff & 
chew 
2008 Zambia Revenue Authority 2008 (178) 
*Numbers in parentheses correspond to full citations in the References at the end of this chapter. 
Abbreviations: kg = kilogram; TMA = Tobacco Merchants Association.  
  






The scarcity of data on tax evasion and avoidance makes it extremely difficult to determine the effective 
tax rate in traditional markets. We know very little about the market penetration of custom-made, 
cottage-industry, or illicit ST products. However, it can be expected that the effectiveness of tax 
collection for less prominent ST products is worse than for more prominent products like cigarettes.41  
Despite these challenges, some ST taxes in traditional markets are collected and can contribute 
significantly to a government’s revenue. Table 5-11 shows that ST taxes in India contributed between 
3.84% and 11.98% of the total tobacco excise tax revenue from 1999 to 2007. During this time, the ST 
tax rate increased from 33% to 50% of the retail price (Figure 5-3). This tax rate increase, combined 
with population growth, resulted in higher ST tax revenue in both real and nominal terms (Figure 5-3 
and Table 5-12).64  
Table 5-11. Percentage contribution of various tobacco products to total tobacco excise tax revenues 
in India, 1999–2007 
Years Cigarettes Bidis Chewing tobacco Other tobacco products 
1999–2000 86.18 5.70 6.22 1.89 
2000–2001 84.75 5.79 6.96 2.50 
2001–2002 78.52 5.54 9.79 6.15 
2002–2003 80.00 5.61 9.84 4.55 
2003–2004 82.82 5.07 9.25 2.87 
2004–2005 83.60 4.86 8.05 3.49 
2005–2006 84.76 4.39 3.84 7.01 
2006–2007 76.95 4.64 11.98 6.43 
Source: Calculated by the authors based on data from John et al. 2010 (64). 
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Figure 5-3. Excise tax and tax revenue from chewing tobacco in India 
 
Source: John et al. 2010 (64). 
Table 5-12. Tax revenue from chewing tobacco in India, adjusted and unadjusted for inflation,  
1999–2007  
Year 
  U.S. dollars in millions  
 Adjusted Unadjusted 
  Indian rupees in millions  
 Adjusted Unadjusted 
1999–2000  83.734 78.141  3,763.2 3,511.8 
2000–2001  90.228 90.228  4,257.5 4,257.5 
2001–2002  125.242 129.747  6,088.0 6,307.0 
2002–2003  126.641 135.670  5,899.3 6,319.9 
2003–2004  119.838 135.385  5,430.6 6,135.1 
2004–2005  108.819 130.905  4,798.9 5,772.9 
2005–2006  56.681 71.170  2,568.1 3,224.5 
2006–2007  201.589 266.843  8,335.5 11,033.7 
Source: John et al. 2010 (64). 
  






The volume of ST tax revenue collected by the Indian government contrasts with the ST tax revenue 
collected in Bangladesh, the second-largest ST market based on the number of ST users, where ST tax 
revenue represents only 0.4% of the total tobacco tax revenue.65  
Sensitivity of Smokeless Tobacco Demand 
Data on the responsiveness of ST demand to changes in price and income in traditional markets are even 
more limited than in modern markets. There are gaps in consumption and price data, and the absence of 
standard packaging makes it difficult to calculate unit prices. Some evidence indicates that ST users in 
traditional markets are price-sensitive and that higher prices on ST would lead to lower 
consumption.66,67 No existing research appears to clarify the relationship between income and ST use in 
traditional markets. 
The price elasticity of tobacco leaf demand in India has been estimated at –0.883, meaning that for every 
10% increase in tobacco leaf prices, the consumption of tobacco leaf will decrease by 8.83%.64,68 This 
suggests that, as higher prices for the raw tobacco used in ST products are passed on to consumers in the 
form of higher retail prices, overall tobacco use will be reduced, and most likely ST use as well. Another 
study from India used micro-level data to estimate that a 10% increase in the price of gutka would 
decrease consumption by 5.8% and prevalence of gutka use by 2.7%.69 
One study used macro-level data to calculate the cross-tax elasticity between cigarettes and betel quid 
without tobacco (a product that can serve as a proxy for ST use because it is consumed in a similar way) 
and the own-price elasticity of the demand for betel nuts in Taiwan.70 The cross-price elasticity between 
cigarettes and betel nuts ranged from –0.082 to –0.131, suggesting that these two products are 
complements.70 This could be similar to the relationship between ST consumption and cigarette prices 
found in some studies using modern market data.72 The own-price elasticity of betel use was –0.384, 
which was lower than the own-price elasticity of cigarette demand (–0.609 to –0.824) calculated in the 
same study,70 but comparable to estimates from ST studies in modern markets.59,60,71–73 
Economic theory predicts that ST products would be more price-elastic in traditional markets than in 
modern markets because many consumers can easily substitute custom-made tobacco products for 
manufactured ST products. However, more research is needed to support or reject this hypothesis. 
Since about 2001, the economies of traditional markets have grown more rapidly than economies of 
modern markets, which has increased the affordability of all products, including ST products. In India, 
for example, chewing tobacco became much more affordable from 2001 to 2007 despite the higher ST 
tax and price increases, because these increases were not sufficient to offset the level of inflation and 
income growth (Table 5-13). Greater affordability may explain the growing consumption of chewing 
tobacco in India.64 
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Note: The affordability of smokeless tobacco is measured as the percentage of per capita gross domestic product required to 
buy 100 packs of chewing tobacco. The higher value indicates less affordability.  
Source: John et al. 2010 (64).  
Gaps and Limitations 
Very few data exist on ST prices, tax rates, and tax structures, which makes research into the impact of 
ST taxes and ST prices on ST use very difficult, if not impossible. Very little is known about the extent 
to which higher ST taxes translate into higher ST prices and how these prices affect the affordability of 
ST products. The affordability of ST should be studied in conjunction with the affordability of smoked 
tobacco (cigarettes) to determine how the population responds to changes in the relative prices of these 
two types of tobacco products.  
Establishing a standardized unit of consumption and gaining a better understanding of the ST market 
structure will also be important for future studies on the price and income elasticities of ST demand. 
These future studies can help determine whether ST products are used as substitutes for or in 
combination with smoked tobacco, and if this relationship changes over time or according to pricing 
structure. Such findings will inform the development of public policies to control both smoked and ST 
use. 
Summary and Conclusions 
The tax system that best suits public health goals is likely to be country-specific. As a general rule, an 
excise tax system that effectively raises the prices of ST products and makes them less affordable over 
time is ideal because it would discourage consumption. Countries experiencing rapid economic growth 
may need to increase their ST taxes at a pace that ensures that prices for ST products increase faster than 
inflation and income growth. Another option would be to equalize tax at high rates across all tobacco 
products to limit substitution.  
Best practice for cigarette taxation favors the use of a specific tax that is regularly adjusted for inflation 
because it reduces the price gap between the less expensive (most affordable) and more expensive 
products.41 In some cases, a mixed excise tax system that contains both ad valorem and specific 
components can most efficiently deal with the tobacco industry’s efforts to avoid taxes by manipulating 
the tobacco content of ST products. For example, reducing the content of tobacco in a product reduces 






the tax burden if the specific excise tax depends on the tobacco weight of a product. On the other hand, 
lowering the declared value of a product reduces its tax burden if the tax is levied ad valorem. More 
studies are needed to clarify both the relationship between ST and smoked tobacco products, and how 
consumers respond to relative and absolute price changes of these products. Answers to these questions 
will have implications for the design of an efficient tobacco tax regime.  
Smokeless tobacco tax revenue is expected to increase with higher ST tax rates because the demand for 
ST is price-inelastic. However, this revenue increase depends on the efficiency of a country’s tax 
collection system. System improvements, such as switching from taxing producers based on production 
volume to taxing based on production capacity, can theoretically increase the efficiency of collecting 
taxes. (India levies tobacco excise taxes based on the production capacity of a facility, rather than the 
declared production volume generated by a facility. The production capacity is always greater than or 
equal to the production volume.) 
The effectiveness of tax collection systems and the impact of higher taxes on ST use will also depend on 
the standardization of ST products.74 Lack of standardization complicates not only tax collection but 
also scientific research, as it hinders the use of econometric methods.  
A standard unit can be based on a dose, the weight of tobacco, or the weight of a product. The weight of 
a product includes its water content and the weight of any additives, which is especially important in 
smokeless tobacco. The weight of tobacco refers to the weight of dry leaf in the product, which will be 
smaller than the total weight of the product. These varying definitions of a standard unit have advantages 
and disadvantages. A dose is equal to the average amount of a product used in a single session, but not 
all products are sold in pre-portioned single servings. In addition, different ST products are used for 
different lengths of time. For example, a Camel Orb (a dissolvable tobacco product) dissolves in the 
mouth in under 20 minutes, whereas a betel quid can stay in a user’s mouth for over 12 hours. Using the 
weight of tobacco as a standard measurement focuses on the primary concern of tobacco use. However, 
the tobacco content in an ST product would have to be determined or reported by ST manufacturers. For 
this reason, using the weight of an ST product as a base for calculating taxes would be easier than using 
the weight of tobacco in a product. Although information on total product weight is usually readily 
available in countries that have specific excise tax regimes, this standard would tax products with higher 
tobacco density (e.g., dry snuff) less than products with lower tobacco density per unit of weight (e.g., 
moist snuff). This discrepancy in taxation rates can be leveled by setting different tax rates for different 
types of tobacco products. Standardization methods can also be combined. For example, tax liability can 
be assessed based on the weight of the ST product, and a minimum tax amount can be set per dose. 
Because the multinational tobacco corporations have recognized ST as the next frontier in expanding 
their business,38 tobacco control research must adjust its resources in anticipation of the increased 
demand for these products. 
Implementation of an appropriate surveillance system will be required to better understand the ST 
marketplace and the economic incentives linked to ST use. Systematic data collection on both the 
prevalence and the intensity of ST use by ST product type is necessary to assess the size of the ST 
marketplace, the level of substitution between various ST products and substitution with smoked 
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tobacco, and the introduction and uptake of novel ST products. To evaluate the opportunity costs 
associated with ST use, personal and/or household expenditures on ST products must also be tracked.  
Data on ST prices, taxes, ST tax revenue, and ST trade (including illicit) are needed. This information 
could be collected by changing WHO FCTC reporting to require collection of data on all tobacco 
products, not just cigarettes. Designing an effective ST tax regime will require monitoring and 
regulation of the ST supply chain (i.e., manufacturing, trade, and distribution). Taxing tobacco leaves 
could help control the use of ST in the diverse and multilayered traditional markets.  
In conclusion, the development of recommendations for the most appropriate ST tax structures must 
take into account the type of ST product and the tax structure applied to other tobacco products sold in a 
particular market. A WHO study group recommended that several economic and tax-related guidelines 
be followed in the formulation of ST control policy.75 Namely, the study group recommended that 
(1) ST be taxed “at a level sufficient to act as a disincentive, and at least at the level at which cigarettes 
are taxed,”75,p.64 (2) taxes should increase in real terms over time, and (3) a portion of ST tax revenue 
should be earmarked to support health promotion efforts.75 Recent (2010) guidelines for tobacco 
taxation stipulate that equal tax rates should be imposed on all tobacco products.41 The WHO technical 
manual recommends that the excise tax on cigarettes (either specific or ad valorem) make up at least 
70% of the retail price, and it favors the use of the specific excise tax because of its administrative 
simplicity and effectiveness in reducing tobacco use. Smokeless tobacco products should meet an 
equivalent standard to shift discussions of smokeless tobacco and cigarette tax structures in the direction 
of tobacco tax structures.41 This cohesive approach to tobacco control policy can produce more 
consistent, comprehensive, and effective tobacco control legislation over time.  
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Cigarette markets are declining in high-income economies such as North America and Europe due in 
large part to effective tobacco control policies. Implementation of demand-reduction policies called for 
in the World Health Organization Framework Convention on Tobacco Control (WHO FCTC)—such as 
smoking restrictions in public spaces, enhanced health warnings, increased taxes, and increased support 
for smoking cessation—are likely to further constrict these cigarette markets and slow the increase in 
smoking in low-income countries.1 However, these changes also open opportunities for the tobacco 
industry to expand into new areas. Societal pressures discouraging cigarette use may impel smokers to 
use other forms of tobacco, for example. Such changes have precedent, as over time different forms of 
tobacco have seen changes in popularity among users (e.g., nasal snuff, pipes, cigars).2,3 Econometric 
analyses4 have examined the latent (i.e., untapped or potential) demand for smokeless tobacco (ST) in 
different world regions, concluding that demand would be highest in Asia and the Middle East 
(US$3.97 billion), followed by North America (US$2.82 billion) and Europe (US$2.78 billion). Thus, 
there is incentive for producers to bring new products to market and to expand into areas where ST 
products are not currently used. 
Smokeless tobacco covers a wide range of products used orally or nasally. A number of other reports5–11 
and chapter 3 of this volume have examined the variety of ST products and their contents. This chapter 
will not address product variety and contents in depth, but will focus on data on marketing practices 
available mostly from high-income countries.  
Since 2001, a number of manufacturers have introduced novel ST products that differ in numerous ways 
from traditional products (Table 6-1). Manufacturers have introduced products that are formulated 
differently (e.g., with reduced nitrosamines, in dissolvable form, spitless) and marketed differently 
(made available in new markets, targeted toward current smokers, contained in innovative packaging) 
relative to the traditional ST products in a given market. For example, introduction of snus products in 
the United States or South Africa would be considered novel, but emergence of new Swedish snus 
brands in Sweden probably would not fit this description.  
Also since 2001, companies that historically had predominantly marketed cigarettes have entered the 
ST market. R.J. Reynolds purchased Conwood, manufacturer of Grizzly and other popular moist snuff 
products, in 2006. British American Tobacco began test marketing snus products in 2006. In 2009, 
Altria acquired U.S. Smokeless Tobacco (UST), thereby gaining control of UST’s best-selling Skoal and 
Copenhagen brands. Philip Morris International (PMI) entered into an agreement with Swedish Match in 
2009 to market ST outside the United States and Scandinavia (as of 2012, test-marketing in Canada and 
Russia). PMI also purchased the South African operations of Swedish Match in 2009. Consequently, a 
number of ST products co-branded with cigarettes have emerged, which represents an additional layer 
of novelty.  
  
 
6. Changing Smokeless Tobacco Products and Marketing Practices by Industry 




Table 6-1. Novel smokeless tobacco products introduced since 2001 
Brand Type Company Country Year Still sold? 
Revel Snus UST United States 2001 No 
Exalt Snus Swedish Match United States 2001 No 
Catch Snus Swedish Match  South Africa 2001 No 
Ariva*  Dissolvable Star Scientific United States 2001 No 
Stonewall* Dissolvable Star Scientific United States 2003 No 
Interval Dissolvable Brown and Williamson United States 2003 No 
Magne* Snus Swedish Match South Africa 2003 No 
Tobaccorette  Snus Swedish Match South Africa 2003 No 
Skoal Dry Snus UST  United States 2006 No 
Taboka Snus Philip Morris U.S.A. United States 2006 No 
Camel Snus Snus Reynolds American/Japanese 
Tobacco International 
United States, Sweden 2006 Yes 
Peter Stuyvesant  Snus BAT South Africa 2006 No 
Lucky Strike  Snus BAT South Africa, Sweden 2006 No 
Triumph Snus Lorillard/Swedish Match United States 2007 No 
Grand Prix Snus Lorillard/Swedish Match United States 2008 No 
Tourney  Snus Liggett Group/Snus AB United States 2007 No 
Marlboro Snus Snus Philip Morris U.S.A. United States 2007 Yes 
General  Snus Swedish Match South Africa, United 
States, Canada  
2008 Yes 
Catch Dry  Snus Swedish Match South Africa 2008 No 
du Maurier  Snus Imperial Tobacco (BAT) Canada 2008 No 
Pall Mall Snus BAT Sweden 2009 No 
Camel Orbs Dissolvable Reynolds American United States 2009 Yes 
Camel Sticks Dissolvable Reynolds American United States 2009 Yes 
Camel Strips Dissolvable Reynolds American United States 2009 Yes 
Skoal  Snus UST  United States 2010 Yes 
Zip Snus West African Tobacco  Nigeria 2010 Yes 
Marlboro Sticks Dissolvable Philip Morris U.S.A United States 2011 Yes 
Skoal Sticks Dissolvable UST  United States 2011 Yes 
Marlboro Snus Swedish Match Sweden 2011 Yes 
Ettan Snus Swedish Match United States 2011 Yes 
* Star Scientific discontinued its dissolvable products in early 2013. 
Abbreviations: UST = U.S. Smokeless Tobacco Company; BAT = British American Tobacco. 
Note: This table is intended as an overview of novel products introduced; it is not necessarily comprehensive as there is no formal 
mechanism on a global scale for reporting new smokeless tobacco products.  






The tobacco market into which these novel products are being launched is influenced to a certain 
extent by the success of traditional tobacco control activities, such as smoke-free environments, high 
cigarette taxes, and increased awareness of the health effects of tobacco use.12 Smokeless tobacco 
products have engendered controversy within the tobacco control community. Some public health 
advocates see ST as a substitute for cigarettes and a bridge to quitting, whereas others view it as a step 
toward smoking and a perpetuator of nicotine addiction through multiple product use.13–16 These views 
are not necessarily mutually exclusive. Some models of the population impact of ST suggest that 
increased promotion of ST could draw smokers away from cigarettes with minimal offsetting use by 
non-smokers, former smokers, or youth.17 Other models suggest that even aggressive ST promotion may 
have no public health benefits.18  
In the United States, the Family Smoking Prevention and Tobacco Control Act gives the U.S. Food and 
Drug Administration (FDA) the authority to regulate the marketing of tobacco products to protect public 
health. The Act specifically prohibits “modified risk” claims for tobacco products in the absence of a 
marketing order from FDA. The Act also instructs that FDA only issue a marketing order if the applicant 
has met certain conditions, including a demonstration that the novel product will result in significantly 
reduced harm for tobacco users and will benefit the health of the population as a whole.19,20 A recent 
Institute of Medicine report provides a broad framework for thinking about the evaluation of such 
claims, but there is not yet a scientific consensus about the specific methods to be used or the threshold 
of evidence that should be required.21  
Understanding potential users of products is the realm of consumer psychology, which integrates 
behavioral and social sciences to understand the purchasing behaviors of specific segments of the 
population and methods to enhance these behaviors.22,23 Marketing can be viewed in part, then, as the 
practical application of consumer psychology. Traditionally, marketing is conceived as a mix of “4 P’s”: 
product, price, placement, and promotion—that is, products are designed to meet consumer needs at a 
desirable price and are promoted effectively using multiple communication channels in places where 
consumers can interact with the product. This chapter explores the available research on the changing 
ST market, focusing primarily on the marketing of ST in new forms and in new ways, and how these 
influence the appeal of such products to consumers. The chapter is framed around these four primary 
aspects of marketing as they relate to the changing ST market: product, promotion, placement, and price.  
Product 
The characteristics and performance of a product can greatly influence its overall attractiveness. 
Smokeless tobacco products can be differentiated from one another most clearly in terms of product 
design, which may be tailored to achieve chemosensory effects and nicotine delivery targets and paired 
with marketing to appeal to varied subpopulations (women, youth, African Americans, people of low 
socioeconomic status). Over the past two or three decades, there has been substantial innovation in the 
ST market, particularly in North America and Sweden. In this section, we focus on three key areas that 
are likely to influence the attractiveness of novel ST products: product formulation, nicotine content and 
availability, and flavorings. 
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An obvious difference among ST products is the form in which the products are presented for use. The 
tobacco in individual products can range from simply dried, cured tobacco leaves cut or torn in various 
ways, to moistened, fermented tobacco strips, to finely powdered dry tobacco. At present, most ST 
consumed in the United States is in the form of moist snuff, which is fermented, whereas in Sweden 
most ST is in the form of non-fermented, pasteurized Swedish snus. In both countries, loose product 
dominates, though portioned forms are growing in popularity. More novel ST formulations, available in 
the United States, include powdered tobacco compressed into different shapes, such as tablets, sticks, or 
thin strips. 
Portioned pouch products were introduced in Sweden in the 1970s and in the United States with Skoal 
Bandits in 1983. These products were explicitly developed to be easier to use, neater, and more 
appealing to novice users.24,25 In Sweden, pouches generally come in two forms: original, where the 
pouch is moistened and appears brown; and white, which is not premoistened and appears white. Three 
sizes (mini [0.5 g], normal [1 g], maxi [approximately 1.7 g]) are available. U.S. smokeless tobacco 
manufacturers began introducing products patterned after Swedish snus in the early 2000s, and as of 
2011, Marlboro Snus, Skoal, General, and Camel Snus were in national distribution. In all cases, U.S. 
snus products have been introduced in portioned pouches, similar to the Swedish white portioned 
format. In 2012, Camel Snus was available in two portion sizes (approximately 0.5 g and 1.0 g). 
Swedish and U.S. snus products differ in nicotine levels and pH, and studies have even shown regional 
variation among U.S. snus products.5,8,26 (Information on toxicant levels is provided in chapter 3.) 
Compressed formulations of powdered tobacco specifically designed to dissolve in the mouth are among 
the ST products that have emerged in the United States during the 2000s. Two early examples, which 
are no longer available on the U.S. market, are Star Scientific’s Ariva (introduced in 2001) and 
Stonewall (introduced in 2003). In 2009, Reynolds American introduced three dissolvable tobacco 
products, Camel Orbs (a lozenge), Camel Sticks (a thin, 4-inch stick), and Camel Strips (a thin, 
rectangular sheet). In 2011, Philip Morris U.S.A. and UST introduced Marlboro and Skoal Sticks, 
respectively, which consist of a small amount of finely milled tobacco applied to a toothpick-sized 
wooden dowel. Such products have attracted considerable concern because of their physical similarity to 
confectionary products and the ease with which use can be concealed, potentially making them attractive 
to youth.27 An additional concern with such products is accidental ingestion by young children, which 
happens most commonly with cigarettes, followed by traditional smokeless tobacco.28 To date, analyses 
of poison control center data find little evidence of specific problems with the ingestion of 
dissolvables,29 although it is unclear how much of the apparently low rate of accidental ingestion of 
dissolvables can be attributed to their low prevalence of use or to the appeal and safety of their 
packaging for children.  
Novel products typically weigh less (net weight of product, without packaging) than traditional snuff 
products, thus data tracking ST sales can only give hints about sales trends. For example, in the United 
States, moist snuff is typically packaged in approximately 1.2-ounce (oz) (34.0 g) cans. In contrast, a tin 
of Camel Snus weighs about 0.32 oz; a box of Ariva weighed about 0.34 oz. Data from 2002–2010 
reported to the U.S. Federal Trade Commission (FTC) show changes in sales of ST by the size of 
package (Figure 6-1; package sizes up to 5 oz shown only, as these are the most common).30 Sales of 






ST products sold in units weighing less than 1 oz (which would include most novel ST products) grew 
more than sixfold between 2002 and 2010. In 2010, disclosures of product-level data for sales of snus 
and dissolvables were required. Snus sales in that year totaled 61.3 million units, 99.9% of which were 
less than 1 oz in size.30 Among ST products weighing less than 1 oz, snus made up over one-third (37%) 
of ST sales in 2010. 
Figure 6-1. Change in smokeless tobacco sales by weight class, 2002–2010, United States 
 
Source: U.S. Federal Trade Commission 2012 (30). 
Consumer Responses to Different Product Formats 
Research comparing consumer responses to novel ST products with responses to conventional cigarettes 
or nicotine replacement products has yielded varying results. One study of Ariva found that it was 
preferred by smokers over a pure pharmaceutical nicotine lozenge.31 A different study showed that novel 
ST products had drug effects, liking measures, and nicotine-withdrawal symptoms similar to those of 
pharmaceutical lozenges, and use of pharmaceutical lozenges resulted in lower craving scores than those 
observed with one of the novel tobacco products.32 Examinations of biomarkers found evidence that 
users of the novel products had been exposed to as much nicotine as in the pharmaceutical lozenges, but 
there was little evidence of exposure to nitrosamines.33 Carpenter and Gray34 found that use of Ariva and 
Stonewall was associated with a reduction in cigarette consumption and an increase in intentions to quit 
among smokers who received these products compared to the smokers who didn’t receive them. 
An emerging theme from research on use of novel ST products is that sampling of different types of 
ST products may be important in assessing appeal to cigarette smokers.35,36 Hatsukami and colleagues35 
showed that after 2 weeks of sampling oral products (General snus, Camel Snus, Marlboro Snus, Ariva, 
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Stonewall), smokers rejected General snus, and showed no significant preference for any of the other 
products (i.e., about 25% chose to use each of the products other than General). When the smokers quit 
smoking, those using Camel Snus reported greater relief of cravings and withdrawal symptoms 
compared to those using other oral products. O’Connor and colleagues36 showed that when smokers not 
intending to quit were allowed to sample multiple products (Stonewall, Marlboro Snus, Camel Snus, 
Commit lozenges) simultaneously for 1 week followed by 1 week of preferred product use, the smokers 
most preferred the pharmaceutical nicotine lozenge and least preferred Stonewall. Interestingly, in the 
2011 relaunch of Camel dissolvables, Reynolds American offered a variety pack containing all three 
versions of the product, presumably so consumers could try all three with less investment to find a type 
that suited them. This is also consistent with approaches used by UST to attract new users to Skoal 
Bandits: One-on-one sampling was identified as the “number one objective” for sales staff.37  
Nicotine Content and Availability  
Nicotine is the sine qua non for tobacco use in any form. The form of the product may have distinct 
effects on the form of nicotine (bound vs. free nicotine) and its delivery to the body. A prime example is 
the manipulation of acid/base chemistry to affect the proportion of free nicotine in the mixture, which 
impacts systemic absorption.5,38 Specifically, free nicotine is readily absorbed across mucous 
membranes, leading to rapid uptake into the brain, thus enhancing centrally mediated nicotine reward. 
Manufacturers can use buffering agents and salts to raise pH and thereby raise the level of free nicotine 
in a product (or use these agents to lower pH and lower the amount of free nicotine). Lauterbach and 
colleagues39 note that the measurement of free nicotine in ST may be complicated by other elements of 
the mixture (such as salts, pectins). Makers of custom-made products also manipulate the pH of their 
products when they add alkaline substances such as punk ash and slaked lime (calcium hydroxide) to 
products such as iqmik (used by Alaskan Natives), South African custom-made snuff, betel quid, and 
mawa. In manufactured products, there may be tiers of products at different pH levels.37,40  
Variation of product pH (and thus free nicotine) was central to the “graduation” strategy pursued by 
UST in the 1980s.37 Low-pH, low-nicotine products (e.g., Skoal Bandits) introduced novice users to 
product use, and as they developed tolerance to nicotine and experienced other effects, users would 
gravitate toward increasingly higher nicotine products, such as Skoal Fine Cut, and eventually to 
Copenhagen. One UST ad campaign explicitly stated: “Sooner or later, it’s Copenhagen. It satisfies.” 
UST was not alone in this approach of multiple product offerings: Pinkerton Tobacco and Conwood 
offered similar opportunities for graduation.37 
Relatively few studies, however, have directly examined whether levels of free nicotine in ST influence 
how attractive a product is to consumers. Alpert and colleagues41 linked reported free nicotine levels to 
ST prevalence and market sales data, and concluded that “changes in design, as reflected by variation in 
free nicotine associated with pH or tobacco leaf, or both, have enhanced the ease and uniformity of 
dosing,”41,p.332 which likely contributes to growth in sales of moist snuff. Fant and colleagues42 and 
Kotlyar and colleagues32 showed that product pH appeared to relate to the level of nicotine absorbed. 
Subjective measures of product strength and satisfaction also followed a similar pattern. Kotlyar’s study 
included Ariva, Revel, and Stonewall, all of which delivered less nicotine and had lower scores of 
subjective effects than Copenhagen moist snuff.  






As novel ST products emerge and are promoted to smokers, there is concern that snus-type products 
sold in the United States and South Africa, having been shown to contain much lower free nicotine,8,43 
may not relieve nicotine craving and may promote dual use. Indeed, Hatsukami and colleagues35 
showed that among smokers who abstained from smoking and switched to ST, products with lower 
nicotine levels did not suppress smoking behavior as well as products with higher levels of nicotine. 
Yet a separate study shows that products with higher nicotine levels may be more likely to be misused 
or cause dependence.44  
Flavorings  
Smokeless tobacco preparations may range from simple unflavored tobacco to tobacco with added 
flavorants (such as wintergreen, apple, bourbon) to more complex mixtures of tobacco with additional 
plant materials (herbs, spices, leaves, nuts).  
In North America, traditional chewing tobacco is either unflavored or incorporates some sweetener 
(e.g., molasses). Moist snuff traditionally was available unflavored or with the addition of wintergreen 
(methyl salicylate).45 This began to change in the 1970s, however, as UST and others introduced moist 
snuff products with a far greater variety of flavors, including citrus, berry, apple, bourbon, and spice. In 
Sweden, common Swedish snus flavorants include mint/wintergreen, licorice, juniper berry, and 
eucalyptus. The flavors used in snus products in South Africa include coffee, tropical fruits, mint, and 
eucalyptus. Emerging dissolvable tobacco products have been marketed with flavors including mint and 
coffee. Chemical analysis of Camel dissolvables identified flavorants such as coumarin, vanillin, and 
cinnamaldehyde, along with sweeteners such as sorbitol and xylitol.46 As of September 2009, FDA 
regulations banned the use of characterizing flavors other than menthol in cigarettes but not in other 
tobacco products, including smokeless tobacco.  
The issue of flavors with oral ST products adds another dimension to exposure assessment because the 
flavorants themselves are ingested along with the tobacco. Chen and colleagues45 measured the mint 
and wintergreen contents of leading U.S. moist snuff products and showed that these products contained 
far more of these flavorants than are found in hard candies; a typical ST user could ingest up to 12 times 
the acceptable daily level. Additionally, ST products may contain additives prohibited for use in food. 
For example, coumarin, identified in Camel Mellow Orbs,46 is banned as a food additive due to its 
liver toxicity.  
Promotion  
Advertising and promotion are the most visible methods for fostering the growth of a market and 
attracting new customers, often through creating a specific brand image (i.e., glamour, sophistication, 
ruggedness, convenience, use of the latest technology).47–49 Marketing messages can underscore 
desirable design features, such as flavorings, ease of use, and nicotine delivery, potentially increasing 
products’ attractiveness.50 New marketing approaches helped revive the snus market in Sweden 
beginning in the late 1960s. At the time, the median age of Swedish snus users was over 40 years, but 
new product development and intensive promotion by Swedish Match increased snus use among young 
Swedish men, so that by 1973 the median age of Swedish snus users had declined to 30 years.51 In 1999, 
Swedish Match divested its cigarette business to focus on other tobacco products, primarily Swedish 
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snus and cigars.52 In the United States, UST aggressively promoted moist snuff starting in the 
mid-1970s in an attempt to reach a younger market and combat declines in use over the course of 
the early 20th century.37,53 This strategy was successful, as ST use among young men increased 
ninefold between 1970 and 1987.54,55 In 2010, the major U.S. smokeless tobacco companies spent 
US$257,879,187 advertising and promoting moist snuff, and an additional US$57,394,000 advertising 
and promoting snus. In terms of return on investment, these companies spent $0.11 in advertising and 
promotion for every $1.00 in sales of moist snuff, and $0.70 for every $1.00 in snus sales.30  
Evolving Target Markets 
A key way for manufacturers to grow the ST market is to attract new groups of users. Mejia and Ling56 
have reviewed tobacco industry documents examining U.S. smokeless tobacco user characteristics 
dating back to the 1960s. They note that historically, ST use was concentrated in low-income, 
less-educated, white males, though an increase in use was observed in the 1990s among more active 
males engaged in outdoor activities such as hunting and fishing. Product marketing in the 2000s 
sought to expand beyond these traditional groups and attract more upscale, urban, and female users. 
Since about 2010, the ST industry has shifted its magazine advertising from men’s sporting magazines 
to magazines with more general readership,57 presumably in an attempt to broaden the appeal of 
ST beyond white males. 
Smokers 
One potential user group of interest is current cigarette smokers, who are already familiar with tobacco 
use (and addicted to nicotine). Smokeless tobacco manufacturers, at least in the United States, have 
been targeting smokers for the past few decades.58 For example, advertising for Skoal Bandits in 1983 
encouraged smokers to “Take a Pouch, Not a Puff.” Marketing to smokers increased with the 
proliferation of workplace and public space smoking restrictions in the United States through the 
1980s and 1990s.  
Reviews of tobacco industry documents reveal the extent of the research the industry conducted on 
developing ST products that could attract smokers.59 These reviews note that while manufacturers 
initially considered capturing those smokers who might otherwise quit smoking and converting them 
to ST alternatives, the manufacturers eventually refocused on promoting products designed to support 
temporary abstinence in situations where smoking was restricted. Some manufacturers accomplished 
this through the development of line extensions (e.g., Marlboro cigarettes, Marlboro Snus). In addition, 
the tobacco industry has advertised these products as alternatives to cigarettes in locations where they 
are otherwise prohibited and has also packaged these non-combustible and ST products in a manner 
that closely resembles the size and shape of cigarette packs. The potential effect of this approach, then, 
could be to undermine the impact of smoke-free laws on cigarette consumption by allowing for use of 
ST products in smoking-restricted environments. The original test markets for snus-like products (such 
as Camel Snus, Taboka) occurred in cities that had recently enacted smoke-free regulations.  
Use of cigarette brand names to sell ST products is presumably aimed at smokers. In branding, the name 
carries with it a set of associations beyond the product characteristics, implying a certain level of quality 
and conveying a certain image.60,61 Branding can communicate “a series of attachments and associations 






that exist over and beyond the objective product.”61,p.745 That is, if someone self-identifies as a Marlboro 
cigarette user, then trying a Marlboro-branded snus product may seem more consistent with that identity 
than using another brand, such as Skoal.  
Women 
Historically, in the United States and in Scandinavia, ST has been used primarily by men. In 
Scandinavia, product developers have been explicitly targeting women with product innovations and 
attractive packaging since 2008, which may have contributed to an upward trajectory for Swedish 
snus use among women compared to stable levels among men.62 In the United States, use of ST by 
women remains very low (<1%),63 and studies show that men are far more interested in trying newer 
ST products (e.g., Taboka, Camel Snus) than women are.64,65 Nonetheless, there are regional pockets 
with substantial use of ST by women (e.g., Alaska, Mississippi).66 In some parts of South Asia67 and 
Africa,68 use of ST products is equally common among women and men, and in some cases ST use is 
more common than cigarette smoking among women, whereas smoking is much more common than 
ST use among men. The international experience demonstrates that, given the right context and product, 
ST products can appeal to women.  
Youth 
Although no tobacco manufacturer publicly acknowledges targeting youth, capturing this market is 
essential for the future sustainability of the ST enterprise, just as it is for cigarettes.49,69,70 Morrison and 
colleagues71 showed that ST advertising in U.S. magazines with substantial adolescent readership had 
increased over time, consistent with the observed shift away from men’s sporting magazines to those 
with broader readership.  
Adolescents can become dependent on ST just as they can on cigarettes. According to DiFranza and 
colleagues,72 adolescent snuff users report levels of dependence similar to those of cigarette smokers 
with comparable histories of use; more than 50% of adolescents with less than 100 lifetime uses of 
either product reported at least one dependence symptom, whereas over 90% of those with more 
than 100 lifetime uses reported at least one symptom. Swedish youth report similar patterns, as 
well as particularly high dependence and withdrawal among dual users.73 In the United States, UST 
aggressively promoted low-nicotine products to young people starting in the mid-1970s in an attempt 
to graduate these new users to higher nicotine products as they become more dependent on nicotine.37 
A number of public health advocates have expressed concern about the appeal of novel ST products to 
youth. Regarding snus, attractive advertising and packaging have been a particular concern; for 
dissolvables, an additional issue has been their similarity to confections.28,74 Studies examining youth 
awareness of, interest in, and use of novel ST products are few, however. Data from one survey indicate 
that 29% of young adult men (aged 18–25 years) living in test market cities had tried snus.65 A study of 
18- to 30-year-old smokers in Canada75 showed that two-thirds would be willing to try ST (Marlboro 
Snus, du Maurier, Copenhagen, or Ariva), with du Maurier snus rated most appealing (du Maurier is a 
leading Canadian cigarette brand).  
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Of particular concern is whether novel products could initiate adolescents to nicotine use, leaving them 
more likely to try and eventually adopt cigarette smoking. Evidence for such “gateway” effects of ST is 
mixed, with Swedish studies consistently showing no significant effect.76–79 Some U.S. studies80–82 show 
increased likelihood of smoking subsequent to ST use, but others show no effect.83–85 This inconsistency 
in patterns across countries points to the complexities of carrying evidence across national and cultural 
borders. As Rosendahl and colleagues note,86 parental modeling of tobacco use can also be important. In 
Sweden, where more men use snus and more women smoke, adolescent smoking was predicted by 
parental smoking but not parental snus use, whereas adolescent snus use was predicted by parental snus 
use. The lack of “gateway” effects seen in Sweden may, in part, be a result of the greater adoption of 
ST use by adults, who are modeling this behavior for youth, in addition to other potential contributors 
such as Sweden’s ban on tobacco advertising and increased taxation of tobacco products. In the United 
States, smoking is far more common and remains more socially accepted; however, snus use as a 
precursor of smoking is a potential concern.87 Another possible contributor to the observed difference in 
gateway use patterns is the difference in product formulation (discussed earlier)—lower nicotine levels 
in “starter” brands may prime users for either higher nicotine ST products or for cigarettes.  
Messaging 
As target markets for ST products have evolved, so have the messages and themes used to promote 
them. Mejia and Ling56 note that, whereas earlier messaging for traditional moist snuff was directed 
toward men and emphasized rugged masculinity, messaging for novel snus products centers on 
enjoyment of indoor activities where smoking is prohibited and is couched in imagery that emphasizes 
trendiness, urbanity, and sophistication for both men and women. Timberlake and colleagues88 
confirmed this in a content analysis of Camel Snus advertising during the years 2007 to 2010. They 
noted that in 2009, themes of temporary substitution were supplanted by the “Break Free” campaign, 
which provided more ambiguous messages tied to freedom, independence, and behavior change. 
Since that paper was published, Reynolds American appears to have married the two types of 
messaging, timing major campaigns to coincide with New Year’s Day 2012 (New Year’s is a peak 
time for quit attempts among smokers) and with the implementation of a May 2011 smoking ban in 
New York City public parks (Figure 6-2). In 2011, Reynolds American launched a 7-day switching 
challenge, suggesting that the company may begin to encourage full substitution of snus for cigarettes 
(Figure 6-3). Reynolds American and Star Scientific have employed similar themes for their dissolvable 
tobacco products.  






Figure 6-2. Example of smokeless tobacco messaging emphasizing using smokeless tobacco when 
smoking is prohibited 
 
Figure 6-3. Camel Snus ad promoting 7-Day Switch Challenge, 2011 
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Packaging as Marketing 
Packages can serve as key aspects of tobacco marketing, both by reinforcing brand imagery 
communicated through other media, and by serving as a communication vehicle at the point of 
sale.89 Packaging has become a more central marketing tool as other communication vehicles such 
as billboards, magazines, and mass media have been restricted or eliminated. Cigarette 
manufacturers use colors (e.g., dark versus light), images (healthy, sexy, serious) and words 
(full-flavored, light, mild, smooth, natural, low tar) to communicate specific product features to 
consumers.69,90,91 Industry documents reveal that manufacturers pay careful attention to the messages 
conveyed by packaging.60 As noted by a Philip Morris executive: “Our final communication vehicle 
with our smoker is the pack itself. In the absence of any other marketing messages, our packaging … is 
the sole communicator of our brand essence. Put another way—when you don’t have anything else—our 
packaging is our marketing.”92,p.ii73 
Outside the United States, promotion of novel ST products in new markets (e.g., Tobaccorette and 
Lucky Strike snus in South Africa) has also tended to emphasize ability to use the novel product in place 
of cigarettes (Figure 6-2).  
Packaging innovations can also play a role in the appeal of a product,60 especially in high-income 
countries. In the United States, efforts to market ST to smokers have been accompanied by increased 
attention to attractive packaging. For example, Camel Snus has come in three different packaging 
configurations over time: originally a round tin, later an oblong tin, and finally an embossed metal tin 
with a design incorporating the newly required front-of-package health warning (Figure 6-4). Smokers 
may have been more explicitly considered in the design of Marlboro Snus, which comes in both round 
tins and cardboard sleeves (containing fewer sachets) that can be carried along with cigarettes 
(Figure 6-5). Reynolds American has also encouraged consumers to engage with the company in 
creating attractive packaging for both cigarettes and smokeless tobacco.93,94 In low- and middle-income 
countries manufacturers have also introduced innovative packaging to make sale and use more 
convenient. In India, for example, the gutka industry promotes a packaged, ready-to-use product based 
on a traditional custom-made product.  






Figure 6-4. Evolution of Camel Snus packaging, 2006–2011 
 
Source: Photos courtesy of Maansi Bansal-Travers, Roswell Park Cancer Institute. 
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Figure 6-5. Evolution of Marlboro Snus packaging, 2007–2011 
 
Source: Photos courtesy of Maansi Bansal-Travers, Roswell Park Cancer Institute. 
  






Camel’s dissolvables line has been at the forefront of packaging innovation, using plastic shell cases 
with unique opening mechanisms on the initial release, designed to be child resistant.28 The 2011 
relaunched products have gone a step further, coming in distinctive matching containers and available in 
a variety pack. Also of note is the inclusion of Camel imagery on the package’s Universal Product Code 
(UPC) (Figure 6-6). Embedding images in UPCs is an emerging trend in marketing,95 which could 
increase in prominence on tobacco products as other avenues for communication are restricted or 
packaging of tobacco products becomes standardized.  
Figure 6-6. Universal product code designs on Camel dissolvables, 2011 
 
Source: Photo courtesy of Maansi Bansal-Travers, Roswell Park Cancer Institute.  
Emerging Marketing Strategies 
The evolution of technology has created opportunities for innovative forms of product marketing, and 
the ST industry has taken advantage of the Internet and other emerging marketing practices to increase 
interest in its products. In the last decade, stealth marketing has become an important strategy to increase 
product awareness.96 Stealth marketing typically involves spreading information about a product among 
consumers who are not aware that they are being marketed to or do not know that the person spreading 
the information is an agent or employee of the company or a consumer compensated for their activity. 
Other emerging strategies include viral marketing (a marketing technique that uses pre-existing social 
networks and technologies to increase product sales and brand awareness through self-replicating, much 
like the spread of a virus), celebrity endorsements, product placements, and “brand pushers,” all of 
which try to “catch people at their most vulnerable by identifying the weak spot in their defensive 
shields.”96,p.6 Some of these practices—particularly when the relationship with the company is not 
disclosed, or the practice is otherwise deceptive, intrusive, and/or exploitative of consumers—can be 
regarded as unethical.97  
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Freeman and Chapman93 have noted that such activities have the potential to erode the impact of 
advertising restrictions on tobacco products. Accumulating evidence points to an increasing Web 
presence by tobacco companies, as well as consumers sharing user-generated content that is pro-tobacco 
(which may or may not be spurred on by the tobacco industry).98–102 A formal analysis of message board 
content posted on the website for Camel Snus showed that the board helped create a community of users 
who could share use experiences, and that the message board also served a marketing function by 
gathering information on consumer responses in the test markets.103 Reynolds American maintains 
websites for Camel Snus and Camel dissolvables, with evolving content that includes message boards, 
frequently asked questions, contests, and testimonials (Figure 6-7). In the past, website users have been 
asked to design new signature flavors and packages for Camel cigarettes,93 and a 2011 website feature 
allows users to custom design a snus tin.104  
Figure 6-7. Example of message board from Camel dissolvables website 
 







Positioning as a Quit Aid 
Some have argued that ST, particularly snus-type products and dissolvables, could play a role in 
smoking cessation.15,105,106 In Sweden, some studies have found that men have used snus to quit 
smoking, although there is not enough evidence to demonstrate that snus would be an effective cessation 
aid.78,107–110 In fact, the development of pharmaceutical nicotine gum was inspired in part by Swedish 
submariners who used snus to alleviate nicotine withdrawal when unable to smoke.111 However, in the 
United States, evidence for smokers’ use of ST as a means to successfully quit smoking is mixed.112–114 
Novel ST products have not been promoted directly as cessation aids. In many countries, including the 
United States, doing so would require manufacturers to go through a pharmaceutical approval process 
and provide strong evidence of their effectiveness for cessation. However, Ariva was packaged in 
pharmaceutical-type blister packaging and was sometimes shelved behind pharmacy counters near 
nicotine replacement products. 
Increasing Availability and Access 
Another marketing approach is to increase the availability of products, making access to them much 
easier. This is best illustrated by attempts by snus manufacturers to convince the European Union (EU) 
to lift its ban on the sale of moist snuff/snus (except in Sweden, which is exempt from the ban). Snuff 
sales are also banned in New Zealand, Australia, Turkey, Israel, Taiwan, Thailand, Singapore, Hong 
Kong, and the UAE,11,115 but there have not been similarly strong public pushes to lift those restrictions. 
The EU ban, enacted in 1992, has been criticized by some for restricting access to a class of ST products 
that may be less toxic (that is, Swedish snus) while permitting sales of cigarettes and other forms of oral 
tobacco that have been associated with high toxicity and disease risks (e.g., gutka).116 The European 
Commission (EC) directed its Scientific Committee on Emerging and Newly Identified Health Risks to 
review the health effects of ST products. The committee concluded that: 
STP [ST products] are addictive and their use is hazardous to health. 
Evidence on the effectiveness of STP as a smoking cessation aid is 
insufficient, and relative trends in progression from STP into and from 
smoking differ between countries. It is thus not possible to extrapolate the 
patterns of tobacco use from one country where oral tobacco 
is available to other countries.117,p.5 
In the end, the committee did not recommend either relaxing or lifting the ban. On December 19, 2012, 
the EC adopted its proposal to revise the Tobacco Products Directive (see chapter 10).  
Another approach to increasing ST use is to introduce ST products into markets where they have been 
used rarely or not at all. Manufacturers such as BAT, PMI, and Swedish Match have attempted to 
introduce snus products in such markets as South Africa and Canada. South Africa provides an 
interesting example of this process. South Africans, particularly black women, traditionally used 
handmade ST preparations (commonly nasally), although a few manufactured products were 
available.118 In 2004, Ayo-Yusuf and colleagues118 noted that a recently introduced snus-like product 
(Tobaccorette) had a low percentage of free nicotine available for absorption compared to more 
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traditional products. In 2006, BAT introduced snus products using familiar cigarette brand names, Peter 
Stuyvesant and Lucky Strike, into the South African market. Although there are no published data on 
consumer perceptions or snus usage estimates, a national survey in 2007 showed that only 1.6% of 
South African ST users surveyed reported using snus (Olalekan Ayo-Yusuf, personal communication, 
2013). These few events and findings point to the need for greater monitoring and more research on 
marketing practices in low- and middle-income countries. 
Price 
Monetary Costs 
Cost is often a significant factor in whether consumers will be interested in using a product. Depending 
on the jurisdiction, ST is taxed in various ways; tax authorities can apply a specific tax (per package or 
by weight) or an ad valorem tax (see chapter 5 for greater detail). In most cases, ST costs less per unit 
dose than cigarettes.  
Tax is not the only driver of effective price paid by consumers; manufacturers can also influence 
product price. In the United States in 2008, according to the FTC, tobacco companies reported spending 
a record US$324.6 million on ST price discounts (“payments made to smokeless tobacco retailers or 
wholesalers in order to reduce the price of smokeless tobacco to consumers”30,p.3). Although companies 
spent less in 2010 (US$95 million), price discounts continued to be the single largest expenditure for ST 
advertising and promotion, amounting to more than one fifth (21.4%) of all ST advertising costs.30 
Tactics such as price discounts can soften the impact of tax increases at the retail level, blunting their 
effect on consumption.  
Another way tobacco companies can alter the monetary cost to consumers is to offer tiers of products 
at different price points. This became an established practice in the cigarette market in the 1980s, 
primarily in response to increasing tobacco taxes,119 and discount brands appear to be used most by 
more-dependent smokers of lower socioeconomic status.120 U.S. smokeless tobacco companies also have 
pricing tiers: UST offers both premium (Skoal, Copenhagen) and discount (Red Seal) brands, as does 
American Snuff (Grizzly and Kodiak vs. Cougar). Premium brands tend to be most commonly used by 
adolescents, whereas discount brand users tend to be older.121–124 Smokeless tobacco manufacturers have 
tended to introduce novel ST products at a premium price point.125 
With novel ST products, a barrier to entry can be the cost of trying them, since consumers may be 
reluctant to spend money on a product they may not like. Thus, free trials and sampling are often 
important to fostering initial use of the product.126 Free sampling, particularly on college campuses, 
was a key component of UST’s product promotion strategies in the 1980s and 1990s.37 U.S. data show 
dramatic increases in free samples of ST in the years 2002 to 2008—a 719% increase in free samples of 
units weighing less than 1 oz (which would include most snus and dissolvable products).30 Free 
sampling was important to the initial launch of Camel Snus,127 and a free variety sampler pack of Camel 
dissolvables was available with the purchase of a Reynolds American–branded tobacco product on 
initial launch.104 Sampling and initial trial experiences can then diffuse through a user’s social network, 
increasing sales (i.e., contagion).128 Therefore, providing free samples can be viewed as an investment in 
future sales potential if a sufficient number of users adopt the product.  






Other Conceptions of Cost 
Price can be conceptualized as broader than simply monetary costs and may include social perception 
and perceived risks and benefits of use. Understanding consumers’ knowledge, attitudes, and beliefs 
about ST, then, is important to projecting product appeal. Several studies have found that consumers 
incorrectly believe nicotine causes cancer69,129,130 and that ST products are as dangerous as cigarettes, 
if not more dangerous.130–133 Surveys have attempted to tap consumer interest in novel products, 
usually couched in terms of their risk relative to smoking. Timberlake noted that 13% of California 
smokers were receptive to substituting ST for cigarettes,83 whereas similar studies in Australia and 
New Zealand show one-half and one-third of smokers in those countries, respectively, were receptive to 
substitution.134,135 Shiffman and colleagues136 described a smoking substitute as either a nicotine-based 
product or a tobacco-based product, finding that U.S. smokers generally preferred the former to the 
latter. Up to 75% of smokers in Edmonton, Canada, were willing to try a hypothetical oral tobacco 
product described as 99% less hazardous than smoking.133  
Social norms can represent a powerful influence on behavior.137 This concept underlies the tobacco 
control strategy of denormalization, which has resulted in significant gains in terms of reduced smoking 
prevalence (particularly among adolescents), increased support for smoke- and tobacco-free 
environments, greater voluntary adoption of smoke-free homes, and support for regulation of the 
tobacco industry. However, the denormalization of cigarette smoking also leads to greater stigmatization 
of smokers.93,138–140 This may present a marketing opportunity for novel ST products: Because use of 
ST, particularly spitless forms, is less visible to others, it may carry less social stigma than smoking, 
thus making ST increasingly more attractive to smokers. Reynolds American’s 2011 Camel Snus 
campaigns touch indirectly on this issue in their use of tag lines like “Smoke-Free. Spit-Free. 
Drama-Free” [emphasis added].  
Summary and Conclusions  
Tobacco manufacturers have begun to introduce ST products in new forms using new marketing 
techniques. Product innovations such as portion pouches, dissolvable tablets, unique flavorings, and 
varying nicotine levels may make novel products more attractive to potential consumers. Internet-based 
marketing appears to be increasingly important to the diffusion of novel ST products. Changing social 
norms and denormalization of smoking may contribute to increased attractiveness of ST products in 
markets where smoking prevalence is declining. In particular, ST products are being marketed toward 
smokers as substitutes to use in situations where they cannot smoke. On the one hand, such 
developments may be positive for public health if they draw substantial numbers of smokers away 
permanently from cigarettes. On the other hand, novel products and marketing approaches have the 
potential to undermine public health efforts to the extent that they attract non-users and youth to adopt 
use or deter smoking cessation by encouraging dual use.  
Understanding consumer perceptions and responses to novel products is important to predicting their 
likely public health impact. Evolving regulatory frameworks under the FDA and the WHO FCTC may 
also help define the effects of these novel products at the population level. The FDA has authority to 
allow the entry of novel products, potentially allow claims of exposure or risk reduction for these 
products, evaluate substantial equivalence for product modifications, and set product standards. 
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Given these authorities, it is essential to develop the scientific evidence base to support regulatory 
decisionmaking. Effective regulation of product advertising and promotion must focus on consumer 
perceptions of messaging and take into account the emergence of Internet-based advertising and the role 
of product packaging. Increased and improved monitoring of marketing practices in low- and middle-
income countries will benefit these countries by yielding an evidence base about regulating ST 
marketing in those countries. Finally, tobacco control efforts may need to evolve with the changing 
tobacco market to maintain progress in reducing morbidity and mortality. 
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Interventions for Smokeless Tobacco Use 
Public health efforts to reduce the overall prevalence of tobacco use must focus on both prevention and 
cessation of all tobacco products. Although cigarettes continue to be the primary tobacco products used, 
as of 2012, high prevalence rates of smokeless tobacco (ST) use are being reported among males and 
females, both youth and adults, in a significant number of countries, varying widely by region and area 
(see chapter 2). Even in countries that currently have low rates of ST use, vigilance is necessary because 
tobacco companies adapt their products and marketing approaches in response to greater tobacco control 
restrictions and reduced smoking prevalence. For example, tobacco companies promote ST as a way 
to adapt to concerns about the health effects of exposure to secondhand smoke in public places.1 In 
addition, cigarette companies are introducing novel ST products, including “spit-free” forms, and the 
marketing of these products may increase use by young people and by smokers responding to 
environmental restrictions (chapter 6). 
This chapter reviews a wide variety of available interventions to prevent and reduce the use of ST, 
ranging from intensive clinical interventions to high-reach, low-intensity public health programs. The 
chapter focuses first on prevention, emphasizing its importance especially among youth. Although by 
far the most research on youth tobacco use centers on smoking, there is an increasing awareness of the 
potential increased use of smokeless tobacco by youth and young adults. Because resources and cultures 
vary across countries, examples of interventions from a range of available countries are provided. Most 
of the current research, however, concentrates on high-income countries and school-based interventions. 
Several studies use the term point prevalence to mean self-report of abstinence from use of any tobacco 
product for the past 7 days or the past 30 days. Although some studies use continuous abstinence, most 
give the point prevalence estimate both at the end of the study and for follow-up periods. Two different 
measures of dependence have been used: the modified Fagerstrom scale and the Severson Smokeless 
Tobacco Dependence Scale (SSTDS).2 
Interventions to Prevent Smokeless Tobacco Use Among Young People 
To date, only limited efforts have been made to prevent ST use among children and adolescents in the 
United States and other countries. Compared to the extensive research on prevention of smoking, few 
publications have reported on empirical evaluations of ST prevention interventions. Considering the 
effects of ST, its health consequences, and its impact on public health, it is clear that more tobacco 
control efforts and interventions are necessary. Available prevention studies are described in Table 7-1, 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7. Prevention and Cessation Interventions 




Community- and Health Care–Based Prevention 
Community-based efforts—which use a comprehensive approach that includes schools, media, family, 
advocacy, and public policy—may be effective in helping to prevent ST use by youth. The fact that 
community interventions can reach young people who may not be attending school is an advantage, 
because school dropouts and non-attending youth may have higher tobacco use rates than youth who are 
attending school.3 Project SixTeen,4 a randomized controlled trial (RCT) conducted in the United States 
(Oregon), tested whether a comprehensive communitywide effort to prevent teen tobacco use was a 
better deterrent than a school-based tobacco prevention program alone. The community intervention 
included media advocacy, a youth anti-tobacco module, family communication activities, and a youth-
access campaign. The school-only intervention consisted of an evidence-based curriculum called 
Programs to Advance Teen Health. The study found that the community intervention had a significant 
effect on the prevalence of ST use by males after one intervention year, which suggests that a 
multicomponent community-based intervention can have stronger preventive effects than a school-based 
program alone, which was not as effective at preventing smoking initiation and future increases in 
smoking prevalence.  
Despite a relative lack of specific ST prevention efforts in the United States, studies have documented 
an overall decline in adolescent ST use since the late 1990s and an increase in the percentage of 8th, 
10th, and 12th graders who perceive regular ST use as harmful.5 However, the most recent national 
survey data suggest that during the past 10 years, ST use among high school students has remained flat; 
perceptions of ST harm among 8th, 10th, and 12th graders also were constant through 2010, but as of 
2012, perceived risk of ST use has decreased among 8th and 10th graders.6,7 Temporary improvement of 
ST perceptions may have been the result of the extensive anti-tobacco efforts targeted toward young 
people throughout the United States in the 1990s, although these efforts focused primarily on cigarette 
smoking.5 For example, in 1993, the Massachusetts Tobacco Control Program began a statewide 
comprehensive youth tobacco (ST and cigarette) prevention campaign in communities and schools and 
through the media. An analysis of school survey data between 1993 and 1996 found a greater decline in 
the state than had occurred nationally, suggesting the program was effective in preventing ST use.8 This 
decline had continued as of 2005.9 
Visits with oral health care providers offer a natural opportunity to deliver a brief ST intervention 
because these providers are in a unique position to identify the oral consequences of ST use. Although 
dental settings have been a venue for several cessation studies in the United States that have 
demonstrated efficacy in ST cessation,10–12 they have not been evaluated for providing preventive 
interventions. Pediatricians might be in a similarly advantageous position to provide brief counseling to 
young people about avoiding tobacco use, as indicated in Indian health care settings,13 but the only study 
evaluating this approach, which took place in the United States, did not find that counseling by 
pediatricians significantly prevented ST use.14 
Few evaluations of U.S. programs to prevent young people from starting to use ST or preventing their 
continued use have been focused on interventions in communities, families, or health care settings. The 
results reported by Project SixTeen4 are encouraging, but additional research is needed to determine 
effective ways to educate both children and parents about the health risks of ST use. The dental office 
setting offers a unique and timely opportunity to provide preventive education, but studies in this 






setting to date have focused on cessation; there are no published evaluations of prevention efforts in 
dental settings. 
In low- and middle-income countries, community-based interventions may have significant potential 
for reducing ST use. A study with 10- to 19-year-olds in two low-income communities in Delhi, India, 
compared a community that received the intervention with another community that served as the 
control. A significant difference in current tobacco use was observed between the study groups, with 
the intervention group showing a reduction in ST use and the control group showing an increase in 
use. Postintervention, there were significantly fewer new tobacco users in the intervention group 
compared with the control group. No significant differences were observed in tobacco quit rates 
between the two groups.15 
Based on the success of this demonstration study, a group RCT called Project ACTIVITY (Advancing 
Cessation of Tobacco in Vulnerable Indian Tobacco Consuming Youth) was implemented to reduce 
tobacco use among disadvantaged youth (aged 10–19 years) in 14 low-income communities in Delhi. 
The study was conducted in collaboration with Health-Related Information Dissemination Amongst 
Youth (HRIDAY) and the University of Texas in the United States. In 2009, seven communities were 
randomly assigned to receive a 2-year intervention, and another seven served as controls.16 The 2-year 
intervention targeted intrapersonal and socio-environmental risk factors to prevent initiation of smoking 
and ST use, and to promote tobacco cessation.17 Four intervention strategies—training workshops, 
community-based cessation camps, interactive activities, and policy enforcement—were used, with an 
emphasis on leadership education and enforcement of tobacco control laws. Although final quantitative 
outcome data for this study are not available, preliminary qualitative results show that community-based 
interventions can be effective in preventing adolescents from starting tobacco use in a low-resource 
setting such as India, in changing community norms around tobacco use and denormalizing ST use 
among all community members.18 
School Curriculum Interventions 
Most interventions to prevent tobacco use have been school based because schools provide access to 
young people, and many interventions are designed to teach youth to resist peer pressure in relation to 
using tobacco products.19 Some promising school-based programs are reviewed below and summarized 
in Table 7-1. 
One study conducted in the United States evaluated a classroom-based social influences program 
delivered by teachers and peer leaders in randomly assigned schools. The goal of the intervention was 
to sensitize students to overt and covert pressures to use tobacco. Even though only two of the seven 
class periods focused on ST-specific content, the intervention resulted in diminished ST use among 
males (the predominant users of ST) in the 7th and 9th grades. The program had a significant effect on 
reducing ST use among the boys in the 7th grade.20 
Another example of a successful school-based program, Project SHOUT, evaluated an intervention 
delivered to 7th grade students in 22 California middle schools. Directed toward grades 5 through 9, 
the Project SHOUT program combined education, social activism, behavioral strategies, and telephone 
support from an older peer. At the 3-year follow-up, results showed a significant decrease in cigarette 
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use (OR = 0.77), ST use (OR = 0.47), and combined cigarette and ST use (OR = 0.71) at the school level 
within the past month.21 
A California school tobacco prevention curriculum, Project Towards No Tobacco Use,22,23 also showed 
promising results for ST prevention. This program corrected misperceptions about ST use, taught about 
the physical consequences of use, and tested the effectiveness of refusal skills. Although the combined 
curriculum was effective in reducing initial and weekly use of ST, the results of a 2-year follow-up 
showed that only the physical consequences curriculum sustained its benefit over the long term, which 
suggests that teaching students about the physical consequences of ST use in personally relevant ways 
can be important to preventing ST use. 
School- and community-based intervention and prevention efforts in high-income countries have shown 
promising results, but prevention programs that target both substance use and tobacco may not offer 
enough information to have a significant impact on ST initiation. Most tobacco prevention programs 
focus on smoking and give little attention to ST in their curricula or activities. 
School curricula targeting prevention of tobacco use, including ST, in some low- to middle-income 
countries (such as India) have been tested and also show promising results. Project MYTRI (Mobilizing 
Youth for Tobacco-Related Initiatives) was a multicomponent intervention aimed at reducing tobacco 
use among adolescents in schools in Delhi and Chennai, India. Students from 32 schools in the two 
cities were randomly assigned to either an intervention group or a control group. Baseline, intermediate, 
and outcome data were collected from two cohorts of 6th and 8th graders beginning in 2004; from 2004 
to 2006, 14,063 students completed surveys. The Project MYTRI intervention is based on social 
cognitive theory and existing evidence-based smoking prevention programs which were appropriately 
translated to match the needs of adolescents in India.24,25 The intervention consisted of behavioral 
classroom curricula, school posters, a parental involvement component, and peer-led activism. 
Classroom activities were based on a graded curriculum, and multiple sessions were implemented each 
year. In both years of interventions, high participation rates were achieved for classroom interactive 
activities. The peer-led component involved training a large number of students as peer leaders, while 
training teachers to supervise and assist the peer leaders in conducting classroom activities.25 The 
control group received only a diet and physical activity intervention. 
Over the 2 years of the MYTRI intervention, significant differences were noted between the intervention 
and control groups in the trajectories of cigarette smoking and bidi smoking, but no significant between-
group difference was seen in trends in ST use behavior.26 However, there were significant differences 
between groups in students’ intentions to use ST and their social susceptibility to ST, suggesting that the 
intervention had some positive impact. 
Project MYTRI’s baseline data indicated that the prevalence rate for ever-use of ST for girls and boys 
was 12% and 16%, respectively.27 In the intervention schools, ST adoption for girls decreased 
marginally over time compared to initiation of ST use by girls in control schools, where there was 
no change.25  
Smokeless Tobacco and Public Health: A Global Perspective 
227 
Individualized Preventive Interventions 
Among youth in the United States and other high-income countries, ST use is considerably lower than 
cigarette smoking, although higher rates of ST use occur in certain subgroups. Smokeless tobacco use is 
much more common in boys than in girls,28 and the highest rates of use in the United States are observed 
among Native Americans and Alaska Natives, in the Southern states, and in rural areas of low 
socioeconomic status.29 Smokeless tobacco is also more common among young male players of certain 
sports, such as baseball.30 Some prevention programs concentrate on these subgroups. 
One study that focused on Native American youth31 developed and tested a skills- and community-based 
approach to preventing substance abuse, including ST use. The program was carefully tailored to the 
cultural values and everyday realities of Native American youth in the targeted western reservations. 
The study found follow-up rates of ST use were lower for youths who received the skills intervention 
than for those in the control group, which did not receive an intervention. 
Although not a special population of users, youth aged 10–14 years were targeted by a program that was 
implemented in 4-H clubs throughout California. This program focused on education about tobacco use 
in general, not specifically ST use. A youth development organization, 4-H is popular in rural areas and 
small towns in agricultural regions, and these voluntary clubs provided a unique opportunity to reach 
young people. Seventy-two 4-H clubs (with a total of 1,438 members) were matched and randomly 
assigned to an intervention (tobacco education delivered by volunteers in five successive monthly club 
meetings) or to a no-treatment control.32 At a 1-year follow-up, club members in the intervention group 
showed significant effects in improved knowledge of the harmful effects of tobacco. Seven of 24 
program effects were significant at 1 year in increasing knowledge, improving perceptions, and 
decreasing intentions to smoke, but no significant effect on reducing tobacco use was seen at the 
2-year follow-up. 
Studies conducted in the United States have documented that high school males frequently use ST when 
playing or watching a sport,33–35 and the greater their athletic involvement, the more likely they are to 
use smokeless tobacco.36 A behavioral intervention targeting male high school baseball athletes37 was 
designed to discourage ST initiation and promote cessation. The intervention included an interactive 
peer-led component and a dental component with an oral cancer screening exam. Although the 
intervention was effective in promoting ST cessation, it was ineffective in preventing initiation. One 
predictor of ST initiation was that young people perceived that most of their teammates used ST 
(OR = 4.73), suggesting that correcting this overestimation would be an important component of an 
effective ST prevention program. 
Smokeless Tobacco Prevention Among Youth—Summary 
The studies conducted in India and the United States strongly suggest that communitywide programs can 
significantly reduce intentions to use smokeless tobacco. The cultural adaptations made in Project 
ACTIVITY also demonstrate that community interventions can succeed in challenging environments 
such as very poor neighborhoods of Delhi, but more studies are still needed in other countries. 
Some well-designed school-based interventions tested in the United States have also shown positive 
results in preventing ST use, but the number of ST interventions is much lower than the number of 
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smoking prevention interventions conducted in the United States in recent years. School-based 
prevention programs that focus specifically on the negative health and physical effects of ST and 
combine educational strategies with social activism can significantly reduce the likelihood that young 
men will start to use smokeless tobacco. Since ST use is especially high in some special populations, it 
is encouraging that interventions have been targeted toward these groups. Recent comprehensive 
reviews and meta-analyses confirm that school-based drug interventions can be successful provided 
they: (1) are interactive, (2) engage peer facilitators, (3) involve parents and other segments of the 
community, (4) are theory based and follow the social influences model, (5) adequately train teachers 
and support health-promoting school policies, and (6) are provided in multiple years, starting with age of 
initiation.3,38,39 School-based interventions in India did not successfully reduce ST rates, although they 
changed intentions, attitudes, and knowledge of health risks. In conclusion, although there is a need to 
address ST use through curricula and school-based programs that target ST use by adolescents, broad 
community-based interventions appear to have more effect than school-based programs alone. However, 
school-based programs containing the six components listed above can produce at least short-term 
effects and reduce the prevalence of tobacco use among school-aged youth, particularly when they are 
implemented in combination with other initiatives such as mass media campaigns and state and 
community programs.40 
Smokeless Tobacco Cessation 
Abstinence is the most effective way to prevent the morbidity and mortality associated with ST use. 
Evaluations of behavioral and pharmacologic interventions to treat ST use have shown that these 
interventions have had varying degrees of success, as measured by short- and long-term (≥6 months) 
tobacco abstinence rates. In addition to promoting ST cessation, these interventions can be effective 
in treating tobacco craving and nicotine withdrawal symptoms. Most published RCTs evaluating 
interventions for ST use were conducted in the United States and may have employed slightly different 
measures of cessation, making it difficult to generalize the findings to other nations with different 
types and patterns of ST use. However, results of these trials can form a foundation upon which to 
construct interventions specifically tailored to regionally or culturally driven patterns of ST use. 
Table 7-2 lists ST cessation interventions that have been conducted at the community, organizational, 
and individual levels. 
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Tobacco cessation efforts in low- to middle-income countries are primarily community-level 
interventions, reflecting, in part, limited resources and a scarcity of professional ST cessation training. 
For example, the Global Adult Tobacco Survey (GATS), conducted in India during 2009 and 2010, 
found that 47% of ST users had visited health care providers in the past 12 months, but only 34% of 
those users were asked about ST use, and only 27% of those who had visited health care providers in the 
past 12 months were advised to stop tobacco use.41 These findings support implementing cessation 
efforts at the community level and offering more cessation training to health care providers.41,42  
Myanmar and India are implementing tobacco control programs with legislation, community awareness, 
community mobilization, and/or health promotion activities as main components. 
Myanmar piloted a community tobacco use cessation project.43 In this pilot study, community 
facilitators in two regional divisions, Yangon and Bago, were selected and trained. Community-based 
cessation activities included roundtable discussions with the community; advocacy talks with 
community leaders; Information, Education, and Communication (IEC) materials; dissemination of 
tobacco control messages during festivals; monthly meetings between facilitators and quitters; and 
billboard postings. The impact of these cessation activities varied widely in different communities 
depending on the intensity of the interventions. Among smokers, 11% completely stopped smoking and 
15.4% were in the process of quitting; among ST users, one community reported a quit rate of 11%.43  
A large community-based cessation intervention was also tested in one state in India. The intervention 
included personal and mass media communications to motivate smokers and ST users to quit, which 
contributed to significantly more quit attempts among program participants in the intervention group 
(9.4%) than in the control group (3.2%) after 5 years of intervention.44 This intervention was effective 
across all demographic groups but had a greater impact on men, ST users, older people, and those with a 
shorter duration of tobacco use.45 The researchers also reported a reduced 5-year age-adjusted incidence 
rate of leukoplakia (oral lesions) after tobacco cessation. 
Another community-based tobacco control education program was implemented in the Kolar district in 
Karnataka (India). In an effort to prevent individuals from initiating tobacco use in any form and to quit 
use if already using, this program used health education materials, consisting of films, exhibits, and 
displays of photographs of harmful effects. Program results were evaluated through changes in 
prevalence rates, quit rates, and initiation rates, and the effects of 2 years of intervention were assessed 
by follow-up surveys after the second and third years. In the intervention cohort, the quit rate for ST use 
was 30.2% among males (vs. approximately 1.15% in the control group). A higher proportion of men 
had quit ST use (30.2%) than had quit smoking (20.4%).46 
In 2002, with support from the World Health Organization (WHO), the Government of India, through 
its Ministry of Health and Family Welfare (2009),47 established 19 tobacco cessation clinics (TCCs) 
across the country, primarily in cancer, surgical, and cardiology clinics, and in some nongovernmental 
organization settings. The TCCs provide behavioral therapy, education, tips for quitting, motivation 
to change, and relapse prevention counseling.47 Experiences from the TCCs were pooled, and baseline 
information was obtained on 23,320 individuals from the first 5 years of the TCCs’ operations. 






Sixty-nine percent of the individuals received behavioral therapy only, and 31% received both 
behavioral therapy and pharmacotherapy.48 Younger men, ST users, and those receiving combination 
therapies had relatively better outcomes at 3-, 6-, and 9-month follow-ups. Continued follow-up was 
found to contribute to better outcomes in these clinics. However, more research is needed to determine 
whether these outcomes are sustainable over the long term. Barriers to ST cessation were low levels of 
awareness of the harms from ST use and lack of knowledge about the benefits of quitting and methods 
of quitting. 
The tobacco cessation experience in India suggests that clinics have better outcomes with ST users than 
with smokers. Moreover, the “5 A’s” approach for smoking cessation translates well into ST cessation: 
(1) Asking all treatment seekers about their tobacco use, (2) Advising them in clear terms about the risks 
of continuing use and the advantages of stopping, (3) Assessing their readiness to quit, (4) Assisting 
them in quitting, and (5) Arranging for referral or follow-up. Health professionals and community staff 
in existing health systems can be trained in using the 5 A’s, which can easily be integrated into health 
initiatives in various health care settings.49,50 
Organization-Level Behavioral Interventions 
A variety of behavioral interventions for the treatment of ST use have been evaluated in a broad array 
of different populations of ST users at the organizational level (e.g., school, clinic, military unit). 
Successful interventions have used psychosocial education, social support, relapse prevention strategies, 
and an oral examination with feedback about changes in oral health caused by ST use. Interventions 
have been based on social influence theory,32 the health belief model,51 diffusion of innovation theory,52 
and cognitive social learning theory.53 
Youth Cessation 
Few researchers have focused on developing efficacious, practical cessation tools for young ST users. 
The small number of ST interventions designed for youth are usually incorporated as secondary 
elements of multicomponent ST tobacco use prevention programs. Although school- or community-
based programs may help reduce initiation or early use, any effort to reduce prevalence must include a 
focus on helping young users quit. In the United States, most ST cessation programs for youth focus on 
high school or college athletes, groups that are known to have higher rates of ST use.33,36,37 Some 
interventions designed to reduce the adoption of tobacco use by middle school and high school youth 
examine program effects on cessation among students who were already using tobacco products, but few 
programs have included ST-specific cessation components. 
Cessation programs for youth often use multisession, multicomponent, cognitive behavioral 
interventions that include self-monitoring of ST use, education about health risks, and behavioral coping 
strategies for helping young people quit. These programs face challenges in motivating young users to 
quit and overcoming high drop-out rates and attrition levels.29 These programs tend to be more 
successful for lower level users who use less ST and therefore are probably less dependent. 
Group- or organization-level behavioral interventions have been effective in increasing rates of long-
term tobacco abstinence among adolescent ST users. One large study,37 involving 22 treatment schools 
 
7. Prevention and Cessation Interventions 




and 22 control schools, examined the impact of ST cessation efforts aimed at high school baseball 
players randomly assigned to treatment or to a control condition. Treatment consisted of discussion of 
the harmful effects of ST use, refusal skills training, encouragement of cessation by a strong peer 
opinion leader, a meeting with coaches, a self-help guide to quit, and a dental exam with cessation 
advice from a dentist. Sustained ST cessation was significantly higher in the treatment compared to the 
control group (27% vs. 14%, respectively). Results of this intervention were based on self-reports, but 
the researchers obtained saliva samples from participants to increase the accuracy of self-reports and 
used the “bogus-pipeline” procedure, in which participants were informed that the samples could be 
used to ascertain the veracity of the self-reports.53,54 Using oral health screening exams, brief counseling, 
and peer-led educational sessions helped to double the quit rate compared to quit rates of students in 
control schools. Previous cessation research studies with adults have found that oral exams can be 
significant motivators for ST users to quit.29,55 
A similar study found that a college-based ST cessation intervention targeting college athletes was more 
effective than no intervention for increasing long-term tobacco abstinence among these participants.56 
The study was an RCT involving baseball and football athletes at 16 California public colleges, both 
rural and urban, which were matched on prevalence of ST use. Players completed questionnaires 
assessing their tobacco use. The intervention was a team-based cessation program based on cognitive 
social learning theory57 in which a dentist performed oral soft tissue exams with each team member, 
advised users to quit, pointed out ST-related tissue changes in their mouths, showed photographs of 
cancer-related facial disfigurement, provided a self-help cessation guide, and offered users a single 
15- to 20-minute session of counseling. Individuals who wanted to quit received 2 mg nicotine gum to 
treat tobacco withdrawal symptoms. Dental hygienists met with non-users in small groups to discuss the 
quitting process and encouraged them to support the ST users in quitting. Those trying to quit received 
two support phone calls. Among the 360 ST users, the intervention significantly increased ST abstinence 
rates at 1 year compared to the rates for participants in the control groups. On average, the observed 
self-reported quit rates were 34.5% for intervention schools and 15.9% for control schools. Besides 
doubling the quit rate, the intervention led to significant reductions in reported tobacco use for those 
who did not quit. 
Another study involved athletic trainers directing an ST cessation program with collegiate baseball 
players,58 who are known to be high users of snuff. This study involved 52 California colleges in a 
stratified, cluster-RCT of an intervention intended to prevent initiation and promote cessation of ST use. 
Intervention components included videoconference training, newsletters, an oral cancer screening exam, 
a self-help guide for quitting, and a counseling session for interested players. Those wanting to quit 
received follow-up support from the athletic trainer on the quit date and three booster sessions 1 week 
apart. Athlete peer leaders conducted a single 60-minute educational team meeting that included video 
and slides. Although the program had the significantly positive effect of reducing initiation of ST use at 
1-year follow-up, there was no significant difference in cessation between intervention and control 
groups (95% CI: 0.70–1.27). The authors attribute this lack of effect on cessation to the small number 
of dependent ST users enrolled in the study. 
Walsh and colleagues59 conducted a randomized study involving male students in 41 rural high schools. 
The students received an intervention consisting of a peer-led educational session plus an oral exam with 






feedback and three nurse-led group cessation counseling sessions, or no intervention. In the peer-led 
educational session, student peers presented videos and slides and then led a discussion about the 
2 videos and 10 slides related to ST use, and about the role of the tobacco industry in targeting young 
men. A school nurse conducted the oral exam and pointed out any tobacco-associated lesions to the 
students. The nurses also asked about tobacco use, advised users to quit, assessed users’ readiness to quit 
in the next month, and assisted with the quitting process by offering a self-help guide. The nurse-led 
counseling consisted of three non-compulsory, 1-hour cessation sessions held after school approximately 
1 week apart. Non-smoking ST users in the intervention group were significantly more likely to have 
stopped using ST at the 1-year follow-up than those in the no-intervention group (62% vs. 36%).  
An ST cessation study involving younger users (aged 10–14 years) was conducted in California 
agricultural youth 4-H clubs (methods described in “Individualized Preventive Interventions” section 
above). Four months after the intervention, the intervention group showed significantly improved 
knowledge, attitudes, and behavioral intention; however, no differences in behavior (no increase in 
cessation or abstinence) were seen at either the 4-month or the 2-year follow-up.32 
Burton and colleagues60 reported a school-based study that compared two models of cessation for 
smokers and ST users in 16 high schools. Students were randomly assigned to an addiction group, a 
psychosocial dependency group, or a control group. The addiction model focused on psychological 
aspects of addiction and the effects of nicotine, whereas the psychosocial dependency model focused on 
social and psychological aspects of tobacco use and on stress management. The majority of the 
participants were smokers, but the treatment groups shared some components, and the sessions were 
divided between information presentations and group discussions. Smokeless tobacco users were 
significantly more likely than smokers to abstain from tobacco use at the 4-month follow-up, when the 
validated quit rates were 14.3% for ST users and 6.5% for cigarette smokers; the control groups had no 
subjects reporting ST abstinence and 3.2% reporting cigarette abstinence. 
Adult Cessation 
Both smoked and smokeless tobacco use rates in the U.S. military are higher than in the rest of the U.S. 
population.61,62 Effective interventions focusing on the treatment of ST dependence are critical for 
reducing adverse health consequences among military personnel. In a study of U.S. military recruits 
entering basic military training (BMT), during which no tobacco use is allowed, 33,215 subjects were 
randomly assigned to either a tobacco use intervention, including an ST component, or a health 
education control group.63 The ST component included a discussion of the positive changes since 
quitting (upon entering BMT), information about the negative consequences of ST use, a visual 
demonstration, encouragement to use oral substitutes (non-nicotine and non-tobacco herbal chews), 
and discussion of the progression from ST to other tobacco products. Smokeless tobacco users in the 
intervention group were significantly more likely than ST users in the control group to be continuously 
abstinent at follow-up. 
Dental offices provide a unique and effective point of intervention for ST users. In a study involving 
75 U.S. dental offices, 633 ST users were randomly assigned to a behavioral intervention consisting of 
usual dental care combined with advice to quit, setting a quit date, self-help materials (pamphlets; 
non-tobacco, non-nicotine oral replacement products; and a specialized video for smokers and ST users), 
 
7. Prevention and Cessation Interventions 




and phone support. The control group received usual dental care only.11,12 The intervention was 
associated with significantly increased 3- and 12-month ST abstinence rates compared to usual dental 
care (10.2% vs. 3.3%).11  
Dental setting interventions in both military and civilian populations have been effective in increasing 
tobacco abstinence rates among ST users. In a study of 24 U.S. military dental clinics, 785 ST users 
were randomly assigned to usual care or telephone counseling with a trained cessation counselor. Those 
in the phone counseling group received assistance in quitting ST use (if desired) along with a mailed 
videotape and military-specific self-help guide.64 The first phone counseling call occurred about 1 week 
after a dental visit. Individuals accepting materials were offered two or more calls coinciding with 
receipt of the mailed materials and their ST quit date. Subjects in the ST cessation program were 
significantly more likely to be abstinent from all tobacco, as assessed by repeated point prevalence at 
both 3 and 6 months (25.0%), and were significantly more likely to be abstinent from ST for 6 months 
as assessed by prolonged abstinence (16.8%) compared with usual care (7.6%, repeated point 
prevalence; 6.4%, prolonged abstinence).  
Another program identified active-duty military ST users during preventive health screenings and 
provided an intervention consisting of an ST treatment manual, a video, and several supportive phone 
calls from a cessation counselor.65 At 3 months, tobacco abstinence rates in the intervention group were 
double those in the usual care group (41% vs. 17%), but the difference was not significant at 6 months 
(37% vs. 19%).65 
The authors of another study cite feedback from oral exams as a key motivational factor for getting 
patients to try to quit. In a program conducted in 11 dental clinics, 518 ST users were randomly assigned 
to usual care or a behavioral intervention incorporating an oral exam with feedback, advice to quit from 
both a hygienist and a dentist, a self-help manual, a video, setting a quit date, telephone support from a 
counselor, a free helpline, and six newsletters.66 The behavioral intervention significantly increased 
long-term abstinence rates; abstinence among the intervention subjects at both 3 and 12 months was 
18.4% compared to a rate of 12.5% among those who received usual care.  
A 2010 review of behavioral interventions for oral tobacco cessation offered in countries other than the 
United States suggested that behavioral interventions and components such as telephone counseling and 
oral examination may particularly enhance abstinence rates.67 
Individual-Level Behavioral Interventions 
Behavioral interventions for ST users conducted at the individual level are described in Table 7-2. 
Youth Cessation 
The high prevalence of Internet and computer use among young people suggests that technology-based 
interventions might offer an innovative opportunity to engage young users in the quitting process. 
Several studies of these interventions have been conducted in the United States. Fisher and colleagues68 
reported on the use of an interactive computer-mediated intervention designed to help individuals quit 
using ST, a mode of delivery that is an attractive alternative to school or clinical settings. A small pilot 






study was conducted with 50 individuals who accessed a program called Chewer’s Choice, which used a 
baseball field interface to appeal to users, most of whom were male. The authors reported that at the 
6-week follow-up, 85% of all subjects had made a quit attempt, and 58% of all subjects reported having 
quit all tobacco for at least 24 hours. 
Another pilot study evaluated an Internet ST cessation program with 18 baseball players at California 
colleges in 2008. The 26% self-reported reduction in ST use at 1-month follow-up indicates that this 
may be a feasible program acceptable to users.51 
A Web-based program designed specifically for young users could be a low-cost alternative for 
promoting cessation. An RCT evaluating a Web-based cessation program69 offered to ST users ages 14 
to 25 years (described at http://ww.mylastdip.com) examined the efficacy of two websites designed for 
young ST users. The “basic” condition provided a text-based site offering an evidence-based cessation 
program plus information and resources on ST cessation. The “tailored” condition was a customized, 
interactive site providing video and other engaging activities plus the opportunity to post on “blogs” 
(Web-based message boards). A unique feature of this study was that no parental consent was required 
to participate, as previous research has shown that requiring active consent from parents can 
significantly deter enrollment in cessation or prevention studies.70,71 Preliminary results showed 
relatively high self-reported quit rates at 3 months (38% for the basic condition; 41% for the tailored 
condition). Although there were no differences between conditions at either the 3-month or the 6-month 
follow-up, both groups had self-reported rates of abstinence comparable to rates for treatments involving 
more intense in-person interventions.69 
Adult Cessation 
Telephone support from trained counselors along with self-help materials can enhance tobacco 
abstinence rates among adult ST users. In a study that randomly assigned 1,069 ST users to a self-help 
manual only (MAN) condition or to assisted self-help (ASH), the ASH intervention resulted in 
significantly higher ST quit rates (23.4% vs. 18.4%) and rates for quitting all tobacco products 
(21.1% vs. 16.5%) at 6 months.72 The ASH condition included an ST intervention manual, a video, and 
two support phone calls. Since this combination of assisted support, including the video and the phone 
calls, greatly increased quit rates, it can be considered a key ingredient for improving success in quitting.  
In an RCT of a phone-based intervention, 406 adult ST users in the U.S. Midwest were randomly 
assigned to self-help alone (a manual only) or to a “QL” condition, consisting of a tobacco quit line with 
self-help combined with proactive phone counseling that emphasized support, problem-solving, use of 
cognitive-behavioral strategies (such as setting a quit date, examining use patterns, reducing stress, and 
avoiding known triggers).73 Prolonged abstinence (after a 30-day grace period) from all tobacco was 
significantly higher at 3 months for the QL intervention group (QL intervention, 30.9% vs. manual only, 
6.8%) and at 6 months for the QL intervention group (QL, 30.9% vs. manual only, 9.8%). Phone 
counseling again appears to be an important element in increasing quit rates. 
Web-based interventions have increased abstinence rates among adult ST users. In a study of Web-based 
ST interventions, 2,523 U.S. smokeless tobacco users were randomly assigned to an “enhanced” or a 
“basic” website intervention.74 The enhanced intervention included personal quitting aids with a guided, 
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interactive program; printable resources; and links to other websites, Web forums, and education 
modules. The basic intervention consisted of static text. On the basis of the repeated point prevalence of 
all tobacco use at 3 and 6 months, the enhanced intervention significantly increased tobacco abstinence 
rates compared to the basic intervention (12.6% vs. 7.9%, respectively). 
Non-pharmacologic Therapy 
Herbal chew is a nicotine-free, non-tobacco product available in U.S. convenience stores or on the 
Internet. A chopped mint or other plant blend product to be placed in the mouth, herbal chew is intended 
to replace the oral sensation of ST, which may help users achieve abstinence. One study evaluated the 
efficacy of an herbal chew product (herbal mint snuff) in a 2 x 2 design with 402 subjects randomly 
assigned to a nicotine patch or a placebo crossed with herbal mint snuff or no herbal mint snuff.75 Herbal 
mint snuff did not increase abstinence rates but significantly reduced cravings and symptoms of 
withdrawal. 
Several studies have noted that non-nicotine oral substitutes can help reduce withdrawal and aid in 
ST cessation. Smokeless tobacco cessation guides suggest a wide range of products, including chewing 
gum, nuts, sunflower seeds, beef jerky, or cinnamon sticks.76,77 Chakravorty assigned 70 rural male 
ST users aged 14 to 18 years, who averaged 1.5 dips/day, to one of three conditions: use of a 
non-tobacco product (herbal mint snuff), use of nicotine chewing gum, or only attending a lecture 
(control condition). Subjects in the herbal mint snuff group were significantly more likely to report 
decreased use of ST than subjects in the other two conditions. Oral substitutes might be an important 
element in assisting users to quit ST, and a variety of substitutes exist for this purpose. 
Pharmacotherapy 
Pharmacotherapies evaluated for the treatment of ST users include nicotine replacement therapy 
(NRT patch, gum, and lozenge), bupropion sustained-release (SR), and varenicline (Table 7-2). 
Nicotine Replacement Therapy  
Limited evidence is available regarding the efficacy of NRT. Available evidence suggests that NRT 
does not seem to increase long-term (≥6 months) abstinence rates in ST users; however, it does appear 
to decrease nicotine withdrawal and craving, and some forms of NRT may increase short-term  
(10–12 weeks) abstinence rates.78–80 Treating withdrawal is important because ST users experience a 
constellation of withdrawal symptoms upon cessation (craving, irritability, frustration, anger, difficulty 
concentrating, restlessness, impatience, increased appetite, and depressed mood). 
Nicotine Gum—In a study evaluating the efficacy of 2 mg nicotine gum for treatment of ST use, 
210 adult users were randomly assigned to 8 weeks of 2 mg gum or a placebo along with either a group 
behavioral intervention or minimal contact.81 Nicotine gum did not significantly increase tobacco 
abstinence rates. However, during the 8-week treatment, 2 mg gum use significantly decreased tobacco 
craving and nicotine withdrawal compared to placebo. 






Nicotine Lozenge—In a study evaluating the efficacy of the 4 mg nicotine lozenge for treatment of 
ST use, 270 subjects were randomly assigned to a 12-week tapering regimen of lozenges or a placebo.78 
Compared to a placebo, at 12 weeks the 4 mg lozenge significantly increased self-reported all-tobacco 
abstinence (44.1% vs. 29.1%) and self-reported ST abstinence (50.7% vs. 34.32%), although 
biometrically confirmed tobacco abstinence rates were not significantly different between the placebo 
and NRT groups. The nicotine lozenge significantly decreased tobacco craving and nicotine withdrawal 
compared to the placebo. In a small randomized pilot study (N = 60) evaluating the efficacy of mailing 
the 4 mg lozenge to ST users combined with phone support, the lozenge significantly decreased 
withdrawal symptoms compared to the placebo.80  
Nicotine Patch—Another study compared the 15 mg nicotine patch with brief counseling advice alone. 
The 130 subjects were UK–resident Bangladeshi women who volunteered in response to community 
outreach. These subjects chewed betel quid (i.e., betel leaf, areca nut, slaked lime [calcium hydroxide], 
and brown powder paste; also known as paan) with tobacco. They were matched on age and amount of 
ST use. Of the successful quitters at the end of the 4-week study, 22% had received NRT, and 17% had 
received brief advice and encouragement alone. This pilot study demonstrated that methods used to help 
smokers quit can be successfully adapted for use with Bangladeshi women who use betel quid.82 
In a study evaluating the efficacy of the 15 mg/16-hour patch for ST users, 410 adult ST users were 
randomly assigned to the patch or a placebo plus a behavioral intervention for 6 weeks.83 All 
participants received two sessions with a pharmacist at baseline and at 4 weeks, as well as self-help 
materials and phone support at 48 hours and 10 days after the target quit date. Use of the patch 
significantly increased abstinence rates at 3 months compared to placebo (31% vs. 25%, respectively); 
less craving was observed at 48 hours after the target quit date. This program demonstrated the 
potential of using pharmacists as interventionists; other professional groups could expand the reach of 
cessation programs. 
Another patch study evaluating the 21 mg/day nicotine patch for 6 weeks with a 4-week taper compared 
to a placebo. Four hundred subjects were randomly assigned to active patch with and without herbal 
mint snuff or to a placebo patch with or without herbal mint snuff.75 Compared to placebo, the nicotine 
patch significantly increased tobacco abstinence rates at 10 weeks (67% vs. 53%) and at 15 weeks 
(52% vs. 43%). The patch significantly decreased craving and withdrawal symptoms. 
Stotts and associates84 examined whether ST users aged 14 to 19 years were aided in their cessation 
attempts by using nicotine patches and receiving several follow-up counseling phone calls. Over 
300 students were randomly assigned to one of three conditions: (1) counseling only (6 weeks of 
50-minute, age-relevant behavioral intervention classes based on materials from the National Cancer 
Institute); (2) counseling plus an active nicotine patch and phone support; and (3) counseling plus a 
placebo patch and phone support. Participants in the two groups receiving the patch plus phone support 
also received seven 15-minute counseling phone calls. Analysis of 1-year follow-up results indicated no 
differences between the placebo and active patch groups, but when combined, these conditions were 
significantly more successful in encouraging cessation for ST (32.8%) than the counseling-only 
condition (22.9%). This study did not find that nicotine replacement was effective long term 
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(≥6 months), a finding that is consistent with other studies of the efficacy of nicotine replacement for 
ST cessation with adults. 
In a study evaluating high-dose nicotine patch therapy, 42 ST users were randomly assigned to a 
63 mg/day patch, a 42 mg/day patch, a 21 mg/day patch, or a placebo.85 Patches were used for 8 weeks, 
and all subjects received behavioral counseling. No significant differences were observed in abstinence 
rates between the four groups at 6 months. However, a statistically significant relationship was observed 
between higher patch doses and a greater degree of withdrawal symptom relief. 
Bupropion 
Bupropion has not been demonstrated to increase short- or long-term abstinence rates among ST users, 
but two studies found that it may decrease tobacco craving and delay postcessation weight gain. In a 
study evaluating the efficacy of sustained release (SR) bupropion, 225 subjects were randomly assigned 
to medication or a placebo for 12 weeks.86 Bupropion SR led to significantly less tobacco craving up 
to 14 days after the target quit date and less weight gain (1.7±2.9 kg increase for bupropion vs. 
3.2±2.7 kg for the placebo). This weight gain attenuation was also observed in a smaller pilot study of 
bupropion SR for ST users,87 in which the mean weight change from baseline to the end of treatment 
was 0.7±1.9 kg for bupropion and 4.4±2.4 kg for placebo (p = .03). 
Varenicline 
Varenicline, which came on the market in the United States and the European Union in 2006, has 
been demonstrated to be effective in treating nicotine dependence among cigarette smokers, yet few 
studies have assessed its effect on ST abstinence. In a study evaluating its efficacy for ST users, 
431 Scandinavian snus users were randomly assigned to varenicline at a target dose of 1.0 mg by mouth 
twice daily for 12 weeks, or to a placebo. Compared to the placebo, varenicline significantly increased 
continuous tobacco abstinence rates at weeks 9 to 12 (59% vs. 39%; p <.001) and at weeks 9 to 26 
(45% vs. 34%; p = .012).88 A pilot study that randomly assigned 76 U.S. smokeless tobacco users to 
12 weeks of varenicline or a placebo found that varenicline significantly decreased tobacco craving,89 
but the study was underpowered to assess abstinence outcomes. 
Concerns have been raised about the possibility of adverse effects related to the use of varenicline. The 
U.S. Food and Drug Administration has required a boxed warning on the varenicline label to alert 
physicians and subjects to behavior change risks.90 The labeling warns of the risk of behavioral changes 
such as depression, hostility, aggression, suicidal thoughts, suicide, and the risks of vehicular crashes. 
However, available research has not established a clear causal link between the drug and adverse 
psychiatric events.91–93 Additional concerns about adverse cardiovascular effects94 have been raised but 
remain controversial.95 The U.S. Food and Drug Administration required the manufacturer of 
varenicline to conduct a meta-analysis on the cardiovascular effects of varenicline, which revealed a 
small increase in adverse cardiovascular effects, but the increase was not significant.96 As with any 
pharmaceutical intervention, doctors are advised to weigh the benefits and risk of varenicline use and 
patients should be monitored for treatment responses and adverse effects. 






Gaps and Limitations 
While several studies have examined interventions for prevention and cessation among adults and youth, 
some of the studies reviewed here were conducted at least 10 years ago. Over that time period the types 
of ST products available and the marketing of those products have changed considerably. Therefore, the 
information on the interventions presented in this chapter should be examined in the current context to 
see if the findings can be replicated. In addition, standard definitions for cessation could be adopted or, 
at least, durations of abstinence should be consistently reported. When possible, biochemical validation 
of abstinence is also valuable. Finally, when evaluating interventions, additional consideration should be 
given to the applicability of these findings for low-income countries as well as the sustainability of the 
programs described. 
Summary and Conclusions 
Effective preventive and cessation interventions as well as public policy efforts can reduce ST use.  
School-based and community prevention programs produce short-term effects such as reduced rates of 
prevalence, experimentation, and intention to use ST, as well as some reduction of use among those 
already using. Youth and parental involvement in planning and executing these programs may be an 
important component. Most prevention programs focus on younger adolescents (aged 12–15 years) and 
emphasize understanding social influences and developing the social skills needed to resist the social 
pressures to use smokeless tobacco. Many programs involve peer leaders rather than adult providers. 
School programs supplemented by effective family-based or mass media programs can produce larger 
effects than school-based programs alone. There is potential for young people to become involved in 
planning prevention programs for youth that are interactive, engage peer facilitators, and involve parents 
and other segments of the community. These programs may be more effective if they are theory based, 
continuous, provide adequate training for teachers, and are supported by school policies that promote 
health and by government tobacco control policies. 
Most cessation programs have been evaluated with adult ST users; they show positive results for dental 
office interventions and clinical interventions involving multiple sessions and counselor support. Phone 
counseling and feedback on dental exams appear to be key elements in successful cessation programs. 
Oral health professionals can be further engaged as a “front line” in the prevention and treatment of 
ST dependence. To better support cessation interventions, oral health professionals can be trained to 
recognize oral disease caused by ST use and to deliver tobacco use interventions or refer patients who 
want treatment to physicians or counselors with the necessary training. Models such as “Ask-Advise-
Refer” should be adopted and implemented in health care systems. A drawback of dental office 
interventions is that many high-risk youth and adults do not see a dentist, therefore considering other 
potential avenues for intervention is important. 
The evidence suggests that pharmacologic aids such as nicotine replacement (e.g., patches, gum, or 
lozenges) can help reduce withdrawal symptoms and cravings in ST users, but so far they have been 
found to be ineffective for increasing long-term ST abstinence rates. At least one study has shown 
significant increases in short- and long-term abstinence rates with varenicline in ST users. So far, 
however, these medication aids have been approved by regulatory agencies for smoking cessation but 
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not for ST cessation or for reducing symptoms or cravings. Where available, medication may be helpful 
in reducing symptoms associated with quitting tobacco use and, in the case of varenicline, increasing 
short-term quit rates. More research is needed to support specific indications for cessation medications 
in ST users. Additionally, most of the evidence for medication aids comes from high-income countries, 
and more research is needed to develop and test interventions that can be effective in resource-
constrained environments. 
Some targeted interventions for youth have demonstrated efficacy, but available studies have shown 
varying success. A limitation of many of the studies reported is that they are based on self-reported data 
that is often school-based and concentrated in high-income areas. Additional research is needed on 
different types of interventions and programs among a diverse range of countries and groups for youth. 
Interventions for special populations of ST users (such as Native Americans and athletes) have been 
developed and evaluated and are available for implementation. Cultural adaptations are needed to 
provide interventions that are appropriate for both the context of ST use and the ST products being used 
in different regions, especially when translating a program to a region such as India, where a variety of 
different oral tobacco products are used. 
In environments where resources are limited or clinics are inaccessible for ST users needing or wanting 
treatment (because of distance or lack of transportation) there may be ways to facilitate cessation, such 
as mailed self-help materials with follow-up telephone contact. Web-based programs may also be an 
effective alternative in countries that have widespread access to the Internet. Most evaluation studies to 
date have been carried out in the United States. Additional evaluation of self-help cessation programs is 
needed in other countries. 
Evidence indicates that the detrimental health effects of ST use are not well known in low- and middle-
income countries. Educating the populations in low- and middle-income countries about the harmful 
effects of ST through media and health care systems is essential. 
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The Role of Regulation and Policy 
Regulatory and policy actions on the part of governments and international organizations are vital to 
addressing the global tobacco epidemic and protecting human health. One of the principal requirements 
of the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) is to 
“adopt and implement effective legislative, executive, administrative, and/or other measures…at the 
appropriate governmental level to protect all persons from exposure to tobacco smoke.”1 Furthermore, 
according to the WHO FCTC, “the consumption of smokeless tobacco is a global concern and not 
limited to a few countries. During the negotiations leading to the WHO FCTC, Parties agreed to address 
concerns relating to all forms of tobacco, not only the smoking forms.”2,p.4 The need for regulation 
guided by effective policy can be seen in the measures the FCTC calls for: taxation and pricing, 
regulation of tobacco product contents, product packaging and labeling requirements, restricting 
marketing and advertising, as well as prohibiting sales to minors, preventing illicit trade, and others. 
The key to successful use of regulatory tools is that they be grounded in scientific evidence. In 
recognition of this basic principle, the FCTC calls on the Parties to the Convention to develop and 
promote research in the field of tobacco control.3 Through evidence-based regulation, governments can 
reduce their populations’ exposure to harmful toxicants in smokeless tobacco (ST) products. Youth 
initiation of ST use can also be reduced through restrictions on advertising, marketing, and promotion, 
and through aggressive enforcement of restrictions on youth access to tobacco products. 
The Global Community and Smokeless Tobacco Regulation 
The global public health community has long focused primarily on cigarette smoking. Smokeless 
tobacco use has received less attention because it imposes a comparatively smaller burden on human 
health, and because it has been seen as confined to a few South Asian countries, Sweden, and the 
United States, and therefore not of worldwide concern. However, the reality is that ST use is not simply 
a local or regional problem but a major challenge facing a large percentage of the world’s population. 
In addition, several factors suggest that the public health impact of ST use is likely to intensify. First, 
major cigarette companies have moved into the ST market by purchasing ST manufacturing companies, 
and have expanded their operations (see chapters 2 and 6). Second, the tobacco industry is promoting 
ST use as a short-term substitute for smoking in countries that have made good progress in ensuring 
smoke-free environments (Figure 8-1).4 Third, ST use has been promoted by some as a cessation aid and 
a harm-reduction tool for cigarette smokers, although there is insufficient evidence for the effectiveness 
of ST as a cessation aid.5 
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Figure 8-1. Camel Snus advertisement 
Note: This advertisement appeared after New York City amended its smoke-free law in 2003 to include all restaurants and bars. 
Caption says, “Smokers, switch to smoke-free Camel Snus and reclaim the world’s greatest city. No matter where you go, or what 
you do, Camel Snus is the perfect tobacco pleasure to enjoy virtually anywhere. Camel Snus—the pleasure’s all yours.” 
Key Provisions of the FCTC 
The WHO FCTC was negotiated between 1999 and 2003 and came into force in 2005. During the 
negotiations, some WHO member states opposed including ST in the Framework Convention. It was 
argued that the body of evidence was insufficient for a concerted global action against ST, and that ST 
use was at most a regional concern in Asia that should be addressed by a regional policy. However, the 
majority view on the harms associated with ST use prevailed, and ST was incorporated into the FCTC. 
Although the FCTC covers all tobacco products, many of the strategies developed under the Convention 
to date are focused on cigarettes only. However, in recognition of the emerging global threat from ST, 
the fourth session of the Conference of the Parties discussed the issue and requested a comprehensive 
report on the Parties’ experience with smokeless tobacco.6 The fifth session of the Conference of the 
Parties further discussed efforts to control smokeless tobacco and electronic cigarettes, and the Parties 






will continue to review evidence on ST and the prevention and control of e-cigarette use, and report on 
this review during the sixth session of the Conference of the Parties,7 which convenes as this report goes 
to press. 
The following paragraphs describe measures called for by the FCTC (warning labels, toxicant testing, 
and illicit trade) as they relate to ST, and how these measures have been implemented by the Parties.  
Warning Labels on Product Packaging 
Parties to the treaty often apply WHO FCTC requirements differently to smokeless forms of tobacco as 
compared with cigarettes. For example, Article 11 sets standards for warning messages to be displayed 
on tobacco product packaging,8 but many Parties have lower standards for ST packaging than for 
cigarette packages. Most European Union (EU) countries, the Russian Federation, and other countries 
allow health warnings to cover a smaller proportion of the principal display area of ST packages than of 
cigarette packages. Some countries (e.g., Thailand, Bangladesh, Venezuela, and Pakistan) have 
mandated that health warnings appear at the top of the principal display area for cigarettes but not for 
ST. In addition, many countries (e.g., the United Kingdom, Turkey, Sweden, and Vietnam) mandate 
alternating health warnings for cigarettes but not for ST products. Similarly, countries such as Australia, 
Canada, Malaysia, Switzerland, Jordan, and Djibouti require graphic/pictorial warnings for cigarettes 
but not for ST products. 
The issue of package warnings also illustrates how evidence regarding ST use provided to governments 
and decisionmakers can lead to policy change. Data from the 2009–2010 Global Adult Tobacco Survey 
(GATS) for India showed an alarming increase in the prevalence of ST use in India. This evidence 
aroused great concern in the Indian government, which then formulated a requirement for pictorial 
health warnings for ST products.9 (This requirement went into effect in December 2011.) The more 
current data on the prevalence of ST use that has been furnished by the GATS and other national surveys 
attracts greater policy attention to smokeless tobacco.  
Toxicant Testing 
Articles 9 and 10 of the FCTC stipulate the testing and measurement of contents and emissions of 
tobacco products. The numerous different ST products contain widely varying levels of toxicants and 
include some products with very high amounts of toxic substances. In view of this variability, the WHO 
Study Group for Tobacco Product Regulation (TobReg) has recommended mandating upper limits for 
toxicants in ST products.10,11 The TobReg Study Group produced a review, published in two technical 
reports, of the available global data on toxicant levels in ST products, with emphasis on two 
carcinogens, tobacco-specific nitrosamines (TSNAs) and benzo(a)pyrene (BaP). The Study Group 
recommended setting an upper limit for both N’-nitrosonornicotine (NNN) and 4(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK) at 2 micrograms per gram of dry weight tobacco, and an upper limit for 
BaP at 5 nanograms per gram of dry weight tobacco. These recommendations were based upon 
extensive review of the evidence on methods to reduce these carcinogens and the feasible limits to 
which they can be reduced in available products. Although not formally adopted by the Conference of 
the Parties, the Study Group’s recommendations can serve as a basis for future regulations or can be 
adopted by countries where ST use is highly prevalent and constitutes a major public health problem.12 
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Importantly, TobReg emphasized that “regulators must assume responsibility to ensure that consumers 
are not told directly or indirectly or led to believe that ST products that meet the carcinogen limits 
established pursuant to this proposal are less hazardous than similar products, have been approved by the 
government or meet government-established health or safety standards.”11,p.34–35 
The WHO established the Tobacco Laboratory Network (TobLabNet), an international collaborative 
network of testing laboratories, to validate testing methods for selected ingredients in tobacco products 
and emissions in smoked tobacco products. The experience gained in testing smoked products is clearly 
important in informing future regulatory efforts aimed at ST and other tobacco products.13 As of 
September 2014, TobLabNet has successfully completed the validation of testing for nicotine and 
humectants in cigarettes, and BaP, TSNAs, and carbon monoxide in mainstream cigarette smoke. 
Validation of ammonia in cigarette tobacco filler, and volatile organic compounds (VOCs) and 
aldehydes in mainstream cigarette smoke is currently under way. 
Illicit Trade 
To further develop the provisions of Article 15 of World Health Assembly Resolution 56.1 on 
preventing illicit trade, the second WHO FCTC Conference of the Parties established the 
Intergovernmental Negotiating Body (INB) on a Protocol to Eliminate Illicit Trade in Tobacco Products, 
which met five times between 2008 and 2012. Despite an INB consensus that strong supply chain 
measures are critical to eliminating illicit trade in tobacco products, some Parties cited domestic or 
regional/legal constraints and opposed stringent measures, such as unique identification markings and 
tracking and tracing (T&T) of ST products.14 After extensive negotiation, the Parties agreed to put a 
T&T mechanism in place for cigarettes within 5 years of the Protocol’s entry into force and within 10 
years for all other tobacco products.14  
The decision to delay T&T for ST highlights the need to expand the ST evidence base not only for 
health and economic implications, but also for trade and financial transactions. In some regions not 
much is known about the nature and volume of ST trade transactions within countries and across 
borders. Sharing trade information as well as trend analysis data on illicit trade detected by 
governmental enforcement authorities would do much to reduce this lack of information. It is equally 
important to engage with other relevant intergovernmental organizations, such as the World Customs 
Organization and World Trade Organization, and intelligence organizations such as the European 
Commission Anti-Fraud Office and others.  
During the fifth session of the Conference of the Parties, the Protocol to Eliminate Illicit Trade in 
Tobacco Products, the first of its kind for the Convention, was developed. The Protocol states that the 
Parties “shall adopt and implement effective measures to control or regulate the supply chain covered by 
this Protocol in order to prevent, deter, detect, investigate and prosecute illicit trade.”15,p.7 The Protocol 
also calls for control of tobacco licensure for tobacco retailing, manufacture, and growth; for Parties to 
track and trace tobacco manufacture, sale, and shipments; and for ensuring legislative action on unlawful 
or illicit activities. 






Description and Analysis of Key Tobacco Control Policy Interventions 
Changing trends in the use of ST products make it even more important for countries to develop 
comprehensive tobacco control programs that address the use of smokeless tobacco. Intervention 
strategies must fit the context of the local society, its tobacco use rates, and trends in consumption of 
tobacco products including smokeless tobacco. Interventions may include: health warnings on product 
packaging; comprehensive bans on advertising, promotions, and sponsorships as well as bans on ST 
product sales, trade, and use; restrictions on sale to minors; training and capacity building; tax and 
pricing policies that discourage ST use; and information, education, and communication strategies and 
campaigns to increase awareness of the harmful health effects of ST use. Social, cultural, and economic 
factors are central to how individuals perceive the health risks of smokeless tobacco. This section 
highlights several measures that have successfully addressed these considerations. 
Education and Awareness Efforts 
The effectiveness of health warnings and comprehensive bans on cigarette advertising, promotions, and 
sponsorships16–18 strongly suggests these steps will be successful in curbing the demand for smokeless 
tobacco. Given the lack of awareness of the hazards of ST, some countries have launched mass media 
and other awareness-building campaigns. A long-term investment by governments in sustained mass 
media campaigns will bring a high degree of awareness and create change in social norms.  
An example of this kind of effort was the “Mukesh campaign” conducted by the Ministry of Health in 
India in 2009–2010, acting in concert with Tata Memorial Hospital in Mumbai and the World Lung 
Foundation (WLF). The campaign consisted of media spots that followed a 24-year-old male ST user, 
Mukesh Harane, from his diagnosis with throat cancer caused by ST use, through his treatment and 
eventual death. An evaluation by the WLF in 2010 showed that viewers had a high degree of recall of 
the media spots, as well as a significantly enhanced appreciation for the devastating effects of smokeless 
tobacco use.19,20 Another positive result of the campaign was that an advertisement that included 
pictures of the damage oral cancer wreaks on the human body was aired nationwide in 12 vernacular 
languages. At that time, the country did not have pictorial warnings on ST labels. This campaign served 
as a useful tool to communicate the harmful effects of smokeless tobacco to a large audience. 
The availability of accurate data has been instrumental in initiating policy change. For example, the 
2009 Bangladesh GATS report indicated a very high level of ST use among women in rural 
Bangladesh.21 This finding prompted the government to request the WHO Tobacco Free Initiative (TFI) 
to provide technical assistance on developing a strategy for tackling the problem. Likewise, following 
India’s release of its 2009–2010 GATS report,9 the government of India increased funding for media 
campaigns against ST use in 2010–2012 and announced a stronger set of health warnings.22 Smokeless 
tobacco cessation has been included in the Indian government’s national guidelines on tobacco 
dependence treatment as well as in training modules for doctors and health workers.  
In some cultures, ST is mistakenly believed to have beneficial effects—for example, that oral tobacco 
cures toothache (India) or that ST cures morning sickness during pregnancy (Bangladesh). The high 
prevalence of ST use among women in South-East Asian countries is associated with low levels of 
awareness regarding its harmful effects, which include addiction, especially when such products are 
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promoted as a dentifrice. Use of ST to clean the teeth is common in some countries, especially among 
women, and it is important not only to raise public awareness, but also to target and educate women, 
schoolteachers, dentists, health workers, and others on the risks associated with use of ST products.  
Excise Taxes and Pricing Policies 
Because ST products are cheaper and easier to access than cigarettes in some countries, with high social 
acceptance rather than stigma attached to their consumption, the young and the poor may predominantly 
consume ST instead of smoked tobacco. Given the price sensitivity of these groups, raising prices by 
raising excise and other taxes on ST is, therefore, one of the most effective measures to reduce demand. 
However, any efforts to levy taxes must also be fully supported by well-managed tax administration and 
compliance systems.  
Administering taxation on ST products is especially challenging because of the high likelihood of illicit 
trade and tax evasion with these products. Smokeless tobacco products are easy to manufacture with 
small machines in limited spaces, and it is easy to trade these products illegally and avoid paying taxes 
on them. In addition, because products in some countries are made in traditional markets and by 
individuals for their own use, it is difficult to determine how taxation systems would be implemented 
and enforced in these countries. To better regulate ST products, securing the supply chain is essential in 
order to guarantee taxes are paid. For example, in response to rampant tax evasion, the Indian 
government changed the excise tax collection on gutka and other ST to a system of presumptive tax 
(compounded levy per manufacturing machine). The resulting fourfold increase in excise collection 
since 2009 indicates ST’s tax potential if proper taxation systems are put in place.  
Bans on Smokeless Tobacco 
The sale of several types of oral tobacco is banned in all EU countries except Sweden.23 Smokeless 
tobacco has also been banned at various levels in New Zealand, Australia, Turkey, Israel, Taiwan, 
Thailand, Singapore, Hong Kong, and the United Arab Emirates (UAE).24 Specifically, the UAE bans 
the importation of ST, and Israel, Taiwan, Thailand, Singapore, and Hong Kong ban the manufacture, 
sale, and import of ST products. Turkey, Australia, and New Zealand limit ST sales and supply. By law, 
the government of Bhutan has banned the cultivation, sale, and purchase of all tobacco products, 
including ST, making it the first country to introduce such a comprehensive ban.  
In India, a national-level group of experts convened by the Ministry of Health in April 2011 strongly 
recommended that the government ban the sale of gutka and all other smokeless forms of tobacco 
nationwide, based on India’s current laws. Many Indian states, territories, and subregions have 
subsequently banned the sale, manufacture, distribution, and storage of these products.  
A ban on ST tobacco products, however, is difficult to implement if it is the sole tobacco control 
measure in place in a given country. If a ban is accompanied by a comprehensive tobacco control 
program that includes tobacco dependence treatment and education on the danger of using ST, it may 
further enable existing users to quit. Setting up a comprehensive program requires strong will among 
decisionmakers and a consensus among the majority of the population, as well as an environment 
amenable to legislation and the administrative capacity to fully implement the ban. 






Not only is it difficult to implement ST bans in isolation from a comprehensive program of tobacco 
control measures within a country, it may be also difficult to enforce a ban on ST in only one country, 
given the trend toward elimination of non-tariff barriers to trade between countries. In the case of 
Bhutan, illicit trade and smuggling of tobacco products from neighboring countries reportedly have 
increased, thereby keeping up the supplies of tobacco products, including ST products, which Bhutan 
has banned. The example of Bhutan clearly exemplifies the difficulties in enforcing bans and illustrates 
the need to take cross-border issues and international policies into consideration before implementing 
these types of measures.  
A further concern related to banning ST, particularly in countries with substantial ST use, is whether or 
not such a ban would result in ST users switching to cigarettes or initiating cigarette smoking, which 
would result in higher tobacco-related mortality and morbidity.  
Regulatory Experience of Countries and WHO Regions 
The South-East Asia and Western Pacific Regions 
Some Asian countries have begun regulating and banning ST products to keep pace with industry 
developments and to take steps to preempt the entry and spread of products in local markets. For 
example, under the Tobacco (Control of Advertisements and Sale) Act, Singapore has banned chewing 
tobacco since 1993.25 In July 2010, an amendment was passed that expanded the scope of this act. Novel 
and emerging forms of tobacco products, such as tobacco derivatives (dissolvable tobacco) and nicotine-
based products, are now subject to the same regulatory control as existing ST products, and the Minister 
for Health is empowered to ban a wider array of products, including more types of smokeless tobacco. 
Singapore has a lab for testing contents and emissions of cigarettes and measuring nicotine content in 
ST products such as chewable tobacco, betel quid, and khaini. However, other Asian economies 
including the countries where the ST burden is extremely high—India, Bangladesh, and Myanmar—
generally lack laboratory capacity to test ST products.25  
The European Region 
Regulations governing the use of ST vary widely within Europe. In EU member countries, ST is 
regulated under EU Tobacco Products Directive 2001/37/EC, which prohibits the sale of tobacco for 
oral use. The EU Directive defines “tobacco for oral use” as “all products for oral use, except those 
intended to be smoked or chewed, made wholly or partly of tobacco…particularly those presented in 
sachet portions or porous sachets, or in a form resembling a food product” (Directive 2001/37/EC, 
Article 2: Definitions23).  
As a result of negotiations at the time Sweden entered the EU, Sweden was exempted from this 
regulation, and the manufacturing, sale, and marketing of snus are legal within its borders. This form of 
tobacco is traditional in Sweden and represents a major proportion of the tobacco consumed in that 
country.26  
In many Eastern European countries, ST use is rare.27 In many of these countries, ST is subjected to 
regulations regarding advertising and health warnings similar to those of smoked tobacco products. 
Because of the high prevalence of use of smoked tobacco products in the region, many Eastern 
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European countries have undertaken aggressive tobacco control measures. The Russian Federation has 
set a timetable to put into effect all FCTC articles by 2015. Such measures will also restrict the use of 
smokeless tobacco. Moreover, several Eastern European countries have joined the EU (or are in the 
process of joining) and consequently must observe the existing EU directive regarding ST use. 
The Americas Region 
United States 
The Family Smoking Prevention and Tobacco Control Act, enacted in 2009, set in motion a new 
regulatory regime for tobacco products in the United States. This law enables the U.S. Food and Drug 
Administration (FDA) to regulate the manufacture, sale, and distribution of tobacco products, including 
ST products. Provisions of the law include manufacturer registration and product listing requirements, 
warning labels, and enforcement of a minimum-age-of-sale restriction. The FDA has authority to set 
tobacco product standards including, for example, imposing limits on the amounts of nicotine, toxicants, 
and/or additives that will be permitted in ST products.28 The FDA is also examining the public health 
impact of novel smokeless/dissolvable tobacco products. 
Canada 
Generally, the prohibitions and requirements for tobacco products defined in Canada’s Federal 
Tobacco Act apply to ST products, including the prohibition of selling tobacco to youth, restrictions 
on promotion, and requirements for reporting by manufacturers. 
The labeling regulations, known as the 2000 Tobacco Products Information Regulations, also apply, but 
only to chewing tobacco, nasal snuff, and oral snuff. For these classes of products, the regulations 
require text-based health warnings that occupy at least 50% of the principal display surfaces.29 In 2011, 
the Canadian House of Commons passed requirements, applicable only to cigarettes and little cigars, 
that limit the addition of flavorings, restrict the use of color packages (to make them less appealing to 
children), call for graphic health warnings on packages, and mandate that minimum quantities be 
purchased rather than single items (e.g., cigarettes must be sold in packs with a quantity of 20; sales of 
“loose” cigarettes are prohibited).30–32 Smokeless tobacco products, however, will continue to be 
regulated under the 2000 regulations. 
Brazil 
Although at the forefront of tobacco product regulation, Brazil mainly targeted cigarettes for many 
years. Despite the low consumption of smokeless products in Brazil,33 regulatory authorities have 
detected a slight increase in the use of other tobacco products, including ST products, since the passage 
of a 2007 law, Regime Diferenciado de Contratações Públicas (better known as “RDC”) 090/07.34 
Tobacco companies or importers must submit information about tobacco product contents and 
emissions, packaging, and design features.34 Brazil requires that ST products be registered with the 
Brazilian health surveillance agency, ANVISA (Agência Nacional de Vigilância Sanitária), in order to 
be sold within the country, but as of 2012 no ST products are registered, which means that they cannot 
be legally sold (and thus are effectively banned); labels on illegally marketed products do not display 
health warnings. In 2010, a regulatory task force conducting surveillance in the small municipality of 






Maringa in southern Brazil seized the unique ST product rapé, which often contains agents such as tonka 
bean that have very high levels of coumarin, a liver toxicant (personal communication, Andre Oliveira). 
Tonka bean and coumarin are both banned in food for human consumption in the United States.28 
The Eastern Mediterranean Region  
Well-structured interventions and regulatory policies regarding ST product use are for the most part 
absent in the Eastern Mediterranean region. Only Bahrain and the UAE have introduced policies 
banning ST and ST sales. In 2009 the government of Bahrain introduced strong antismoking regulations 
and a law that prohibits the importation of ST products.35 In 2008, Ajman Municipality in the UAE 
banned the sale, import, storage, and possession of ST and imposes heavy fines on violators.36  
The African Region 
Despite increasing prevalence of ST use, the countries of Sub-Saharan Africa have limited 
ST regulations and programs. Since ST is primarily produced by cottage industry in this region, 
distribution and marketing of these products often takes place on a local rather than national or 
international scale. Collating relevant data and information about importation and use of ST in African 
countries is important to helping these countries develop their capacity to regulate ST products. 
Challenges and Recommendations for Regulation and Policy  
Smokeless Tobacco Product Heterogeneity and Novelty 
One of the challenges to creating and implementing any regulatory framework is the heterogeneity of 
ST products from country to country and within countries. Added ingredients and levels of nicotine and 
other toxic constituents vary widely among the various types of ST products, and forms of ST that are 
produced using non-standardized methods often pose the greatest risk to health because of the levels of 
toxicants they contain. 
The wide variety of products and methods of manufacturing and distribution within a country make it 
more difficult for the country to set up regulatory means of dealing with them, and a wide variety of 
products across countries makes international cooperation on tobacco control more difficult. These 
difficulties are encountered especially in countries where products are manufactured and distributed in 
informal, cottage-industry-like settings that are less amenable to a conventional regulatory system of 
product registration, inspection, and enforcement.  
The situation is further complicated by the fact that the novel forms of ST products introduced into some 
markets over the past decade—such as dissolvable tobacco sticks, strips, and lozenges—are unlike most 
of the oral ST products that preceded them. These products also pose new questions about use, 
especially because in some countries they are explicitly marketed to be used along with cigarettes. This 
dual use of ST with smoked tobacco, or any other form of tobacco, presents a further risk to the health of 
individuals and populations. 
Understanding the toxicity and addictiveness profiles of the diverse and novel ST products requires 
thorough scientific evaluation. The research community could increase its efforts to provide data on 
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these products, their contents and toxicant levels, in order to help governments in countries and regions 
create effective systems for regulation. Dual use of smoked and smokeless products must be evaluated 
for its potential impact on quitting intentions, quitting behavior, and initiation of use; dual use of ST 
products and other tobacco products must also be addressed in developing cessation strategies and 
programs for smokeless tobacco. 
Testing Challenges 
Laboratory testing of tobacco products is a major challenge in regulating tobacco products. Although 
validated methods have been identified for measuring some constituents, most countries have not yet 
adopted specific product standards or testing regimens, and further development is needed in this area. 
Additionally, countries differ in their capacity to test tobacco products. Countries with limited budgets 
face significant challenges in acquiring costly equipment and in securing resources for technical training 
of staff.  
The global tobacco testing network coordinated by the WHO Tobacco Free Initiative (TFI), TobLabNet, 
is validating standard operating procedures for testing the contents and emissions of tobacco products. 
Though time-consuming and costly, this effort is essential to global regulatory efforts. Although 
progress has been made in building capacity in a few selected laboratories in developing countries, 
regional and reference laboratories are still being relied on to assist in the technical training of staff in 
individual country laboratories. Regional efforts to consolidate tobacco product testing are ongoing and 
are exemplified by the European Network of Government Laboratories for Tobacco and Tobacco 
Products, and by the work of Brazil’s ANVISA to coordinate testing activities and procedures in Latin 
America. The WHO TFI, the Centers for Disease Control and Prevention, the Netherlands National 
Institute for Public Health and the Environment, and other laboratories have been providing training and 
technical assistance to laboratories in low- and lower middle-income countries.  
Further research is needed on the development of additional standardized testing methods that can be 
used to set limits on the allowable levels of toxicants in ST products. 
Coordinated testing by region is valuable because of the unique characteristics of ST products in South-
East Asian, North African, and Gulf countries. Although there are recognized inter-country differences 
in these products, coordinated testing can be useful for countries that have limited funding for 
independent testing. TobLabNet continues to explore the feasibility of scaling up lab capacities in low- 
and middle- income countries. A centralized website could serve as a source of validated information on 
tobacco product contents and emissions. It is also important that global partners help countries develop 
the capacity to identify counterfeit ST tobacco products in addition to counterfeit cigarettes.  
The Evidence Base and Information Gaps 
Effective policies to tackle the challenges posed by ST require quantification of the risks associated with 
ST use, including the burden on health, the economy, and the environment, and the social costs of 
increasing ST use by young people. There has been very little study or documentation of the adverse 
health care costs and the economic costs of ST use.37 The WHO, government agencies, and academic 






institutions have important roles to play in generating data and developing a body of evidence about the 
individual and societal risks of ST use.  
A clearer picture of these risks could be achieved by disaggregating ST-related data from existing 
Global Tobacco Surveillance System studies such as the Global Youth Tobacco Survey (GYTS) and 
GATS, as well as from the WHO STEPwise Approach to Surveillance (WHO STEPS) and other 
national surveys. Valuable information could be obtained from investigations by academic and research 
institutions on the local factors responsible for high rates of ST use in some communities, as well as 
many other aspects of smokeless tobacco.  
Current information-gathering tools should be adapted to collect more information on smokeless 
tobacco. Some deficits of information about ST reflect a lack of attention paid to ST by these 
instruments. For example, the WHO Report on the Global Tobacco Epidemic, 2011 (GTCR) 
provides a qualitative assessment of progress made by countries in implementing the MPOWER 
package, which is a list of demand-reduction measures formulated by the WHO as guidance for 
countries implementing the FCTC’s tobacco control guidelines.18 The GTCR covers smokeless as 
well as smoked tobacco products, but the report does not contain ST-specific information regarding 
relative progress on interventions such as package warnings and labeling, taxation, or enforcement of 
bans on advertising, promotion, and sponsorship.18 Similarly, the reporting instrument of the Conference 
of the Parties captures the progress made by Parties to the FCTC, but it does not include questions 
specifically on smokeless tobacco. Volunteering specific information on ST is left to the discretion of 
the individual Parties.  
Information Dissemination 
Smokeless tobacco products have a high degree of social acceptance in many countries, and their low 
cost and widespread availability make them easily accessible, especially for vulnerable groups such as 
youth and women. Much of the world’s population is unaware of the dangers of using these products, 
and marketing efforts by the tobacco industry further distort the dangers. Even in high-income countries 
where information about the harms of tobacco use is more widely available, the tobacco industry has 
been marketing ST products as a safer substitute for cigarettes among adult smokers and adolescent 
initiators, particularly for use in situations where smoking is not allowed or where the smoker wants to 
use tobacco discreetly.38  
Increasing public awareness of the risks and consequences of using ST products is critical to 
safeguarding public health. Depending on the country or region, this can mean combating long-held 
local customs as well as industry marketing efforts by delivering accurate information to dispel myths 
about ST use and explain the hazards of dual use of ST and cigarettes. Adolescent, school health, and 
maternal–child health programs are valuable means of educating the public about ST use.  
It is essential that information and evidence about smokeless tobacco use be disseminated among 
policymakers, researchers, and other professionals in order to establish programs to combat ST use  
and ameliorate its effects. Nongovernmental organizations (NGOs) could play an important role in 
generating international awareness of the hazards of ST use through all relevant forums, such as the  
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WHO FCTC, the World Conference on Tobacco or Health, and other international conferences. NGOs 
could also share best practices for advocacy efforts and for building local, NGO, and country-level 
capacity. As part of the global tobacco control effort, the Conference of the Parties to the WHO FCTC 
should consider extending its efforts to coordinate the dissemination of product information on ST 
products. It is critical that these organizations and institutions continue to provide policymakers with the 
evidence necessary for ST control, surveillance, training of health professionals, and capacity building 
for cessation initiatives for smokeless tobacco. 
Smokeless Tobacco Product Regulation  
In addition to granting higher priority to the control of ST use, the global community can advance 
evidence-based ST regulation and policy in a number of ways. 
 Providing technical assistance. Given the limited knowledge and expertise in the area of ST, 
it is important for global partners to develop their ability to deliver technical assistance in 
building the capacity to regulate ST in each country. The partners could assist governments by 
providing information on global best practices and by developing the ability to monitor and 
regulate the ST industry by carrying out all the key provisions of the Protocol to Eliminate Illicit 
Trade, including, for example, mandating secure supply chain controls. This international 
cooperation is especially important to protecting young people and assisting countries that have 
inadequate resources. 
 Developing and disseminating testing protocols and product standards. Companies and 
organizations with advanced laboratory capacity can assist in developing product testing capacity 
where it is needed. They can also assist in disseminating basic product manufacture and handling 
standards—for example, by indicating the manufacturing date on packages and controlling 
temperature conditions until sale to prevent further increases in carcinogens during storage. 
Additionally, WHO’s TobLabNet and TobReg have developed common testing protocols and 
recommended specific limits for some known constituents. 
 Revising existing tobacco control programs to better address smokeless tobacco. A 
comprehensive tobacco control program that deals with ST and smoking on an equal footing is 
critical for the effective regulation of smokeless tobacco. Such a program would include 
legislative and administrative measures that address issues such as advertising, cross-country 
trade, Internet purchases, tax evasion by industry, and low levels of taxation on ST products. In 
regard to taxation, the global community should focus on building the capacity to administer 
taxes on all tobacco products, including ST products, especially in low- and lower middle-
income countries. High-income countries with more mature tobacco control programs may want 
to review their policies in light of the latest evidence on ST use. Countries that have been 
successful in controlling the tobacco epidemic and are experiencing a decline in smoking 
prevalence should examine whether ST use is replacing smoking in a manner that is causing net 
harm at the population level. 
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Description of the Region  
According to the United Nations’ World Population Prospects, the World Health Organization (WHO) 
Region of the Americas includes 35 countries (Table 9-1), accounting for a land area of around 41 
million square kilometers, from the northern reaches of the Canadian Arctic to the southern parts of 
Argentina and Chile just above Antarctica.1  
Table 9-1. Population and land area of countries in the Americas Region 
Country* Area (km2) Population (thousands) 
Antigua and Barbuda† 440 90 
Argentina 2,694,133 40,412 
Bahamas 13,720 343 
Barbados 429 273 
Belize 22,286 312 
Bolivia (Plurinational State of) 1,103,333 9,930 
Brazil 8,475,913 194,946 
Canada 11,339,000 34,017 
Chile 744,087 17,114 
Colombia 1,129,146 46,295 
Costa Rica 51,198 4,659 
Cuba 110,373 11,258 
Dominica† 750 68 
Dominican Republic 48,424 9,927 
Ecuador 283,627 14,465 
El Salvador 21,065 6,193 
Grenada 342 104 
Guatemala 109,008 14,389 
Guyana 188,500 754 
Haiti 27,758 9,993 
Honduras 111,779 7,601 
Jamaica 11,008 2,741 
Mexico 1,955,569 113,423 
Nicaragua 128,622 5,788 
Panama 74,830 3,517 
Paraguay 403,438 6,455 
Peru 1,264,217 29,077 
Saint Kitts and Nevis† 260 53 
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Country* Area (km2) Population (thousands) 
Saint Lucia 539 174 
Saint Vincent and the Grenadines 387 109 
Suriname 175,000 525 
Trinidad and Tobago 5,138 1,341 
United States of America 9,699,500 310,384 
Uruguay 177,316 3,369 
Venezuela (Bolivarian Republic of) 905,625 28,980 
Total 41,276,760 929,079 
*Unless otherwise indicated, data are from United Nations 2011 (1).  
†World Bank, 2010–2011 (93). 
Abbreviation: km = kilometer. 
The Region of the Americas holds a special place in the history of tobacco use because the tobacco plant 
is thought to have originated in this region. Cultivation of tobacco in the Americas dates back at least 
5,000 years, and Native Americans were probably the first people to smoke, chew, and inhale tobacco. 
This chapter presents an overview of smokeless tobacco (ST) use in countries in the Region of the 
Americas for which data are available. It discusses prevalence of use and the various forms of ST used, 
their toxicity and nicotine profiles, and their adverse health effects. Prevalence is usually reported in 
terms of current use, which can be defined in various ways. For example, some surveys define current 
use as any use within the past 30 days, while other surveys ask about different time periods; some 
surveys collect data on daily use and use on some days, and still other surveys ask about “current” use 
without defining the term further. 
Prevalence of Smokeless Tobacco Use 
Data on ST use prevalence are available for only a limited number of countries in the region. For data on 
young people, the Global Youth Tobacco Survey (GYTS) collected data on ST use in 14 countries in the 
region during the period 2007–2010, although the samples in Brazil and Mexico were for specific 
localities in those two countries and were not nationally representative. For Canada, data on tobacco use 
by youth (grades 6–9) are from the Youth Smoking Survey (YSS)2; for the United States, data on 
tobacco use by youth (grades 6–8) are from the National Youth Tobacco Survey (NYTS).3 These data 
are summarized in Table 9-2. Because there are some differences in survey methods and questions (e.g., 
the inclusion criteria, question wording), comparisons of the estimates among the surveys should be 
made with caution. Overall national youth prevalence of current ST use ranged from 1.8% in Canada to 
9.8% in Barbados. Smokeless tobacco use was more prevalent among boys than among girls in nearly 
all countries and localities. The prevalence of ST use among boys ranged from 2.6% in Canada to 11.5% 
in Barbados, and ST use among girls ranged from 0.8% (Canada) to 8.5% (Jamaica).  






Table 9-2. Percentage of adolescents aged 13–15 years who currently used smokeless tobacco in the 
Americas Region, from the Global Youth Tobacco Surveys, 2007–2010 
Country* Year Total (%) Boys (%) Girls (%) 
Argentina 2007 4.3 5.5 3.2 
Bahamas 2009 6.6 7.5 5.5 
Barbados 2007 9.8 11.5 8.2 
Brazil – Campo Grande 2009 8.2 9.1 7.5 
Brazil – Vitόria 2009 3.6 5.0 2.4 
Brazil – São Paolo 2009 5.5 6.3 4.6 
Canada† 2009 1.8 2.6 0.8 
Dominica 2009 8.4 10.2 6.4 
El Salvador 2009 3.7 4.5 2.8 
Grenada 2009 8.4 10.1 6.9 
Guyana 2010 7.5 7.9 6.6 
Jamaica 2010 8.5 8.5 8.5 
Mexico – Pachuca 2008 5.3 6.6 4.1 
Mexico – Tlaxcala 2008 5.3 7.9 3.0 
Mexico – Saltillo 2008 4.5 4.9 3.9 
Mexico – Campeche 2008 6.3 5.1 7.2 
Mexico – Villahermosa 2008 5.0 5.8 4.4 
Mexico – Aguascalientes 2008 2.8 3.3 2.2 
Mexico – Colima 2008 8.4 8.7 8.0 
Mexico – Morelia 2008 4.4 5.6 3.3 
Mexico – Queretaro 2008 4.1 4.6 3.5 
Mexico – La Paz 2008 7.3 7.7 5.3 
Mexico – San Luis Potosi 2008 4.1 5.3 3.1 
Panama 2008 3.5 3.8 3.2 
Peru 2007 4.7 4.3 4.8 
Trinidad and Tobago 2007 5.5 5.4 5.5 
United States of America‡ 2009 2.6 4.1 1.2 
Venezuela 2010 5.1 6.9 2.6 
*Unless otherwise indicated, data are from the 2007–2010 Global Youth Tobacco Survey (35). 
†Health Canada 2010 (2). 
‡National Youth Tobacco Survey, Grades 6–8 (3). 
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For adults, basic ST prevalence data were available for nine countries in the region (Table 9-3; 
Map 9-1). Rates among men appear to be higher than among women, with the largest percentage 
among men reported in the United States (7.1%), and the highest rate among women, in Haiti (2.5%). 
(Statistical tests were not conducted.)  
In general, detailed information on ST use is sparse or nonexistent for most countries in the Region of 
the Americas. This section describes trends for several countries where more detailed information exists.  
Table 9-3. Percentage of adults who currently used smokeless tobacco in the Americas Region,  
2005–2012 
Country Year Age group (years) Total (%) Men (%) Women (%) 
Barbados* 2007 25+ 0.3 0.0 0.6 
Brazil† 2008 15+ 0.4 0.6 0.3 
Canada‡ 2010 15+ 1.0 1.0 — 
Dominican Republic§ 2007 Men, 15–59;  
Women, 15–49 
— 1.9 0.3 
Haiti§ 2005–2006 Men, 15–59;  
Women, 15–49 
— — 2.5 
Mexico† 2009 15+ 0.3 0.3 0.3 
Saint Kitts and Nevis 
(subnational)* 
2007 25–64 0.1 0.3 0.1 
United States¶ 2012 18+ 3.6 7.1 0.4 
Uruguay† 2009 15+ 0.0 0.0 0.0 
*WHO Report on the Global Tobacco Epidemic, 2011 (94). 
†Global Adult Tobacco Survey, 2008–2010 (34).  
‡Canadian Tobacco Use Monitoring Survey, 2010 (95).  
§Demographic and Health Survey, 2007 (96). 
¶National Survey on Drug Use and Health, United States, 2012 (7). 






Map 9-1. Prevalence of smokeless tobacco use among adults in the World Health Organization’s 
Region of the Americas 
 
Sources: WHO Report on the Global Tobacco Epidemic, 2011 (94); Global Adult Tobacco Survey, 2008–2010 (34); Canadian 
Tobacco Use Monitoring Survey (95); Demographic and Health Surveys (96); National Survey on Drug Use and Health (7). 
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By total volume, the United States is among the world’s largest producers and consumers of 
commercially manufactured ST products, and the vast majority of ST products consumed in the country 
are commercially manufactured. In 2008, 119.92 million pounds of ST (1.3 billion units) were sold in 
the United States, and another 31.7 million units were given away to wholesalers.4 However, a diversity 
of products are being used and prevalence varies widely by region, ethnicity, and other population 
characteristics. Most of the ST products used in the United States are broadly categorized as snuff or 
chewing tobacco. Moist snuff, the dominant product category, accounted for 68% of ST sales in 2007.5 
Three companies account for nearly 90% of the retail market: U.S. Smokeless Tobacco Company (UST; 
a subsidiary of Altria), American Snuff Company (a subsidiary of Reynolds American, formerly 
Conwood Sales Company), and Swedish Match North America.6 Small retailers such as convenience 
stores and small groceries represented 72% of the ST sales volume in 2010.6 
General Population 
Most U.S. surveillance systems used to monitor the prevalence of tobacco use do not report separate 
data for snuff and chewing tobacco, but report the prevalence of ST use in aggregate.  
Smokeless tobacco use is a predominantly male behavior in the United States, although use among 
females is relatively common in selected regions and populations. In 2012, 7.1% of U.S. men and 
0.4% of U.S. women ages 18 years or older had used ST in the past month. Current use was more 
common among men ages 18–25 years (10.5%) than among males ages 12–17 years (3.7%) or 26 years 
old or older (6.5%).7 According to the 2009 Behavioral Risk Factor Surveillance System, the prevalence 
of current ST use by men varied widely among U.S. states, from a high of 17.1% in West Virginia to a 
low of 2.0% in the District of Columbia.8 
Smokeless tobacco use by high school students had been declining for more than a decade when 
prevalence rates began to climb rapidly in about 2003 (Figure 9-1). The Youth Risk Behavior Survey 
found a 35% increase in the prevalence of current use by males in 12th grade between 2003 and 
2009,9,10 a pattern that was confirmed by the Monitoring the Future Survey.11 
One emerging trend is a growing prevalence of dual use of cigarettes and ST, particularly among boys 
and young men. For example, about 60% of male high school students who use ST are also current 
smokers.12 Most adult dual users are 18–34 years old, report using ST largely in places where they 
cannot smoke, and do not believe ST will help them quit smoking.13 Nearly half of U.S. dual users have 
no plans to quit using tobacco.13 






Figure 9-1. Trends in the prevalence of current smokeless tobacco use by U.S. male high school students 
in grade 12, from the Monitoring the Future Survey and Youth Risk Behavior Survey, 1993–2009  
 
Sources: Monitoring the Future (MTF) Surveys, 1975–2010 (11); Youth Risk Behavior Survey (YRBS), 2009 (10); YRBS, 1995–2009 (97); 
YRBS, 1993 (97). 
Special Populations 
A high prevalence of ST use has been reported among some groups of athletes in the United States, 
including about one-quarter of professional baseball players.14,15 Relatively high rates of ST use also 
have been reported among college athletes16–18 and high school athletes.16,19–21 
Nationally, Native Americans and Alaska Natives have a higher prevalence of current use of ST 
(8.9%) than any other racial or ethnic group.7 Alaska Native prevalence of use varies widely, ranging 
between 3% and 34%, and the statewide prevalence of ST use among Alaska Native adults is almost 
three times that of Alaska non-Native adults (11% vs. 4%).22 Tobacco use does not serve a spiritual 
function for Alaska Natives as it does for some Native American tribes.23–25 Both commercial and 
homemade chewing tobacco are used throughout Alaska. The homemade product known as iqmik, 
unique to Alaska, is most common in the western region of the state,23,24 where prevalence is 16–22% 
among adults.26,27  
Immigrants to North America frequently bring their patterns of ST usage with them. For example, use of 
gutka or betel quid with tobacco was found to be very common among first-generation immigrants from 
Bangladesh and India (Gujarati) living in New York City.28 South Asian males living in New Jersey had 
the highest prevalence of ST use of any ethnic group in the northeast region of the United States.29  
Canada 
Most of the ST products used in Canada are commercially manufactured and are categorized as snuff or 
chewing tobacco. Nearly all the snuff sold in Canada is U.S.-style moist snuff, and the chewing tobacco 
products available in Canada are predominantly the same as those sold in the United States. In 2010, 
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moist snuff accounted for 84% of ST sales by volume and 86% of sales by value.30 The National 
Smokeless Tobacco Company dominates the Canadian market, with an 82% volume share; its primary 
brand names are Copenhagen and Skoal. 
The prevalence of ST use among youth in Canada is similar to that in the United States. The Youth 
Smoking Survey, a school-based survey administered to 50,000 Canadian students in 2008–2009, 
showed that rates of ever having tried ST were 3.3% for boys and 1.1% for girls in grades 7–9, and 
15.5% for boys and 3.8% for girls in grades 10–12.2 
Based on the 2010 Canadian Tobacco Use Monitoring Survey (CTUMS), ST use within the 30 days 
before the survey was more prevalent among men than among women, although it was used by less than 
1% of Canadians ages 15 years or older of either sex.31 Use of snuff or chewing tobacco was higher 
among adults ages 20–24 than among other age groups, although prevalence was still less than 2%. 
Usage rates show little regional variation, with the highest prevalence reported for Saskatchewan, 
1.7% of adults, and less than 1% reported in all other provinces.31  
Although sales of ST in Canada by weight have hit some high points and low points between 1989 and 
2010, the long-term trend has been relatively flat during the past two decades.5 
Mexico 
Little information is available on ST use in Mexico. The only known type of commercial product on the 
Mexican market is imported U.S.-style moist snuff. The market is dominated by Lieb International SA 
(importing and distributing products made by Swisher International Group), which essentially dominates 
the competitive landscape, eliminating competition for ST products.32 Sales appear to be limited to one 
chain of variety stores and to tobacco specialty shops. 
The 2009 Global Adult Tobacco Survey (GATS) conducted among a national sample of adults in 
Mexico reported an estimated prevalence of use of 0.3%, which did not differ appreciably by sex, age, 
education, or place of residence.33,34 The Global Youth Tobacco Survey (GYTS) was conducted among 
13- to 15-year-old students in 11 Mexican cities in 2008 (Table 9-2).35 Among those cities, the 
prevalence of current ST use ranged from 2.8% (Aguascalientes) to 8.4% (Colima), with a median of 
5%. Current use of those products generally was higher among boys (median = 5.6%) than among girls 
(median = 3.9%). 
Venezuela 
The main ST product used in Venezuela is chimó, a mixture of cooked tobacco leaves and flavorings 
(described below). The Venezuelan GYTS, conducted among students in grades 7–9, was the first 
tobacco-specific population surveillance system to estimate the prevalence of smokeless use and related 
behaviors in that country. GYTS results for Venezuela nationally and for the states of Barinas, Cojedes, 
Monagas, Nueva Esparta, Trujillo, Zulia, Yaracuy, and Lara in the years 2000, 2004, and 2008 found 
that the prevalence of chimó use was not uniform among the states: It ranged from 3.8% to 20.7% for 
boys and from 2.0% to 6.6% for girls, with a higher overall prevalence in Barinas, Cojedes, Monagas, 
and Lara.36 The GYTS also found that students in grade 7 used chimó more often than cigarettes, which 






may reflect the fact that school-based tobacco prevention programs only address cigarette smoking.36–38 
Based on the 2007 Lara State Heart Health Survey of adults over the age of 15, 15.4% of males and 
3.1% of females reported ever using chimó, while 6.2% of males and 1.5% of females were current 
users.39  
Brazil 
In 2010, Brazil was the world’s second largest tobacco producer and the world’s largest tobacco 
exporter.40 Despite barriers to implementing effective tobacco control policies, the prevalence of current 
tobacco use declined from about 33% of Brazilians in 1989 to 17% in 2008.41 Brazil is among the few 
countries in the world to establish a public-health-based regulatory structure for tobacco products 
through its national health surveillance agency, ANVISA (Agência Nacional de Vigilância Sanitária) 
which was established in 1999. 
There are two groups of smokeless products used in Brazil: 
 Global products like dry snuff, snus, and chewing tobacco from multinational companies. 
These products are primarily used by young people and are common at rodeos and other 
rural-themed events. 
 Regional products used only in Brazil, made by farmers, small tobacco industries, or native 
peoples. Examples of regional products include a type of dry snuff called rapé, chewing tobacco, 
and products used by natives, such as porronca. These products are available in a wide variety of 
flavors and forms (Andre Luiz Oliveira da Silva, unpublished results, 2012). 
Data on the use of ST products in Brazil are very limited. About 17 million Brazilians use tobacco; most 
(>95%) are cigarette smokers. The use of ST is quite low, at around 0.4% of the general adult population 
(640,000 users), with 0.6% of men and 0.3% of women reporting current ST use. In Brazil, ST is 
primarily used in rural areas and is less common in urban environments.34 
Types of Smokeless Tobacco Products and Patterns of Use 
Snuff 
Two types of snuff are manufactured and used in the United States: moist snuff and dry snuff (also 
called Scotch snuff). Moist snuff is by far the most widely consumed type in the United States4 and 
Canada.30 It is typically made from a mixture of fire-cured and air-cured tobacco laminae and stems, 
which are then shredded.42 Traditional moist snuff contains 20%–60% moisture and often is flavored 
with wintergreen or various fruit flavors. Moist snuff consists of small particles of tobacco product of 
varying particle size. It is typically sold in 1.2 ounce (34 gram) tins and is also available in small teabag-
like sachets. It can be as inexpensive as $1.50–$2.50 per can for some wholesale brands.43 
Swedish-type “snus” moist snuff products were introduced on the U.S. market in about 2000. Although 
both Swedish snus and the U.S. product are marketed as “snus,” research suggests that snus sold in the 
United States is a modified version of its Swedish cousin, and limited research is available to specify 
exactly how U.S. and Swedish snus differ in terms of chemical composition or manufacturing process.44 
Some of the snus products marketed in the United States bear the same brand names as popular cigarette 
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brands (e.g., Marlboro Snus and Camel Snus). Snus products sold in the United States generally are 
marketed in sachet-form and have moisture contents on the order of 10%–30% by weight, which is 
lower than in traditional moist snuff and Swedish snus products.44,45  
Dry snuff is a finely powdered tobacco product produced mainly from Kentucky and Tennessee 
fire-cured tobaccos.42 It can be used either nasally or orally, although oral use predominates in 
North America.  
Chewing Tobacco 
Three types of chewing tobacco are sold in North America: loose leaf, plug, and twist. Loose-leaf 
chewing tobacco consists mainly of air-cured tobacco and generally is heavily treated with licorice and 
sugar.42 Plug tobacco is produced from heavier grades of tobacco leaves that are harvested from the top 
of the plant and separated from the stems. The tobacco then is immersed in a mixture of licorice and 
sugar, pressed into a plug, covered with a wrapper leaf, and reshaped. Twist tobacco is made from air- 
and fire-cured burley tobacco and is twisted to resemble a decorative rope. Prices vary for chewing 
tobacco products but average about $3.00 per can.46 
Dissolvables 
“Dissolvable tobacco products”, or “dissolvables” were introduced on the U.S. market starting in about 
2001. Dissolvables are made of ground tobacco shaped into compressed pellets, lozenges, strips, or 
sticks and sometimes packaged to resemble breath-freshening mints or strips. These products include 
Camel Sticks, Strips, and Orbs (R.J. Reynolds), Marlboro and Skoal Smokeless Tobacco Sticks (Philip 
Morris USA and UST, respectively), and Ariva and Stonewall lozenges (Star Scientific). Camel 
dissolvables cost on average $3.59–$4.19 for each package.47 In January 2013, Star Scientific 
discontinued the manufacture, distribution, and sale of Ariva and Stonewall lozenges, which were the 
first dissolvable products on the market, introduced in the early 2000s.48 Some dissolvable tobacco 
products have only appeared in test markets.  
Iqmik  
Alaska Native people make an ST mixture known as iqmik (Figure 9-2) by combining tobacco with the 
ashes from fungus or wood.23 This custom-made ST mixture, with some regional variations, is used 
among the indigenous populations in western Siberia, Yukon, Labrador, the coast of British Columbia, 
and Nova Scotia.49 
Iqmik, also known as “blackbull” or “dediguss,” is traditionally used by the Cup’ik and Yup’ik Eskimo 
people of Alaska. Fungus ash, also called punk or buluq, is prepared by burning the basidiocarps of 
Phellinus igniarius, a fungus that grows on birch trees throughout Alaska. If the region is devoid of 
birch trees, such as in the coastal regions, where tundra does not support their growth, ash from 
driftwood, willow wood (Salix arbusculoides), or alder bushes (Betulaceae Alnus glutinosa) is used. 
The uncut air- or fire-cured twisted or leaf tobacco used in iqmik is a commercially packaged tobacco 
available in local stores.23,24 Iqmik is prepared either by premastication or by hand mixing, using air- or 
fire-cured full leaf or twisted leaf tobacco in varying proportions, and different types of ashes based on 






the user’s personal practice.49 In rural regions of Alaska, iqmik can be purchased for an estimated 
$5.00 a can.50 
Figure 9-2. Iqmik preparation and use 
 
Source: Photos courtesy of Caroline Renner, Alaska Native Medical Center, 2011. 
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Chimó is the main ST product used in Venezuela (Figure 9-3). Chimó is typically used by placing a 
small amount under the tongue or between the lip or cheek and the gum, and left in place for about 
30 minutes. The black-stained saliva is then expectorated.36  
Figure 9-3. Examples of chimó product from Venezuela 
 
Source: Photos courtesy of Scott Tomar, University of Florida School of Dentistry, 2011. 
During the initial days of European exploration of the Americas, a 1497 report from Amerigo Vespucci 
provided one of the earliest written references to the Caribbean practice of chewing tobacco mixed with 
ashes.51 According to a popular legend, “Chimauchu” was the name of a “cacique” (aboriginal chief) 
who first used tobacco in the form of a paste, now called chimó. Traditionally, chimó was the primary 
type of ST used in Venezuela, the Colombian state of Norte de Santander, and at one point, in Cuba. Use 
of chimó declined in the second half of the 20th century with the increase in urbanization and the 
introduction of mass-produced cigarettes. By the 1980s, chimó use was regarded as confined to older 
adults living in poor rural areas. In the past 20 years, chimó has re-emerged as a trendy urban youth 
phenomenon and is perceived among some sectors of Venezuelan society as part of the national identity.  
Most chimó production occurs in small family-operated factories scattered across the Andes and the flat 
lands of Venezuela and Colombia. However, commercially manufactured production of chimó is 
growing in Venezuela, with increasing sophistication of equipment and methods.36 The process is 
simple: The factory buys leftover tobacco leaf (commonly N. tabacum or N. rustica) from commercial 
cigarette manufacturers and some local tobacco producers. The tobacco leaf is cooked in large metal 
containers for several days to discharge fiber and starch. Within 48 hours, the mixture turns from a light 
to a dark brown color and increases in viscosity. At the end of this phase the product is a sticky, heavy 
black liquid that exudes a penetrating odor. This product is called “basic” chimó paste, which is stored 
for maturation for up to 2 years. Production of 1 kilo of this concentrated product requires about 10 kilos 
of tobacco leaf. The basic paste is then mixed with other ingredients: sodium bicarbonate, brown sugar, 
molasses, ashes from tobacco leaf and mamón trees (Meliccoca bijuga), vanilla, anisette, alkaline ash, 
yoco vine (Paullinia yoco), plantain peel, avocado seed, sodium hypochlorite, hot chili, burned sodium 
bicarbonate, and other ingredients that are part of a “secret” recipe that each factory has. 






In Venezuela, chimó is widely available at local convenience stores across the country. It is produced by 
either commercial or cottage industries. Sold tax-free, chimó is relatively inexpensive compared with 
cigarettes, the price ranging from 1 bolívar fuerte (BsF) to 5 BsF (US$0.23–US$1.16) for each package, 
which contains at least 5 doses. In comparison, a hamburger meal at most international chain restaurants 
costs 47 BsF (US$10.93).  
Rapé 
In Brazil, regional ST products include a type of dry snuff called rapé (Figure 9-4). Rapé is used 
primarily in rural areas and small towns, or by Brazilian aboriginals in the Amazon rainforest, and 
cultural and historical elements are connected with its use (Andre Luiz Oliveira da Silva, unpublished 
results, 2012). Preliminary data from analysis of Brazilian rapé in 2011 show that the major constituents 
of the rapé samples (tonka bean, clover, cinnamon powder, and camphor) are unique compared with 
components of other smokeless products (Andre Luiz Oliveira da Silva, unpublished results, 2012). 
Since this product is mostly sold locally and in cottage industry settings, typical pricing information and 
evidence-based literature on the manufacture and use of rapé are not readily available. 
Figure 9-4. Examples of Brazilian rapé 
 
Source: Photos courtesy of Clifford Watson and Stephen Stanfill, Centers for Disease Control and Prevention, 2011. 
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Toxicity and Nicotine Profiles of Products 
Moist Snuff 
During the processing (curing, fermentation, and aging) of moist snuff, nitrosation of nicotine and 
the minor tobacco alkaloids nornicotine, anatabine, and anabasine gives rise to carcinogenic tobacco-
specific nitrosamines (TSNAs).52 TSNAs are widely considered the major class of carcinogens in 
ST products.42,53 TSNA levels in the 39 top-selling brands of United States moist snuff ranged from 
4.87 micrograms per gram (μg/g) (wet weight) for Red Seal Long Cut Wintergreen to 90.0 μg/g (wet 
weight) for Skoal Key.54 All U.S. products had higher TSNA levels than the Swedish product Ettan 
snus (Swedish Match), which had a TSNA level of 2.8 μg/g. In the top selling U.S. brands, total 
nicotine ranged from 4.42 to 25 milligrams per gram (mg/g) (wet weight). The free nicotine in these 
same moist snuff products ranged from 0.01 to 7.81 mg/g (wet weight), which represents a free nicotine 
percentage between 0.3% and 79.9%, and pH values between 5.54 and 8.62.54 Although the technology 
to reduce TSNA levels exists, U.S. smokeless tobacco manufacturers do not apply it to their most 
popular products.55 
Iqmik 
Because the alkaline ash used in iqmik has extremely high pH levels, nearly all nicotine in iqmik is in 
the free form, which is more rapidly absorbed than bound nicotine, the more common form in ST 
products with lower pH levels.56 The total nicotine and free nicotine levels in iqmik are much higher 
than in popular U.S. commercial smokeless products.  
Chemical analysis of iqmik samples found pH values between 11 and 11.8, and a total nicotine 
concentration of 22.9–23.38 mg/g. In addition to high levels of free nicotine, iqmik contains other 
hazardous substances such as TSNAs, polycyclic aromatic hydrocarbons (PAHs), and heavy metals.57 
In 17 iqmik tobacco samples, the average arsenic, cadmium, lead, and nickel concentrations were 
0.19±0.06 µg/g, 1.41±0.56 µg/g, 0.55±0.19 µg/g, and 2.32±1.63 µg/g, respectively.58  
Chimó  
Chemical analysis of selected samples of commercially manufactured and cottage industry chimó 
products found the following upper values: pH = 9.82; total nicotine concentration = 30.1 mg/g; 
percentage of free nicotine = 95.9%; and free nicotine concentration = 27.4 mg/g. Therefore, chimó 
could be characterized as having among the world’s highest levels of nicotine content and alkalinity in 
an ST product.59,60 The concentrations of TSNAs were: N’-nitrosoanabasine (NAB), 57.3 ng/g; 
N’-nitrosoanatabine (NAT), 965 ng/g; N’-nitrosonornicotine (NNN), 4,620 ng/g; 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK), 2,600 ng/g; 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), 
1,330 ng/g; and total TSNAs, 9,390 ng/g.60  






Health Problems Associated With Product Use 
All ST products contain nicotine, an addictive substance that has cardiovascular and other physiologic 
effects. These products also contain varying levels of TSNAs, several of which are human 
carcinogens.53 This section summarizes documented health effects of various ST products used in the 
Region of the Americas. It should be noted that for some products, little research has been conducted. 
North American Snuff 
Use of U.S.-type snuff causes cancer in humans, particularly cancers of the oral cavity.53 U.S. forms of 
snuff are strongly associated with oral mucosal lesions and localized gingival recession. Snuff use may 
increase the risk of fatal myocardial infarctions.  
Snus  
Although Swedish snus has been used in the Nordic region of Europe for many years, a modification of 
Swedish snus has only been marketed in North America since about 2000. Thus, as of 2012, no research 
is available on the long-term health effects of the products being marketed in the Americas. In Europe, 
the particular manufacturing process for Swedish snus has been in place for less than 15 years (since the 
late 1990s), so the health effects of long-term exposure to Swedish snus are largely unknown.  
While snus use has demonstrated increased risks of oral cancer in some studies,61 there is a lack of 
clear and consistent evidence that snus use is associated with oral cancer.53,62,63 Several epidemiologic 
studies in Scandinavia and Asia have demonstrated a causal link between the use of snus (and other ST 
products) and pancreatic cancer.53,62,64 
Swedish snus use appears to increase the risk of mortality from cardiovascular disease, including 
myocardial infarction and stroke,65 but the evidence regarding its relation to stroke is too limited to 
allow firm conclusions. Heavy use of Swedish snus appears to be associated with an increased risk of 
developing type 2 diabetes,66 while evidence from a few studies on insulin resistance, metabolic 
syndrome, and diabetes have yielded conflicting results.53,66 
Using Swedish snus during pregnancy may increase the risk for adverse birth outcomes, including 
pre-term delivery, pre-eclampsia, stillbirth, neonatal apnea, and infants who are small for their 
gestational age.67,68 
Iqmik 
Abnormal neonatal neurobehavioral outcomes associated with iqmik were assessed in a pilot study of 
41 pregnant Alaska Native women.69 Compared with women who used no tobacco products, women 
who used iqmik had significantly higher levels of nicotine and cotinine in umbilical cord blood and 
higher levels of cotinine in maternal blood. Neonates born to mothers who used iqmik during pregnancy 
had a significant increase in the number of abnormal neurobehavioral signs, as assessed by the Lipsitz 
score (a scoring system for neonatal drug-withdrawal),70 compared with infants born to mothers who did 
not use tobacco. 
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The acute physiologic effects of using chimó include elevation of blood pressure and heart rate. 
Chimó produces histologic changes in oral tissues, from tooth stain to orthokeratosis, epithelial 
dysplasia, granulocytes, hyperkeratosis, acanthosis, fibrosis, stroma collagen disease, chronic 
inflammation, and cancer.37,59,71 
The commercial and cultural profile of chimó can be explained by a matrix of factors including health 
beliefs. Popular folklore considers chimó a beneficial product for health, and some youth link it to the 
national identity.36,72 These beliefs even influence health professionals. For example, while the majority 
of dentists in Venezuela’s Lara State think chimó is a drug that is and will remain a public health 
problem, 33% think it is harmless or even beneficial for health. Fourteen percent of male dentists and 
18.8% of female dentists think it does not cause damage to oral tissues. However, few of those dentists 
had received information on this product, 79% never had a lesson about chimó as undergraduate 
students, and less than 30% had ever read a scientific article about chimó. Eighty percent of the dentists 
said they had not had a patient who used chimó in the last year, but among those dentists, 60% said they 
never asked their patient about their possible use. Eighty percent of dentists thought they were prepared 
to help patients stop using tobacco, but 40% never offered any counseling.72  
Brazilian Products 
Data about health impacts of the products sold in Brazil are very limited. However, one study 
conducted among 129 ST users found that 49 had gingival recession, 25 exhibited leukoplakia, and 
14 had dental pigmentation.73  
Marketing and Production Practices of Industry 
Marketing practices vary throughout the Americas Region, depending on the type of product used and 
its scale of production. For example, while the U.S. market consists of many commercially 
manufactured brands (which are exported to many areas including Canada and Mexico), in countries 
like Brazil and Venezuela ST is a cottage industry product. For decades, the U.S. smokeless tobacco 
market was dominated by a small number of companies that sold only smokeless tobacco. That changed 
with the acquisitions of Conwood Company by R.J. Reynolds in 2006 and U.S. Smokeless Tobacco 
Company by Altria Group in 2009. Cigarette companies also have introduced new ST products, 
including moist snuff, snus, and dissolvable products, which are sold under cigarette brand names such 
as Marlboro and Camel.  
Adolescent and young adult males have long been the primary target of ST marketing in North 
America.74,75 Two patterns of marketing and promotion of ST have emerged: (1) continued marketing to 
traditional targets such as men living in rural areas and those engaged in outdoor and sporting activities; 
and (2) increasing promotion of ST products as an alternative to cigarettes where smoking is not 
permitted.76,77 Smokeless tobacco continues to be heavily advertised in U.S. magazines with substantial 
youth readership, as it had been before the 1998 Smokeless Tobacco Master Settlement Agreement 
(STMSA) was reached between state attorneys general and the U.S. Smokeless Tobacco Company.75 
(The STMSA was executed specifically for ST products at the same time as the more widely known 






Master Settlement Agreement for cigarettes.) Although data on advertising and promotional 
expenditures by ST companies are available only through 2008, the pattern during the past decade 
indicates a massive increase in spending to market moist snuff products. Expenditures to advertise 
and promote moist snuff in the United States increased by 257% between 1998 and 2008, from 
$117.3 million to $287.3 million.4 Not only has ST been marketed as an alternative to cigarettes and 
for use in indoor settings, but the proportion of advertisements related to flavored products increased 
markedly between 1998–1999 and 2005–2006.77 In addition, ST manufacturers increasingly are using 
YouTube and other online social media to market their products.78  
Data are lacking on marketing of traditional and cottage industry products. In Venezuela, packaging of 
chimó is becoming more sophisticated, including the use of attractive candy-style packaging and small 
tin cans. In Brazil, no ST products, including rapé, are registered with the national health regulatory 
agency ANVISA, which means that these products are sold illegally. Because most users of rapé are 
residents of rural areas and small towns or are Brazilian aboriginals living in the rainforest, there are no 
large-scale marketing or advertising activities. 
Interventions and Policies 
United States  
The Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) gave the U.S. Food 
and Drug Administration (FDA) regulatory authority over ST products.79 Signed into law on June 22, 
2009, the Tobacco Control Act required FDA to reissue regulations prohibiting: (1) sales of cigarettes 
and ST to individuals less than 18 years old; (2) sales of cigarettes and ST in vending machines, self-
service displays, and other modes of sale that lack direct, face-to-face exchange, except in very limited 
situations; (3) tobacco brand name sponsorship of any athletic, musical, or other social or cultural event, 
or any team or entry in those events; and (4) gifts or other items in exchange for buying cigarettes or ST 
products, and sale or distribution of items with tobacco brands or logos, such as hats and tee shirts. The 
law also limits distribution of smokeless tobacco products and requires that audio advertisements use 
words only, with no music or sound effects. Effective July 22, 2010, the law prohibited the 
manufacturing, distributing, importing, selling, or advertising of ST products unless they carry text 
warnings that take up at least 30% of each principal display panel on the package and at least 20% of 
advertisements, with four specific rotating random messages: (1) “WARNING: This product can cause 
mouth cancer.” (2) “WARNING: This product can cause gum disease and tooth loss.” (3) “WARNING: 
This product is not a safe alternative to cigarettes.” (4) “WARNING: Smokeless tobacco is addictive.” 
[Sec. 204(a), Smokeless Tobacco Labels and Advertising Warnings79].  
The Tobacco Control Act also gives the FDA authority to set tobacco standards and establish 
manufacturing practices, requires premarket review of new tobacco products, and requires 
manufacturers who wish to market a tobacco product with a claim of reduced exposure, risk, or 
harm to obtain a marketing order from the FDA. 
The requirements set forth in the Tobacco Control Act differ for regulation of smokeless tobacco 
manufacturing and marketing compared to cigarette manufacturing and marketing. For example, the 
Act does not require FDA to issue regulations requiring pictorial labeling on ST packaging as it does 
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for cigarettes; does not ban characterizing flavorings in smokeless tobacco as it does for cigarettes; 
and does not call for a report and recommendations on certain characterizing flavors (i.e., wintergreen) 
of ST products as it does for menthol cigarettes. However, the Act does give the FDA the authority to 
require pictorial warnings or ban flavorings in smokeless tobacco products by issuing a regulation. 
In the United States, taxes are levied at the federal and state levels. The federal tax rate on snuff 
products in 2012 was $1.51 per pound, which translates to 11.3 cents per typical (1.2 oz) package of 
moist snuff, and 1.6 to 7.7 cents per 20-piece package of snus or dissolvables. Chewing tobacco is 
taxed at 50.3 cents per pound, or 9.3 cents per 3-ounce package. This is compared to the $1.01 federal 
tax on a pack of 20 cigarettes.80,81 State excise taxes on ST products vary widely in rate and formula. 
Some states apply an excise tax rate based on weight, ranging from Alabama’s rate of 1.0 cent per ounce 
for snuff, to 202.0 cents per ounce in Maine in 2012.82 Other states set their ST excise tax rate as a 
percentage of wholesale price, ranging from a low of 5% in South Carolina to a high of 95% in 
Washington State.80,82,83  
U.S. prevention and cessation programs have largely been focused on cigarette smoking, given the 
higher percentage of use. However, effective interventions for ST use have been developed and are 
described in detail in chapter 7. 
Canada 
Advertising of smokeless tobacco is subject to the same restrictions as cigarette advertising: These 
products can only be advertised to retailers or to adults through direct mail or in adult-only venues such 
as bars. Tobacco products cannot be sold to children (that is, anyone under 18). Smokeless tobacco 
manufacturers must report their products’ ingredients and additives to Health Canada. However, ST 
products in Canada can still be sweetened with sugar or contain fruit flavorings, even though such 
flavorings have been banned in cigarettes and little cigars. One of four rotating health messages is 
required on ST product packaging: (1) “This product is highly addictive.” (2) “This product causes 
mouth diseases.” (3) “Use of this product can cause cancer.” (4) “This product is not a safe alternative 
to cigarettes.” Unlike cigarettes, ST products do not have to display pictorial warnings. Although 
smoking has been banned in indoor public spaces and workplaces in Canada, ST products generally can 
be used in those venues.84  
Smokeless tobacco products are subject to federal and provincial tobacco laws in Canada, including 
taxation. Excise taxes on ST products vary by province, but they are taxed by weight at rates comparable 
to excise taxes on cigarettes.85–87 Smokeless tobacco products are not subject to a minimum package size 
as are cigarettes or little cigars, but they are taxed in a way that discourages the sale of quantities less 
than 50 grams.84  
Mexico 
Mexico has few restrictions or policies related to smokeless tobacco. There are no bans on consumption, 
no known restrictions on advertising, no requirements for warning labels, and taxes are relatively low 
compared with taxes on cigarettes.32 The General Health Law of Mexico prohibits the sale of tobacco 
products including ST products to anyone younger than 18 years old.88  







In Venezuela, ST sales are subject to the same legal regulations as cigarettes and cigars, but chimó is not 
taxed. Resolutions 11 and 12 from the Ministry of Health prohibit sale of any tobacco product to anyone 
less than 18 years of age, and sales are prohibited in retail outlets near schools.89,90 Although pictorial 
health warnings covering 50% of the pack are required for cigarettes, no such warnings are required for 
ST products sold in Venezuela.91,92  
There are no specific ST prevention initiatives in Venezuela. A nongovernmental cardiovascular 
health organization called ASCARDIO offers a cessation program for chimó as part of its Tobacco 
Cessation Clinic.  
Brazil 
In Brazil, manufacturers must submit information about the contents, emissions, packaging, and design 
of every tobacco product to ANVISA, the national health surveillance agency. However, because the list 
of commercially permitted brands in Brazil does not include ST brands (effectively making ST product 
sales illegal), smokeless products marketed and sold illegally in Brazil usually do not contain any 
health warnings. 
In the Brazilian legislation, ST products are classified as “other tobacco product (not cigarette).” 
Taxes include: 
 Importation taxation: 14% 
 PIS/COFINS (Social Integration Program/Contribution to Finance Social Security): 9.25% 
 Industrialized products taxation: 30% 
 State taxation on commercialized products: 25% (the same applies to cigarettes). 
Still, ST prices in Brazil are considered very low, making purchasing them relatively affordable for 
young people. 
Because of the much higher prevalence of cigarette smoking, health professionals generally do not focus 
on treating ST use. Health promotion and cessation efforts concerning smokeless products essentially do 
not exist. 
Summary and Conclusions 
The Region of the Americas holds a place of significance in the history of tobacco use because the 
tobacco plant is thought to have originated on the mainland in North, Central, or South America. In the 
United States and Canada, moist snuff is still the most widely consumed smokeless product type by far. 
Since 2001, companies in this region began selling novel ST products, which include dissolvables. 
Across North America, three types of chewing tobacco are sold: loose leaf, plug, and twist. Other types 
of products in the region include iqmik, traditionally used by Alaska Natives; chimó, the main 
smokeless product used in Venezuela; and rapé, a type of dry snuff used in Brazil.  
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In this region, current ST use among youth ranged from 1.8% in Canada to 9.8% in Barbados. 
Smokeless tobacco use was more prevalent among boys than among girls in nearly all countries and 
localities, with the greatest gender difference in the United States. For adult men, the highest prevalence 
of use was in the United States (6.9%), while use among women was highest in Haiti (2.5%). In general, 
detailed information on ST use is sparse or nonexistent for most countries in the region. Additionally, 
little is known about potential adverse health effects of many of the locally used products such as rapé 
and iqmik. 
Regulation of ST products in the Americas is variable; in some countries it is generally weak or absent, 
while others have placed regulations on sales, marketing, and product ingredients. Many tobacco control 
measures applied to cigarettes are not applied to ST products or are less stringent, such as lower taxes, 
lack of pictorial warning labels, and lack of targeted cessation interventions. In Brazil, no ST products 
are licensed for sale, but they are still available in some areas. Stronger tobacco control policies and 
programs are needed that are targeted to smokeless tobacco. Established tobacco control measures, such 
as increased pricing (mainly achieved through taxation), graphic warning labels, and limits on 
advertising and promotion, are not currently applied consistently across all tobacco products. Taxation 
may be optimal if applied equally to all tobacco products, and taxes for both ST and cigarettes could 
then potentially be set at the same rate and increased at the same time, which would change the focus 
from ST tax structures or cigarette taxation to tax structures that address all tobacco use. Controlling and 
taxing cottage industry products such as rapé poses a greater challenge. Surveillance of ST products, 
particularly in areas where there are indications that these products are being used, could be enhanced. 
And continuation of epidemiologic studies on the adverse health effects of a variety of ST products, 
including traditional products, and of dual use of ST and cigarettes is critical.  
Implementation of the World Health Organization Framework Convention on Tobacco Control and 
proliferation of smoke-free regulations throughout the region can be expected to accelerate the decline 
in consumption of cigarettes. The social acceptability of smoking continues to wane. At the same time, 
major cigarette manufacturers now control of most of the ST industry in North America and are 
marketing novel products to non-traditional users, including cigarette smokers. Dual use of cigarettes 
and ST is an emerging pattern, especially among young people, and may be influenced by marketing 
that encourages dual use. In this dynamic and shifting landscape, it is increasingly urgent to address ST 
throughout the region, while preserving the gains made in reducing smoking consumption. 
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Description of the Region 
The World Health Organization (WHO) European Region consists of 53 member states and a population 
of over 890 million. The European Region includes high-income countries (e.g., Germany, Norway) and 
lower income countries (e.g., Uzbekistan, Georgia, Kyrgyzstan).1 This region also includes the European 
Union (EU), which consists of 27 predominantly Western European member countries with a population 
of over 500 million (see Table 10-1 for the population of select European countries). The five Nordic 
countries, all considered high-income countries, have a total population estimated at 25.5 million. 
Within the EU, tobacco products remain widely traded. Globally, the EU is the fourth largest tobacco 
producer, after Asia, the Americas, and Africa.2  
The European Region is home to two populations that have longstanding traditions of smokeless tobacco 
(ST) use: Scandinavians, particularly in Sweden and Norway, and the large South Asian community that 
has immigrated to Europe and especially to the United Kingdom (UK). Sweden is exempt from the EU’s 
tight regulations on the sale of many types of oral and ST products and can therefore manufacture and 
sell snus legally nationwide.3 The UK is home to the largest South Asian community within Europe, 
estimated at 4.2 million people in 2011.4 Research shows that these groups have to varying degrees 
brought ST products with them from their countries of origin such as Bangladesh and India, which have 
the highest rates of ST use in the world. And studies show that a third population, the Uzbeks, have one 
of the highest rates of ST use in the European Region, although published information about ST use in 
Uzbekistan is limited.5  
This chapter examines ST use—its health effects, industry marketing practices, government policy, and 
interventions to combat use—in the United Kingdom, the Scandinavian countries (especially Sweden), 
Kyrgyzstan, and Uzbekistan. These countries were selected based on the availability of survey and other 
research information and on the availability of documented ST prevalence rates. Because survey 
methods and questions differ, comparisons of estimates among the surveys should be made with caution. 
Prevalence of Smokeless Tobacco Use 
European regional data on tobacco use are largely focused on cigarette smoking; limited information is 
available on ST use.6 In addition, surveys’ definitions of current use may vary. For example, some 
surveys define current use as any use within the past 30 days, while other surveys ask about different 
time periods; some surveys ask about daily use and use on some days, and still other surveys ask about 
“current” use without defining the term further. 
The Global Youth Tobacco Surveys provide national and/or subnational prevalence data for 
adolescents aged 13–15 years in 12 countries7 (Table 10-2). The prevalence of current ST use 
among adolescents (defined as use in the past 30 days) ranges from 1.1% in Montenegro to 6.9% in 
Estonia. Smokeless tobacco use appears to be higher among boys than girls in all countries and 
locations except in Warsaw, Poland.7 
  
 




Table 10-1. Population and land area of selected countries in the European Region 
Country Area (km2) Population (thousands) 
Albania 28,864 3,204 
Armenia 29,731 3,092 
Azerbaijan 86,679 9,188 
Croatia 56,449 4,403 
Denmark 43,023 5,550 
Estonia 44,700 1,341 
Finland 335,313 5,365 
Georgia 70,194 4,352 
Germany 356,286 82,302 
Hungary 93,308 9,984 
Iceland 106,667 320 
Kyrgyzstan 197,556 5,334 
Latvia 64,343 2,252 
Macedonia 25,730 2,061 
Moldova 33,867 3,573 
Montenegro 13,717 631 
Norway 375,615 4,883 
Poland 70,144 38,277 
Russian Federation 17,869,750 142,958 
Serbia 88,000 9,856 
Slovenia 20,300 2,030 
Sweden 46,667 9,380 
Switzerland 41,204 7,664 
United Kingdom 243,278 62,036 
Ukraine 605,973 45,448 
Uzbekistan 449,918 27,445 
Total 21,397,252 492,929 
Abbreviation: km = kilometer. 
Source: United Nations 2011 (69). 






Table 10-2. Percentage of adolescents aged 13–15 years who currently used smokeless tobacco in the 
European Region, from the Global Youth Tobacco Surveys, 2007–2009 
Country Year Total (%) Boys (%) Girls (%) 
Albania 2009 2.0 2.3 1.7 
Croatia 2007 1.9 2.7 1.1 
Estonia 2007 6.9 9.4 4.5 
Hungary 2008 1.7 2.1 0.9 
Kyrgyzstan 2008 2.5 3.3 1.8 
Macedonia 2008 3.0 3.2 2.8 
Moldova 2008 3.8 5.2 2.6 
Montenegro 2008 1.1 1.1 0.9 
Poland – Warsaw 2009 1.8 1.3 2.2 
Poland – Mazovia Province 2009 1.4 1.5 1.0 
Serbia 2008 1.2 1.6 0.7 
Slovenia 2007 2.2 2.0 1.8 
Srpska 2008 1.4 1.8 1.1 
Source: Global Youth Tobacco Survey, 2007–2009 (7). 
  
 




National prevalence data on ST use among adults (people aged 15 years and older) are available in 
16 countries in this region (see Table 10-3; Map 10-1). These data were collected from multiple surveys 
including the Global Adult Tobacco Surveys (GATS), the Demographic and Health Surveys (DHS), the 
WHO STEPwise Approach to Surveillance (WHO STEPS), and individual country surveys as reported 
in the WHO Report on the Global Tobacco Epidemic, 2011 (GTCR). While these surveys may employ 
different measures for smokeless tobacco use, comparisons among them should be made with caution; 
however, they represent the best available national estimates of prevalence. Reported prevalence of 
current ST use among adults (defined as use on some days or every day) varies from 0.1% in 
Switzerland to 17.0% in Sweden. Men reported higher rates of current use of ST products than women, 
with 17.0% of Norwegian men, 22.5% of Uzbek men, and 26.0% of Swedish men reporting current use.  
Table 10-3. Percentage of adults who currently used smokeless tobacco in the European Region, 
2005–2010 
Country Year Age group (years) Total (%) Men (%) Women (%) 
Armenia* 2005 15–49 — 1.8 0.0 
Azerbaijan* 2006 Men, 15–49 — 0.3 — 
Denmark† 2010 15+ 2.0 3.0 1.0 
Finland† 2009 15–64 — 5.5 0.4 
Georgia‡ 2010 18–64 0.6 1.0 0.2 
Iceland† (daily use only) 2008 15–89 2.9 6.0 — 
Kyrgyzstan† 2005 15+ 3.4 7.0 0.3 
Latvia† (daily use only) 2008 15–64 0.1 0.2 — 
Moldova* 2005 Men, 15–19; 
Women, 15–49 
— 0.1 0.0 
Norway† 2009 16–74 10.0 17.0 5.0 
Poland§ 2009 15+ 0.5 1.0 0.1 
Russian Federation§ 2009 15+ 0.6 1.0 0.2 
Sweden† 2010 16–84 17.0 26.0 7.0 
Switzerland† 2009 14–65 0.1 0.2 0.0 
Ukraine§ 2009 15+ 0.2 0.5 0.0 
Uzbekistan† 2006 15+ 11.3 22.5 0.4 
*Demographic and Health Surveys (71). 
†Individual country surveys from: WHO Report on the Global Tobacco Epidemic, 2011 (15). 
‡WHO STEPS from: WHO Report on the Global Tobacco Epidemic, 2011 (15). 
§Global Adult Tobacco Survey (70). 
 
 







































































































































































































































































Varying estimates of the prevalence of ST use in South Asian communities in the UK have been 
reported in 22 published papers.8 The most comprehensive dataset is provided by the Health Survey for 
England (HSE), which has oversampled black and minority ethnic groups. The 2004 HSE suggested a 
decrease in use among Bangladeshis in the UK compared to a similar survey conducted in 1999.9 Only 
two studies validated self-reported tobacco use with salivary cotinine analyses. One found a prevalence 
of 26% for Bangladeshi women in 1999 and 16% in 2004,9 but the second found a prevalence of 48.5% 
for the same population in 2000–2001.10 Thirteen other studies focusing on Bangladeshi samples yielded 
prevalence estimates between 2% and 57%, with prevalence rates higher among women.8  
Evidence that prevalence is declining is contradicted by other sources, which indicate that (1) legal 
imports of ST from India increased nineteenfold between 1995 and 2009; (2) the number of retail 
outlets for these products has not decreased in one London municipal area, where a large Bangladeshi 
community lives, in the previous 11 years11; and (3) generational analyses have identified no significant 
differences in consumption between first and second generation immigrants.12  
Studies of ST use in the UK have been criticized for using poor quality sampling methods, relying on 
self-reports,8 and asking ambiguously worded questions. Terminology is also an issue. Members of 
Indian communities will more commonly use the term paan instead of betel quid (the term this report 
uses), whereas members of Bangladeshi communities might also use khilli paan. Many studies have 
failed to distinguish between paan or khilli paan with or without tobacco. The HSE includes paan 
masala as a possible response even though samples of this product, when analyzed in the laboratory, 
rarely contain tobacco.  
No data are available on the use of ST products by the general population of the United Kingdom.5 
Nordic Countries 
In addition to the EU’s ban on the sale of Swedish snus, individual countries have further restricted ST 
products. Sweden was exempted from the ban when it joined the EU in 1995. The market for Swedish 
snus in Finland and Denmark is limited because both countries are members of the EU; Swedish snus 
has been marketed more widely in Norway and Iceland, neither of which are EU members.  
According to national WHO surveys conducted in 2009 using representative samples, the prevalence of 
daily snus use among adults in Sweden was 19% for men and 4% for women.13 In Norway, 11% of men 
and 1% of women use snus every day.14  
Uzbekistan and Kyrgyzstan  
According to WHO data, in 2006 the prevalence of current ST use was 11.3% among the Uzbek 
population aged 15 years and older.15 Males in this age group (22.5%) were much more likely to be 
users than females (0.4%). An earlier national survey found an “ever in lifetime” prevalence of 37.9% 
among males and 0.4% among females.16 A separate study found that men who are married (odds ratio 
[OR] = 2.8, 95% confidence interval [CI]: 1.5–5.1), older (35–54 years: OR = 2.5, 95% CI: 1.3–4.8), or 
live in rural areas (negatively associated with urban residence: OR = 0.5, 95% CI: 0.3–0.7) were more 






likely to use nasway, a form of ST widely used in Uzbekistan.17 It may be that the prevalence of 
nasway use in Uzbekistan is influenced by the relatively higher price of cigarettes. 
Less information is available for Kyrgyzstan. According to data from the National Epidemiological 
Study of Tobacco Use Prevalence in Kyrgyzstan, in 2005, 3.4% of adults currently used smokeless 
tobacco. Among men, 7% reported current ST use, compared to only 0.3% of women.15  
Types of Smokeless Tobacco Products and Patterns of Use 
Europeans use a variety of ST products. Snus originated in Sweden and is traditionally used in the 
Nordic countries of Sweden, Norway, Finland, and Iceland; a range of products are imported from 
South Asia (India, Pakistan, Bangladesh, and Sri Lanka) and used by communities of South Asian 
origin in Great Britain; and three national companies produce twisted tobacco for oral use in Denmark, 
Germany, and the UK (primarily used by the Danes). The product used in Kyrgyzstan and Uzbekistan is 
nasway or nasvay, a multinational product made of locally grown tobacco and an alkaline modifier such 
as ash or slaked lime (calcium hydroxide).  
United Kingdom 
Following a protocol for determining the availability of South Asian ST products in England,18 
researchers identified municipal areas with high proportions or numbers of residents of South Asian 
origin catalogued ST retail outlets in these areas. Then ST products for each outlet were listed, along 
with their branding, regulatory compliance, and sale price. South Asian ST products were found to be 
widely available from a variety of outlets.  
Employing this protocol in a further exploration of product and brand availability within the five 
London municipal areas with the highest numbers of residents of South Asian origin, 54 non-duplicated 
brands were identified. These were prepackaged products, excluding in-store, custom-made products or 
products sold loose. Fifty-two percent of them originated in India, and 33% in Bangladesh. The three 
main types available for purchase were zarda (60%), gutka (14%), and khaini (11%).19 Other available 
products included tobacco leaf, toothpowder, mawa, and qiwam. Common ingredients in zarda, gutka, 
and khaini are tobacco flakes or powder, with slaked lime (calcium hydroxide) as an alkalinity enhancer. 
Gutka also contains areca nut, which is recognized by the International Agency for Research on Cancer 
(IARC) as a carcinogen.20 Gutka and zarda contain additional spices and flavorings such as saffron and 
menthol. Zarda is often mixed with areca nut and other ingredients to produce the homemade product 
paan/khilli paan. Gutka and khaini are typically sold in small individual sachets, and zarda is sold 
in larger containers so it can be used in the production of paan by the user at home or by a vendor at 
a kiosk.  
Seven brands have been identified as dominant—six from India and one from Bangladesh 
(Table 10-4).19 Within individual boroughs, or neighborhoods, these brands represented between 
one-quarter and two-thirds of the products available. Outlets serving communities of Indian origin 
were likely to sell a more homogeneous group of products (gutka and khaini), but those serving the 
Bangladeshi community were more likely to sell a variety of zarda brands from Bangladesh. These 
variations reflect differing cultural contexts, with domestically made khilli paan being the predominant 
 




form of consumption in Bangladeshi communities. Zarda is produced commercially, gutka and khaini 
are often produced by both commercial and cottage industries, but betel quid is mostly a cottage industry 
or custom-made product. 
Table 10-4. Dominant smokeless tobacco products and brands available in five London boroughs 
Product Brand  Origin  
  Price per portion  
U.S. UK Weight Warning 
Gutka Tulsi Mix India US$1.25–$4.20 80p–£2.69 20 g Yes 
Gutka RMD India US$0.40–$1.98 25p–£1.20 5 g No 
Zarda Baba 120 Blend India US$4.94–$11.56 £2.99–£7 50 g No* 
Zarda Baba 600 Blend India US$57.78–$82.55 £35–£50 50 g No* 
Zarda Dulal Bangladesh US$0.83–$1.63 50p–99p 15 g No 
Khaini Mirage India US$0.83–$1.24 50p–75p 12 g No 
Khaini Kuber India US$1.47–$2.81 89p–£1.70 10 g Yes 
Khaini Ansal Udta Panchi India US$1.47–$2.81 89p–£1.70 10 g No 
*A correctly worded warning sticker is now placed on the base of the packaging.  
Source: Croucher 2011 (19). 
According to an assessment of 73 types of paan/khilli paan prepared for local consumption and 
purchased from 31 shops in these five areas of London, the mean total weight was 10.06 grams (g) 
per packet (95% CI: 9.26–10.86) with a mean price of US$2.32 (£1.43) (range = US$0.81–5.68,  
£0.50–3.50) per packet. Zarda alone was the most commonly used tobacco type in paan/khilli 
paan (64.4%).21  
The excise duty for these products as of 2011–2012 was US$14 (£8.49) per 10 grams of weight, 
regardless of the proportion of tobacco present.21 It has been estimated that the legal price (incorporating 
excise and other taxes) of a 5-gram individual packet should be at least US$1.14 (69p), but the prices 
identified were almost always higher. The approximate retail price of a pack of 20 cigarettes in January 
2011 was US$10.95 (£6.63). Although smokeless tobacco products are required to display warning 
labels, it was found that the dominant brands identified here were mostly non-compliant.  
The assumption that ST use will decline as immigrants become acculturated is not supported in the 
literature. First, chewing of paan/khilli paan with tobacco is recognized as a longstanding traditional 
behavior among South Asian women, whereas cigarette smoking stigmatizes women in South Asian 
communities. Second, although paan/khilli paan without tobacco may be chewed from an early age, 
women start to add tobacco to it as they reach early adulthood, marry, and leave their family home. 
Women’s initial use of these products with tobacco is commonly attributed to social pressure from 
family and friends; Bangladeshi male smokers are sometimes described as chewing paan/khilli paan 
with tobacco as a way of building a relationship with their wives, although chewing is not regarded as a 
male behavior. Third, use of paan/khilli paan with tobacco is thought to relieve various health problems. 
It is mistakenly believed to alleviate nausea during pregnancy, promote digestion, and reduce bad 






breath; there are recurrent reports that its use alleviates dental pain.22 Finally, in the Hindu tradition, 
areca nut is considered a vital ingredient in paan/khilli paan and is known as the food for God; it may be 
used while praying if images or idols are unavailable. Paan/khilli paan is very commonly offered to 
guests at social occasions such as weddings. 
Nordic Countries 
Although snus is the Swedish word for all oral or nasal tobacco products, it has become synonymous 
with the oral moist form of pasteurized ST placed under the upper lip, and is increasingly recognized as 
such in the international literature. Snus has been manufactured and marketed in Sweden since the 
1820s. It remained the best-selling tobacco product in Sweden for the next 100 years, until the early 
1940s, when cigarettes became the preferred way to consume tobacco. Snus use and tobacco chewing 
were strictly male behaviors, and spittoons were found in banks, on railway trains, and in hotels. 
However, with the rapid increase in smoking, snus use came to be seen as a behavior of rural and 
older men.  
In Sweden, snus consumers are now mainly under the age of 50, which reflects heavy marketing efforts 
by the commercial industry since the 1970s, when snus use was becoming unfashionable.23 Patterns of 
snus use between regions of Sweden, however, may differ. The proportion of snus users is greater in 
the northern parts of Sweden, particularly among women. Cultural barriers against snus use by women 
have been lowered, but the percentage of women who are daily users is still low—less than 5%.13 
Among Swedish 6th graders, 2.7% of boys and 1.8% of girls use snus in addition to the 15% of boys 
and 5.2% of girls who use both cigarettes and snus.24  
Swedish snus is sold either packed loose or portion-packed in small teabag-like sachets. Both varieties 
are sold in tins or round paper or plastic boxes. Loose snus is a moist powder which can be formed into a 
cylindrical or spherical shape with the fingertips. The end result is referred to as a pris (pinch) or prilla. 
Longtime users may simply pinch the tobacco in place under the upper lip where it is kept in the recess 
between gingiva and lip. Prepacked portion snus, the better selling variety, usually contains smaller 
doses that can be used more discreetly. Swedish snus, in both loose and sachet forms, is placed under the 
upper lip for a period of 30 minutes to a couple of hours. The nicotine in snus is absorbed through the 
mucous membrane of the oral cavity, as are other substances. The juice produced in this process is 
usually swallowed and spitting is uncommon. Prepacked portion snus comes in two variants. The 
original portion, introduced in 1977, is packed in a moisturized brown material when manufactured; the 
white portion is packed in white sachet material and not moisturized. Prepacked portion snus is available 
in three different sizes: mini, normal/large, and maxi. Total portion weight in boxes or tins may vary, but 
mini portions weigh 0.5 g, normal/large portions weigh 1 g, and maxi portions weigh 1.7 g. Swedish 
snus is sold in general stores, convenience stores, gas stations, tobacco shops, and from vending 
machines in shops and restaurants. It is often stored in refrigerators to minimize fermentation and 
bacterial growth.  
The price of snus compared to cigarettes varies according to country. A box of the General brand 
of Swedish snus costs between US$5.50 and $7.20 (37 to 49 Swedish kronor), and a pack of 
Marlboro cigarettes costs US$7.20 (49 Swedish kronor).25 In Norway these two products cost 
 




between US$8.50 and $13.50 for General snus (51 to 81 Norwegian kronor) and roughly US$14.00 
(84 Norwegian kronor) for Marlboro cigarettes.26 
In 2012, it was estimated that over 200 different varieties of snus were offered on the Swedish market.27 
The products differ in packaging, alkalinity, other additives, and flavoring. Flavoring of snus is 
abundant. The largest manufacturer, Swedish Match, lists over 240 ingredients that are used as flavors in 
snus, including herbal extracts (e.g., menthol), spices/flavorings (ginger, basil, and lime oil/extract), and 
alcohol (whiskey).28 General is the best-selling brand of snus in Sweden. 
Snus manufactured in Sweden is sold in Nordic countries as well as in other countries around the world. 
There are about a dozen manufacturers of snus, and Swedish Match is the dominant producer, with 
about 85% of the market in Sweden and 70% of the market in Norway.29 Smaller domestic companies 
market products mostly within the Nordic region. The Nordic market has been fairly stable since the 
year 2000. In European Region countries other than the Nordic countries, international tobacco 
companies such as British American Tobacco, Japan Tobacco International, Philip Morris, and Imperial 
Tobacco market snus products that are not considered Swedish snus and do not meet the manufacturing 
standards set for Swedish snus. 
Uzbekistan and Kyrgyzstan  
In both Uzbekistan and Kyrgyzstan, the most commonly used form of ST is known as nasway or nasvay. 
As central Asian countries, they are geographically close to Pakistan and Afghanistan (in the WHO 
Eastern Mediterranean Region) where this product is referred to as nass, naswar, or niswar.20,30 Nasway 
contains the same main ingredients as nass, but the published information is insufficient to determine if 
nass and nasway are exactly the same product. 
In Uzbekistan and Kyrgyzstan, nasway is mostly produced as a custom-made or cottage industry 
product. Nasway is partially manufactured before it is sold to consumers. The core ingredients are 
locally grown, sun-dried tobacco and an alkalinity modifier such as ash or slaked lime (calcium 
hydroxide).20,30 Other flavorings and spices such as cardamom or menthol may be added according to 
preference. The product also contains an emulsifying agent such as butter or oil. Water is added during 
mixing of the ingredients, and the mixture is then rolled into balls. A ball is placed under the tongue on 
the floor of the mouth and sucked. Nasway is sold in 15- to 20-gram packs at US$0.21 in Uzbekistan, 
where it is cheaper than locally produced cigarettes (US$0.35 per pack).17  
Toxicity and Nicotine Profiles of Products 
United Kingdom 
Some of the South Asian ST products used in the UK contain Nicotiana rustica, a tobacco with high 
alkalinity and a higher concentration of nicotine than the more commonly used tobacco, N. tabacum. 
In India, most ST products are made of N. rustica, while smoking tobacco tends to be made of 
N. tabacum. (For more information on the toxicity and nicotine profiles of ST products used in England, 
see chapter 3.) 






One study investigating the toxicity of some of the products available in the UK assessed data on 
nicotine content and tobacco-specific nitrosamine levels, and found that all the tested products were 
likely to be hazardous to users’ health, with all but 1 of 11 tested brands containing tobacco-specific 
nitrosamines (TSNAs) at varying levels. Nicotine ranged from 3 milligrams per gram (mg/g) to 
83.5 mg/g in these tobacco products, with gutka at the low end of the range and tobacco leaf at the 
highest. Free nicotine was also high in several of the gutka products as well as in tooth-cleaning powder 
and Swedish snus (between 3 mg/g and 63.2 mg/g in these products). Gutka and tooth-cleaning powder 
also had the highest pH levels of the products tested.31 
An additional UK data source is the Niche Tobacco Products Directory (NTPD).32 This website informs 
the activities of local authorities and excise enforcement officers with respect to ST regulation and 
seizure. The directory focuses primarily on the tobacco content of a product; it does not report additional 
toxicity information. The NTPD data suggest that tobacco content varies considerably, particularly in 
Bangladeshi products; the tobacco content of one popular zarda brand was observed as varying between 
5% and 20%. An assay of the contents of paan/khilli paan sold in London found that the mean tobacco 
weight was 0.65 g (95% CI: 0.56–0.76) and the mean weight of slaked lime (calcium hydroxide) was 
0.58 g (95% CI: 0.41–0.75).21 Although zarda alone has a relatively low pH, the mixture of slaked lime 
and zarda used in paan/khilli paan varied between pH 12.2 and pH 12.5, indicating that 99% of the 
nicotine was available as free nicotine.21  
Nordic Countries 
Swedish snus products vary in their levels of nicotine content and free nicotine. For example, so-called 
“starter” brands such as Catch Mint often have a lower pH and less free nicotine, and stronger varieties 
such as General, the market’s leading brand, have a higher alkalinity. 
All manufacturers of Swedish snus pasteurize their products, and most adhere to the GothiaTek standard 
(Table 10-5).33 As a consequence, snus products manufactured in Sweden using this standard have lower 
levels of toxicants than most products found in other countries. This voluntary standard34 comprises the 
following requirements with respect to: 
 Manufacturing  
 Adherence to the International Organization for Standardization’s quality standard 
ISO 9001:2000 and environmental standard 1401:1996.  
 Raw materials 
 Selected leaf tobacco is used; additives should comply with requirements specified in the 
Swedish Food Act.  
 Process  
 Snus pasteurization involves heat treating to kill the natural microbial flora. The 
manufacturing process must be performed in a closed system, and the tobacco must be 
comminuted (i.e., made into a powder) in a controlled process. Directly after packaging, the 
finished product is placed into cold storage with a maximum temperature of 8ºC. 
 




 Manufacturing hygiene 
 All product exposure must satisfy the hygiene requirements of food manufacturing.  
 The processing equipment is cleaned and disinfected at least once in every production cycle, 
and packaging machinery is cleaned and disinfected at least once every 24 hours. Water 
activity, bacterial content, and shelf-life stability are tested on finished products. The 
packaging material must also satisfy hygiene standards.  
 The results of all controls must meet the tolerance limits specified for Swedish snus by 
GothiaTek.  
Table 10-5. The GothiaTek standard limits and average content for important toxic constituents in 
tobacco, 2011 
Component Limit 




Content* (2011)  
(±2 SD) 
Nitrite (mg/kg) 3.5 1.0 (<0.5–1.9) Cadmium  0.5 0.2 (0.1–1.4) 
TSNA (mg/kg) 5 0.7 (0.5–1.1) Lead 1.0 0.1 (0.05–0.2) 
NDMA (µg/kg) 5 0.4 (<0.3–1.1) Arsenic 0.25 <0.05 (<0.05–0.09) 
BaP (µg/kg) 10 0.5 (<0.5–0.8) Nickel 2.25 0.7 (0.3–1.0) 






Match internal  
limits 
Chromium 1.5 0.3 (0.1– 0.6) 
*Limits and average contents are based on Swedish snus with 50% water content.  
Abbreviations: TSNA = tobacco-specific nitrosamines; NDMA = N-nitrosodimethylamine; BaP = benzo(a)pyrene; SD = standard 
deviation; mg/kg = milligram per kilogram; µg/kg = microgram per kilogram. 
Source: Swedish Match 2012 (34). 
Uzbekistan and Kyrgyzstan  
The predominant product in these countries, nasway, is made from N. rustica, which has a higher 
concentration of nicotine than common tobacco. Nasway samples have high pH levels and contain 
more than 70% free nicotine, indicating their high potential for causing dependency.35  
Health Problems Associated With Use 
The carcinogenicity of ST has been evaluated by the IARC,20 which concluded that ST is carcinogenic. 
This section discusses data on cancer, addiction, and other health problems associated with ST use 
specific to the UK, the Nordic countries, Uzbekistan, and Kyrgyzstan. 
United Kingdom 
Data on cancer incidence rates suggest that cancer of the oral cavity (excluding the inner part of 
the lip and the hard palate) is one of the most common subtypes of head and neck cancer.36 Among 
the more than 6,400 people diagnosed with head and neck cancers in 2007 in the UK, more than 






2,000 (approximately 1,200 men and 800 women) had oral cavity cancer. Rates of oral cavity cancer in 
the UK increased between 1990 and 2007 by nearly 30%.36 In addition to smoking and drinking alcohol, 
chewing paan/khilli paan by ethnic South Asians is suggested as the main risk factor. London, which has 
many South Asian communities, has the highest incidence rate for oral cancer, with a higher incidence 
of oral and pharyngeal cancer among women of South Asian origin. Other data indicate that women of 
South Asian origin were more than three times more likely to have oral cancer than non–South Asian 
women (incident rate ratio = 3.7, 95% CI: 3.0–4.5), after controlling for levels of social deprivation.37 
A second major health consequence in the UK is the creation of nicotine dependence, specifically 
among people who chew paan/khilli paan with tobacco. Studies validating self-report measures of 
dependency with salivary cotinine scores found associations with a high daily consumption frequency, 
having the first paan within 1 hour of waking, and feelings of craving.11 Of particular concern in relation 
to high dependency is the dual use of tobacco leaf and zarda together in paan/khilli paan.  
Nordic Countries 
Because the GothiaTek standard of snus manufacturing and storage was adopted in the late 1990s, the 
health effects of long-term exposure to modern Swedish snus manufactured under this standard are 
largely unknown as of this writing (2014).  
Habitually placing snus in the same place in the mouth often leads to irritation of the gum (“the snus 
lesion”).38 A comprehensive meta-analysis of the health effects of ST found mixed, inconclusive 
evidence for the role of snus in periodontal conditions including gingival diseases.38 This work (and the 
earlier reviews underpinning it) was supported by Philip Morris Products, Swedish Match, and the 
European Smokeless Tobacco Council (comprised of tobacco manufacturers and distributors and 
representing tobacco industry interests). 
In 2008 the EU Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) 
published its opinion “Health Effects of Smokeless Tobacco Products,” with particular emphasis on 
snus, noting that these products are addictive and hazardous to health.30 Results of epidemiologic 
studies on snus use and cancer are not fully consistent. A 2008 review39 of the existing evidence 
concluded that snus is carcinogenic. In Northern European studies, the relative risk of snus use for 
esophageal cancer was found to be 1.6 (95% CI: 1.1–2.3) and for pancreatic cancer, 1.6 (95%  
CI: 1.1–2.2). A meta-analysis funded by the European Smokeless Tobacco Council found that when 
adjusting for smoking, smokeless tobacco products in general had a significant association of 1.4 for 
oropharyngeal cancer (95% CI: 1.0–1.8) and 1.3 for prostate cancer (95% CI: 1.1–1.6).40 When only 
looking at reports published since 1990, the Council found that the association with oropharyngeal 
cancer was not significant. 
Epidemiologic studies and experimental animal studies show that snus affects the cardiovascular 
system—for example, blood pressure and pulse rate. The evidence regarding an association between 
long-term use of snus and hypertension is not consistent. Snus use does not appear to increase the risk of 
myocardial infarction (heart attack),41,42 but it is associated with an increased risk of mortality from heart 
disease, including myocardial infarction.41,43 Similarly, long-term snus users seem to be at increased risk 
for fatal stroke (relative risk: 1.4, 95% CI: 1.3–1.5).41,44  
 




The available evidence is too limited to allow firm conclusions about snus use in relation to diabetes. 
The evidence regarding snus use during pregnancy is also limited. Results of one Swedish study showed 
an increased risk of pre-term delivery and pre-eclampsia for mothers who used snus during pregnancy.45 
Uzbekistan and Kyrgyzstan  
In addition to the potential for dependency, the literature identifies use of nasway in these countries 
as a risk factor for esophageal squamous cell carcinoma and oral precancerous lesions such as oral 
leukoplakia (precancerous lesions).46 Lifetime Uzbek nasway users were more than five times as likely 
(OR = 5.2, 95% CI: 3.1–8.6) to develop oral leukoplakia as never users.46 
Marketing and Production Practices of Industry  
United Kingdom 
Marketing of ST in the UK is informal, relying on point-of-sale displays, packaging styles, and 
affordability. Since most of the ST products in the UK are imported from India, they are marketed 
and sold to differing ethnic subgroups in the region.  
Product brands and their associated packaging and displays follow recognizable themes: 
 Respect. “Baba,” the name of a zarda brand from India, is an honorific denoting respect; it means 
sir, father, grandfather, wise old man. References to age and wisdom may also be made through 
illustrations on packaging. 
 Health, medicinal plants. “Tulsi,” a gutka brand from India, is the name of the herb basil, which 
contains eugenol, a substance with analgesic and antiseptic properties. Basil is widely known 
across South Asia as a medicinal plant and is commonly used in Ayurvedic medicine to treat a 
range of conditions, including bronchitis, asthma, malaria, and arthritis. 
 Prosperity. “Kuber,” a khaini brand from India, is the name of the lord of wealth in Hindu 
tradition; he is also recognized within Buddhism and Jainism. Kuber is usually depicted as a fat, 
bejeweled man carrying a money bag.  
Nordic Countries 
As previously mentioned, all manufacturers of Swedish snus must adhere to the GothiaTek quality 
standard that was voluntarily adopted by the industry in the late 1990s.33 Initial efforts to improve 
production standards began in the late 1960s when concerns were raised about the formation of 
ammonia and nitrate in snus, as well as other quality problems. In 1971, snus came under jurisdiction 
of the Swedish Food Act, requiring manufacturers to implement new quality control measures, which 
continued to be developed over several decades.33  
The EU prohibits the sale of oral tobacco products—that is, moist snuff or snus—in EU countries such 
as Denmark and Finland, but allows these products to be sold in Sweden. Swedish snus is rarely used 
in Denmark, but it is acquired illicitly in Finland, particularly by that country’s Swedish-speaking 
minority. The prohibition of snus sales within the EU has repeatedly been challenged by Swedish Match 
and by the Swedish Ministries of Trade and of Health and Social Affairs. Swedish Match dominates 






the production in this region, and its market has not changed much in the last decade. Internet 
purchases are still possible, but most Internet-based vendors are located in Sweden and they market 
to other EU citizens.47  
Point-of-sale advertising is largely unrestricted in Sweden but banned in Norway, where all tobacco 
products are stored behind closed shutters marked “Tobakk” (grey cabinet) or “Snus” (white cabinet). 
Media advertising of all tobacco products (on TV, radio, print media, and outdoor billboards) is banned 
or restricted in Sweden, Norway, and Iceland. Norway’s comprehensive ban on tobacco advertising also 
bans indirect advertising, such as advertisements for non-tobacco products that depict tobacco or 
advertising using colors and designs that resemble tobacco brands.  
Uzbekistan and Kyrgyzstan 
Nasway is produced by cottage industries, or in some cases, is custom-made. Nasway originating 
from Pakistan is available for wholesale purchase on the Internet. No marketing data are available 
for Kyrgyzstan. 
Current Policy and Interventions 
The European Union 
The health risks of tobacco use are well recognized within the EU, where initial tobacco control 
measures were introduced in 1987.48 The EU is the only regional political and economic entity that 
has become a full signatory to the WHO Framework Convention for Tobacco Control (FCTC). At the 
beginning of the FCTC negotiations, the EU had already implemented a public information campaign 
and banned TV advertising of tobacco products and sponsorship by tobacco companies.49 The EU 
tobacco product labeling requirements predate FCTC Article 11. Since the introduction of the FCTC, 
the EU has chaired the Intergovernmental Negotiating Body on Illicit Trade (FCTC Article 15). 
EU tobacco control activity is cross-cutting, also affecting taxation, illicit trade, and agricultural 
policies. As of 2013, two Nordic countries, Norway and Iceland, are not EU members but follow most 
of the EU tobacco regulatory framework. 
The EU Tobacco Products Directive (EU Directive 2001/37/EC) was issued in 2001 and intended 
to be a model on which individual states could pattern their own tobacco regulations.3 The Directive 
establishes warnings on packs, product traceability, annual reporting of ingredients, and maximum 
yields of tar, nicotine, and carbon monoxide in cigarettes, and prohibits use of the terms “mild” and 
“light.” According to the Directive, text warnings are mandatory but pictorial warnings are optional 
(Table 10-6). Seven EU member states and three non–EU European states have adopted pictorial 
warnings for cigarettes.  
 




In December 2012, the EU adopted a proposal to revise the Tobacco Products Directive that would 
further restrict the manufacture, sale, and presentation of tobacco products. The proposal maintains a 
ban on oral tobacco products, except in Sweden, and proposes major revisions such as a ban on 
characterizing flavors, prior notification for retailers intending to sell products across borders (such as 
Internet retailers) and for manufacturers intending to sell novel tobacco products, and mandatory 
pictorial health warnings for cigarettes but not ST products. The proposal is expected to be adopted by 
the EU in 2014 and go into effect in 2015–2016. 
Table 10-6. EU Tobacco Products Directive: Regulations for cigarettes and smokeless tobacco in the 
2001 Directive (2001/37/EC) and the December 2012 proposal 
Legal control Year Cigarettes Smokeless tobacco 
Ingredients 2001 List of ingredients and their quantities, 
purpose, and health effects must be 
disclosed and made public 
List of ingredients and their quantities, 
purpose, and health effects must be 
disclosed and made public 
 2012 Proposal Ban on characterizing flavors Ban on characterizing flavors 
Maximum yields 
information 
2001 Maximum yields of tar, carbon 
monoxide, and nicotine covering at 
least 10% of the package 
No maximum yields required 
 2012 Proposal Maximum yields are maintained, but 
labeling of this information is considered 
misleading and will be changed 
No maximum yields required 
Traceability 2001 Code identifying place, time, and date 
of manufacture 
Code identifying place, time, and 
date of manufacture 
 2012 Proposal Fully implement tracking system with 
security features to easily identify 
authentic tobacco products and hinder 
illicit trade 
Same as cigarettes, except ST 
products are granted a 5-year 
transitional period 
Health warnings 2001 Two warnings: Front: One of two general 
warnings covering at least 30% of 
surface; Back: One of 14 rotating 
warnings covering at least 40% of 
surface 
One warning: “This product can 
damage your health and is 
addictive.” Warning covers at least 
30% of surface 
 2012 Proposal Combined pictorial and text warning 
must cover 75% of front and back of the 
package 
Health warning must be placed on 
both sides package, but size remains 
the same 
Pictorial warnings 2001 Optional* Optional  
 2012 Proposal Required Optional 
*As of 2011, pictorial warnings for cigarettes have been adopted voluntarily by seven EU members.  
Sources: For information on the 2001 Directive: The European Parliament and the Council of the European Union 2001 (3). For 
information on the 2012 proposal: European Commission 2012 (72).  
  






With respect to ST products, the Directive distinguishes between: 
 Tobacco products: “products for the purposes of smoking, sniffing, sucking or chewing 
inasmuch as they are, even partly, made of tobacco,” and 
 Tobacco for oral use: “all products for oral use, except those intended to be smoked or 
chewed, made wholly or partly of tobacco, in powder or particulate form … particularly those 
presented in sachet portions … or in a form resembling a food product.”3 
Tobacco products “for oral use,” namely snus and moist snuff, are prohibited within the EU at this 
writing (2013). The UK had previously banned these products following an attempt in the mid-1980s to 
introduce a new ST product (Skoal Bandits) that targeted adolescents in the UK.50 Sweden was allowed 
to retain its use of snus, an oral moist snuff, at its accession to the EU.  
The Directive’s regulations differ for smoked tobacco and ST (see Table 10-6), most obviously with 
respect to requiring that packaging display health warnings. There have been no EU–wide proposals for 
pictorial warnings on ST products specifically, although some member states have proposed adopting 
pictorial warnings and increasing the size of warnings for cigarettes. 
Reports and consultations from the UK have contributed to regional debates about the possible role 
of ST in helping smokers quit, and about appropriate public health responses to diversification of 
the ST market.51,52 These efforts have collectively highlighted the need to develop a consistent and 
inclusive regulatory approach sufficient for all nicotine-containing products, whether medicinal, 
smoked, or smokeless.  
United Kingdom 
An example of a campaign to prevent the adverse health effects of ST use, an oral cancer prevention 
program, Open Up to Mouth Cancer, developed by Cancer Research UK, was introduced in a 
Bangladeshi community in the UK.53 More than 1,300 participants were recruited, of whom 75 were 
urgently referred for further investigation. Participants with low education levels or who chewed paan 
with tobacco were more likely to be referred for further investigation. Four in 10 tobacco users attending 
one phase of the screening were recruited into a flexible community outreach service offering cessation 
support.53 An evaluation of the campaign materials developed for this community demonstrated that 
accessing these materials improved participants’ knowledge of oral cancer prevention and of the adverse 
effects of using smokeless tobacco.54 
Regarding ST cessation interventions, the English National Health Service developed guidance for the 
Stop Smoking Service55,56 that reflects advances in the evidence base. These guidelines advise that 
cessation services for ST users should be discretionary, and limited evidence suggests that behavioral 
support may be effective for some individuals.  
Two studies have been published on cessation support for UK resident Bangladeshi ST users.22,57 The 
first study compared a single session of brief advice and encouragement with weekly behavioral advice 
and access to nicotine replacement therapy (NRT) patches. The researchers found that the intervention 
providing advice and access to NRT was associated with more successful, although not statistically 
 




significant, cessation with respect to cotinine-validated abstinence at 4 weeks. The second report, a 
prospective cohort study of a flexible community outreach service, found that NRT use, community 
recruitment, and living in a relatively less deprived area predicted short-term self-reported quit success. 
Wider dissemination of this service delivery model has continued to demonstrate similar outcomes and 
high levels of client satisfaction.58 
The tobacco control plan for the UK as of 2011 is built around the WHO MPOWER principles and 
includes proposals for (1) harmonizing the regulation of smoked and ST products within the context of 
the EU Tobacco Products Directive, (2) implementing the Health Act (2009), and (3) calling upon the 
National Institute for Health and Clinical Excellence (NICE) to provide public health guidance to help 
people of South Asian origin stop using smokeless tobacco.59 Although the UK was the third country in 
the EU to introduce pictorial warnings on cigarettes specifically, it was the first nation to introduce them 
on all tobacco product packaging.60 The 2009 Health Act prohibits displays of tobacco products, 
whether smoked or smokeless, at point of sale, and is the first UK legislation to include both tobacco 
types. However, the timetable for implementing the Act has been relaxed, and small retail outlets, such 
as those selling ST products, will not be required to comply until 2015. The NICE Public Health 
guidance, published in 2012, proposes a systematic engagement with South Asian communities in the 
planning and implementation of smokeless tobacco cessation services.61 While endorsing the current 
advice to adopt behavioral support for cessation attempts, the report notes that nicotine replacement 
therapy should be used for clients with demonstrable clinical need. The UK’s tobacco control plan 
commits to further developing the Web-based Niche Tobacco Products Directory. 
In addition, local initiatives have also been attempted, such as classifying spitting paan/khilli paan juice 
as criminal damage liable to a fixed-penalty enforcement.62  
Nordic Countries 
Prominent among the nongovernmental organizations in Sweden that have successfully advocated for 
tobacco control is Health Professionals Against Tobacco. This alliance of doctors, dentists, nurses, 
teachers, and psychologists has worked since 1992 to promote a tobacco-free Sweden through 
monitoring the political process, increasing awareness and availability of information material, and 
engaging in international cooperation.63 
Although switching from cigarette smoking to snus use is sometimes presented as a preventive measure, 
the public health community has not supported it. No community programs have advised this switch, 
but an estimated 20% of general medical practitioners may advise individual patients to switch from 
smoking to snus.64 However, rates of cessation and attempts to quit are lower among snus users than 
cigarette users.65,66 Although limited research is available for snus-specific interventions, varenicline 
has been demonstrated to significantly aid snus cessation.67 






Uzbekistan and Kyrgyzstan 
Kyrgyzstan is an FCTC signatory; Uzbekistan is not. The two countries vary in their commitments to 
population protection, cessation promotion, provision of health warnings, and enforcement of bans on 
tobacco advertising. Kyrgyzstan has adopted specific national objectives for tobacco control and a 
tobacco control budget that funds a national unit for tobacco control, but Uzbekistan has undertaken 
neither of these initiatives. 
In Uzbekistan, health warnings are required on cigarette packaging only. Tobacco advertising in the 
national media and outdoors is banned. Kyrgyzstan is reported to require health warnings on ST 
products. Legal mandates also control the percentage of the package these warnings will cover and 
specify the number and wording of health warnings as well as the fines for violations. Kyrgyzstan has a 
wider range of bans on tobacco advertising, promotion, and sponsorship than Uzbekistan. 
Summary and Conclusions 
Given that the European Region contains two populations with longstanding traditions of ST  
use—the Scandinavian countries of Sweden and Norway, and the large South Asian community 
that has immigrated to Europe, particularly the UK—the trajectory of ST use in this region is of 
vital importance.  
European regional data on tobacco use are primarily focused on cigarette smoking, therefore additional 
information is needed on smokeless tobacco. The dataset cited in this chapter provides adult ST 
prevalence data for fewer than one-third of the European Region’s countries. In addition to the paucity 
of data about adult prevalence, little information is available on youth ST use. From the available 
evidence, ST prevalence among adults varies from 0.1% in Switzerland to 17.0% in Sweden.  
Swedish snus has been historically used in the Nordic countries, and additional products are imported 
from South Asia and used by communities of South Asian origin in the UK. In the European region, 
nasway (nasvay) is used primarily in Uzbekistan and Kyrgyzstan. In Denmark, Germany, and the UK, 
national companies produce twisted tobacco for oral use.  
Swedish snus and South Asian ST products have demonstrably different health risk profiles, although 
the adverse health effects of snus products specifically manufactured according to the GothiaTek 
standard are largely unknown. With respect to preventing ST use, screening and diagnosing health 
consequences, and assisting chewers to quit, there is little coherent activity throughout the region. 
Prevention and cessation efforts have remained focused predominantly on smoking. The mandated 
requirement in Kyrgyzstan for health warnings on nasway is an example from outside the EU of tobacco 
control regulation that may have a wider geographical applicability.  
This chapter has highlighted the role of the EU as a key player in leading tobacco control efforts within 
the European Region. Although the sale of moist snuff or snus is restricted in EU countries such as 
Denmark and Finland, it is allowed in Sweden. The prohibition of snus sales within the EU has been 
challenged by Swedish Match and by the Swedish Ministry of Trade and Ministry of Health and Social 
Affairs on numerous occasions. Identified gaps in surveillance activity have had a negative impact on 
 




the development of coherent, inclusive, evidence-based tobacco control regulation within the EU. 
Characterizing some of these products as “niche” or marginal may preclude development of the desired 
evidence base.  
In addition to European Union efforts, local initiatives can make important contributions to global 
tobacco control and prevention. For example, bilateral agreements could ensure that exported ST 
products comply with regulations of the importing countries. Three of the seven leading ST brands sold 
in the UK are manufactured and distributed by two Indian conglomerates. Implementation of bilateral 
arrangements might also benefit consumers in these conglomerates’ domestic markets. The number of 
gutka brands available for purchase in the UK declined following a 2011 Indian Supreme Court order 
banning the use of plastic as a gutka packaging material,68 thus restricting its export. In Sweden, there 
are no fines for throwing away cigarette butts and snus sachets on the streets, and these discarded items 
make up most of the litter on the streets; the environmental impact of this litter awaits appropriate 
investigation. In the UK, the 2009 Health Act demonstrates how ST products can be included in 
legislation along with smoked tobacco products simply by using the more general term “tobacco” to 
define these products. Lastly, in the UK the Niche Tobacco Products Directory illustrates the potential 
of a publicly available Web-based resource to strengthen the ST policy agenda.  
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Description of the Region 
According to the World Health Organization (WHO), the Eastern Mediterranean Region consists of 
23 countries, extending from Morocco to Pakistan. It includes most countries of the Middle East, North 
Africa (except Algeria), and South-West Asia (Table 11-1). The Eastern Mediterranean Region covers 
an area of 13,962,083 square kilometers, and its population is estimated at 608 million people, or about 
8% of the total world population.1 Tobacco use is prevalent in this region, the predominant form being 
manufactured cigarettes, followed by tobacco used in waterpipes (shisha, nargila).  
Table 11-1. Population and land area of countries in the Eastern Mediterranean Region 
Country* Area in km
2
 Population (thousands) 
Afghanistan 654,412 31,412 
Bahrain 694 1,262 
Djibouti 23,395 889 
Egypt 1,001,494 81,121 
Gaza Strip (Palestine)† 360 1,710 
Iran (Islamic Republic of) 1,643,867 73,974 
Iraq 439,889 31,672 
Jordan 89,667 6,187 
Kuwait 17,773 2,737 
Lebanon 10,414 4,228 
Libya 1,588,750 6,355 
Morocco 443,764 31,951 
Oman 309,111 2,782 
Pakistan 796,298 173,593 
Qatar 10,994 1,759 
Saudi Arabia 2,111,385 27,448 
Somalia 622,067 9,331 
South Sudan† 644,329 10,625  
Sudan 2,561,882 43,552 
Syrian Arab Republic 185,555 20,411 
Tunisia 163,765 10,481 
United Arab Emirates 83,467 7,512 
West Bank (Palestine)† 5,860 2,623 
Yemen 552,891 24,053 
Total  13,962,083 607,668 
*Unless otherwise indicated, data are from: United Nations 2011 (1).  
†For data on the Gaza Strip, the West Bank, and South Sudan: Central Intelligence Agency 2012 (57). 
Abbreviation: km = kilometer. 
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Prevalence of Smokeless Tobacco Use 
In a few countries of the Eastern Mediterranean Region, such as Sudan, Yemen, and Pakistan, locally 
made or produced smokeless tobacco (ST) products are widely consumed. In other countries such as 
Egypt, the most populous Arab country, ST use has markedly increased among adults, according to the 
Global Adult Tobacco Survey (GATS).2,3 This section focuses on the prevalence of ST use among adults 
in countries for which some data are available. Table 11-2 shows the types of ST products used in 
Eastern Mediterranean Region countries.  
Table 11-2. Types of smokeless tobacco products used in the Eastern Mediterranean Region, by country 
Country Smokeless tobacco product used Source* 
Bahrain Chewable-based tobacco products 
(undefined) 
Time Out Bahrain 2009 (55) 
Egypt Undefined World Health Organization (WHO) 2010 (2) 
Iran Nass Islami 2009 (51); Joint Iran–International Agency for 
Research on Cancer Study Group 1977 (52) 
Libya Chewing tobacco (undefined) International Agency for Research on Cancer 
(IARC) 2007 (32); WHO 2011 (11) 
Pakistan Paan and naswar Ali 2009 (7); Imam 2007 (9); Khawaja 2006 (8); 
Merchant 2000 (12); Maher 1994 (13); Shah 1992 
(14); Euromonitor 2010 (6) 
Qatar Chewing tobacco (undefined) Al-Kuwari 2008 (58) 
Saudi Arabia Mainly shammah Allard 1999 (17); Ibrahim 1986 (18); Salem 1984 (19) 
Sudan Toombak Costea 2010 (39); Ibrahim 1996 (41), 1998 (42); 
Ahmed 2003 (36), 2007 (37); Ibrahim 2002 (43); Idris 
1991 (44), 1992 (45), 1994 (46), 1995 (47), 1995 (48), 
1996 (49), 1998 (4), 1998 (50); Elbeshir 1989 (40); 
Boulos 1977 (38) 
Tunisia Snuff WHO 2011 (11); Fakhfakh 2005 (59) 
United Arab Emirates Paan and niswar The National 2009 (15); Bowman 2008 (16) 
Yemen Shammah Ministry of Public Health (Yemen) 2003 (5) 
*Numbers in parentheses correspond to full citations in the References at the end of this chapter. 
Few studies and reports have been published on ST use in the Eastern Mediterranean Region. Table 11-3 
illustrates the prevalence of ST use among adolescents aged 13 to 15 years, and Table 11-4 and 
Map 11-1 show the prevalence among adults, according to national surveys. Data was collected from 
multiple surveys including the Global Youth Tobacco Survey (GYTS), Global Adult Tobacco Survey 
(GATS), WHO STEPwise Approach to Surveillance (WHO STEPS), and various individual country 
surveys as reported in the WHO Report on the Global Tobacco Epidemic, 2011 (GTCR). Some clinical 
researchers have reported the use of ST in specific countries without stating the prevalence of use in 
those countries. Comparisons among surveys should be made with caution because of differences in 
definitions and methods, including sampling methods, used across surveys. Surveys’ definitions of 






current use vary. For example, some surveys define current use as any use within the past 30 days, while 
other surveys ask about different time periods; some surveys ask about daily use and use on some days, 
and still other surveys ask about “current” use without defining the term further. Surveys of this region 
define current use by youth as at least one use in the past 30 days; current use among adults is defined as 
daily or less than daily use.  
Table 11-3. Percentage of adolescents aged 13–15 years who currently used smokeless tobacco in the 
Eastern Mediterranean Region, from the Global Youth Tobacco Surveys, 2007–2010 
Country Year Total (%) Boys (%) Girls (%) 
Djibouti 2009 12.6 15.2 9.0 
Gaza Strip (Palestine)* 2008 8.9 9.2 8.3 
Iraq – Baghdad 2008 6.9 7.2 5.8 
Iran 2007 5.1 5.4 4.8 
Libya 2010 2.3 2.0 2.3 
Lebanon* 2008 6.5 6.5 6.4 
Oman 2010 1.6 2.5 0.9 
Pakistan – Karachi 2008 10.8 13.8 7.4 
Pakistan – Quetta 2008 7.5 6.8 7.9 
Pakistan – Lahore 2008 4.2 5.8 3.1 
Pakistan – Peshawar 2008 6.0 8.0 2.6 
Qatar 2007 7.0 7.6 6.1 
Saudi Arabia 2010 3.4 4.8 1.8 
Syrian Arab Republic 2010 5.7 7.9 3.5 
Tunisia 2010 2.3 3.9 0.9 
West Bank (Palestine) 2008 9.1 7.7 9.2 
Yemen 2008 8.6 8.2 8.4 
*These surveys were conducted in schools run by UNRWA (the U.N. Relief and Works Agency for Palestine Refugees in the 
Near East). 
Source: Global Youth Tobacco Surveys, 2007–2010 (60). 
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(years) Total (%) Men (%) Women (%) 
Egypt* 2009 15+ 2.2 4.1 0.3 
Libya† 2009 25–64 1.2 2.2 0.1 
Saudi Arabia† 2004 15–64 — 1.3 0.5 
Tunisia‡ 2005–06 35–70 5.4 8.6 2.2 
Yemen‡ 2003 15+ 10.7 15.1 6.2 
*Global Adult Tobacco Surveys, 2008–2010 (3). 
†WHO STEPS from: WHO Report on the Global Tobacco Epidemic, 2011 (11). 
‡Individual country surveys from: WHO Report on the Global Tobacco Epidemic, 2011 (11). 
Map 11-1. Prevalence of smokeless tobacco use among adults in the World Health Organization’s 
Eastern Mediterranean Region 
 
Note: Prevalence rate for males and females combined was not available for Saudi Arabia. A total figure was calculated by 
averaging the available male and female rate. 
Sources: Global Adult Tobacco Surveys, 2008–2010 (3); WHO STEPS from: WHO Report on the Global Tobacco Epidemic, 2011 (11); 
Individual country surveys from: WHO Report on the Global Tobacco Epidemic, 2011 (11).  







Toombak is the type of ST most commonly used in Sudan, where historical prevalence of use was 
reported at 34.0% among men and 2.5% among women in the Nile states.4 According to 2011 
unpublished estimates presented by the Sudan Toombak and Smoking Research Center, the prevalence 
of toombak use is 24.2% in the Nile states, 40.7% in the Northern states, 36.5% in the Eastern states, 
and 21.2% in the capital, Khartoum. In western Sudan, the prevalence of use is exceedingly low, which 
reflects cultural and tribal influences on the use of tobacco.  
Yemen 
Despite the wide use of ST, known as shammah, in Yemen, up-to-date data are limited. The most 
comprehensive study is the 2003 Family Health Survey, which used weighted sampling units or cluster 
methodology to produce estimates of general indicators for Yemen as a whole and for urban and rural 
areas.5 The total sample size was 13,815 households (3,173 in urban areas, and 10,642 in rural areas). 
According to this survey, 10.7% of the population aged 10 years or older used shammah; in rural areas, 
this percentage was 12.5%. In addition, 6.2% of females were current users of shammah (Table 11-5), 
while current use among men was reported as 15.1%. The percentage of current users increased with age 
for both males and females (Figure 11-1). 
Table 11-5. Prevalence of shammah use in Yemen, by residence and sex  
Shammah* Urban Rural Male Female Total† 
Current users 5.2% 12.5% 15.1% 6.2% 10.7% 
Previous users 0.5% 0.8% 1.0% 0.5% 0.8% 
Never used 93.7% 86.1% 83.3% 92.7% 88.0% 
Don’t know/not stated 0.6% 0.6% 0.6% 0.5% 0.6% 
Total respondents 15,030 46,568 31,094 30,504 61,598 
* Prevalence is indicated in this table by number and percentage of individual users; the text describes the prevalence by 
household. 
†Because of rounding, percentages total 100.1%.  
Source: Ministry of Public Health (Yemen) 2003 (5). 
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Figure 11-1. Prevalence of shammah use in Yemen, by age and sex  
 
Source: Ministry of Public Health (Yemen) 2003 (5). 
Egypt 
The 2009 Global Adult Tobacco Survey in Egypt2,3 found that between 2% and 3% of the population 
uses smokeless tobacco. This is the first study in Egypt to document that ST is the third most widely 
used form of tobacco in the country after cigarettes and shisha. Among survey respondents aged 
15 years and older, 2.2% (over 1 million Egyptians) used ST; prevalence of ST use was 4.1% for males 
and 0.3% for females. Daily use of ST increased with age: from 1.9% for males aged 15–24 years to 
greater than 5% for men over the age of 25.  
Prevalence of current ST use among males and females ranged from 1.4% in urban Lower Egypt to 
3.5% in rural Upper Egypt; in the most urbanized cities, called the Cosmopolitan Governorates, 
5.3% of males and 0.6% of females were ST users (Figure 11-2). The use of ST was higher for males 
with at most some primary education (8%, 95% confidence interval [CI]: 5.9%–10.9%) compared with 
those with university or higher education (2.4%, 95% CI: 1.6%–3.7%) (Figure 11-3). 






Figure 11-2. Percentage of the Egyptian population using smokeless tobacco, by geographic area 
 
Source: World Health Organization 2010 (GATS, Egypt) (2). 
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Figure 11-3. Percentage of the Egyptian population using smokeless tobacco, by education level  
 
Source: World Health Organization 2010 (GATS, Egypt) (2). 
  






Pakistan and India 
High rates of ST use are reported in both Pakistan and India. The traditional product, paan (also known 
as betel quid) which can be used with or without tobacco, has been losing favor in recent years (as of 
2010) to gutka and khaini, the two tobacco products most widely used in India.6 Other frequently used 
tobacco products in Pakistan include naswar.6  
In a cross-sectional study of 502 adults attending family practice clinics, 52.4% used ST in at least one 
form.7 In another study in a low socioeconomic group in Karachi, 40% of those surveyed were daily 
users.8 Use by men significantly exceeds use by women.9 As noted in many low- and middle-income 
countries, social acceptance of ST is widespread, its serious health complications are not recognized, 
and ST use is promoted to youth.7,10  
Other Countries 
Individual country surveys reported in the WHO Report on the Global Tobacco Epidemic, 201110,11 
reveal the following prevalence rates: 
 The 2009 Libyan STEPwise approach to Surveillance (STEPS) Survey showed that 2.2% of 
men, 0.1% of women, and 1.2% of total participants between the ages of 25 and 64 years were 
current users of smokeless tobacco.  
 The Saudi Arabian STEPS Survey in 2004 showed that 1.3% of males and 0.5% of females 
between 15 and 64 years old were daily users of smokeless tobacco.  
 In Tunisia, the National Survey for Morbidity and Care-Seeking (Enquête nationale morbidité 
et recours aux soins) in 2005–2006 showed that the prevalence of snuff use by people aged 35 to 
70 years was 5.4% (8.6% among men, 2.2% among women). 
Types of Products and Patterns of Use 
As in other regions of the world, the production of ST reflects a combination of cultural practices, local 
preferences, and the availability of particular tobacco leaves and other ingredients. Products and usage 
patterns are also influenced by the practices brought by immigrants from their home countries—such as 
the large population of Asian workers, many from the Indian subcontinent, who have immigrated to 
some Gulf countries.  
Nass (or naswar) and paan are the most commonly used ST products in Pakistan6–9,12–14 and the United 
Arab Emirates (UAE).15,16 Shammah is mostly used in Yemen5 and Saudi Arabia,17–19 and toombak is 
used in Sudan.4  
Nass  
Nass, also known as naswar or niswar depending on the region in which it is made, is used in many 
countries, notably Iran (where it is known as nass) and Pakistan (where it is commonly known as 
naswar). It is made mainly of tobacco, ash, cotton or sesame oil, water, and sometimes gum. Nass is 
processed by mixing dried tobacco leaves, slaked lime (aqueous calcium hydroxide paste), ash from tree 
bark, flavoring and coloring agents, and water. Nass users roll this mixture into balls to be placed in the 
 
11. Smokeless Tobacco Use in the Eastern Mediterranean Region 




mouth for 10 to 15 minutes and chewed slowly.20 Nass is produced in cottage industry settings and is 
occasionally custom-made.21,22 It costs approximately US$1.79 for 50 grams (g) in Pakistan. 
Paan and Tombol  
Paan or betel quid, with or without tobacco, is used mainly in Pakistan. It is produced commercially or 
by vendors or prepared at home. Slaked lime (calcium hydroxide) and catechu (extract from the acacia 
tree) are smeared on a betel leaf, which is folded into a funnel shape to which tobacco, areca nut, and 
other ingredients are added. The tobacco used may be raw, sun dried, or roasted, and it is finely 
chopped, powdered, and scented. Alternatively, the tobacco may be also boiled, made into a paste, and 
scented with rosewater or perfume. After the betel leaf funnel is filled with the ingredients, the top of the 
funnel is folded over, resulting in a quid which is placed in the mouth, usually between the gum and 
cheek, and gently sucked and chewed. Paan is sometimes served in restaurants after meals.23 Each piece 
typically costs between US$0.05 and US$0.45.24,25 
A national product used in Yemen, tombol, has much of the same ingredients, with some variation in 
flavorings,26 and is not always made with tobacco. Tombol is made from the tombol leaf (also known as 
betel leaf), fofal (areca nut), noura, slaked lime (calcium hydroxide), and catechu (Figure 11-4). Tombol 
leaf, which requires a hot, humid climate, is cultivated in the Hadramout area of southern Yemen. As an 
ST product, there are three types of tombol: (1) sweet (a sweetening agent, often coconut, is added to the 
basic components described above, with or without tobacco); (2) bitter (additives like clove oil, 
cardamom, and herbal medicine are used, with or without tobacco); and (3) tombol with toombak 
tobacco (a local type of tobacco), which is available in two varieties: socha, or dry, thin pieces of 
Yemeni tobacco (similar to Indian pattiwalla), and zarda, scented tobacco from India.26 Tombol is 
mostly a custom-made product, therefore pricing information is not readily available. 
Figure 11-4. Tombol and its preparations 
 
Source: Photos courtesy of Mazen Abood Bin Thabit, University of Aden, 2011. 
Some forms of tombol, such as those used in Yemen, contain khat (Catha edulis) (Ghazi Zaatari, 
unpublished results, 2013; Figure 11-4), a plant that has psychoactive properties.27 Khat is used in East 
Africa, Yemen, and Ethiopia. In Yemen, approximately 80% of males and 30% of females chew khat on 
a regular basis.28 Khat contains cathinone, an alkaloid with amphetamine-like stimulant properties, 






which is purported to cause euphoria, excitement, increased energy, and loss of appetite.27–29 Cathinone, 
like amphetamine, is a potent agent that causes norepinephrine and dopamine to be released in the 
body.30 Khat is added to tombol by spreading it in powder form onto a betel leaf to which an alkaline 
agent (noura) is then added (Ghazi Zaatari, unpublished results, 2013). When an alkaline substance such 
as noura is added to tombol, it increases pH and converts a great fraction of the total nicotine to free 
nicotine, the form of nicotine that is more readily absorbed. Tombol containing only khat and tobacco 
without noura would contain less free nicotine (chapter 3). 
Shammah  
Shammah is made from powdered tobacco, slaked lime (calcium hydroxide), ash, oils, black pepper, and 
flavoring agents.31 The tobacco leaves are sun dried and pulverized with bombosa (sodium carbonate), 
and the preparation is usually sold as a dry product. Shammah is placed between the cheek and gums or 
between the cheek and lips. Various types of shammah are available in the market: bajeli, haradi, 
sharaci, black shammah, and white shammah (Figure 11-5), but shammah is most frequently sold as a 
cottage or custom product, therefore pricing information is not readily available. Black shammah is 
prepared by mixing tobacco leaves with a solution of bombosa in water; it is sold as wet shammah.  
Figure 11-5. Types of shammah 
 
Source: Photos courtesy of Mazen Abood Bin Thabit, University of Aden, 2011. 
Toombak  
Toombak,32 used in Sudan as a national product, is made of sun-dried tobacco (wild Nicotiana rustica) 
(Figure 11-6) mixed with an aqueous solution of sodium bicarbonate called atrun. The mixture is kept in 
an airtight container for about two hours, after which it is ready for sale. Toombak is rolled into a ball, 
called saffa, weighing about 10 g. The saffa is dipped into the mouth; men preferentially hold it between 
the gum and the lip, but women, for aesthetic reasons, hold it between the gum and the cheek or under 
the tongue on the floor of the mouth. It is sucked slowly for 10 to 15 minutes; a few users may extend 
this to several hours. Men usually spit periodically, whereas women users typically swallow the saliva 
generated. Users usually rinse their mouths with water after the saffa is removed.10 Occasionally 
toombak is also used nasally or placed behind the ear with transdermal effect. The price of 50 g of 
toombak is around US$0.22 (Ghazi Zaatari, unpublished results, 2013). 
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Figure 11-6. Toombak  
 
Source: Photos courtesy of Ali Idris, Toombak and Smoking Research Center, 2011. 
Toxicity and Nicotine Profiles of Products 
Toxicity and nicotine profiles are only documented for nass and toombak.32 Chemical analysis of nass 
revealed the following concentrations of the carcinogenic tobacco-specific nitrosamines (TSNAs):  
 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)—up to 309 nanograms per gram (ng/g) 
wet tobacco 
 N’-nitrosonornicotine (NNN)—up to 545 ng/g wet tobacco 
 N’-nitrosoanabasine (NAB)—up to 30 ng/g dry tobacco 
 N’-nitrosoanatabine (NAT)—up to 300 ng/g dry tobacco. 
Toombak has the highest levels of free nicotine and nicotine-derived TSNAs ever measured in tobacco 
products (free nicotine: 5.16–10.6 milligrams per gram [mg/g] wet weight) (TSNAs: NNN = as high as 
368,000 ng/g wet weight, and NNK = up to 516,000 ng/g wet weight) (Table 11-6). 
Table 11-6. Nicotine and nitrosamine levels in naswar (nass) and toombak 
Product pH 
 Total nicotine Free nicotine 
mg/g wet weight 
 NNK NNN NNAL Total TSNAs*  
ng/g wet weight 
Toombak 7.38–10.1  9.56–28.2 5.16–10.6 147,000–516,000 115,000–368,000 4,550–6,770 295,000–992,000 
Naswar 8.76–9.14  10.5–14.2 8.84–13.2  29.4–309 363–545 8.56–104 478–1380 
*Total TSNAs = Sum of NNK, NNN, NNAL (shown); NAT, NAB (not shown). 
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; NAT = N’-nitrosoanatabine; NAB = N’-nitrosoanabasine; mg/g = milligram per gram; ng/g = nanogram per 
gram; TSNAs = tobacco-specific nitrosamines.  
Note: Data in this table are for select products and may not represent all products of this type. Data are expressed on a per gram 
basis for products analyzed as received. The amount absorbed depends on the amount of tobacco used. 
Source: Stanfill 2011 (33). 
  






A 2011 global surveillance report on oral tobacco products33 confirmed that, compared to a variety of 
other global ST products, toombak is among the highest in nicotine concentration, which ranged from 
9.56 to 28.2 mg/g in four different samples, and in concentrations of NNK (147,000–516,000 ng/g) and 
NNN (115,000–368,000 ng/g).  
Naswar (nass) contains various toxic/carcinogenic substances, such as heavy metals, in addition to 
TSNAs. An assessment of the potential toxicity of 30 brands of naswar available in the Pakistani 
market34 showed that the average values of all toxicants studied were above limits deemed allowable by 
the Agency for Toxic Substances and Disease Registry at the U.S. Centers for Disease Control and 
Prevention (CDC). For instance, the amounts of cadmium and lead in the products would be associated 
with a calculated lifetime cancer risk from 100,000 to 1,000,000 times higher than the minimum target 
range for potentially hazardous substances. Similarly, the level of arsenic in the products exceeded 
allowable standards, and the average minimum daily intakes of chromium and nickel were 4 to 5 times 
higher than the allowable limits.34 
Health Problems Associated With Product Use 
There are at least 30 carcinogens in ST products used globally (see chapter 3, Table 3-2). These products 
have been associated with increased risk of developing precancerous and cancerous lesions of the oral 
cavity, nasal cavity, and sinuses, and most commonly, squamous cell carcinoma35 (Figure 11-7) (see 
chapter 4). 
Cellular abnormalities and genomic alterations associated with use of the highly carcinogenic toombak 
have been repeatedly documented in studies in Sudan.4,41–50 In Iran, studies have demonstrated an 
association between ST use and development of esophageal cancer.51,52 Oral submucous fibrosis,7 oral 
carcinoma,8,9 and head and neck cancers12 have been reported in Pakistan as being associated with 
chewing areca nut, nass, and paan.8 In Saudi Arabia, studies have identified an association between the 
use of shammah and the incidence of oral and head and neck cancers.17–19 High prevalence of oral 
cancer and other oral lesions was similarly reported among shammah users in Yemen.31,53 Pancreatic 
cancer has been described in other regions as a risk associated with the use of ST,35 although this 
observation is not made in reviewed reports for the Eastern Mediterranean Region. The risk of 
pancreatic cancer in association with ST use has not been studied in a systematic fashion in the region.  
Although cancer risks associated with ST use have been the focus of many publications, ST use is also 
associated with several non-neoplastic oral complications, such as gingivitis, periodontitis, poor dental 
hygiene, dental caries, and sinusitis.54 
An important factor in the assessment of health effects associated with ST products in this region is the 
cancer risk that is independently associated with some substances used as ingredients in these products, 
such as areca nut.12 In addition to this cancer risk, areca nut use has been associated with oral 
submucous fibrosis.13  
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Figure 11-7. Health complications associated with toombak use in Sudan  
 
Source: Photos courtesy of Ali Idris, Toombak and Smoking Research Center, 2011. 
  






Marketing and Production Practices of Industry 
In the Eastern Mediterranean Region, the production and marketing of ST products such as nass, paan, 
shammah, and toombak are primarily cottage industries (Figure 11-8) that are mainly centered in areas 
of tobacco farming. The ST industry relies on locally available resources both for producing ST products 
and for marketing and distributing them to retailers under brand names intended to attract customers in 
their areas. For example, vendors use names such as Sultan Elkayef (i.e., the one that masters the mind), 
Wad Amari (a reference to the person who introduced the plant to the area), and Alsanf (which means 
“the best brand”). Toombak in Sudan is sold in small metal containers called hookahs or in plastic bags 
called keece.  
Figure 11-8. A local vendor of toombak in Sudan 
 
Source: Photo courtesy of Ghazi Zaatari, American University of Beirut, 2011.  
Some ST products brought in from the Indian subcontinent are marketed to the large immigrant Asian 
labor force in the Gulf region. In a few countries, such as the UAE, there are reports of health inspectors 
and police inspecting and shutting down illegal manufacturing of nass and paan.15,16 
Current Policy and Interventions 
Well-structured interventions and regulatory policies, as well as ST cessation and prevention programs, 
are not present in the Eastern Mediterranean Region. Only Bahrain and the UAE have introduced 
policies banning smokeless tobacco. In 2009 the government of Bahrain introduced strict antismoking 
regulations and banned the importation of chewable tobacco products.55 Ajman Municipality in the UAE 
banned the sale, import, storage, and possession of chewing tobacco and prescribed heavy fines for 
violations of the new law.16  
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Eastern Mediterranean Region countries have not made use of taxation as part of a policy of tobacco 
control. Taxes on ST products and prices of all types of tobacco products are among the lowest in the 
world. In 1999, cigarettes in this region were taxed at 47% of their base price on average. The 
corresponding cigarette product prices were low, only approximately US$0.93 per pack, leaving room 
for potential tax increases. Product prices and likewise taxes in the region ranged from US$0.30 in 
Lebanon, where the tax was 19% of the retail price, to almost US$1.40 in Morocco, where the tax was 
30% of the retail price. The UAE and Tunisia have the highest taxes, at 65% and 67% of retail price, 
respectively, for a corresponding rate of approximately US$1.10 and US$1.18 per pack. Since tobacco 
taxes as a total proportion of government taxes collected remains low (1%–2% in Syria, Lebanon, 
Egypt, and Kuwait; and 4% in Tunisia), countries in this region have the opportunity to increase tobacco 
taxes and introduce taxes specifically on ST products.56 
Summary and Conclusions 
Smokeless tobacco is still an under-investigated topic in the Eastern Mediterranean Region because 
most production and marketing are cottage industry activities. A lack of comprehensive surveillance and 
lack of updated data on ST use and its adverse health effects may limit the ability of governments to 
introduce regulatory policies and design programs to combat ST use in their countries. 
The most frequently used products in the region include toombak, paan, shammah, and nass. Especially 
high prevalence of use has been documented in Sudan and Pakistan, but consumption is widespread 
across Yemen and other areas of the region as well. Prevalence is substantially higher among men than 
among women in the region, although women engage in the practice as well.  
Specific toxicity profiles are available only for nass and toombak. Of these, toombak has been reported 
to have the highest levels of nicotine and TSNAs ever measured in tobacco products. Research has 
documented associations between the use of toombak, shammah, nass, and paan and precancerous 
abnormalities as well as oral cancer and head and neck cancer.  
In the Eastern Mediterranean Region, production and marketing of ST products are centered in areas 
of tobacco farming and rely on locally available resources. Some ST products originating from the 
Indian subcontinent are marketed to the large immigrant Asian labor force in the Gulf region.  
Well-structured interventions to prevent or promote cessation of ST use are lacking in the region. 
The price of ST products remains low, and countries have generally not made use of taxation as a 
tobacco control policy. The government of Bahrain banned the importation of chewable tobacco 
products in 2009, and a municipality in the UAE banned the sale, import, storage, and possession 
of chewing tobacco. 






Based on the available information from this region and the experiences of other countries, Eastern 
Mediterranean Region governments may benefit from considering the following: 
 Subjecting ST to the same regulation as cigarettes and other tobacco products, if possible, given 
the proliferation of cottage industries 
 Requiring the display of visible health warnings on all tobacco products for those that are 
manufactured and, if possible, those from cottage industries 
 Including ST in tobacco control efforts, culturally relevant prevention strategies, and culturally 
relevant cessation interventions 
 Educating individuals about the risks of ST use, using appropriate channels of communication in 
their countries. 
To further inform regulatory policies, research is needed that leads to greater understanding of ST use 
and documents risks and health effects of products specific to this region.  
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Description of the Region 
The African Region of the World Health Organization (WHO), as a geographic entity, refers to the area 
of the African continent that lies south of the Sahara, excluding the Sudan, South Sudan, and Somalia, 
but including Algeria and Mauritania. It covers a total area of about 30 million square kilometers.1 The 
African Region consists of 46 countries2 divided into 5 subregions: Western, Eastern, Southern, Central, 
and Northern. The population of the African Region was estimated at 839 million in mid-2010,1 or 
12.2% of the world’s population, with a 2.5% rate of natural increase.3 Table 12-1 displays land area and 
population information for 34 of these countries.4 Rural Africans have the lowest level of accessibility in 
the developing world: less than 40% of rural Africans live within two kilometers of an all-season road.5  
Of the 46 countries in the region, 41 had ratified the WHO Framework Convention on Tobacco Control 
(FCTC) as of September 2013.6 The five countries that had not ratified the Convention as of 2012 are 
Malawi, Zimbabwe, Mozambique, Eritrea, and Ethiopia (Mozambique and Ethiopia have signed but not 
ratified). Malawi is one of the leading tobacco producers in the world, with an estimated yield of 
208,105 metric tons in 20097; tobacco is grown on about 3% of Malawi’s total agricultural land.7 South 
Africa is the largest and arguably the most lucrative cigarette market in the WHO African Region. 
Multinational tobacco companies are involved in the manufacture of both cigarettes and smokeless 
tobacco (ST) products in South Africa.  
Table 12-1. Population and land area of selected countries in the African Region 
Country Area (km2) Population (thousands) 
Algeria 2,364,533 35,468 
Benin 112,025 8,850 
Botswana 669,000 2,007 
Burkina Faso 274,483 16,469 
Cameroon 478,024 19,599 
Cape Verde 4,033 496 
Central Africa 628,714 4,401 
Chad 1,247,444 11,227 
Congo 336,917 4,043 
Côte d’Ivoire 323,574 19,738 
Democratic Republic of Congo 2,357,000 65,966 
Gambia 11,294 1,728 
Ghana 239,137 24,392 
Guinea 243,463 9,982 
Kenya 578,757 40,513 
Lesotho 30,153 2,171 
Liberia 110,944 3,994 
Madagascar 591,829 20,714 
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Country Area (km2) Population (thousands) 
Malawi 118,262 14,901 
Mali 128,083 15,370 
Mauritania 1,153,333 3,460 
Namibia 761,000 2,283 
Nigeria 926,450 158,423 
Rwanda 26,362 10,624 
Sao Tome and Principe 959,302 165 
Seychelles 458 87 
Sierra Leone 7,156 5,868 
South Africa 1,222,756 50,133 
Swaziland 17,441 1,186 
Tanzania (United Republic of)  954,064 44,841 
Togo 56,868 6,028 
Uganda 240,468 33,425 
Zambia 769,941 13,089 
Zimbabwe 392,844 12,571 
Total 18,336,112 664,212 
Abbreviation: km = kilometer. 
Source: United Nations 2011 (4).  
Prevalence of Smokeless Tobacco Use 
Use of ST products is common in some countries of the African Region, and various forms of products 
are used. Little information is available on prevalence of use in the region, and the data that are available 
tend to be dated and/or limited to small areas or subregions. Tables 12-2 and 12-3 present the prevalence 
data for each African Region country for which data are available, by the types of products used and the 
age of users, and Map 12-1 illustrates the available adult prevalence rates by country. Caution should be 
exercised when comparing the estimates from different surveys, because of the differences in sampling, 
questions asked, and definitions. The definition of current use varies. For example, some surveys define 
current use as any use within the past 30 days, but other surveys ask about different time periods; some 
surveys ask about daily use and use on some days, and still other surveys ask about “current” use 
without defining the term further.  
The prevalence of ST use varies across countries and across geographic areas within countries. For 
example, national prevalence rates for adults in Nigeria are relatively low (Table 12-3), but higher rates 
have been found in a state in the northeastern geopolitical zone of Nigeria among people aged 15 and 
older (10.8% for males and 4.1% for females).8 
  






Table 12-2. Percentage of adolescents aged 13–15 years who currently used smokeless tobacco in the 
African Region, from the Global Youth Tobacco Surveys, 2007–2009 
Country Year Total (%) Boys (%) Girls (%) 
Botswana 2008 11.3 11.3 11.4 
Burkina Faso – Bobo Dioulasso 2009 13.2 12.1 14.0 
Burkina Faso – Ouagadougou 2009 10.2 11.2 9.2 
Cameroon – Yaounde 2008 5.1 5.4 4.4 
Cameroon – outside Yaounde 2008 10.9 12.0 9.4 
Central African Republic – Bangui 2008 15.4 21.9 8.0 
Congo 2009 16.4 18.3 14.1 
Côte d’Ivoire 2009 5.6 6.2 4.9 
Democratic Republic of Congo – Kinshasa 2008 20.8 20.6 20.1 
Democratic Republic of Congo – Lubumbashi 2008 17.8 18.3 16.4 
Gambia – Banjul 2008 21.9 20.1 23.3 
Lesotho 2008 14.4 14.7 13.6 
Liberia – Monrovia 2008 8.3 9.0 6.6 
Madagascar 2008 5.7 6.2 5.4 
Malawi – Lilongwe 2009 11.0 10.3 11.7 
Malawi – rest of country 2009 8.9 11.3 6.7 
Namibia 2008 16.0 15.6 15.8 
Rwanda 2008 7.4 8.3 6.0 
Seychelles 2007 5.5 5.2 5.4 
Sierra Leone – West urban 2008 17.3 13.6 18.8 
Sierra Leone – West rural 2008 22.7 18.9 24.5 
Swaziland 2009 5.4 6.0 5.0 
Tanzania – Arusha 2008 6.2 6.9 5.5 
Tanzania – Dar es Salaam 2008 4.6 4.6 4.3 
Tanzania – Kilimanjaro 2008 5.7 5.6 5.7 
Togo 2007 6.2 6.9 4.8 
Uganda 2007 9.4 8.6 9.6 
Zambia – Lusaka 2007 15.6 0.9 15.4 
Zambia – Kafue 2007 16.7 17.0 16.5 
Zambia – Chongwe and Luangwa 2007 14.1 15.3 13.2 
Zimbabwe – Bulawayo 2008 5.4 7.5 3.5 
Zimbabwe – Harare 2008 5.7 6.4 5.0 
Zimbabwe – Manicarland 2008 7.6 8.3 6.3 
Source: Global Youth Tobacco Surveys, 2007–2009 (50). 
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Table 12-3. Percentage of adults who currently used smokeless tobacco in the African Region, 
2003–2010  
Country Year Age Group (Years) Total (%) Men (%) Women (%) 
Algeria* 2010 15+ 5.7 10.4 0.8 
Benin† 2008 25–64 9.2 12.7 5.7 
Cape Verde* 2007 25–64 4.6 3.5 5.8 
Chad (subnational)* 2008 25–64 1.2 1.9 0.4 
Ethiopia‡ 2005 Men, 15–59; Women, 15–49 — 3.0 0.6 
Gambia† 2010 25–64 1.1 0.8 1.4 
Ghana‡ 2008 Men, 15–59; Women, 15–49 — 0.9 0.2 
Guinea (subnational)† 2009 15–64 1.4 1.4 1.5 
Kenya‡ 2008–2009 Men, 15–54; Women, 15–49 — 1.8 1.3 
Lesotho‡ 2009 Men, 15–54; Women, 15–49 — 1.3 9.1 
Liberia‡ 2007 15–49 — 2.3 2.4 
Madagascar‡ 2008–2009 Men, 15–59; Women, 15–49 — 22.6 19.6 
Malawi† 2009 25–64 3.5 1.9 5.0 
Mali (subnational)† 2007 15–64 2.7 5.0 1.2 
Mauritania† 2006 15–64 9.0 5.7 28.3 
Namibia‡ 2006–2007 15–49 — 1.8 2.3 
Nigeria‡ 2008 Men, 15–59; Women, 15–49 — 3.2 0.5 
Sao Tome and Principe† 2009 25–64 2.8 3.8 1.9 
Sierra Leone‡ 2008 Men, 15–59; Women, 15–49 — 1.3 4.7 
South Africa* 2003 15+ — 2.4 10.9 
Swaziland† 2007 25–64 1.6 2.6 0.8 
Uganda‡ 2006 Men, 15–54; Women, 15–49 — 3.9 2.6 
Zambia‡ 2007 Men, 15–59; Women, 15–49 — 0.2 1.2 
Zimbabwe‡ 2005–2006 Men, 15–54; Women, 15–49 — 1.9 0.5 
*Individual country surveys from: WHO Report on the Global Tobacco Epidemic, 2011 (51).  
†WHO STEPS from: WHO Report on the Global Tobacco Epidemic, 2011 (51). 
‡Demographic and Health Surveys (52). 






Map 12-1. Prevalence of smokeless tobacco use among adults in the World Health Organization’s 
African Region 
 
Note: A rate for males and females was not available for Ethiopia, Ghana, Kenya, Lesotho, Liberia, Madagascar, Namibia, 
Nigeria, Sierra Leone, South Africa, Uganda, Zambia, or Zimbabwe. For each of these countries, a total figure was calculated by 
averaging the available male and female rate. 
Sources: Individual country surveys from: WHO Report on the Global Tobacco Epidemic, 2011 (51); WHO STEPS from: WHO Report 
on the Global Tobacco Epidemic, 2011 (51); Demographic and Health Surveys (52). 
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Types of Products and Patterns of Use 
Smokeless tobacco products available in the region include premade manufactured products as well as 
those produced by small cottage industries, and custom-made products for personal use or for sale by 
street vendors. These ST products are sniffed, chewed, sucked, or applied to the teeth and gums. 
Smokeless tobacco products are generally much cheaper than cigarettes8,9 and are more widely used by 
people who are socioeconomically disadvantaged8,10 and by older adults compared to younger 
adults.8,11,12 
Snuff use is considered outmoded by many African people, thus it is not often practiced in public.13 
However, ST products such as snuff and areca nut with or without tobacco, previously popular only in a 
limited number of countries, are now being marketed heavily to specific target groups, including 
women, young people, and smokers.14 Smokeless tobacco products are advertised to women, as an 
alternative to smoking in cultures where smoking by women is not socially acceptable; to young people, 
for whom flavored and milder-tasting “starter” products have been developed; and to smokers, for use 
where smoking is prohibited.14 For those who are already tobacco dependent, snuff products are 
suggested as the most affordable and accessible way of getting sufficient nicotine.15 Dual use of ST and 
cigarette smoking has been found to be common among South African adolescents in some parts of that 
country (55.2% of those who use ST are also smokers).9 Similarly, data on adults from Nigeria suggest 
that as many as 21.1% of the surveyed ST users also smoked cigarettes.8  
In Algeria, ST, especially moist snuff, has been consumed traditionally by the majority of men in all 
social groups. Locally, chemma or shammah is the term given to moist snuff, which is put directly on 
the gums or placed in paper and then placed in the mouth. Dry snuff is called neffa, which is taken in 
through the nose. Chemma, the most prevalent category of ST used, is available via both legal and 
illicit channels.13  
In a number of West African countries, including northern Nigeria, Cameroon, Senegal, and Chad, a 
smokeless product locally known as taaba is widely consumed orally or by nasal inhalation. It is 
prepared from dry fermented tobacco pulverized to fine particles and mixed with natron (a mixture of 
sodium bicarbonate and sodium chloride). For oral consumption, a pinch of the product is placed 
between the lower gum and the lip, and the pinch is left in position for a few minutes to half an hour, 
until some active ingredients are absorbed. Taaba is also sometimes placed on the tongue and sucked. In 
several rural and urban areas of Nigeria, taaba is reportedly used because of its purported ability to 
“cure” certain medical ailments and because of its traditional place in social gatherings.8 
Toombak imported from Sudan is also fairly common in Chad, in the West African region. Toombak is 
an oral snuff that is traditionally made by small local vendors in rural areas and transported to markets in 
the city for sale. Toombak is a custom-made blend of leaves of the Nicotiana rustica variety of tobacco 
mixed with sodium bicarbonate (baking soda) and stored for two hours or longer before sale.16  
In Ghana, local snuff is prepared by mixing the dried tobacco leaf indigenous to the forested areas 
(N. tabacum) with chemicals such as saltpeter (potassium nitrate) and then grinding it into a fine 
powder. Dried tobacco leaves are also a form of ST, which users chew. After roasting the tobacco 
leaves, users traditionally dip the roasted tobacco into the fly ash of wood before inserting it between the 






lower gum and lip.17 To intensify the delivery of free nicotine, users add an alkaline agent (in this case, 
ash) as do other producers of tobacco products worldwide.18 Snuff is consumed mostly by older adults in 
Ghana, but youth are reportedly becoming more interested in using it.17 The increasing interest among 
youth is consistent with findings from the Global Youth Tobacco Survey (GYTS) from Ghana, which 
showed that 10.4% of youths surveyed reported using tobacco products other than cigarettes.19 Further 
inquiries with those who conducted the survey suggest that these “other tobacco products” are 
predominantly snuff (Edith Wellington, personal communication, 2011). 
In South Africa, snuff is applied nasally and orally, and tobacco is chewed. Historically, inhalation is the 
most common practice (about 75% of ST users sniff). Snuff use in South Africa is predominantly found 
among African women, who traditionally have low smoking rates.12 In a qualitative study carried out in 
South Africa involving a focus group of black women, there was consensus among all participants that 
cigarettes and snuff were the types of tobacco most commonly used in the community.20 However, snuff 
was considered women’s tobacco, commonly used by older women and rarely used by men.20 South 
African women of Indian descent mostly chew areca (betel) nut. Most users prefer only the nut, some 
the betel quid with or without tobacco, and some use both the nut and the quid.21,22 Other ingredients 
may be added by the user to taste or based on traditional customs and usage.21  
In South Africa and neighboring countries, including Lesotho, similarly prepared traditional homemade 
products and a limited range of premade products are used. Some traditional products are prepared by 
hand-mixing finely ground sun-dried tobacco leaf and ash (mokgako) from local plants, depending on 
plant availability and cultural preference. Mokgako is used as a condiment or flavor intensifier.23–25 
With regard to commercially manufactured products, since 2003 multinational tobacco companies 
such as British American Tobacco and Swedish Match have continually introduced various local 
brand equivalents of Swedish snus in test markets across South Africa, albeit with limited sales 
success to date.26,27  
In Uganda, the use of gutka is said to be increasing among adolescents as a result of imports by the 
Indian community, although the use of ST among South Africans of Indian descent has declined to 
become almost insignificant. The dry snuff known as taaba is also consumed in Uganda, particularly by 
the Bakiga tribe and some other rural tribes, and primarily by middle-aged men and women. Taaba is 
mainly sniffed, but is occasionally held in the cheek. Fresh or dried tobacco leaves are also wrapped 
around magadi (sodium bicarbonate) and placed in the cheek until the desired effect is obtained.  
In Tanzania, three types of ST products are used. Kuberi and ugoro (moist oral snuff) are used by 
indigenous people, and thinso (tobacco with areca nut, more widely known as gutka), which is used by 
migrants of Indian descent. Kuberi is the most popular product, followed by ugoro. Ugoro is either 
placed under the tongue or sniffed. Thinso is either placed in the cheek or chewed, together with areca 
nut, similar to the practice in India. Tobacco is imported from India in many flavors, but areca nut is 
grown locally. Use of areca nut with tobacco appears to be on the increase, especially among Asians in 
the country.8  
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From the limited data obtained from 10 countries covering almost half of the region’s total population, it 
can be deduced that, in general, products and customs associated with ST use in different parts of Africa 
vary widely (Figure 12-1). There is a widespread perception that snuff possesses “medicinal” 
properties.8,20,23,28 Medicinal uses that have been reported include relief from physical conditions such as 
headache, nose bleeds, sinus problems, and toothache. Reports of these beliefs highlight the importance 
of cultural sensitivity in the development of public health education interventions to reduce ST use in the 
region.  
Figure 12-1. Snuff products used in some African countries 
 
Source: Photos courtesy of Olalekan Ayo-Yusuf, University of Pretoria, 2011. 






Toxicity and Nicotine Profiles  
Only limited data are available on the toxicity of ST products used in the region, but product testing 
suggests considerable variability in the toxicity and nicotine profiles of these products. Generally, the 
commercialized products tend to have lower levels of carcinogenic tobacco-specific nitrosamines 
(TSNAs) than traditional custom-made products, one exception being traditional products used in 
Nigeria, which contain notably lower levels of TSNAs than traditional products in Chad, Ghana, and 
South Africa, and even lower than the levels in the manufactured snus products on the South African 
market (Table 12-4).  
Table 12-4. Toxicity and nicotine profiles of selected smokeless tobacco products used in the 
African Region 
Country Products (n) 
  Heavy metals (ppm)  






(mg/g) (% of 
total nicotine) 











 9–84 6–8 1.1–1.5 25–87 4,550 20,500 
(n = 1) 
9.29 5.01 (94.8%) 
 Commercial 
snuff (3) 








  1,520 9.42 2.39 (96.1%) 
 Commercial 
snuff (1) 
  2,420 9.02 6.72 (90.7%) 
*Data on Sudanese toombak are presented here for comparison purposes. 
Abbreviations: ppm = parts per million. Cr = chromium, Pb = lead, Cd = cadmium, Ni = nickel, BaP = benzo(a)pyrene, 
ng/g = nanograms per gram of tobacco, TSNAs = tobacco-specific nitrosamines, mg/g = milligrams per gram of tobacco.  
Sources: For South Africa, Nigeria and Chad, data on pH, nicotine, and TSNA: Stanfill et al. 2011 (29); For Ghana, heavy metals 
data: Addo 2008 (17); for South Africa, heavy metals and BaP data: Keen 1973 (53). 
Health Problems Associated With Product Use  
An important consideration is that biologic effects of ST observed in Western countries may not be 
generalizable to Africa because of differences in the composition of ST products and cultural differences 
in patterns of use.23  
In general, only limited data are available on the negative oral health effects of ST use in the region. In 
South Africa, where the highest pH values of any premade manufactured ST brands have been found,29 
snuff-dipping has been associated with oral keratotic lesions,30 which were more severe with the higher-
pH manufactured snuff brands than with traditional products.23 Past studies have demonstrated that 
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Indian women in South Africa have the highest incidence of oral cancer, which has been associated with 
the use of areca nut with or without tobacco,22,30 compared with women in any other population group in 
the country. Since about 1990, however, no large population studies have been carried out on oral cancer 
incidence among South Africans. As of 2005, in North Africa, snuff has been associated with a 
significant increase in the risk of nasopharyngeal cancer.31 
In terms of reproductive outcomes, ST use in South Africa has been associated with significantly 
reduced gestational age, but not with low birth weight.32 A study in the Democratic Republic of Congo 
suggested that as many as 41% of pregnant women had ever tried snuff, compared to 14% who had ever 
tried cigarettes.33 Similarly, about 8% of pregnant women in Lesotho reported snuff use during 
pregnancy.34 Such high rates of use by pregnant women indicate a need for further studies on the effect 
of ST on reproductive outcomes in the African Region. In addition, a 2009 study on a population of 
women in Côte d’Ivoire associated ST use with a precursor lesion for cervical cancer.35 
Demographic and Health Survey data have suggested that South African nasal snuff is associated with 
an increased risk for chronic bronchitis and tuberculosis.36 Consistent with this finding is a report from a 
study of lung function among snuff industry workers in Nigeria, which showed that chronic exposure to 
snuff dust was associated with impaired lung function which was worse depending on the length of 
exposure in the industry.37 The impact of nasal application of ST on the already high burden of 
respiratory diseases such as tuberculosis in the African Region requires further investigation. 
Heavy snuff use among South African women has been associated with significantly increased blood 
pressure to levels that increase the risk for cardiovascular diseases at a population level.10 A small study 
from 1992 in Nigeria also demonstrated that snuff use was associated with increased systolic and 
diastolic pressure, although this effect was less pronounced when natron was not an ingredient in the 
snuff mixture.38 These findings are consistent with results of a multicountry study that included ST users 
in Africa; this study showed that ST use was associated with a significantly increased risk of non-fatal 
myocardial infarction (MI).39 However, according to a meta-analysis, heterogeneous results have been 
obtained for the role of ST in non-fatal MI, and this research suggests that the risk of fatal MI may be 
greater than the risk of non-fatal MI among ST users.40 
Despite the popular belief that ST has “medicinal effects,” a pilot study from South Africa on the 
antibacterial potential of ST found that the snuff products tested did not inhibit bacterial growth; the 
study instead demonstrated possible bacterial activities in both the commercial and non-commercial 
snuff products tested.25 
Although few studies in the African Region have addressed the level of nicotine dependence associated 
with ST use, the nicotine profiles of some of the products studied suggest significant potential for 
nicotine dependence.29 A previous South African qualitative study found that as many as 36% of women 
snuff users who reported having made an attempt to quit had no success, but about 67% of surveyed 
users wished to quit,20 thus suggesting that snuff use is as difficult to quit as cigarette smoking. Another 
study among an elderly Nigerian population also reported that as many as 50% of those surveyed were 
diagnosed with “snuff tobacco dependence.”41 






Marketing and Production Practices of Industry 
Production  
Except in a few African Region countries where imported commercially manufactured ST products are 
available, most of the ST products used in the region are made by the users themselves or by small 
cottage industries. Traditional or custom-made brands are more commonly used in rural areas, whereas 
commercially manufactured brands are more common in urban areas.42 
The biggest manufacturer of ST in Algeria is the Société Nationale des Tabacs et Allumettes (SNTA), a 
public entity with a market value share of 88% in 2009.13 SNTA produces the leading brands Makla El 
Hilal and Nedjema. A private company, Bentchikou Tabacs Algérie, which accounts for the remaining 
market share, has gained ground since it entered the country in 2006 with its brands Naffa Africaine, 
Makla Ifriquia, and Makla Bouhlel (Figure 12-1). The national company SNTA had a monopoly on 
production before the appearance of this competitor, and it remains the category leader because 
consumers are used to its products. However, Bentchikou Tabacs Algérie, which imports its products 
from its headquarters in Belgium, is steadily gaining market share in Algeria.13 
The two leading premade manufactured brands in South Africa, Taxi and Ntsu, were largely under 
the control of two small local manufacturers until 1999, when Swedish Match bought out the company 
that manufactures Taxi.43 More recently, in 2009, Phillip Morris International paid approximately 
US$225 million (ZAR1.75 billion) to purchase Swedish Match South Africa.44  
Products used in Nigeria, similar to products used in the rest of Africa, are largely locally made by 
cottage industries, but limited numbers of premade manufactured brands are also available. The most 
commonly found imported brand is Medicated Snuff 99, manufactured by Joseph & H. Wilson, which is 
based in the United Kingdom.  
Distribution  
In Algeria, news agents/tobacconists or kiosks remain the leading distribution channel, representing 
67% of the sales volume in 2009. Tobacconists and kiosks are widely distributed across the country, 
and they offer the largest stock range. They distribute both legal and illegal products,13 although illicit 
tobacco products may also be available from other street or local vendors. 
Smokeless tobacco products in South Africa are sold mostly by street vendors, local convenience stores, 
or at kiosks, where they are displayed together with cigarettes, candy, and confections. More recently, 
South African snuff brands manufactured by Philip Morris International have become available on an 
Internet snuff sales website based in the United Kingdom. Custom-made or traditional snuff products are 
sold from plastic buckets in open markets in South Africa and Nigeria and are dispensed in spoon-sized 
portions that are transferred to plastic bags, as requested by the customer. In Nigeria, it is also possible 
to request a mixture of local products and imported products. Ugoro, wrapped in banana bark, is sold in 
Tanzania in open-air markets. 
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Being primarily a cottage industry or custom-made product in this region, smokeless tobacco is not 
widely advertised. In Algeria, tobacco promotion is permitted at points of sale, but ST is not usually 
advertised, primarily because neither manufacturers nor retailers find it useful to create displays. In 
Tanzania, to market to adolescents, ST is often given a flavor or described as a type of nutrient 
supplement.14 Larger industries such as British American Tobacco and Swedish Match attempted to 
introduce snus equivalents, particularly in South Africa, between 2001 and 2008, but have had limited 
success.26,27 In this region, snus has also been promoted with health claims and for use in situations 
where smoking is not permitted (Figure 12-2), which may encourage dual use. 
Previously confidential industry documents suggest that additives or flavorings may be added to mask 
the poor quality of some products or to target certain population groups, as indicated by the following 
quotes related to snuff manufacture in Nigeria and South Africa, respectively: 
“Many snuff formulations are flavoured with added levels or top dressing 
flavours. … Top dressing flavours include menthol, peppermint oil, 
wintergreen, attar of roses and clove oil. I suggest a menthol and 
peppermint flavoured version might be appropriate for the Nigerian 
market as a significant proportion of your cigarettes are mentholated. The 
added flavour may also help to cover some of the product deficiencies 
(sic) that a connoisseur of classic European snuff might find in a simple 
domestic product.”  
(Letter from D. E. Creighton, British American Tobacco Company,  
to R. M. H. Duncan, Nigerian Tobacco Company,  
July 3, 1985)45 
“One major point is that with our wet snuff there must be a noticeable 
ammonia nose to the product, all products have this distinct 
characteristic and [it] is sought after by the Black consumer in this 
country.” 
(Letter from G. A. S. Wingate-Pearse, United Tobacco/Tabak,  
to B. Louw, British American Tobacco Company,  
October 12, 1987)46 






Figure 12-2. Snus information leaflets promoting situational use 
 
Note: These leaflets are available at points of sale in South Africa. 
Source: Photo courtesy of Olalekan Ayo-Yusuf, University of Pretoria, 2011. 
Current Policy and Interventions 
In general, no organized public health education programs or cessation programs for ST exist in the 
African Region. In Tanzania, the sale of ST was officially banned in 2006, although it has been 
suggested that more stringent monitoring and enforcement are needed.14 In Algeria, ST containers are 
subject to the same legislation as the packaging of other tobacco products, which includes specified 
health warnings. However, cigarette packages have multiple “rotating” health warnings on their 
packages, which are required to cover 15% of the entire package, but these same requirements are not 
mandated for ST products.47 The government does not regulate the marketing or distribution of ST 
products in Algeria, nor does it regulate Internet retailing and advertising of tobacco products. However, 
as a result of limited Internet penetration, the introduction of payment cards, and inadequate delivery 
systems, Internet sales do not exist in Algeria for any category of tobacco products.13 
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In the Democratic Republic of Congo, traditional snuff is more expensive than cigarettes: A portion 
of snuff (~2 grams [g]) costs about US$0.50, whereas a pack of cigarettes costs about US$2.00. In 
South Africa, excise tax is payable on cigarettes but not on ST or snuff products, therefore snuff is 
much less expensive than cigarettes in South Africa: A 20 g can of snuff typically costs ZAR5 
(US$0.70), compared to ZAR27 (US$3.50) for a pack of 20 cigarettes. Traditional homemade snuff 
products are even cheaper. South African law, however, prohibits the sale of any tobacco products to 
minors (<18 years) and bans advertisement and promotion of all ST products as well as cigarettes. 
Furthermore, manufacturers of ST products are required by regulation to place the phrase “Causes 
cancer” on every can of snuff.48 
Summary and Conclusions 
The Demographic and Health Survey52 conducted in many African countries provides an opportunity to 
study the prevalence and, in some instances, the health effects of these products. Prevalence of ST use 
varies widely across countries, with the national prevalence in Madagascar as high as 22.6% for men 
and 19.6% for women, whereas in Nigeria rates are as low as 3.2% for men and 0.5% for women, 
although other data have suggested that prevalence may be higher in certain areas of Nigeria such as the 
northeastern geopolitical zone. 
Smokeless tobacco products in the African Region are consumed in a variety of ways (sniffed, chewed, 
sucked, or applied to teeth and gums) and for a variety of reasons, including the perception that snuff has 
medicinal properties. With a few exceptions, most products available in the region are produced by 
small cottage industries and sold by local vendors.  
More studies are needed on the extent of use, toxicity profiles, and health effects of ST used in the 
region. Although available data are somewhat limited, the nicotine content and toxicity of ST 
products appear to vary widely in this region. There are a few exceptions, but for the most part, 
premade manufactured products tend to have lower levels of tobacco-specific nitrosamines than 
custom-made products. 
Data on the health effects of ST products in this region are also quite limited; however, existing data 
from some parts of Africa suggest that these products are associated with increased risk of oral 
pathologies and elevated blood pressure. Nasal snuff use is associated with increased risks of 
nasopharyngeal cancer and respiratory disease. More information on the health effects of ST use may 
provide governments with much needed incentives to take urgent action to curb the further spread of 
ST use and its health consequences.  






Articles in the WHO FCTC should be considered for implementation for smokeless tobacco use. Few 
studies have assessed how effective graphic health warnings covering 50% of the package display area 
will be for ST, and this would be an area worth evaluating. Wherever it is clear that ST is a popular 
commercial product, the guidelines on Articles 9 and 10 of the Framework Convention, adopted by the 
Conference of Parties in 2010, could provide a legal basis for governments to consider banning the use 
of flavorings in these products in order to reduce their attractiveness to youth. African countries, many 
of which are parties to the WHO FCTC, could benefit from extending the other relevant sections of the 
Convention in order to control ST use, including implementation of the guidelines related to banning 
advertisements for such products (Article 13), educating the public (Article 12), and promoting tobacco 
use cessation (Article 14). Public education could include teaching local vendors and small-scale 
producers how to limit nitrosamine content through best practices in agronomics (such as by using 
N. tabacum plant species instead of N. rustica, which may reduce levels of carcinogens in some 
products). Parallel to these interventions, the public, including traditional health practitioners, could 
benefit from education about the harms of using ST, and all users should be encouraged to quit. As the 
WHO Study Group on Tobacco Product Regulation suggested, strict regulatory controls, including 
setting manufacturing standards, should be applied to commercial snuff manufacturers, starting with 
limiting the toxicant levels.49 
Finally, considering this region’s limited institutional and financial capacity for tobacco control research 
and for tobacco control in general, future efforts to document and monitor toxicity and the health effects 
of ST products in the region will require international collaboration, as envisaged in Articles 21 and 22 
of the WHO FCTC.  
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Description of the Region 
The South-East Asia Region of the World Health Organization (WHO) consists of 11 countries. Six of 
them are geographically located in South Asia: India, Bangladesh, Nepal, Bhutan, Sri Lanka, and the 
Maldives. Four are located in South-East Asia: Thailand, Myanmar, Indonesia, and Timor-Leste. The 
Democratic People’s Republic of Korea (DPR Korea; North Korea) is also a part of this WHO Region.1 
More than 1.8 billion people live in the South-East Asia countries.2 Although countries in the South-East 
Asia Region comprise only 5% of the world’s surface area, about 26% of the world’s population live 
there.3,4 Five countries account for nearly 96% of the total population of the South-East Asia Region: 
India, Indonesia, Bangladesh, Thailand, and Myanmar (Table 13-1). The annual average population 
growth rate of this region is roughly 1.4%, and about two-thirds to three-fourths of the population are 
rural, with the exception of DPR Korea, which is 60% urban.2 Hence, large rural populations 
characterize the region. Some of the world’s major tobacco producers are South-East Asia countries: 
India, Indonesia, Thailand, DPR Korea, and Bangladesh.5  
Table 13-1. Population and land area of countries of the South-East Asia Region  
Country  Area (km2) Population (thousands) 
Bangladesh  143,942 148,692 
Bhutan 48,400 726 
Democratic People’s Republic of Korea (North Korea) 120,525 24,346 
India  3,283,147 1,224,614 
Indonesia  1,903,738 239,871 
Maldives  298 316 
Myanmar  675,535 47,963 
Nepal  146,858 29,959 
Sri Lanka  65,597 20,860 
Thailand  512,015 69,122 
Timor-Leste  14,789 1,124 
Total  6,914,844 1,807,593 
Abbreviation: km = kilometer. 
Source: United Nations 2011 (3). 
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Types of Products and Patterns of Use 
This chapter will first describe the wide variety of smokeless tobacco (ST) products that are made and 
used in this region. Various ST products are chewed, sucked (dipped), applied to the gums and teeth, 
snuffed, or gargled. Products may be as simple and inexpensive as unmanufactured, loose flakes of 
tobacco leaves that are sold by weight and may be chewed with only slaked lime (calcium hydroxide) 
paste, or as complex as a paste made from boiled tobacco and spice flavorings (e.g., kiwam) and sold in 
small glass bottles.6–9  
A common way of consuming chewing tobacco in the region is as an ingredient in betel quid. Use of 
betel quid is an ancient practice. Tobacco was added as an ingredient in the quid beginning around 1600, 
and it is now used in betel quid in many parts of South-East Asia. Betel quid is composed of pieces of 
areca nuts (from the Areca catechu palm), betel leaf from the Piper betle L. (Piperaceae) vine, aqueous 
slaked lime paste (calcium hydroxide, made from roasted limestone or seashells), and other minor 
ingredients such as catechu (for astringency), cardamom, and clove, according to the taste of the user. 
Some of these components are agricultural products (e.g., betel leaf, areca nut), and others are simple 
ingredients that could be cottage industry products (e.g., slaked lime). They are combined by vendors 
and users and made into fresh betel quids for immediate consumption. Historically, betel quid has been 
incorrectly believed to have beneficial medicinal properties.10,11 The user who incorporates tobacco into 
it may not consider tobacco a harmful addition.12  
Smokeless tobacco products of different kinds with different names are often incorporated into betel 
quid, although some are also used separately. The most common type of tobacco incorporated into betel 
quid is plain tobacco flakes (also called sada pata); sometimes flavored tobacco flakes such as zarda or 
khaini may be added. Snuff-type products, which tend to be applied to gums or teeth rather than chewed, 
are not used with betel quid. Although areca nut itself is mildly addictive, a betel quid user may not 
understand the much higher addictive potential of tobacco in the quid.8 
In India, some products have been manufactured on an industrial scale since 1975. These commercially 
produced ST products, such as pan masala and gutka, are modeled after betel quid and contain many of 
the same ingredients but in a dried form and without fresh betel leaf. The manufactured products were 
designed to be easily carried and consumed anywhere at any time, unlike betel quid, which is highly 
perishable and inconvenient to carry because of its high moisture content. In addition to being dried and 
packaged in single-use doses, these manufactured products contain preservatives to lengthen their shelf 
life. They may also contain other ingredients, such as small pieces of areca nut, calcium hydroxide, 
catechu, sweeteners, perfumes, tobacco flakes and/or powder, and flavorings such as menthol, 
cardamom, and clove. Gutka always contains tobacco, but most brands of pan masala do not. Gutka and 
pan masala products frequently carry the same brand names, allowing manufacturers to circumvent laws 
banning tobacco advertisements since they are able to advertise a product that appears identical to 
tobacco-containing gutka.6  






Each country in this region has its own set of ST products (see Appendix A: Description of 
Representative Products From Four Broad Categories of Smokeless Tobacco Products Used Globally, 
and Appendix B: Global Smokeless Tobacco Product Factsheets):  
 Bangladesh: Products for chewing: sada pata, zarda, and khaini are used; for oral application: 
gul.13  
 Bhutan: Products with various uses: tobacco leaf, snuff, khaini, surti or baba (zarda),7 and gutka. 
Production and commercial imports are banned, but some products are smuggled.14 
 India (the country with the widest product range):  
 Products for chewing: (1) Products made with unprocessed tobacco (sada pata): betel quid 
with tobacco, zarda, and khaini. (2) Products made with cured tobacco: gundi, kadapan, and 
flavored zarda. (3) Products containing areca nut: gutka, mawa, Mainpuri tobacco, and dohra. 
Some forms of khaini contain areca nut as well as tobacco.15 
 Products for oral application: Snuff products including mishri/masheri, bajjar, gudakhu, 
tapkeer, red toothpowder, kiwam, creamy snuff, and gul.  
 Other products or uses: Snuff used nasally, and tobacco water for gargling (tuibur).6,12  
 Indonesia: Products for chewing: chewing tobacco as well as cut strands of tobacco chewed with 
betel quid6,16; also dried tobacco leaves rolled to the size of a thumb and inserted into the mouth 
between lips and teeth.7 
 Maldives: Chewing tobacco with betel quid or areca nut; during the 1990s, chewing tobacco of 
unspecified nature was imported into the country in increasing quantities.17  
 Myanmar: Products for chewing: tobacco mixed with honey, alcohol, or lemon juice (hnat hsey) 
which is usually chewed with betel quid; raw tobacco (most users of unmanufactured or “raw” 
tobacco incorporate it into betel quid); gutka and zarda from India are also available.18 Snuff is 
used both orally and nasally.6,19  
 Nepal: Products for chewing: betel quid with tobacco, khaini, zarda, surti, and gutka.20  
 Sri Lanka: Products for chewing: Chewing tobacco (unmanufactured), mainly used in betel 
quid21; also Indian gutka. 
 Thailand: Snuff tobacco used nasally and orally, chewing tobacco, betel quid with tobacco, and 
other ST products, all made in cottage industries.22,23  
 Timor-Leste: Chewing tobacco.24  
Wherever gutka is sold, generally pan masala without tobacco is also available—that is, in India, 
Bangladesh, Bhutan, Myanmar, Nepal, and Sri Lanka. 
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Prevalence of Smokeless Tobacco Use 
Surveys of ST use employ varying methods, questions, and definitions, and for that reason caution 
should be exercised in comparing estimates of prevalence. Surveys’ definitions of current use vary: 
Some surveys define it as any use within the past 30 days, while others ask about different time periods; 
some surveys ask about daily use and use on some days, and still other surveys ask about “current” use 
without defining the term further.  
Current ST use among youth, typically defined as any use in the past 30 days, is as prevalent as smoking 
or more prevalent than smoking among adolescents in the South-East Asia Region.25 Prevalence of ST 
use among youth aged 13–15 years varies across the region and by sex, as shown by data from the 
Global Youth Tobacco Survey (GYTS) for eight countries (Bangladesh, Bhutan, India, Indonesia, 
Myanmar, Nepal, Sri Lanka, and Thailand)26 (Table 13-2). The prevalence of current ST use among 
boys ranges from 3.3% in Indonesia to 14.1% in Bhutan, and prevalence for girls ranges from 2.3% in 
Indonesia to 6.0% in India. In four of the countries, reported prevalence of current ST use for boys is 
more than twice that for girls. In Bangladesh, the prevalence of use among boys (5.8%, 95% confidence 
interval [CI]: 3.5–9.3) and girls (4.2%, 95% CI: 1.9–9.1) is not significantly different. Despite a national 
ban on the sale of all tobacco products,9 the prevalence of ST use among boys and girls combined in 
Bhutan was 9.4%. India (9.0%) and Sri Lanka (6.8%) also reported high prevalence of ST use for boys 
and girls combined.  
Table 13-2. Percentage of adolescents aged 13–15 years who currently used smokeless tobacco in the 
South-East Asia Region, from the Global Youth Tobacco Surveys, 2007–2009 
Country Year Total (%) Boys (%) Girls (%) 
Bangladesh 2007 4.9 5.8 4.2 
Bhutan 2009 9.4 14.1 5.3 
India 2009 9.0 11.1 6.0 
Indonesia 2009 2.8 3.3 2.3 
Myanmar 2007 6.5 10.3 2.7 
Nepal 2007 6.1 8.8 2.9 
Sri Lanka 2007 6.8 9.6 3.9 
Thailand 2009 5.7 7.3 4.1 
Source: Global Youth Tobacco Surveys, 2007–2009 (26).  






National or subnational prevalence data on current use of ST are available for adults (people aged 15 
years and older) in nine countries in the region for the years 2006–2010 (Table 13-3; Map 13-1).27–29 
Current use among adults is defined as use every day or on some days. For three countries (Bangladesh, 
India, and Thailand), reports of the Global Adult Tobacco Surveys (GATS) are available.28 Data have 
been reported for Bhutan, Myanmar, and Sri Lanka in the WHO Report on the Global Tobacco 
Epidemic, 2011 (GTCR) from the WHO STEPwise Approach to Surveillance surveys (WHO STEPS).27 
Data from the Demographic and Health Surveys (DHS)29 have been reported for the Maldives and 
Timor-Leste, and data for Nepal are derived from the individual country survey reported in the 
GTCR.20,27 
Table 13-3. Percentage of adults (≥15 years) who currently used smokeless tobacco in the South-East 
Asia Region, 2006–2010 
Country Year Age group (years) Total (%) Men (%) Women (%) 
Bangladesh* 2009 15+ 27.2 26.4 27.9 
Bhutan† (subnational) 2007 25–74 19.4 21.1 17.3 
India* 2009 15+ 25.9 32.9 18.4 
Maldives‡ 2009 Men, 15–64; 
Women, 15–49 
— 6.0 4.2 
Myanmar† 2009 15–64 29.6 51.4 16.1 
Nepal§ 2008 15–64 18.6 31.2 4.6 
Sri Lanka† 2006 15–64 15.8 24.9 6.9 
Thailand* 2009 15+ 3.9 1.3 6.3 
Timor-Leste‡ 2009–2010 15–49 — 2.5 1.9 
*Global Adult Tobacco Survey, 2009 (28). 
†WHO STEPS, 2006–2009 from: WHO Report on the Global Tobacco Epidemic, 2011 (27). 
‡Demographic and Health Surveys, 2009–2010 (29).  
§Individual country surveys from: WHO Report on the Global Tobacco Epidemic, 2011 (27). 
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Map 13-1. Prevalence of current smokeless tobacco use among adults in the World Health 
Organization’s South-East Asia Region 
 
Note: A rate for males and females combined was not available for Maldives and Timor-Leste. For each of these countries, a total 
figure was calculated by averaging the available male and female rate.  
Sources: Global Adult Tobacco Survey, 2009 (28); WHO STEPS, 2006–2009 from: WHO Report on the Global Tobacco Epidemic, 
2011 (27); Demographic and Health Surveys, 2009–2010 (29); Individual country surveys from: WHO Report on the Global Tobacco 
Epidemic, 2011 (27). 
  






Prevalence of current ST use among men in the South-East Asia Region is high, ranging between 24.9% 
and 51.4% in five of the countries, although in Thailand it is less than 2%. Among women, prevalence 
of current ST use is high in four countries—Bangladesh, Bhutan, India, and Myanmar—with a range 
from 16.1% in Myanmar to 27.9% in Bangladesh. In Bangladesh the prevalence of ST use among 
women (27.9%) is roughly equal to that among men (26.4%), a unique situation in the region. In India, 
32.9% of men and 18.4% of women use smokeless tobacco. Prevalence is highest in the Central, 
Eastern, and Northeastern States. The highest prevalence of ST use among men (62%) is in Bihar; 
among women, the highest prevalence is 49% in Mizoram.12 
The prevalence of ST use tends to be higher in rural areas in Bangladesh, India, and Thailand than in 
urban areas (which is also generally true for smoking).12,13,22,28 In a study of tobacco users in Myanmar 
in 2004, reports of ST use were higher in metropolitan areas, where smoking prevalence was reported to 
be lower; reports of ST use were lower in the central plain, where smoking prevalence appears higher.18 
Smokeless tobacco users aged 15 years and older in three countries in the South-East Asia Region 
(India, Bangladesh, and Myanmar) number close to 259 million. For the entire region, the estimated 
number of ST users aged 15 years and older is 268.6 million (see chapter 2). Rural users in Bangladesh 
and India make up around 80% of total ST users, reflecting the largely rural populations in these 
countries.12,13 
Product preference information for India and Bangladesh, from 2009 GATS data,12,13 is available for 
individuals aged 15 years and older. In India, tobacco with lime (khaini) appeared to be the most 
common form of ST used (11.6% of adults), followed in descending order by gutka (8.2%), betel quid 
with tobacco (6.2%), tobacco for oral application (4.7%), and other oral/nasal products that may contain 
tobacco (4.4%).12 These findings demonstrate that the centuries-old practice of chewing betel quid with 
tobacco has become less prevalent than use of gutka, which is essentially a dry, commercially 
manufactured version of betel quid developed in the late 1960s.8 Using betel quid with tobacco in India 
is still the most common practice in the Northeastern States and Odisha (formerly known as Orissa); 
elsewhere gutka has overtaken betel quid. The 2009 GATS data for Bangladesh showed that betel quid 
with tobacco was by far the most favored product, with a prevalence of 24.3%, followed by gul (5.3%), 
sada pata (1.8%), tobacco with lime (khoinee) (1.5%), and other products (1.4%).13  
A large international study of betel quid use, the Asian Betel-Quid Consortium (ABC) study, captured 
data on ST use in parts of Nepal, Indonesia, and Sri Lanka in 2010.30 The study found that prevalence of 
chewing betel quid with tobacco was comparatively high in central Nepal (men, 43.6%; women, 34.9%) 
and high among women in Indonesia (men, 10.4%; women, 31.7%), but generally low in Sri Lanka 
(men, 6.4%; women, 3.2%).  
Data from the Myanmar Sentinel Prevalence Studies of Tobacco Use show that prevalence among men 
increased from 23.8% in 2001 to 31.8% in 2007; for the same years, prevalence among women 
increased from 8.0% to 12.1%31 (Figure 13-1). Definitive data on trends in most countries are 
unavailable, because successive surveys with the same methodology have not yet been conducted.  
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Figure 13-1. Prevalence of current smokeless tobacco use among adults (≥15 years) in Myanmar, 
2001, 2004, and 2007 
 
Source: Ministry of Health (Myanmar) 2009 (31). 
Comparing ST use with smoking in the countries of the South-East Asia Region, data from the GATS, 
WHO STEPS, and other surveys12,13,19–22,27–29,32–34 reveal that, among men, smoking is the predominant 
mode of tobacco use in Indonesia, Thailand, Bangladesh, Sri Lanka, and Nepal, whereas ST use is the 
predominant practice in India and Myanmar (Figure 13-2). Smoking rates among women in the region 
remain low—mostly well under 15%. Smokeless tobacco use among women is generally more common 
than smoking, except in Nepal.33 The National Family Health Survey conducted in India in 2005–2006 
was the first survey to find that men had a higher rate of ST use than of smoking.9 






Figure 13-2. Current smoking versus current smokeless tobacco use prevalence among men and 
women in six South-East Asia Region countries, 2006–2009  
 
Source: World Health Organization, 2011 (33). 
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Information on the use of both smoked and ST products, or dual use, is available from the GATS for 
Bangladesh, India, and Thailand (Figure 13-3). In India, 15.4% of tobacco users—42.3 million people—
use both smokeless and smoked tobacco. In Bangladesh, about one-fifth (22.4%) of male tobacco users 
are dual users, compared to approximately 19% in India and only 1% in Thailand. Among women 
tobacco users in Bangladesh, Thailand, and India, only 2.5%, 3.3%, and approximately 5%, respectively, 
both smoke and use smokeless tobacco.12,13,22 In a cross-sectional study of women in a town in Nepal, 
tobacco smokers were twice as likely as non-smokers to chew tobacco (p<0.0001).35  
Figure 13-3. Percent of dual use, smoking only, and smokeless tobacco use only among adult tobacco 
users, by sex and country, GATS 2009–2010 
 
Abbreviation: GATS = Global Adult Tobacco Survey. 
Sources: India: GATS, 2010 (12); Bangladesh: GATS, 2009 (13); Thailand: GATS, 2009 (22).  
  






Toxicity and Nicotine Profiles of Products 
Some types of ST products in the South-East Asia Region are characterized by high levels of tobacco-
specific nitrosamines (TSNAs), including khaini and zarda, and some, such as gul powder, also have 
high levels of nicotine.15,36 In addition, the use of areca nut with tobacco introduces other harmful 
constituents.8 Table 13-4 includes the nicotine and nitrosamine levels of several regional products, 
including gul powder, zarda, gutka (both commercially manufactured and cottage industry products), 
and khaini. 
Table 13-4. Nicotine and nitrosamine levels in selected regional products  
Product pH 
 Total nicotine Free nicotine 
mg/g wet weight 
  NNK NNN NNAL Total TSNAs* 
ng/g wet weight 
Gul Powder 8.79–9.22  33.4–34.1 29.1–31.0  1,330–1,370 5,190–8,020 590–630 13,400–17,100 
Zarda 5.22–6.51  9.55–30.4 0.17–0.63  457–3,840 2,910–28,600 248–3,460 5,490–53,700 
Gutka:    
Manufactured 
(India) 
8.46–8.88  1.09–1.78 0.86–1.78  57.1–456 167–1,280 23.2–258 370–2,250 
Cottage 
Industry (India) 
7.43–8.61  0.91–4.20 0.19–3.33  7.1–375 154–18,600 10.8–1,030 264–23,900 
Khaini 9.65–9.79  2.53–4.79 2.48–4.68  288–502 16,800–17,500 1,350–1,440 21,600–23,500 
*Total TSNAs represent the sum of NNK, NNN, and NNAL (shown); N’-nitrosoanatabine and N’-nitrosoanabasine (not shown). 
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNA = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 
Source: Stanfill et al. 2011 (15). 
Health Problems Associated With Product Use 
A large body of published epidemiologic studies shows strong associations between ST use in the 
South-East Asia Region and several serious health consequences.  
Cancer 
Incidence of oral and pharyngeal cancers is high in the countries of this region compared to most of the 
world.37 The high incidence rates for these cancers have been attributed in large part to ST and areca nut 
use, as well as to smoking products such as bidis, cheeroots, pipes, and cigars. Estimated incidence rates 
for oral cancers (lip and oral cavity) for the countries of the region are shown in Table 13-5. 
Most of the epidemiologic studies on ST come from India and pertain to cancer. The International 
Agency for Research on Cancer (IARC) evaluated existing evidence, including evidence from the 
South-East Asia Region, on the carcinogenicity of ST and of betel quid with tobacco and declared the 
evidence “sufficient,” meaning that a causal relation had been established between ST use and cancer, 
specifically of the oral cavity.8–10 The evidence that betel quid with tobacco causes pharyngeal and 
esophageal cancers was also declared sufficient.8 A few illustrative studies are mentioned below. 
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Table 13-5. Annual age-standardized incidence rate of lip and oral cavity cancers in South-East Asia 
Region countries: Estimates from GLOBOCAN, 2008 
Country 
  Men  
 Cases ASRW 
  Women  
 Cases ASRW 
  Both  
 Cases ASRW 
Bangladesh  5,048 9.6  5,354 9.9  10,402 9.7 
Bhutan  19 6.9  10 4.5  29 5.7 
India  45,445 9.8  24,375 5.2  69,820 7.5 
Indonesia  2,693 2.8  2,310 2.1  5,003 2.4 
Maldives  23 24.5  7 8.2  30 16.5 
Myanmar  1,001 5.1  908 3.9  1,909 4.5 
Nepal  886 10.2  357 3.6  1,243 6.7 
Sri Lanka  1,701 16.5  589 5.0  2,290 10.3 
Thailand  2,038 5.8  2,360 5.8  4,398 5.9 
Timor-Leste  9 3.1  7 2.2  16 2.6 
Democratic People’s Republic 
of Korea (North Korea) 
 138 1.1  122 0.8  260 0.9 
Total for South-East Asia Region  59,001 8.4  36,399 5.0  95,400 6.7 
Abbreviation: ASRW = Age-standardized incidence rate (for the world population) per 100,000 people. 
Source: Ferlay et al. 2010 (37). 
Oral Cancer 
The first known hospital-based case-control study in India was reported by Orr in 1933.38 In the mid-
1960s several additional studies were conducted in South-East Asia Region countries, including a study 
in India and Sri Lanka by Hirayama.8,39 The studies by both Orr and Hirayama found a dose–response 
relationship between chewing betel quid with tobacco and cancer.10,38,39 A 2003 multicenter study from 
southern India found that chewers of betel quid with tobacco had a ninefold excess risk of oral cancer 
compared to never chewers (odds ratio [OR] = 9.27; 95% CI: 6.79–12.66), which was nearly four times 
higher odds than that for smokers.40  
A review article from 1990 found that the peak age of occurrence of oral cancer was at least a decade 
earlier in India than in Western countries. In the 1980s, only 10% to 15% of people with oral cancer in 
India went to the hospital when their cancers were in localized stages, a delay that results in poor 
survival rates.41  
In the South-East Asia Region only a few studies have investigated the use of ST without areca nut. 
Most notable was a large cross-sectional study from the mid-1960s in north-central India, which found 
that, compared to the risk for non-chewers of tobacco, the excess risk of oral cancer was three times 
greater for chewers of plain leaf tobacco and 22 times greater for users of areca nut mixed with tobacco, 
although the statistical significance of this finding was not reported.42  







In a case-control study in central India, chewers of tobacco with traditional/local ingredients (such as 
lime or betel quid) had a ninefold higher risk of oropharyngeal cancer than non-chewers (OR = 9.0; 95% 
CI: 4.6–15.2).43 In a study conducted in southern India, a stratified analysis showed that chewers of betel 
quid with tobacco who had never smoked or been alcohol drinkers had a nearly fourfold excess risk of 
pharyngeal cancer (OR = 3.7, 95% CI: 2.2–6.3).40 Another study found that hypopharyngeal cancer may 
develop from chewing gutka, betel quid with tobacco, zarda, or mawa.44 
Esophageal Cancer 
A 1970s case-control study in Sri Lanka found an association between ST use and esophageal cancer.45 
A more recent (2001) case-control study in northeastern India found that users of dried tobacco leaf 
(chadha) had adjusted excess risks of esophageal cancer between three and five times higher than the 
risks for non-users (p<0.001, adjusted for tobacco smoking and alcohol drinking).46 In a study in 
southern India, users of betel quid with tobacco who did not smoke or drink alcohol had a nearly sixfold 
excess risk of esophageal cancer (OR = 5.7, 95% CI: 3.5–9.4).40  
Other Cancers 
Some evidence from India supports associations between ST and other cancers. Evidence for stomach 
cancer in users of chewing tobacco, betel quid, and tuibur was found in one study in India’s northeastern 
region.47 Moreover, case-control studies have found evidence of associations between betel quid use and 
cervical and breast cancers.48,49 Another study found evidence for an association between use of 
chewing tobacco and snuff and the development of penile cancer.50  
Precancerous and Other Oral Conditions 
Abnormal changes in the oral mucosa often precede the development of squamous cell carcinoma. Oral 
leukoplakia is the most common of these changes. It is generally associated with any form of tobacco 
use, including ST use and smoking.51 Another condition is oral submucous fibrosis (OSF), a progressive 
disease in which the oral mucosa loses elasticity and develops fibrous bands that cause difficulty in 
opening the mouth. OSF can progress to cancer, although the malignant transformation rate of OSF is 
relatively low. It is also associated with chewing areca nut, which is often consumed with tobacco.8  
Gutka chewing is also very strongly associated with the development of OSF. A review showed that five 
studies found a strong relationship between gutka chewing and OSF, including a dose–response 
relationship.52 OSF appears earlier in pan masala and gutka users than in betel quid users. In one Indian 
study, OSF was diagnosed on average about 3 years after individuals had begun using pan masala or 
gutka, compared to roughly 9 years after initiation of betel quid use.53 OSF was even found in 
teenagers.54 Incidence of OSF has also increased. In the Indian state of Gujarat, from 1993–1994 to 
2003–2004, incidence of OSF increased sixteenfold, and incidence of squamous cell carcinoma of the 
oral cavity increased by around 11%.55 
A 2010 cross-sectional study of 1,029 adults in Sri Lanka showed the prevalence of oral disorders to be 
11.3%, or 102 cases; 25 of these cases were OSF cases.56 
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Use of ST during pregnancy can lead to adverse reproductive outcomes such as low birth weight, 
stillbirth, and pre-term birth, as has been demonstrated in numerous studies in India. A cohort study in 
Mumbai in 2004 found that women using ST had a 60% higher risk of having a low birth weight baby 
than non-users (p<0.05).57 After adjustment for potential confounders, users also had a 2.6-times higher 
risk of stillbirth (95% CI: 1.4–4.8). A dose–response relationship was found between stillbirth and use of 
mishri, the most commonly used product in this cohort.58 Other studies have noted that betel quid both 
with and without tobacco may be associated with adverse pregnancy outcomes such as reduced birth 
weight and pre-term birth.8,9  
Cardiovascular Diseases  
Information has been accumulating globally on the association between ST and cardiovascular disease. 
The international INTERHEART study showed an independent association between ST use and 
cardiovascular events such as acute myocardial infarction in different parts of the world, including 
India.59 A similar association was shown in a study of randomly selected death records from a small 
town in Uttar Pradesh, India.60 
Supporting the results on cardiovascular-related events and deaths, other studies show that 
cardiovascular risk factors are higher among ST users than non-users, as they are in smokers compared 
to non-smokers. For example, in a cross-sectional study in India, ST users had a nearly threefold higher 
risk of diastolic hypertension (OR = 2.7, 95% CI: 1.4–4.9) compared to people who did not use tobacco, 
adjusted for age, body mass index, exercise, and family history of high blood pressure.61 In another 
study in India, tobacco chewers had a significantly higher (p<0.001) systolic blood pressure, diastolic 
blood pressure, and resting heart rate, as well as significantly higher levels of total cholesterol, low-
density lipoprotein (LDL) cholesterol, and triglycerides when compared to individuals in a control group 
matched on sex and age. Prevalence of these cardiovascular risk factors was similar among chewers and 
smokers.62  
Overall Excess Mortality  
The conclusion that ST contributes to premature death is supported by the results of a cohort study 
undertaken in Mumbai, where the most commonly used product was mishri (or masheri). Participants in 
this study were 99,244 individuals aged 35 years or older at baseline, with follow-up taking place on 
average at 5.5 years. The study found that the relative risks of premature death associated with ST use 
were significant for both women (25% higher risk) and men (16% higher risk).63 See Table 13-6 for this 
study’s data on all-cause mortality, by type of ST product. 
  






Table 13-6. Relative risks for all-cause mortality by type of smokeless tobacco used, from the 1992–1999 
Mumbai Cohort Study  
Type of Smokeless Tobacco 
  Relative risk* (95% confidence interval)  
 Men Women 
Mishri  1.14 (0.97–1.33) 1.21 (1.10–1.34) 
Mishri plus other smokeless tobacco†  1.18 (1.07–1.31) 1.36 (1.24–1.48) 
Other smokeless tobacco†  1.24 (1.08–1.41) 1.37 (1.09–1.73) 
Never tobacco use  1.0 (reference) 1.0 (reference) 
*Age- and education-adjusted relative risk using Cox model.  
†Other smokeless tobacco was generally tobacco with lime.  
Source: Gupta et al. 2005 (63). 
Dependency Issues 
Tobacco addiction is a major health consequence of ST use. It is characterized by continued frequent use 
of ST and chronic exposure to all the other harmful effects of tobacco and its related conditions. Quit 
rates are very low in the region, as shown in the GATS in India, Bangladesh, and Thailand. The 
proportions of ever users of ST who had successfully quit as of 2009 were 7.8% in Bangladesh, 7.9% in 
India, and 21.8% in Thailand (quit ratios calculated from full GATS reports).12,13,22  
One study in Myanmar found that tobacco users believed that quitting betel quid with tobacco is more 
difficult than quitting smoking.18 Older intervention studies in India found that smokers who also use ST 
have the most difficulty of all.64 The addictiveness of tobacco is the major factor responsible for 
sustaining the market, both for smoking and using smokeless tobacco. 
Marketing and Production Practices of Industry  
With its long tradition of use in the region, ST has economic importance even in countries where 
smoking predominates (Indonesia and Thailand), and its importance has been growing in several other 
countries (Bangladesh, Bhutan, India, Nepal, and Myanmar). 
Production 
Production figures on tobacco destined for smokeless use are available for India only: In 2002–2003, 
India produced about 84.9 thousand tons of tobacco to be used in making chewing tobacco products, and 
6.4 thousand tons of tobacco to be used in snuff products, out of a total of 491.7 thousand tons of 
tobacco produced. Thus, 18.6% of tobacco produced was destined for making ST products.65  
Most ST product manufacturers are cottage-based industries, though some are large factory operations. 
A few multinational corporations have also entered the market in the last 10 years. In 2001, Swedish 
Match launched the Click brand of snus in India, but the product was not accepted as well as expected, 
and after a few years it was discontinued.66,67  
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Cottage-based ST is sometimes packaged in small pouches like the manufactured, commercial products. 
Some products can be made or assembled by a vendor (such as mawa or betel quid with tobacco) on 
demand from users, or users can buy the ingredients from shops and assemble them (as in betel quid and 
tobacco) or process them (such as by roasting and powdering tobacco flakes to make mishri). In India, 
Bangladesh, Myanmar, and to an extent Indonesia, preparation of ST products was traditionally a 
cottage industry, but large manufacturers have entered the scene in more recent years with, for example, 
fire-cured snuff. In India since the early 1970s, and more rapidly since 1991 after the economy was 
liberalized, industrial-scale production of chewing tobacco products, especially gutka, increased. The 
cost of gutka was typically 1 to 2 Indian rupees (INR) (US$0.02–0.04), but it is now being purchased for 
up to INR 7 (US$0.13) for a small sachet.68 Also since the early 1990s, India has seen a rise in industrial 
production of chewing tobacco, from INR 1.1 billion (US$36 million) in 1993–1994 to INR 6.7 billion 
(US$142 million) in 2000–2001, as demonstrated by excise collections.69 
Marketing Practices  
Smokeless tobacco products are made palatable by adding spices, areca nut, sweeteners, and scents. 
They are made attractive to consumers by colorful packaging, and this packaging is convenient as well. 
Since 1985, products have been sold in single-dose plastic sachets. Prices are low, with single-dose 
packages cheap enough that even schoolchildren can buy them (as mentioned above, from INR 2 to 
INR 7, or US$0.04–0.13 for a small sachet).68  
Brand names are chosen to appeal to different social segments: names of resort areas (Shimla and Goa), 
appellatives (e.g., Sir, by which students usually address teachers), names with religious significance 
(Tulsi, meaning holy basil), and fun names (Chaini Khaini). Brand names for products not containing 
tobacco, such as most varieties of pan masala, are the same as those for products containing tobacco 
(gutka, khaini). This identical branding, both of tobacco and non-tobacco products and of smokeless and 
smoked tobacco products, is intended to boost the sales of the lesser known product. Godfrey Phillips 
(partly owned by Philip Morris) entered the chewing product market with a pan masala in 2010, stating 
that the company expected that its cigarette business would “provide the synergy to its chewing 
product.”70  
Identical branding of tobacco and non-tobacco products is also an attempt by manufacturers to 
circumvent India’s ban on tobacco advertising, using the non-tobacco products as surrogates for the 
tobacco-containing products. Thus, advertising for the non-tobacco versions of the tobacco-containing 
products is considered indirect advertisement of those tobacco products.71  
Advertisements for the non-tobacco products have different themes, such as a favorite elderly uncle, 
middle-aged parents, a couple in love, and a sexy young lady. These advertisements are seen on 
television, in outdoor media (such as on buses), and sometimes in newspapers.71  






Distribution and Sales 
A few brands of chewing tobacco, including gutka, are sold nationwide in India; others are sold 
regionally or locally. In the South-East Asia Region, ST products are normally sold through street 
vendors, kiosks, and grocery/convenience stores. At kiosks and street vendor stands they are sold along 
with smoking products, candies, and snacks.  
Smokeless tobacco Internet sites appear to be targeted toward foreign buyers (e.g., 
http://www.Desismoke.com). Companies in Bangladesh, India, Indonesia, Nepal, and Sri Lanka advertise 
their chewing tobacco products on the Internet, and many trade websites display contact information 
for outlets in the region that sell ST, among other products (such as the manufacturer directory at 
http://www.Alibaba.com). On one major website, by far the largest number of exporters, 186, are located 
in India, whereas other individual South-East Asia Region countries have 7 at most.72 Through this 
website, companies in India and Nepal are exporting gutka,72 and India, Nepal, and Indonesia are 
exporting snuff.  
India is one of the world’s largest exporters of tobacco, exporting approximately 50% of its total tobacco 
production to other countries, according to the Directorate of Tobacco Development of the Government 
of India.65 From 2000–2001 to 2009–2010, legal exports of chewing tobacco from India increased nearly 
450%, from 1,953 tons to 8,725 tons.73,74 The value of exported chewing tobacco products in 2009–2010 
was around US$63.6 million. In addition to legal exports, some amount of ST is smuggled to other 
countries in South-East Asia, and possibly around the world.75 During 2009–2010, India exported 
chewing tobacco products to more than 48 countries, and snuff to at least 6 countries. The countries to 
which India exported 11 tons or more of tobacco for chewing include: the United Arab Emirates, 
4,477 tons; Saudi Arabia, 980 tons; Malaysia, 323 tons; the United States, 160 tons; and Kenya, 
77 tons.73 India also exported 85 tons of snuff products in 2009–2010, primarily to China, Tanzania, 
and the United States.  
Smokeless tobacco products exported from India mainly cater to the South Asian diaspora, but use of 
South-East Asian ST products by local inhabitants in various countries has also been reported.52  
Current Policy and Interventions  
Prevention and Cessation Interventions 
School-Based Interventions 
School-based interventions can lead to successful primary prevention of tobacco use. Project MYTRI 
(Mobilizing Youth for Tobacco-Related Initiatives in India) aimed to decrease tobacco use/uptake by 
students in grades 6–9 in 32 urban schools in India. This culture-specific intervention, Indian in content 
and communication, addressed both smokeless and smoked forms of tobacco. Teachers were trained to 
assist with the program, and this teacher training was critically important to rigorous implementation of 
the program. Teacher training, a higher proportion of students participating in classroom discussions, 
and better peer-leader-student communication all helped to support the implementation of the program 
and lower children’s reported susceptibility to chewing tobacco.76 Project MYTRI was conducted in 
schools in Delhi and Chennai by HRIDAY-SHAN (Health Related Information Dissemination Amongst 
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Youth Student Health Action Network), a voluntary organization of health care professionals and 
social scientists.76,77 
Policies that ban all tobacco use on school grounds are in place in federal schools run by India’s central 
government, which are few in number,78 but these bans are not implemented as widely in schools run by 
the states. A study in Bihar found that in federal schools, where there was a policy of no tobacco use, 
teachers’ daily use of ST was significantly lower than in state schools (41.7% versus 14.1%, 
respectively).79 
Although most children have become aware that smoking tobacco and using khaini and zarda are 
harmful to their health, they do not appear to recognize that gutka, an ST product commonly used 
among children, also causes many health problems.80 
Community Interventions  
A program of interventions was conducted in the 1970s and 1980s in three rural areas in India with 
36,000 tobacco users aged 15 years and older (12,000 in each area).64 The interventions included oral 
examinations by dentists at yearly intervals, followed by individual counseling by specially trained 
social scientists81; two documentary films viewed by groups of 20–25 participants, followed by 
discussion; and radio spots, newspaper articles, and posters. Interventions were followed up by small 
group “cessation camps,” in which villagers trying to quit met with counselors, and detailed discussions 
were held daily to address difficulties in quitting until people felt confident of remaining abstinent on 
their own. These interactions were updated and informed by the progress of the intervention.82 Quit rates 
obtained in these single-arm interventions (after 10 years: 15.1% for men and 18.4% for women 
chewers) were higher than those found in the no-intervention population (2.3% of men and 7.8% of 
women).81 Another anti-tobacco community education program in rural India demonstrated similar 
results in the early 1990s: After 5 years, the use of ST decreased approximately 6% (from 16.4% to 
10.8%; p<0.0001) among men in the intervention group compared with a 0%–1% decrease in control 
populations.83  
Various voluntary organizations conduct anti-tobacco interventions from time to time in rural areas of 
the region, but they do not always evaluate the interventions or publish their findings, so the experiences 
are lost to the public health community. Nevertheless, published data show positive results, both in 
terms of cessation and reduction of tobacco use and in the regression of oral precancerous lesions.81 
In 2003, Myanmar piloted a cessation intervention in 13 communities. Over 200 facilitators were trained 
to lead intervention activities, which varied across communities. Some of these activities included 
roundtable discussions, advocacy talks with community leaders, monthly meetings between facilitators 
and quitters, distribution of health education materials, and live entertainment education such as songs 
and plays performed at festivals. The impact of these cessation activities varied widely in different 
communities depending on the intensity of the interventions. Among smokers, 11% completely stopped 
smoking, but ST quit rates across the communities was not reported.84 







A workplace tobacco cessation program was conducted and evaluated at a chemical plant in Ratnagiri, a 
rural district of Maharashtra, India. Before the program, over 48% of the employees used tobacco, 
mostly in smokeless form, with little awareness of its health effects. Precancerous lesions were found in 
40%, mainly in ST users.85 The intervention consisted of awareness lectures, group discussions and 
individual counseling on how to quit, and an offer of pharmacotherapy (bupropion). Awareness 
programs were also arranged for family members and contract employees. Follow-up sessions were held 
every 6 to 8 weeks, and tobacco quit rates improved with each session, reaching 40% at the end of one 
year, which was verified through urine cotinine testing. Among employees who quit, many noticed that 
their oral lesions decreased in size.86  
Evidence From Cessation Clinics 
In 2002, India’s Ministry of Health and Family Welfare and the WHO set up tobacco cessation clinics in 
hospitals and nongovernmental organization (NGO) settings in India. The original 13 clinics expanded 
to 19, and 34,741 participants were registered in the first 5 years. For 69% of the participants, behavioral 
strategies alone were used, and for the remaining 31%, pharmacotherapy was added, mainly bupropion 
and nicotine gum.87,88 The results showed that at 6 weeks, 14% of the study participants had completely 
quit and 22% had reduced their tobacco intake by half. Results at 3, 6, and 9 months showed that 
younger male patients, users of smokeless forms of tobacco, and those receiving a combination of 
pharmacotherapy and behavioral counseling were more likely to reduce tobacco use. 
Mass Media Campaigns 
As a part of the National Cancer Control Programme, the Indian Council for Medical Research and All 
India Radio collaboratively conducted a mass media intervention on drugs, alcohol, and tobacco. Called 
Radio–DATES (for Drugs, Alcohol, and Tobacco Education), the intervention, consisting of 20-minute 
programs, was broadcast in 16 languages on 84 radio stations (of 104 existing stations at that time) once 
a week for 30 weeks.89 To assess the impact and reach of this media campaign, community-based 
surveys were conducted in two rural communities where no organized tobacco control programs existed. 
After hearing the programs, about 6% of tobacco users quit in rural Karnataka and 4% quit in rural Goa. 
In Karnataka, 32% of potential listeners heard at least one episode on tobacco compared to 27% in 
Goa.90 
Current Policy  
All member states in the region except Indonesia have ratified the WHO FCTC.91 As of January 2014, 
nine of the countries that have ratified have adopted comprehensive tobacco control laws.33 (Timor-
Leste has ratified the FCTC and as of December 2013 was in the process of passing national-scale 
legislation.) Table 13-7 summarizes the policies of these countries.  
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Bhutan has introduced the strongest tobacco restrictions of any country in the world. In addition to 
banning imports, Bhutan has banned exports, agricultural production, manufacture, and sale of tobacco 
and all tobacco products. Health warnings are required on tobacco brought in from another country for 
personal use.92  
Implementation and enforcement are a huge challenge in the region for various reasons. In India 
specifically, a major obstacle to implementing tobacco control legislation has been fear of the economic 
consequences of job losses among the country’s large number of tobacco workers (especially bidi 
workers). Other obstacles to successful and efficient implementation include a time lag to prioritize 
allocation of resources, interference from the organized tobacco industry, the informal nature of a large 
part of the industry, and high rates of use in large populations.  














Ban on sale within 
100 yards/meters 
of a school 
Bangladesh     Yes  
Bhutan   *   Yes† N/A‡ 
Democratic People’s 
Republic of Korea 
(North Korea) 
      
India      Yes  
Indonesia        
Maldives     Yes§  
Myanmar      Yes§  
Nepal      Yes§  
Sri Lanka      Yes§  
Thailand      Yes  
Timor-Leste       
 = Ban applied.  
*Bhutan allows limited import of tobacco products for personal consumption only. 
†Health warnings are required on all imported tobacco products (added by the country of origin). 
‡Bhutan banned sale of smokeless tobacco products in any location, therefore a specific ban on sale near schools does not 
apply. 
§Health warnings are required on tobacco products by the national laws, but there is no specific rule for smokeless tobacco.  
Abbreviation: N/A = not applicable.  
Sources: Adapted from World Health Organization, 2011 (19); Bangladesh data from Campaign for Tobacco-Free Kids, 2013 (116). 
  







Unlike taxes on cigarettes, taxes on ST are low or nonexistent. In the South-East Asia Region, 
unmanufactured tobacco sold in loose form is often not taxed. Betel quid with tobacco, which is sold 
fresh by street vendors, is not taxed and has no warning labels. In 2008–2009, the government of 
Bangladesh recognized ST (mainly for chewing) as a manufacturing industry rather than a cottage 
industry and, under the 2011–2012 budget, Bangladesh taxed ST products for the first time.93 In India, 
the ST industry, particularly the gutka industry, has grown tremendously in the last three decades. All 
manufacturers of tobacco products in India are expected to register with the government and pay excise 
taxes, but this is poorly enforced, and it is estimated that only one-fourth of the excise tax due on the 
gutka and pan masala industry is actually paid.94 In 2008–2009, India collected INR 35 billion 
(US$632 million) in taxes on chewing tobacco.95 
Bans on Public Use 
Nepal banned the use of any tobacco product in all indoor public places in its Tobacco Control and 
Regulation Act, which came into force on August 7, 2011.96,97  
Bans on Sale to Minors 
Sale of ST to minors is prohibited in the countries with comprehensive laws (except Bangladesh). India, 
Myanmar, and Nepal are the only countries in the region that prohibit selling tobacco within 100 yards 
of educational institutions. In 2011 India, with the assistance of some NGOs, local governments, and 
courts, intensified enforcement of this ban.98  
Health Warnings on Packages 
India requires textual and pictorial health warnings for ST products sold domestically but not for 
exports. However, industry interference has caused a long delay in introducing pictorial warnings.99,100 
In Thailand, packages of shredded tobacco meant for roll-your-own cigarettes carry a warning about 
smoking, but no warning about using tobacco in smokeless form is required. In Bhutan, commercial 
importation of tobacco is banned, but health warnings are required on tobacco brought in from another 
country for personal use. Nepal passed legislation in 2011 requiring graphic warnings on all kinds of 
tobacco products.101 In much of this region, unmanufactured, loose tobacco is also not advertised and 
does not display any warnings.95 
Restrictions on Advertising 
Bhutan, India, Maldives, Myanmar, Sri Lanka, and Thailand have prohibited advertisements for ST, but 
implementation is inadequate, mainly due to the indirect advertising shown on Indian television (that is, 
advertisements for non-tobacco products that are similar to tobacco products in various ways; see the 
discussion of indirect advertising in “Marketing Practices of Industry,” above). Bangladesh and DPR 
Korea have no restrictions on advertising of smokeless tobacco. Around 70% of adults in Bangladesh 
had noticed advertisements for ST as well as ST company sponsorships or promotions, according to the 
GATS (2009).28,102 In India, a ban on direct advertisements is enforced, but indirect advertisements and 
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surrogate advertisements persist. Direct advertisement continues at points of sale, and 10.8% of adults 
have noticed point-of-sale advertisements or promotions of ST.12  
Bans on Sale  
Bhutan bans the sale of all forms of tobacco. In India, a 1992 amendment to the Drugs and Cosmetics 
Act of 1940 prohibited the manufacture, sale, and distribution of toothpastes and toothpowders 
containing tobacco (such as creamy snuff and red toothpowder), although several studies continue to 
find nicotine in some brands of dental care products.103,104  
In India between 2001 and 2003, five states attempted to ban chewing tobacco (including gutka) and pan 
masala, but Goa is the only state that has managed to actively restrict the sale of chewing tobacco.105 In 
2004, after a group of manufacturers challenged the bans in Maharashtra and Andhra Pradesh, the 
Supreme Court of India ruled that state bans were unconstitutional because only the central government 
has the power to ban such items.106 
Despite the early success in Goa, it would be another 7 years before the next state would ban ST 
products. The Food Safety and Standards Authority of India helped pave the way for states to ban gutka 
and other chewing tobaccos under Regulation 2.3.4 of the Food Safety and Standards Regulations, 2011, 
which prohibits any harmful ingredient, including nicotine and tobacco, from being added to food.107–109 
The Indian Supreme Court determined in 2004 that gutka was a “food product” and was thus covered 
under this regulation. The regulation authorizes state food commissioners to ban all gutka products 
throughout the country, although it was not widely enforced at first. In April 2012, Madhya Pradesh 
became the first state to implement the ban on gutka by invoking Regulation 2.3.4.107,108,110 As of 
October 2013, all of India’s states and union territories except Meghalaya and Lakshadweep have 
banned the sale of gutka.111  
This ban has been enforced in varying degrees across India, and some states, such as Maharashtra and 
Manipur, have banned other types of ST including zarda and khaini.111 While some states and union 
territories have been relatively successful in enforcing the ban on gutka, industry is also circumventing 
these bans by selling pan masala and tobacco in separate pouches.109  
Import Bans 
Thailand (1992) and Bhutan (2011) have banned the import of ST products. Thailand instituted this 
policy out of concern about the possibility of American and European ST products becoming widely 
used in the country. Thailand’s ban on imports was supported by both the public health community and 
the state-owned Thailand Tobacco Monopoly.23 
In 2009, Bhutanese school boys aged 13–15 years had the highest prevalence of ST use by young 
adolescents in the region.26 Bhutan first introduced a ban on tobacco sales and imports in 2004, but 
implementation was weak, and a thriving black market for tobacco developed.112–114 In 2010, Bhutan 
passed the Tobacco Control Act, which imposed harsher penalties and strengthened enforcement.113,115 
Now individuals may bring in small amounts of ST for personal use if they declare it and pay a duty.  






Summary and Conclusions 
Smokeless tobacco use is highly prevalent in the South-East Asia Region, especially when compared 
with other regions of the world, ranging from 25% to 51% in five countries (Bangladesh, India, 
Myanmar, Nepal, and Sri Lanka) compared to only 2% in Thailand. Specifically, governments in this 
region are faced with newer manufactured products such as pan masala and gutka, as well as brands of 
packaged chewing tobacco, which may pose dangers greater than those of traditional products such as 
betel quid and ordinary chewing tobacco. The cottage industry nature of some products complicates 
efforts to understand and regulate traditional products in the region.  
Evidence from existing toxicity profiles indicates high levels of TSNAs in products such as khaini and 
zarda. Harmful constituents are found not only in tobacco, but also in areca nut, which is widely 
incorporated in ST products.  
High incidence of oral cancer exists in several areas of the region, especially in India, and is partly 
attributed to the use of ST and areca nut products. Additional research illustrates other adverse health 
outcomes associated with these products, including negative reproductive outcomes and cardiovascular 
disease. Much of this research is based on data from India, however, and additional research on health 
outcomes from a variety of products across the region is necessary to fully understand the health impact 
of smokeless tobacco.  
Government action is also required to curb illegal imports of ST from other countries within and outside 
the South-East Asia Region. In addition, advocacy campaigns to strengthen and enforce policies 
restricting ST and smoking are needed in most of the region’s countries, but these efforts require more 
resources, both for the present and the long term. Several intervention programs, specifically school-
based interventions, community interventions, and mass media campaigns, have been evaluated and 
shown to have some impact, but most of this work was conducted only in India. Policies to raise 
awareness of these interventions and increase the accessibility of cessation counseling with behavior 
therapy and pharmacotherapy are still needed in many other countries across the region.  
The WHO FCTC has been ratified across South-East Asia, except by Indonesia, but enforcement of 
tobacco control policies is weak in the region. Taxes and health warnings are mostly nonexistent for ST 
products (specifically unmanufactured tobacco). Countries such as Bhutan, India, Maldives, Myanmar, 
Sri Lanka, and Thailand have banned ST advertising, but more work is needed to improve these efforts 
in the South-East Asia Region. 
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Description of the Region 
The World Health Organization (WHO) Western Pacific Region extends from China and Mongolia in 
the north and west to New Zealand in the south and French Polynesia in the east. The region consists of 
37 member states and areas, and today is home to over 1.6 billion people, nearly one-quarter of the 
world’s population.1 
The Western Pacific Region is characterized by great diversity and disparity. Both the most populous 
country (China, with approximately 1.3 billion people) and the least populated territory (Pitcairn Islands: 
population, less than 50) belong to this region1,2 (see Table 14-1 for country land areas and populations). 
This region includes high-income countries as well as some of the world’s lowest income countries. 
Over a thousand languages are spoken within the region, and most of the world’s religions are 
represented. Ethnically, politically, economically, and socioculturally diverse, the Western Pacific 
Region simultaneously poses great challenges and offers substantive opportunities in tobacco control. 
Table 14-1. Population and land area for selected Western Pacific Region countries 
Country/Area* Area (km2) Population (thousands) 
Australia 7,422,667 22,268 
Cambodia 181,256 14,138 
China 9,580,964 1,341,335 
Cook Islands† 236 11 
Fiji 18,319 861 
Macau 26 544 
Malaysia 330,244 28,401 
Micronesia, Federated States of 703 111 
Mongolia 1,378,000 2,756 
Northern Mariana Islands† 464 51 
Palau† 459 21 
Papua New Guinea 457,200 6,858 
Philippines 299,875 93,261 
Singapore 683 5,086 
Solomon Islands 28,316 538 
South Korea 99,554 48,184 
Tuvalu† 26 11 
Vanuatu 12,000 240 
Vietnam 331,502  87,848 
Total 20,142,494 1,652,523 
*Unless otherwise indicated, data are from: World Population Prospects: The 2010 Revision (2).  
†For data on Cook Islands, Northern Mariana Islands, Palau, and Tuvalu: The World Factbook (63).  
Abbreviation: km = kilometer. 
 




Within the Western Pacific Region, several subregional groupings exist, based primarily on political 
and trade alliances. These include the Association of South-East Asian Nations (ASEAN), the Pacific 
Islands Forum, and the Asia–Pacific Economic Cooperation (APEC) forum. Western Pacific Region 
countries also belong to associations with countries outside the region. For instance, American Samoa, 
the Commonwealth of the Northern Mariana Islands, Guam, Palau, the Republic of the Marshall Islands, 
and the Federated States of Micronesia are linked to the United States through the Compact of Free 
Association,3 whereas 14 countries within the Western Pacific, former colonies of the United Kingdom, 
are members of the British Commonwealth.4 
Western Pacific countries are highly impacted by forces of economic globalization, and the high 
priority placed on international trade in the region presents both benefits and obstacles to effective 
tobacco control. For example, governments may be reluctant to impose trade restrictions on tobacco 
products, and this position, driven by economic rather than public health goals, could undermine tax 
policies and other measures to raise tobacco prices. For example, under the ASEAN Free Trade 
Agreement (AFTA), tobacco products made in ASEAN countries with at least 40% of the raw materials 
from the ASEAN subregion are subject to a tariff-reduction scheme mandated in the agreement, thus 
encouraging use of these products.5 Moreover, the tobacco industry and its allies are quick to seize 
opportunities to expand their markets under the banner of globalization. In 2001, when China joined 
the World Trade Organization, the entry of foreign cigarette brands into the Chinese market was one of 
the key points negotiated by the major world economies with China. China, Japan, and Vietnam 
continue to hold a majority stake in their domestic tobacco industries, and in Cambodia, Laos, Vietnam, 
and the Philippines, tobacco agriculture and manufacturing provide jobs and funnel investment dollars 
to the local economies, making governments reluctant to enact legislation and policies to reduce 
tobacco consumption.6 
The Western Pacific Region is the first—and to date, the only—WHO Region to achieve a 100% 
ratification rate for the WHO Framework Convention on Tobacco Control (FCTC). Globalization is 
facilitating the diffusion of ideas and examples of successful national tobacco control strategies 
throughout  the Western Pacific and is mobilizing support for implementation of the FCTC.7  
Prevalence of Smokeless Tobacco Use  
Smoking remains the predominant form of tobacco consumption in the Western Pacific Region, which is 
home to one-third of the world’s smokers.8 It is estimated that two people in the region die every minute 
from a tobacco-related disease.9 The Western Pacific has the largest number of male smokers and one of 
the highest rates of male smoking in the world, and the uptake of tobacco use by women and young 
people is steadily increasing.8  
Prevalence data on the use of smokeless tobacco (ST) in the region are scarce. Based on available data, 
ST use is many orders of magnitude less prevalent than smoking. However, anecdotal reports indicate 
that commercial ST products produced by national and multinational tobacco companies are becoming 
more visible and that advertising for these products is increasing. Regrettably, at present no regional 
mechanism systematically tracks this trend. In addition, the practice of adding tobacco to the traditional 






areca nut/betel quid has begun in certain areas, especially in the Pacific Islands, Cambodia, Vietnam, 
and the Philippines; available data on use of this form of ST are reviewed separately, below.  
Because surveys use different sampling, methods, questions, and definitions, caution should be 
exercised in comparing prevalence information from different surveys as statistical tests were not 
conducted on these comparisons. In particular, the surveys’ definition of current use varies: Some 
surveys define it as any use within the past 30 days, while other surveys ask about different time 
periods; some surveys ask about daily use and use on some days, and still other surveys ask about 
“current” use without defining the term further. For the Western Pacific region, current use by youth 
tends to be defined as any use in the past 30 days. For adults, some surveys define current use as use 
every day, while other surveys include use every day and use on some days in their definition of 
current use. 
Regional Data: Youth 
The Global Youth Tobacco Survey (GYTS) provides an overview of the magnitude of non-cigarette 
tobacco use among youth; this includes use of bidis, hookahs (i.e., waterpipes), and ST products.10  In 
addition to cigarette smoking, almost all participating countries report other tobacco use by youth. 
Consumption of other tobacco products appears highest among the Pacific Island countries, where it 
equals or surpasses smoking prevalence.10 GYTS data specifically on ST use is only available for four 
countries: Cook Islands, Macau, Malaysia, and South Korea (Table 14-2). 
Table 14-2. Percentage of adolescents aged 13–15 years who currently used smokeless tobacco in the 
Western Pacific Region, from the Global Youth Tobacco Surveys, 2008–2010  
Country Year Total (%) Boys (%) Girls (%) 
Cook Islands 2008 8.7 10.5 7.3 
Macau 2010 2.1 2.2 2.1 
Malaysia 2009 4.0 4.5 3.2 
South Korea 2008 6.2 7.2 5.0 
Source: Global Youth Tobacco Survey, 2008–2010 (10). 
 




Regional Data: Adults 
Regional data on overall ST use among adults in the Western Pacific Region are scarce, representing a 
major gap in tobacco surveillance. Prevalence estimates on ST use have been reported for 8 of the 
37 countries and areas in the region (Table 14-3; Map 14-1). Higher prevalence rates of current ST use 
among men than women in Australia, China, the Federated States of Micronesia, Mongolia, and the 
Philippines contrast sharply with the situation in Cambodia, Malaysia, and Vietnam, where female 
consumption markedly surpasses male use rates.11  




(years) Total (%) Men (%) Women (%) 
Australia* 2004 12+ 0.6 0.8 0.4 
Cambodia† 2010 15+ 7.3 0.7 12.7 
China‡ 2009 15+ 0.4 0.7 0.0 
Malaysia† 2006 18+ 0.6 0.5 3.1 
Micronesia, Federated 
States of (subnational)§ 
2002 25–64 11.4 22.4 3.0 
Mongolia§ 2009 15–64 1.7 2.8 0.5 
Philippines‡ 2009 15+ 1.9 2.7 1.2 
Vietnam‡ 2010 15+ 1.3 0.3 2.3 
*National Drug Strategy Household Survey (NDSHS) (64).  
†Individual country surveys from: WHO Report on the Global Tobacco Epidemic, 2011 (11).  
‡Global Adult Tobacco Survey (65).  
§WHO STEPS from: WHO Report on the Global Tobacco Epidemic, 2011 (11). 






Map 14-1. Prevalence of smokeless tobacco use among adults in the World Health Organization’s 
Western Pacific Region 
 
Sources: National Drug Strategy Household Survey (64); Individual country surveys from: WHO Report on the Global Tobacco 
Epidemic, 2011 (11); Global Adult Tobacco Survey (65); WHO STEPS from: WHO Report on the Global Tobacco Epidemic, 2011 (11). 
 




Chewing Tobacco With Areca Nut/Betel Quid 
The literature on ST use in the Western Pacific focuses primarily on chewing tobacco mixed with areca 
nut/betel quid. Historically, the use of areca nut/betel quid is well documented across South-East Asia 
and the Pacific, with evidence of areca nut use occurring during previous centuries in Guam, the 
Northern Mariana Islands, the Solomon Islands, and Cambodia.12–14 However, use of areca nut/betel 
quid does not involve tobacco use in all cultures. For instance, almost 15% of men over the age of 18 in 
Taiwan15 and 64.5%–82.7% of adults in Hunan province, China16 chew areca nut/betel quid, but tobacco 
is not added to the quid. Likewise, users in island countries within Melanesia (Fiji, Papua New Guinea, 
Solomon Islands, Vanuatu) are unlikely to add tobacco to their chew.17 
Where areca nut/betel quid is consumed with tobacco, national and subnational published studies 
indicate that prevalence and patterns of consumption vary both across and within countries. For instance, 
among Asian countries, older women are much more likely to chew tobacco with betel quid. In contrast, 
in the Micronesian islands, the use of areca nut/betel quid with tobacco is observed even among the very 
young, and males have higher consumption rates than females.17  
Cambodia, Malaysia, and Vietnam 
A national survey conducted in 2009 in Cambodia (n = 13,988) revealed current tobacco use prevalence 
rates of 49.0% among men and 20.5% among women, with men predominantly smoking cigarettes and 
women predominantly chewing tobacco as a component of betel quid. The likelihood of women using 
chewing tobacco increased markedly with age, lower income, rural residence, and less education. It is 
estimated that 43.4% of all older women (>48 years) and almost half of all rural women (48.0%) chewed 
tobacco at the time of the survey.18 The higher consumption among older women seen in Cambodia 
parallels that seen in reports from Malaysia19,20 and Vietnam.21 In Malaysia, older women in indigenous 
groups use betel quid with tobacco at a particularly high rate. The most common reasons women gave 
for starting to use tobacco were “the influence of older relatives (31.9%), the need to alleviate morning 
sickness during pregnancy (17.0%), and the wish to experiment (13.9%)”.18 Rural women were more 
likely than urban women to believe that tobacco use would alleviate morning sickness (17.8% versus 
7.5%, respectively).18 
Palau 
Ysaol and colleagues surveyed 1,110 Palauans in 1996 and reported that 55% of those aged 5–14 years 
and 86% of those aged 35–44 years chewed areca nut/betel quid. Eighty percent of users cut up 
cigarettes and added the tobacco to the betel quid, and 24% added other tobacco.22 More recently, the 
Palau Youth Tobacco Surveys from 2001, 2005, and 2009 documented markedly elevated rates of 
chewing areca nut/betel quid with tobacco, although the prevalence appears to decrease over time. In 
2009, 54% of high school youth reported current consumption of betel quid with tobacco, compared to 
61% in 2005 and 68% in 2001. Among elementary school students, 37% reported current use of betel 
quid with tobacco, compared to 43% in 2005 and 54% in 2001. Approximately 1 in 10 of these 
elementary school students started using before the age of 9 years23 (Roman Oseked, Palau Department 
of Health, personal communication, 2011).  






Federated States of Micronesia 
In Pohnpei, one of four states in the Federated States of Micronesia (FSM), a 2002 survey using the 
WHO STEPwise Approach to Surveillance (STEPS)24 found that approximately 29.9% of adults 
reported chewing areca nut/betel quid at the time of the survey, with a significantly higher rate among 
men (43.5%±5.9) than among women (16.0%±3.0).24 Overall, the highest proportions of areca nut/betel 
quid chewers were in the youngest age group, 25–34 years (67% of men, and 28% of women), with 
these proportions declining thereafter with increasing age. Over three-quarters of the survey participants 
who reported current daily use of chewing areca nut/betel quid added tobacco to the betel quid, and the 
percentages were similar across age groups and sexes. 
The 2007 GYTS for Micronesia, the first national survey on youth tobacco use in the country, revealed 
that a greater percentage of males than females had ever tried smoking and currently smoked. 
(Table 14-4). Youth in the FSM were more likely to use other tobacco products than to smoke, and 
close to half of youth (52.6% of males and 43.5% of females) had ever used tobacco with betel quid.  
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Boys 56.2 (49.7–62.6) 26.3 (21.8–31.3) 36.9 (29.9–44.5) 41.8 (34.6–49.3) 67.0 (60.4–73.7) 52.6 (46.0–59.1) 
Girls 34.7 (29.9–39.7) 20.5 (14.9–27.5) 19.8 (15.9–24.5) 32.1 (27.3–37.4) 55.6 (49.9–61.3) 43.5 (40.1–47.0) 
Total 45.6 (41.4–49.8) 24.3 (21.0–28.0) 28.3 (23.9–33.2) 37.0 (32.2–42.1) 61.4 (56.4–66.4) 47.6 (44.0–51.2) 
Note: CI = confidence interval. Confidence interval is 95%. 
Source: Global Youth Tobacco Survey (2007), as provided by Maryann Eperiam, Federated States of Micronesia Substance Abuse 
and Mental Health Program. 
Guam 
The prevalence of areca nut/betel quid consumption with tobacco is relatively low among youth in 
Guam, although there are indications that the practice may be increasing. In 2008, Guam’s Department 
of Mental Health and Substance Abuse commissioned a telephone-based survey that employed 
randomized digit dialing and found that 6% of youth overall reported chewing betel quid, and 24% of 
ethnic Micronesian youth reported chewing betel quid regularly. Forty-four percent of young betel quid 
chewers mixed tobacco with their chew. Among adults, 17% were current users of betel quid, and three 
in five of these chewed it with tobacco.25  
Commonwealth of the Northern Mariana Islands 
A 2005 survey conducted on a convenience sample of 309 high school students on the island of Saipan 
in the Commonwealth of the Northern Mariana Islands (CNMI) revealed that 63.4% chewed areca 
nut/betel quid regularly, but no information was available regarding the addition of tobacco to the areca 
nut. Among these students, 24.9% were also smokers.26 Twenty-four percent of adults participating in 
 




the 2009 Behavioral Risk Factor Surveillance System (BRFSS) survey reported chewing areca nut/betel 
quid, and 68% of these reported adding tobacco to their chew.27 
Prevalence of Using Other Types of Smokeless Tobacco 
It is likely that other types of ST are used in the region, but data on prevalence are not readily 
available. Guam’s 2008 randomized telephone survey revealed that 4% of youth respondents25 and 
5% of adult respondents28 reported using other forms of tobacco such as snuff, dip, or chewing tobacco. 
The 2009 BRFSS survey in CNMI revealed a 14.5% prevalence of chewing tobacco and/or snuff use 
among adults.27 Among CNMI high school students, 17.5% either chewed tobacco or used snuff.26  
In Japan, the Swedish company Swedish Match initiated consumer testing for a brand of tobacco gum 
called “Firebreak” in 2003, and in 2006 the product was launched in Sweden29; however, specific data 
on the prevalence of use of this product could not be found. In Kiribati, young people are using a novel 
form of ST, mixing tobacco from cigarettes with immature green coconuts (Kireata Ruteru, personal 
communication, 2011).  
Types of Smokeless Tobacco Products and Patterns of Use 
Chewing areca nut/betel quid with tobacco (Figure 14-1) is the form of ST use in the Western Pacific for 
which the most data are available. These data show significant geographic variation, both within and 
among countries. 
Figure 14-1. Areca nut being sold in markets in the Solomon Islands 
 
Source: Photos courtesy of James Rarick, World Health Organization Western Pacific Regional Office, 2011. 
Areca nut is chewed by itself or in combination with the leaf or fruit of a pepper plant (Piper betle) and 
lime powder, the mixture being popularly known as “betel quid.” The commonly used phrase “betel nut” 
originated from the association of chewing areca nut with the P. betle leaf. In the Western Pacific, fresh 
nuts are consumed in both the fully ripe and unripe stages.17 In Taiwan and Palau, unripe nuts are used 
in the betel quid. In Guam, changnga (white) areca nuts are preferred when immature and soft, whereas 
the ugam (red) variety is used when the fruit is at the fully mature and hard stage.30,31 






The fine white lime powder (calcium oxide or quicklime) used in betel quid chewing is usually 
what remains after burning coral rock, sea coral, or shells.31 This lime powder must be kept in 
sealed containers to stay dry. As an alternative, water may be added to produce slaked lime (calcium 
hydroxide) for use in the quid. The type of lime and the specific techniques used to reduce the source 
material vary by region. Builders’ lime that is commercially produced may also be used.32 
The areca nut, lime, and other ingredients may be wrapped in a fresh P. betle leaf, or the ingredients 
may be placed in the mouth separately. Tobacco (either loose tobacco or as a portion from a cigarette) 
and other flavorings (spices such as cardamom and even garlic) may be added to the betel quid to 
enhance the flavor and heighten the physiologic effects.17 In some Micronesian islands, the quid is 
dipped in vodka before being consumed (Kerio Walliby, FSM Department of Health, personal 
communication, 2011). Unwrapped quid is preferred in Papua New Guinea and the Solomon Islands, 
whereas wrapped quids are more frequently encountered in Cambodia, Palau, and FSM. Quid 
preferences in Guam appear to be linked to ethnicity: Chamorros (the indigenous people of Guam) are 
more likely to chew the mature nut with P. betle leaf, but without lime or tobacco, and to swallow the 
nut/quid, whereas other Micronesians are more likely to chew fresh nuts with P. betle leaf, lime, and 
tobacco and to spit out the nut/quid.33 Consumption of areca nut/betel quid with or without tobacco is 
often accompanied by smoking and alcohol use.24  
The extensive literature on the cultural importance of areca nut/betel quid chewing in Asia–Pacific 
societies documents the long history of areca nut/betel quid consumption. Areca nut is believed to have 
medicinal uses—as an effective antiparasitic agent, a digestive aid, and an analgesic, among others.31,34 
Use is often culturally or socially ritualized, and usually reserved for older people and high-ranking 
members of the community. Interviews with key informants conducted by the Secretariat for the Pacific 
Community (SPC) in 2005 in several Pacific island countries highlighted the rising prevalence of areca 
nut/betel quid consumption among younger people and the increasing practice of adding tobacco to the 
quid.17 Focus groups conducted among Chamorro and other Micronesian youth in Guam indicated that 
young people may initiate use in the mistaken belief that chewing tobacco with areca nut/betel quid is 
part of traditional Micronesian culture (Caleb Otto, Palau Department of Public Health, personal 
communication, 2011).  
The growing popularity of chewing areca nut/betel quid with tobacco has spurred the emergence of local 
sales of areca nut and prepackaged betel quid as a cottage industry in several Asia–Pacific countries. For 
example, in Palau, it is possible to purchase premade quids from local vendors, and the ingredients for a 
quid are increasingly becoming available at convenience stores and neighborhood shops throughout 
Micronesia (Caleb Otto, personal communication, 2011). Because betel quid is largely sold through 
these local channels, average pricing information is not readily available. 
Sales of areca nut have become a principal income generator, especially for people outside or on the 
fringes of the formal economy in countries such as Papua New Guinea and FSM. The 1996 Mapping 
Agricultural System in Papua New Guinea estimated that 1,227,234 people received income from local 
trade in areca nut in Papua New Guinea; the total income from areca nut was US$7,094,993, or 9.5% of 
the total income from agricultural products.35 Domestic areca nut sales in FSM increased from 
approximately 18,000 lbs. sold in 1999 to about 500,000 lbs. sold in 2004.36 
 




Sales and distribution of areca nut through exports also constitute a growing revenue source for 
governments. For example, in 2007, FSM earned over US$2.2 million from exporting areca nut to 
Guam, CNMI, and the Marshall Islands.36 In addition, migration of Pacific Islanders to the United 
States, Australia, and New Zealand is creating demand for areca nut/betel quid in these countries, 
and consequently opening up new markets for exports. Internet sales are likewise increasing.37 The 
extent of non-commercial export of areca nut/betel quid through the postal system or personal 
luggage is unknown as of this writing, although residents in Micronesia readily acknowledge that 
this occurs frequently. 
Toxicity and Nicotine Profiles 
Nine closely related alkaloids are responsible for the stimulant effect of areca nut. Alkaloid levels are 
highest in the unripe fruit, which may be why some cultures prefer the unripe nuts for consumption: 
They give a better “buzz.”30 The International Agency for Research in Cancer (IARC) considers areca 
nut a Group 1 carcinogen.31 Arecoline, a major areca nut alkaloid, is considered the most important 
carcinogen in the areca nut. Areca nut extract (ANE) is highly cytotoxic and genotoxic to cultured 
human oral mucosal epithelial cells and fibroblasts (connective tissue cells). Researchers from Taiwan 
have published studies on the toxicologic profile of betel quid without tobacco.38 However, toxicity 
information on the combination of areca nut/betel quid with tobacco as used in the Western Pacific 
represents a data gap for the region.  
Health Problems Associated With Product Use 
Data on health effects of chewing tobacco with areca nut/betel quid in the Western Pacific Region are 
minimal. Most studies concentrate on the effect of areca nut/betel quid, and health effects from the 
tobacco added to the quid are largely inferential in nature.  
Oral Health Issues 
In a 2005 study in Saipan, CNMI, high school students who reported regular areca nut/betel quid and 
tobacco use (both smoking and chewing) underwent oral examinations. Oral leukoplakia was found in 
12.9% of the students; 8.8% had oral submucous fibrosis (OSF), and one-third of these already showed a 
restriction in mouth opening.26 Ikeda and colleagues reported that the prevalence of leukoplakia in 
selected Cambodian populations was 2.2% among men and 0.6% among women.39 Several studies have 
reported a particularly high prevalence of oral leukoplakia in Papua New Guinea (4.6%–17%), with the 
rate in the Papua New Guinea lowlands being among the highest in the world.40–45 Although leukoplakia 
can result from multiple causes, regular use of areca nut/betel quid with tobacco in the study populations 
likely contributed to its prevalence in these groups. 
Head and Neck Cancer 
In 2004, the IARC linked the use of betel quid without tobacco to oral cancer, and use of betel quid with 
tobacco to head and neck cancers (see chapter 4).31 






Cancer surveillance and cancer research are not well developed in many of the Pacific islands, but where 
studies exist, they demonstrate that head and neck malignancies occur at elevated rates in countries and 
areas where areca nut/betel quid consumption and tobacco and alcohol use are prevalent. The Guam 
Cancer Registry for 2003–2007 ranked oral cancer as 10th in cancer incidence for Guam, with ethnic 
Micronesians having the highest incidence rate46 compared to indigenous Chamorros, Caucasians, or 
people of Filipino or other Asian descent. Micronesians living in Guam also have the highest prevalence 
of using chewing tobacco with areca nut/betel quid.47 In Papua New Guinea in 1964, Atkinson and 
colleagues reported a disproportionately high incidence of oral cancer (17.8%), with a distinct 
geographic variation that closely matched areas of areca nut use.42 A case-control study of cancer in 
Papua New Guinea in 2007 identified betel quid as an independent risk factor for the development of 
oral cancer.48 Given the available data, it is challenging to separate out the effects of areca nut and/or 
betel quid alone, as well as concurrent smoking, from chewing tobacco on cancer incidence. This is an 
area for further research. 
Reproductive Outcomes 
In a 2008 study among native people in Taiwan, Yang and colleagues found that betel quid chewing 
during pregnancy was associated with lower birth weight and reduced birth length.49 Ironically, one of 
the main reasons pregnant women chew areca nut/betel quid is to prevent morning sickness: 80% of the 
women thought that chewing areca nut/betel quid would not have any effect on the fetus.50 Similarly, in 
Cambodia, almost one in five (17%) rural women started chewing tobacco as a component of betel quid 
to relieve morning sickness.18 These findings highlight the critical need for educational outreach to avert 
the adverse reproductive outcomes of areca nut/betel quid and tobacco consumption. 
Other Health Effects 
The cardiovascular and pulmonary effects of areca nut/betel quid consumption and the cardiovascular 
effects of ST use are recognized in the global literature, but the regional data are minimal. Likewise, the 
association with diabetes51 has not been studied extensively in the Western Pacific. The potential for 
facilitating the spread of communicable diseases, particularly tuberculosis, through the indiscriminate 
spitting of excess saliva, has been raised as an adverse health effect, but definitive data are lacking. 
Marketing and Production Practices of Industry 
At present, sales and marketing of areca nut/betel quid occur through small cottage vendors 
(Figure 14-2). However, in Guam, a community-based participatory research project on tobacco points 
of sale revealed that over 56% of manufactured tobacco retail outlets advertised tobacco products less 
than a foot from displays of candy and other items popular with children and youth52 (Figure 14-3). 
These components can be purchased and used to prepare custom homemade ST products. Since areca 
nut and betel quid have been used historically for medicinal purposes, using these substances is seen 
as a cultural practice by some, limiting the need for extensive marketing outside of local channels. 
Furthermore, the sale and distribution of areca nut also contribute to government revenue sources, 
as described above, and therefore exports of these ST products, to meet the demands of migrants, 
have grown.  
 




Figure 14-2. Pre-wrapped betel quids (areca nut, lime, tobacco, and betel leaf) on sale in a 
public market 
 
Source: Photo courtesy of James Rarick, World Health Organization Western Pacific Regional Office, 2011. 
Figure 14-3. Wrapped fresh betel quids sold alongside cigarette lighters and candy in a Guam store 
 
Source: Photo courtesy of the Community Research for Action Team–Guam (CREATE–GUAM) project at the University of Guam 
Cancer Research Center, 2011. 






In Taiwan, areca growing and the sale of betel quid are rapidly growing businesses and appear to 
parallel the expansion of the cigarette market. Although international tobacco companies have not 
begun marketing the product, Taiwanese betel quid producers have set up neon-lit roadside kiosks 
around the country, where scantily clad young women, known as “Betel Quid Barbies,” sell betel quid 
and cigarettes to motorists.15 Online and through other popular media, the “Betel Quid Barbie” has 
generated global interest as a sex symbol. This marketing strategy resembles cigarette promotions that 
associate the product with sexually suggestive messages and models. 
Current Policy and Interventions 
Existing measures to control ST use in the Western Pacific involve both supply- and demand-reduction 
strategies. Compared to policies and interventions to reduce smoking in this region, actions to control 
ST use in the Western Pacific are rudimentary. 
Supply-Side Interventions 
In 1986, the government of the Australian state of South Australia became the first government in the 
world to ban ST; the ban became national in 1991.53 New Zealand has also banned smokeless tobacco.54 
Taiwan prohibits the manufacture of all types of ST products. Hong Kong, Japan, Singapore, and 
Taiwan also ban importation of ST products, but these bans have no impact on the consumption of areca 
nut/betel quid with tobacco because the tobacco used is often taken from cigarettes. In March 2010, the 
Marshall Islands became the first Pacific island country to ban importation, distribution, and sale of 
areca nut/betel quid, with violations punishable by a fine of up to US$100 and 30 days in jail.55 
Unfortunately, the existing policy interventions are weak and lack consistency and comprehensiveness. 
For example, Australia’s ban on all ST products contains a clause that allows personal users to seek a 
permit to import chewing tobacco and oral snuff in quantities less than 1.5 kilograms if the importer is 
over age 18 and can show that the tobacco products are only for personal use.56 The ban on importation 
of areca nut in the Marshall Islands applies only to commercially imported nuts; individuals are 
permitted to bring in indefinite quantities of areca nuts for personal consumption, although lawmakers 
are considering closing this loophole in the law.57  
Demand-Side Interventions 
Because cultivation, sale, and distribution of areca nut/betel quid with tobacco most often occur as part 
of the informal economy, regulation through taxation (other than taxing cigarettes) is challenging. In 
2008, the rate of taxation on cigarettes was relatively high—for example, the tax on a pack of cigarettes 
accounted for an average of US$1.46 of the pack’s total cost of US$3.42 in this region.58 As of 2012, 
demand-side interventions involve regulating consumption in public places, banning advertising and 
promotion, and enlarging cessation programs to include measures that address the use of areca nut/betel 
quid with tobacco. In FSM, CNMI, and Guam, chewing areca nut/betel quid with or without tobacco is 
prohibited in certain public places, such as hospitals. Both the University of Guam and Guam 
Community College are 100% tobacco-free campuses, and neither permits chewing tobacco within 
campus grounds.59 Guam Community College also bans betel nut from its campus.60 Hong Kong, 
Singapore, and Taiwan prohibit advertising and promotion of ST products. 
 




In many countries, health systems are not optimally set up to take measures to prevent areca nut/betel 
quid and tobacco use, to screen and diagnose health consequences, or to assist chewers to quit. For 
instance, in the U.S.-affiliated Micronesian islands, where health care depends on external aid from the 
United States, health care guidelines and clinical practice standards are often patterned after U.S. 
mainland templates, and tobacco control is focused predominantly on smoking. This has led Pacific 
island stakeholders to note that tobacco control in Micronesia is not “Pacific’lly correct,” in that it fails 
to consider the sociocultural and political context of the region as it relates to other forms of tobacco 
use.61 Even in Western Pacific countries that have ratified the WHO FCTC, tobacco control remains 
skewed toward interventions that address smoking. The tobacco industry in Western Pacific countries 
has reacted to declining smoking rates by increasing its market share for ST products within the region. 
To complement gains made in smoking prevalence reduction, proactive ST interventions targeted to the 
various forms of ST use in the region are urgently needed. 
In part, policy inconsistencies may stem from ambivalence regarding areca nut/betel quid use in contrast 
to tobacco use. This ambivalence arises partly from the long-held popular notion that chewing areca 
nut/betel quid is symbolic of cultural identity, and partly from a general lack of awareness of the 
negative effects of areca nut/betel quid chewing. However, the scientific evidence has irrefutably 
established the harmfulness of areca nut and betel quid without tobacco; the addition of tobacco 
magnifies the adverse health impacts. Thus, policy interventions to counter ST use in the Western 
Pacific should also address areca nut/betel quid use. This will require broad, sustained outreach to 
educate populations about the harmfulness of areca nut/betel quid use, and intensive social marketing to 
dissociate areca nut/betel quid consumption from notions of cultural belonging. It will also require 
reconsidering the promotion of areca nut as a cash crop, which will likely provoke similar arguments 
relating to trade and profit over health that the tobacco control community encountered during the 
inception and development of the WHO FCTC. 
Summary and Conclusions 
This overview highlights ST use as an emerging issue within the Western Pacific Region and pinpoints 
key gaps in information and knowledge that contribute to the lack of action to control the problem. 
Existing data are scarce and fail to provide an accurate and comprehensive picture of the magnitude of 
ST use and its attendant health, economic, and social consequences. Of the few countries that have ST 
data, prevalence rates among men vary from 0.3% in Vietnam to 22.4% in Micronesia, and among 
women, from 0% in China to 12.7% in Cambodia. Without an effective surveillance system, there is no 
reasonable way to gauge changes in prevalence over time within countries and across the region, and to 
measure the effectiveness of policy and program interventions. 
Although areca nut is known to contain carcinogenic compounds, detailed toxicologic data are 
incomplete, with most of the studies conducted on areca nut and betel quid without tobacco. The 
inadequacy of quantitative information on prevalence, epidemiology, and impact is compounded by the 
insufficiency of qualitative data on the sociocultural aspects of chewing tobacco with areca nut/betel 
quid that are needed to develop population-based behavioral strategies. Addressing the multiple data 
gaps should be the first step toward developing an effective and coordinated response to controlling ST 
use in the Western Pacific.  






Some countries, including Australia and New Zealand, have instituted bans on ST, and others, such as 
Taiwan, have specifically banned manufacturing and importation of ST products. Still others—Japan, 
Hong Kong, and Singapore—have banned the importation of ST products. However, these measures 
have no effect on the consumption of areca nut/betel quid with tobacco, because the tobacco used is 
often taken from cigarettes and other sources. Since areca nut/betel quid can have a cultural meaning 
and perceived medicinal benefits, education efforts may be necessary to supplement policy efforts and 
increase awareness of the harmful effects of these products.  
As implementation of the WHO FCTC proceeds within the Western Pacific and smoking reductions 
accelerate, the urgency to address ST will grow.9 Already the tobacco industry is redirecting its 
strategies to circumvent tobacco tax increases and smoke-free public laws by increasing its market 
share for smokeless products within the region. Interventions to address the unique forms of ST use 
in the Western Pacific are needed proactively to preserve and complement gains made in reducing 
smoking consumption. 
The WHO Western Pacific Regional Office, in partnership with the region’s countries and areas, 
initiated a process of assessment and dialogue that resulted in the Review of Areca (Betel) Nut and 
Tobacco Use in the Pacific,17 which defined a comprehensive platform for action to address the trend 
toward increasing use of tobacco with areca nut/betel quid in the region. For four domains—social 
determinants, risk factors, immediate conditions, and end-stage disease, the platform called for actions 
in six areas: policies and legislation, education and advocacy, governance and local reinforcement, 
clinical services, surveillance and research, and partnerships and alliances.  
The platform calls for a balanced, comprehensive mix of legislation and policies that incorporate both 
supply- and demand-reduction strategies, and steps governments can take to curb ST use and deal with 
its negative effects. It recommends the following: 
 Supply-side interventions: restrictions on sales and importation of betel nut and ST products; 
prohibition of sales to minors; anti-smuggling policies; re-assessment of agricultural policies 
regarding promotion of betel nut; and  
 Demand-side interventions: establishment of tobacco-free public places (schools, hospitals, etc.); 
inclusion of ST use within cessation approaches; extensive screening and monitoring for oral 
cancer and funding for cessation services. 
The platform also recommends investments in surveillance and knowledge-management capacity 
building while fully exploring practical approaches, such as integrating questions on chewing tobacco 
with betel nut and other forms of ST use into the Global Tobacco Surveillance System and other existing 
surveillance mechanisms. Furthermore, this platform calls for health systems interventions to prevent 
ST use and include areca nut/betel quid use in tobacco cessation programs. It also calls for screening 
and diagnosis of health consequences to be incorporated into oral health, non-communicable disease 
control, and other related health programs. The Review also addresses public awareness, education, 
communication, and advocacy strategies, and working through alliances and partnerships. The Platform 
for Action has been built into the WHO Western Pacific Plan to operationalize the WHO FCTC,62 which 
was adopted unanimously at the 61st Regional Committee Meeting in Malaysia in October 2010. These 
actions will go a long way toward addressing the gaps and challenges identified in this chapter. 
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Smokeless tobacco (ST) use is a global problem affecting an estimated 300 million people across about 
70 low-, middle-, and high-income countries. All six World Health Organization (WHO) regions contain 
a substantial population of ST users, and almost all countries for which data are available report some 
level of ST use. In countries with the highest prevalence, most current users report daily use of 
smokeless tobacco. Smokeless tobacco use poses an extremely complex public health challenge, as 
product characteristics, patterns of use, health effects, marketing and production practices, and public 
health and policy responses vary widely between countries and regions.  
Prevalence and Patterns of Smokeless Tobacco Use 
Smokeless tobacco has a disproportionate impact in some countries and subpopulations. The majority 
of the world’s adult ST users (89%, or approximately 268 million) live in low- and middle-income 
countries in South-East Asia. There are an estimated 220 million adult ST users in India alone, where 
overall adult prevalence is 26% (exceeding the prevalence of cigarette smoking), followed by 
Bangladesh with 28 million ST users (27%), and Myanmar with 11 million ST users (30%). Adult 
prevalence is high—10% or greater—in 11 countries (Bangladesh, Bhutan, India, Micronesia, Myanmar, 
Nepal, Norway, Sri Lanka, Sweden, Yemen, and Uzbekistan). Six of these 11 countries are located in 
the South-East Asia Region. The figures presented in this report represent only those countries for which 
data are available; data are lacking for some countries in each region.  
Across countries at very different levels of economic development (high-income to low-income), ST use 
is generally higher among rural populations with lower education and lower socioeconomic status. In 
most countries ST use is more prevalent among men than women, but several countries reported high 
use of ST among both men and women. Eight countries (Bangladesh, Bhutan, Cambodia, India, 
Madagascar, Mauritania, Myanmar, and South Africa) reported prevalence of greater than 10% among 
adult women. In several countries in the African, South-East Asian, and Western Pacific Regions, 
prevalence of ST use among women significantly exceeded that of men. Some studies have found that 
women report initiating ST use during pregnancy because they believe it will alleviate symptoms of 
morning sickness,1,2 and ST use during pregnancy has been associated with adverse reproductive 
outcomes, such as pre-term birth or fetal growth restriction. More research is needed to understand the 
factors that lead to high prevalence of ST use among women in these countries.  
Smokeless tobacco use is also prevalent among youth in many countries. All 57 countries for which 
sufficient national data were available to be included in this volume (using Global Youth Tobacco 
Surveys [GYTS] of students aged 13–15 years) reported some ST use among youth, and 33 reported 
overall use greater than 5%. As with adults, ST use is generally higher among males than females, but 
ST use prevalence greater than 10% among girls was reported for several African countries (Botswana, 
Congo, Lesotho, and Namibia). In many regions, ST products are marketed and sold in ways that may 
appeal to youth, such as in publications with a high youth readership or displayed next to candies and 
snacks in street stalls and kiosks.  
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A high prevalence of ST use is also seen among some population subgroups even within countries where 
overall prevalence is low compared with cigarette smoking, particularly among native populations and 
recent immigrants. For example, while prevalence of ST use among Alaskan non-Native adults is similar 
to the U.S. average, prevalence among Alaska Native adults is three times greater. Similarly, in Brazil 
the use of the ST product rapé is rare among urban populations but more common among rural native 
populations. Immigrants from regions where ST use is prevalent may bring their practices with them. 
For example, the use of gutka or betel quid with tobacco has been found to be very common among 
first-generation immigrants from Bangladesh and India living in New York and London. And reports 
suggest that some youth, such as those in Venezuela and Micronesia, may view ST products as a means 
to express national identity or traditional culture. 
Health Effects and Impact of Smokeless Tobacco Products 
There is substantial evidence that ST products cause addiction, precancerous oral lesions, cancer of the 
oral cavity, esophageal and pancreatic cancer, and adverse reproductive outcomes, including stillbirth, 
pre-term birth, and low birth weight. Data from some countries have demonstrated a link between ST 
and increased risk of fatal myocardial infarction or stroke. All ST products contain chemicals known to 
cause harm, such as tobacco-specific nitrosamines (TSNAs) and polycyclic aromatic hydrocarbons 
(PAHs). In fact, a well-developed model describes the mechanistic pathway by which the TSNAs 
N’-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) are 
metabolically activated and induce primary DNA lesions that may ultimately lead to cancer. Thus, all 
ST products are hazardous to use. 
The impact of ST use is related to the disease risks associated with particular products, their prevalence, 
manner of use, and the underlying burden of disease (which may also be influenced by other risk 
factors). Currently available data are insufficient to support an estimate of the total global disease or 
mortality burden of ST use. Additionally, because smokeless tobacco use is a limited or relatively recent 
practice in many countries, particularly in higher income countries, research and data collection have 
lagged. However, estimates of attributable risk for countries where adequate data are available show 
wide variation in the attributable disease burden. For example, most studies from Sweden have not 
shown an association between ST use and oral cancer, but studies in India have shown very high relative 
risks (from 2 to 14) for oral cancer.3 These differences may be due in part to differing levels of harmful 
constituents in the products. For example, reported levels of TSNAs in ST product samples from a 
variety of countries, and within the same country, vary by many orders of magnitude. One laboratory 
study comparing samples of products from India found that total TSNA content varied from 0.1 to 
127.9 micrograms per gram (µg/g). Likewise, an analysis of U.S. moist snuff products showed a 70-fold 
difference in NNAL content across leading brands, whereas products in Sweden show less variation in 
TSNAs because they adhere to specific standards for TSNA levels.  






In general, the greatest disease burden from ST use occurs in low- and middle-income countries where 
the highest relative risks have been recorded and the greatest numbers of users live. An example is 
India’s high oral cancer rates4: It is estimated that more than 50% of oral cancers in India can be 
attributed to ST use.5 In addition to high disease burden, low- and middle-income countries face a 
multi-pronged challenge: They are home to the most diverse array of products, some of which are 
extraordinarily high in toxicants, but their ability to regulate ST products and implement effective 
tobacco control measures is hampered by limited resources and the local, unorganized nature of 
tobacco manufacturing and retailing. 
Diversity of Smokeless Tobacco Products 
The term “smokeless tobacco” covers a large and extremely diverse group of products. They differ in 
color, appearance, consistency, packaging, and manner of use. They also vary in their mode of 
manufacture or preparation (premade vs. custom-made), in the scale of production (large-scale 
manufacturing, cottage industry, or individual vendor preparation), and in their ingredients (type of 
tobacco leaf, alkaline agents, flavorants, and other non-tobacco content, such as areca nut or tonka 
bean). The best estimates indicate that, by volume, 91.3% (648.2 billion tons) of ST worldwide 
(710.2 billion tons) is sold in traditional cottage industry markets.6 Chapter 3 of this report proposes a 
method of categorizing ST products into four groups based on the addition of specific classes of 
ingredients, including alkaline agents, areca nut, and other active chemical or plant ingredients. Though 
this categorization may have some utility, the product-associated risks may vary greatly even within 
these categories.  
Smokeless tobacco products also vary greatly in their chemical composition, with some products 
containing extremely high levels of carcinogens, nicotine, and free nicotine (the most rapidly absorbed 
form). For example, levels of TSNAs in ST products vary by as much as 400-fold.7 A 2008 survey of 
39 top-selling brands of U.S. moist snuff showed a more than fivefold variation in total nicotine levels 
and a more than 500-fold range in free nicotine.8 Levels of toxicity, carcinogens, and free nicotine are 
influenced by a wide range of factors, including species of tobacco plant used, characteristics of the soil 
in which the tobacco was grown (e.g., the concentration of nitrite and certain metals), curing methods 
(air-cured vs. fire-cured), processing methods (pasteurized vs. fermented), addition of certain ingredients 
(tonka bean, areca nut, alkaline agents), and conditions under which the final products were stored. 
Based on research to date, steps could be taken to reduce the presence of carcinogens or other toxicants 
in ST products, including reduction or elimination of the use of fire-cured tobacco, improved prevention 
of microbial contamination, changes in fermentation, elimination of ingredients such as areca nut and 
tonka bean, and improvements in storage conditions.  
Despite the enormous product diversity, some important common cross-product observations can be 
made. The practice of adding alkaline agents to boost nicotine delivery is commonly found in a number 
of traditional and manufactured ST products around the world (such as punk ash added to iqmik in 
Alaska, slaked lime added to khaini in India, or sodium bicarbonate added to toombak in Sudan). 
Adding flavorings (e.g., menthol, cocoa, licorice, rum, aniseed, cinnamon, clove) and sweeteners (e.g., 
molasses, honey, dextrose, sorbitol, fruit juices) is also a common practice and may make the product 
more appealing to youth and new users.9 Additionally, there appears to be a growing emphasis on 
increased convenience and ease of use in the marketing of ST products in countries at different income 
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levels. Gutka, a dried, prepackaged version of the fresh betel quid traditionally mixed to order by a 
vendor or user, has become increasingly popular in India and is now a large-scale industry. At the same 
time, in high-income countries such as the United States, tobacco product manufacturers have packaged 
moist snuff in pouches that do not require spitting, marketing them to smokers as a discreet and 
convenient alternative for settings where they cannot smoke.  
Marketing Strategies and Production Practices: The Evolving Market 
Tobacco industry marketing strategies also show some common trends. Across high-, middle-, and low-
income countries, tobacco product manufacturers utilize colorful packaging, suggestive names and 
slogans, cross-branding with non-tobacco products, price discounts, health or medicinal associations, 
and lifestyle marketing appeals to sell their products. In the United States, U.S. Smokeless Tobacco 
Company aggressively promoted low-nicotine products starting in the mid-1970s to young people in an 
attempt to graduate these new users to products containing higher amounts of nicotine as they become 
more nicotine dependent.10 Longitudinal data provide evidence that switching from lower to higher 
nicotine products does occur among youthful snuff users.11  
In middle- and low-income countries, marketing strategies may pose a particular challenge for tobacco 
control efforts by circumventing existing tobacco control measures, using the same brand names for 
their tobacco products as for non-tobacco products, and using packaging that appeals to youth. For 
example, manufacturers in India use the same brand names for their non-tobacco products as for 
tobacco-containing products in an effort to circumvent India’s ban on tobacco product advertisements 
on television. Use of small single-use packaging makes products inexpensive and more easily available 
to youth and may dilute the impact of tobacco taxes. In addition, large-scale marketing campaigns are 
generally absent for traditional cottage industry products, but large multinational companies have 
entered markets in some low- and middle-income countries and have begun to produce some 
traditionally cottage industry products on a larger, commercial scale.  
In high-income countries such as the United States, a number of manufacturers have introduced novel 
ST products, using new product formulations (e.g., reduced nitrosamines, dissolvable formulations, 
spitless pouches, new flavorings) and marketing practices (e.g., targeting current smokers and devising 
innovative packaging). These products and practices may appeal to new groups of users. For example, 
novel snus products have been marketed to smokers for use in settings where they cannot or do not want 
to smoke, using imagery that emphasizes trendiness, urbanity, freedom, and sophistication for both men 
and women. And U.S. cigarette manufacturers have introduced ST products with popular cigarette brand 
names such as Marlboro and Camel. These new marketing strategies raise concern because they may 
increase initiation, deter people from quitting smoking or other tobacco use, or result in dual use or use 
of multiple tobacco products.  
Policy and Personal Level Interventions 
In all regions, evidence-based interventions tailored to the prevention and cessation of ST use are 
limited. The available evidence suggests that school-based and community prevention programs can 
lead to short-term reduction in prevalence among youth, and that clinic and dental office interventions 
(involving multiple sessions and counselor support) can increase cessation among adults. 






Pharmacotherapies, with the possible exception of varenicline, have not been found to be effective in 
improving cessation in ST users in the United States and Great Britain (chapter 7). In some regions, 
knowledge about the health effects of ST use is limited even among health professionals. The existing 
evidence for treatment programs comes largely from high-income countries, and data on smokeless 
tobacco quit rates are not available for most countries. Thus, there is a particular need to develop 
and test interventions targeted at low-income populations or countries where the burden of ST use 
is greatest.  
A diverse range of programs and policies have been implemented in different countries and 
municipalities to address ST use; however, limited data are available to evaluate the impact of these 
interventions. Some countries and municipalities have banned entire classes of tobacco products, such as 
the ban on gutka sales imposed by some states and subregions in India. In many countries, a lower 
standard has been applied to ST products compared with cigarettes. For example, in many regions, even 
those where ST use is highly prevalent, policies and programs aimed at ST use prevention and cessation 
are generally weaker than those for smoked tobacco products: prices are lower, warning labels are 
weaker or nonexistent, surveillance is weaker, fewer resources are devoted to prevention and control 
programs, and fewer proven interventions are available. While restrictions on smoking in public places, 
even outdoors, have been vigorously pursued in many countries around the world, few efforts have been 
made to apply these rules to non-smoked tobacco products.  
Overall Challenges: Smokeless Tobacco is a Complex Global Problem 
Considering the magnitude and complexity of the smokeless tobacco problem (including industry 
marketing, trends and patterns of use, and a lack of effective interventions), the public health challenge 
of ST warrants far greater attention and action than it has so far received. According to Euromonitor 
International, the global market for both modern and traditional snuff products is projected to increase 
by 24 percentage points between 2011 and 2016, compared to only a projected 7 percentage point 
increase in the market for cigarettes.12 Moreover, while the WHO Framework Convention on Tobacco 
Control (FCTC) applies to all tobacco products, many of the strategies developed under the Conference 
of Parties to date are focused on cigarettes, and no specific guidance has been developed regarding 
ST products. 
The prevalence of ST use is particularly high in some low- and middle-income countries and among 
low-income populations. The major challenge that faces these countries is the limited data to help craft 
policies and programs. For example, data on pricing, tax structures, and sale of ST products are very 
limited, especially in those countries where ST use is most prevalent. Cottage industry production makes 
collection of taxes more challenging and probably less effective. Additionally, information on the cost of 
health care to treat ST-related diseases is extremely limited. This is a particularly significant gap in the 
data needed to inform the control of ST use. 
While the public health burden falls disproportionately on low- and middle-income countries, the 
findings and gaps identified in this report have substantial public health importance for high-income 
countries as well. Countries with the largest populations of ST users include the United States, with 
9 million users. Between 2005 and 2010, sales of moist snuff grew by US$2.04 billion following 
increased marketing of these products.13 National surveys also suggest that between 2000 and 2010, 
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ST use in the United States rose among youth, particularly high school males.14–16 The major challenges 
faced by the United States and possibly other high-income countries include the large number of 
different types of tobacco products that are emerging in the market. As noted previously, novel snus-
type products using familiar cigarette brand names (Camel and Marlboro Snus) are being marketed to 
smokers for use in settings where they cannot smoke.17,18 This trend may adversely impact smoking 
cessation efforts by encouraging dual use as an alternative to tobacco use cessation. Additionally, dual 
use of ST and cigarette smoking could have greater health risks than smoking alone.19,20 Although 
cigarette smokers who permanently switched to exclusive ST use decreased their risk of some diseases 
specific to smoke exposure, those who quit tobacco use altogether lowered their mortality rates from 
lung cancer, coronary heart disease, and stroke more than those who switched to ST use, as indicated by 
the single study that examined this effect.21 
Another challenge revolves around the smokeless tobacco harm-reduction debate. Some have suggested 
that ST products, particularly those low in nitrosamines, could act as harm-reduction agents for cigarette 
smokers, especially in high-income countries with lower disease burdens related to ST use. However, as 
this report suggests, the assessment of risks and benefits in such a strategy, particularly on a population 
level, is complex and uncertain. In almost all countries, ST products have widely varying levels of 
addictive potential and toxicity. Furthermore, available data do not allow for identifying specific levels 
of product constituents with quantifiable risk reductions. Additionally, no rigorous studies have 
demonstrated the effectiveness of an ST product for smoking cessation or as a complete substitution 
for cigarettes. 
To summarize, ST use poses distinct public health challenges in different regions. In some low- and 
middle-income countries ST use is highly prevalent, it is associated with high disease risks, and the 
market is poorly regulated. In contrast, in some high-income nations, overall tobacco use has decreased, 
use of ST products is associated with markedly lower disease risks compared with smoking, and active 
tobacco control programs exist, but the types and products for sale are quickly proliferating and 
marketing of these products is expanding to new populations. While the promotion and use of ST 
products pose serious public health challenges across a wide spectrum of different environments, it is 
important to recognize that this is a complex problem and that solutions need to be tailored to the needs 
of each country. 
Nevertheless, the complexity of this problem should not impede research, capacity building, and policy 
development and evaluation around smokeless tobacco. At the fifth session of the Conference of the 
Parties (COP5) to the WHO Framework Convention on Tobacco Control, held in November 2012, the 
Convention Secretariat provided a background report that emphasized the need to prioritize measures to 
specifically address ST use as part of the full implementation of the Framework Convention.22 Some 
participants argued against making specific recommendations on ST given the wide variation in ST 
products around the world and different marketing dynamics and regulatory experience.23 In the end, the 
COP requested additional information, including identifying and evaluating best practices in prevention 
and control of ST products and identifying research gaps and needs, before taking any action.24 While 
deliberations continue in the global community, it is important to continue to build a global research and 
capacity-building agenda around smokeless tobacco. 






Gaps and Research Needs  
This volume has identified a number of research, capacity-building, and policy needs. This summary 
offers guidance to researchers, public health practitioners, and policymakers on addressing the public 
health impact of ST use around the world.  
Surveillance and Monitoring 
Ongoing, comprehensive surveillance is needed to assess the scope of ST use and changes in patterns 
of use, and to evaluate the impact of policies, interventions, and other steps that could be taken to 
address ST use. However, many countries lack data on ST use; where such data are collected, 
information on the use of specific products is very limited or unavailable. Moreover, in a product 
category that has changed and continues to change dramatically, particularly in recent years, existing 
survey data may not fully reflect the current situation. Surveillance and monitoring of trends in ST use 
should include information on populations and subpopulations of users, types of products, patterns and 
intensity of use, combined use of other tobacco products, and attitudes, beliefs, and perceptions about 
tobacco products. For example, the existing CDC-led Global Tobacco Surveillance System and 
WHO STEPS surveys could be expanded to provide greater coverage of ST, or in-depth analyses could 
be undertaken to document survey findings. Smaller targeted surveys are needed in order to assess the 
impact of novel products or rapid changes in use and to understand patterns among specific subgroups. 
Standardized measures of ST use and exposure, including quantity and frequency of use, are also 
needed. The WHO’s Tobacco Questions for Surveys25 provides a subset of basic questions that can be 
added to existing surveys, and this resource could be further expanded and tailored to specific products 
and regions. The new U.S. Surgeon General’s 50th anniversary report, The Health Consequences of 
Smoking—50 Years of Progress, includes as one of its key recommendations the need to ensure that 
surveillance activities in the different countries monitor use of smokeless tobacco and combined use 
with other tobacco products.26 
Products 
Given the diversity of products and modes of manufacture around the world, a more comprehensive 
characterization of the properties of different products, their constituents, and methods of manufacture is 
needed. Where resources are available, biomarker studies to examine actual human uptake (absorption 
and excretion) of nicotine and toxicants as a result of active, secondhand, and fetal exposure to ST 
would be valuable. Additionally, attention should be given to non-tobacco products that are frequently 
used in conjunction with tobacco, such as areca nut. Further research is needed to develop standardized 
testing methods for diverse products. The laboratory standards being developed by the WHO Tobacco 
Laboratory Network for testing cigarettes could be expanded and adapted for ST products.  
Health Effects 
While there is a significant body of research on particular health effects of ST use in a few countries, the 
diversity of products, practices, and patterns of use precludes broad generalizations about health effects. 
Most studies of health effects have been conducted in Scandinavian countries, the United States, and 
India. Because of the diversity in toxicant and nicotine levels across ST products and patterns or use, 
applying results from one country to another country is problematic. Even within a country, ST products 
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can vary tremendously. Also, mixed results for some health outcomes and disease endpoints in some 
studies (such as in cardiovascular disease effects) and small numbers of participants in others suggest 
the need for further investigation. Across countries there is consensus on the adverse effects of nicotine 
on pregnancy, fetal brain and lung growth, and birth outcomes, such as pre-term birth and stillbirth. 
However, the effects of ST use on birth outcomes need further characterization, especially considering 
the high prevalence of ST use among some subgroups of women of reproductive age. In order to link 
specific types of products with particular health effects, studies are needed that link the constituent 
profile and biomarkers of exposure and biomarkers of effect to specific ST products with health 
consequences; establishing these links may be extremely challenging for custom-made and cottage 
industry products with little or no standardization. Studies should also investigate the health effects of 
other ingredients and combinations of ingredients frequently used in ST products, such as areca nut or 
tonka bean. 
Economics and Marketing 
Very little information is currently available on pricing and sales volume of ST products in many 
countries. While many studies have been conducted on the price elasticity of cigarettes, for example, 
comparable data for ST are very limited. Given the high prevalence of ST use in some low- and middle-
income countries and among poor and rural populations, pricing information may be especially 
important for understanding patterns of use and developing effective public health interventions. 
Information on price, taxes, affordability, and trade should be collected routinely. Additionally, locally 
relevant data are needed to demonstrate the economic benefits of tobacco control measures, because 
some countries with active tobacco industries may seek to delay or defeat actions to reduce ST use out 
of concern for the potential impacts on national economies. Lastly, ongoing surveillance of tobacco 
industry marketing strategies is important, particularly following the implementation of new policies or 
regulations or the entrance of new multinational tobacco companies into the market.  
Interventions 
New interventions for ST use prevention and cessation should be developed and tested at both the 
population and individual levels along with their impact on use of combustibles, cessation, and relapse. 
Interventions tailored to ST users and to specific populations of users, taking into account cultural 
differences within and across regions, are needed. Effective interventions can be developed based on a 
clearer understanding of the factors associated with initiation and maintaining use, the reasons why 
some ST users want to quit, the barriers to quitting, and how best to disseminate treatments based on the 
resources of a particular region. Given that most of the current evidence base for effectiveness of 
interventions comes from high-income countries, development and evaluation of interventions for use in 
low- and middle-income countries and in diverse health care settings are needed.  
Building Capacity 
Enhancing surveillance and synthesis of data, pursuing a research agenda, and implementing new 
policies and interventions to address ST use will require increased scientific and public health capacity 
in low- and middle-income countries, particularly those that are confronted with high burdens of ST use. 
Increased in-country capacity to conduct tobacco control research is critical to the development and 






implementation of effective interventions, as these interventions must be responsive to local populations 
and contexts. In addition, robust local capacity enhances the sustainability and adaptability of evidence-
based policies and programs, as local researchers and institutions are well positioned to respond to 
changes in the tobacco control environment over time by generating new relevant knowledge to inform 
modifications or new approaches. 
At the same time, greater capacity for communication and collaboration across countries is increasingly 
important. As tobacco use trends change, innovative policies and interventions are introduced in 
different countries, and the tobacco industry adopts new marketing strategies, an enormous “natural 
experiment” is under way that provides unique opportunities for research and evaluation. Making use of 
these opportunities will require coordinated surveillance, information sharing, and research efforts. The 
following recommendations, some of which have been described in Article 20 of the FCTC, are made to 
enhance collaboration and infrastructure development: 
 Create regional information clearinghouses for ST that can be readily accessed electronically by 
people from all parts of the world. These clearinghouses can inform stakeholders within and 
outside a region about ST product characteristics, patterns of use, policies and other interventions 
that have been implemented, and the results of any research or evaluation conducted.  
 Strengthen the infrastructure for networking, communication, and collaboration. One mechanism 
for facilitating this goal would be to develop a Web portal to serve as a repository and index to 
information on ST product characteristics, constituents and ingredients, manufacturing and 
promotion methods, product price, and packaging and marketing materials. This Web portal 
could also bring together the regional clearinghouses described above and provide a forum for 
discussion about research design, research results, and policies. 
 Build collaborations among scientists, tobacco control advocates, and policymakers. These 
collaborations are critical for translating research into policy and ensuring that policy needs 
inform research studies. Collaborations across countries and regions are especially important to 
making comparisons between different products, environments, and interventions. Countries 
with more mature tobacco control programs can provide expertise and assistance to countries 
that are in earlier stages of implementing programs and policies. 
 Develop innovative and sustainable approaches to build research capacity by better leveraging 
existing resources such as the Tobacco Laboratory Network, the Global Adult Tobacco Survey 
and Global Youth Tobacco Survey, and the Tobacco Harm Reduction Network. Research 
capacity can also be enhanced by attracting and training new researchers—especially those in 
middle- and low-income countries—and encouraging collaborations between new and 
experienced researchers. 
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Intervention and Policy Needs 
Tobacco control policies, programs, and interventions applied to cigarettes and smoked tobacco products 
should be applied to ST products and enforced and monitored with equal strength, particularly in regions 
where the burden of ST use is high. Prevention and cessation of ST use should form an integral part of 
every comprehensive tobacco control effort. At the same time, ST products pose some distinct 
challenges compared with smoked products, and specific policy needs may vary across countries, 
depending on products, patterns of use, industry marketing, and the tobacco control environment. These 
recommendations are consistent with those made in the 2014 U.S. Surgeon General’s Report.26 In 
particular, the following measures for controlling ST products should be addressed: 
 Effective interventions tailored specifically to ST users should be developed, evaluated, and 
implemented where appropriate, and support for further research in this area is needed. As of this 
writing, few studies have been conducted of interventions targeted to ST users, and 
pharmacotherapies used with cigarette smokers (with the possible exception of varenicline) have 
not generally been found effective with ST users. However, some community-wide prevention 
efforts (especially if they involve youth and parents) have shown success across countries of 
different income levels. The engagement of oral health professionals in recommending or 
providing ST cessation counseling has been shown to be effective in some countries and may be 
applicable to a variety of other communities and nations.  
 Specific guidelines are needed to ensure that the FCTC requirements and MPOWER guidelines27 
can be and are appropriately applied by the Parties to ST products as well as cigarettes. For 
example, the FCTC binds Parties to ban or restrict sponsorship and marketing of tobacco 
products, prohibit sale to minors, and track and monitor illicit trade. Additional guidance can 
help ensure that the FCTC and other requirements are fully applied to a diverse array of ST 
products as well. 
 In all regions, greater awareness is needed about ST use and its health effects, including 
education of health professionals, consumers (with particular attention to youth and women of 
childbearing age), policymakers, and community leaders. Dissemination of information about the 
toxicity of tobacco products may be particularly important in geographic areas where tobacco 
products are premade through cottage industries, or custom-made at home or at the point of sale. 
Greater awareness is also needed among policymakers, health professionals, and the public 
regarding the public health impact of ST use and changing patterns in industry marketing and 
consumer use.  
 Product standards for ST need to be developed, implemented, and evaluated. Levels of known 
toxicants in ST products vary widely, as does the impact of storage and processing practices on 
toxicant levels. Feasible measures for reducing toxicant levels include reducing the use of 
Nicotiana rustica, limiting bacterial contamination that can promote nitrite formation, nitrosation 
and carcinogen formation, and requiring tobacco to be air-cured, pasteurized, and refrigerated. 
The WHO Study Group on Tobacco Product Regulation has recommended mandating upper 
limits on ST toxicants; this would include setting the upper limit of NNN plus NNK at 
2 micrograms per gram of dry weight tobacco, and the upper limit for benzo[a]pyrene at 
5 nanograms per gram of dry weight tobacco.  






 Research is needed that can form the basis for establishing maximum levels of pH in ST 
products. Additives that increase pH in tobacco products boost the amount of free nicotine 
available for absorption, and products with higher free nicotine levels are more addictive. 
 Some countries, such as the United States and Canada, have banned flavorings in cigarettes 
(except menthol), but they have placed no such limits on the use of flavorants in ST products. A 
variety of flavors and other additives are used to enhance the appeal of tobacco products and 
facilitate uptake.9,28 A recent U.S. study showed that more ST users (who were seeking an 
intervention) had initiated with or switched to a mint-flavored ST product than non-flavored 
products.29 Banning or limiting certain additives and flavorants may serve as an effective tool for 
reducing the attractiveness of ST, especially among youth and pregnant women.  
 Stronger, more effective public health warnings are needed on ST products (as recommended in 
Article 11 of the FCTC). Many countries require health warning labels on ST packaging, but 
most of these labels contain only textual warnings and lack the graphic images that have been 
implemented for cigarette labels. For cigarettes, Article 11 of the FCTC recommends pictorial 
warning labels and mandates that health warnings cover at least 50% of the cigarette packet. 
These standards have not been uniformly applied to ST products.  
 Increasing the price of ST products could be implemented, and increasing taxes on ST products 
(as recommended in Article 6 of the FCTC) is the simplest way to increase price. As noted in 
chapter 5, a WHO expert panel recommended that ST be taxed at “a level sufficient to act as a 
disincentive, and at least at the level at which cigarettes are taxed.”30,p.64 The same FCTC 
guidelines for taxing cigarettes could be applied to ST and all other tobacco products. These 
recommendations include an excise tax that makes up at least 70% of the retail price, with the 
use of specific excise tax being favored over ad valorem taxes. Having a more uniform tax 
structure across tobacco products would help curtail the practice of substituting less expensive 
tobacco products for more expensive ones, which would be of particular concern in countries 
where very toxic ST products may be less costly. Due to challenges inherent in tax collection in 
traditional markets, especially from small-scale local producers or sellers, taxation of tobacco 
leaves or a presumptive tax (a compounded levy per manufacturing machine) may be considered 
in countries with diverse ST products and markets. Earmarking a portion of ST tax revenues to 
fund ST prevention and cessation interventions, other tobacco control efforts, or public health in 
general could further increase the overall benefit of taxation. 
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Description of Representative Products  
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A wide range of smokeless tobacco products are used in the 46 countries that make up 
the WHO African Region. Smokeless tobacco 
products can take a variety of forms, are 
available commercially, and can be custom-
made or manufactured in small factories. The 
products can be chewed, sniffed, sucked, 
or applied to teeth and gums. Several of the 
products are summarized here.
Photo courtesy of Olalekan Ayo-Yusuf,  
University of Pretoria
Product Types, Modes of Absorption, 
and Main Geographic Locations
Ghana traditional snuff (tawa) 
This local dry snuff, often called “tawa,” is prepared 
by mixing the dried tobacco leaf with some 
chemicals such as saltpeter (potassium nitrate) 
and grinding it into a fine powder. It may be held 
in the mouth or used nasally to induce sneezing 
to “lighten” the head; it may also be used as a 
depressant or stimulant.1
Neffa (naffa, tenfeha, nufha) 
These are the names given to dry snuff that is 
used nasally in northern Africa. Neffa/naffa is used 
in Tunisia, Libya, and Algeria. Tenfeha is used in 
Morocco, and nufha in Algeria.2
Snuif 
Snuif, the South African word for “snuff,” is not a 
specific type of smokeless tobacco product. Snuif 
is both commercially and locally produced. Some 
brand names are Singleton (dry snuff), Taxi, and 
Ntsu (moist snuff). The custom-made traditional mix 
is prepared by hand-mixing finely ground sun-dried 
tobacco leaf with ash from local plants.3  
Taaba 
This type of smokeless product is used in a number 
of West African countries, including northern 
Nigeria, Cameroon, Senegal, Uganda, and Chad. 
It is locally produced from dry fermented tobacco 
that is pulverized and mixed with natron/atron (a 
naturally occurring mixture of sodium bicarbonate 
and sodium chloride). Taaba can be used nasally or 
sucked orally.  
Prevalence and Demographics 
Ghana traditional snuff (tawa) 
Although no data are available specifically on the 
prevalence of use of traditional snuff, findings from 
the Global Youth Tobacco Survey (GYTS) in 2006 
showed that 10.4% of youths in Ghana reported 
using “tobacco products other than cigarettes,” 
including snuff.4
Neffa 
Neffa is predominantly used by men. Although no 
data are available specifically on the prevalence 
of neffa use, in the Algerian provinces of Oran, 
Constantine, and Setif, youth prevalence of 
tobacco use other than cigarettes was 7.8–8.9%, 
according to the 2007 GYTS.4
Snuif 
Snuif is the name given to snuff in South Africa. Its use 
is most common among women and people living 
in rural areas, as well as individuals who are older, 
black, or have less education and income.5 A 2003 
study in South Africa reported that 2.4% of men and 
10.9% of women aged 15 years and older reported 
ever using any smokeless tobacco, including snuff.6 
The 2008 South African National Youth Risk Behavior 
Survey found that 12.1% of adolescents used 
smokeless tobacco in the past month.7
B-4
Taaba
No data are available specifically on the prevalence 
of dry snuff use, but the 2008 Nigeria Demographic 
and Health Survey found that 3.2% of adult men 
and 0.5% of adult women report using smokeless 
tobacco.8 Although national prevalence data in 
Nigeria suggest relatively low use rates, 2007 data 
from a state in Nigeria’s North-East geopolitical zone 
revealed smokeless tobacco use rates as high as 
10.8% among men and 4.1% among women aged 
15 years and older.9 The 2008 GYTS in Nigeria found 
that youth prevalence of tobacco use other than 
cigarettes was between 13.1% and 23.3% in five 
states.4 In Uganda in 2006–2007, the prevalence 
of any smokeless tobacco use among adults (age 
15–54) was 3.9% for men and 2.6% for women,8 and 
among adolescents (age 13–15), 8.6% for boys and 
9.6% for girls.4
Chemical Measurements
Only limited data are available on the toxicity of smokeless tobacco products used in the region, but recent data 
suggest considerable variability in the toxicity and nicotine profiles of some of the products that have been tested. These 
data are expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type pH
 Total Nicotine Free Nicotine
 mg/g wet wt
 NNK NNN NNAL Total TSNAs*
ng/g wet wt
Snuif, traditional snuff, 
South Africa
9.29  5.29 5.01  1,610 5,570 71.8 20,500
Traditional snuff, 
Nigeria
9.42  2.49 2.39  285 711 29.5 1,520
*Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino) 
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram.
Source: Stanfill et al. 2011 (10).
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For additional information on African traditional snuff products, please refer to Chapter 12: Smokeless Tobacco Use in the African Region.
African Traditional 




Betel quid is commonly used in many countries in the Asia-Pacific region. It can be prepared 
in a variety of ways depending on the region, 
but usually contains areca nuts, slaked lime, and 
catechu (extract of the Acacia catechu tree) 
wrapped in a betel leaf. Betel quid itself is not a 
tobacco product, but tobacco is often added 
to it. Chewing betel quid without tobacco is an 
ancient practice in India; this product is known 
as “tambula” in Sanskrit.1
Photo courtesy of World Health Organization South-East 
Asia Regional Office and Dhirendra N. Sinha
Common Names  
Paan or pan (India), khilli paan (Bangladesh)
Brand Names 
None
Main Geographic Locations 
(WHO Region: Country) 
South-East Asia Region: India, Sri Lanka, Bangladesh, 
Myanmar, Thailand, Indonesia, Nepal, Maldives2; 
Eastern Mediterranean Region: Pakistan, United Arab 
Emirates2,3; Western Pacific Region: Lao Democratic 
People’s Republic, Palau, Cambodia, Malaysia, 
Vietnam, Federal States of Micronesia2,4    
Prevalence and Demographics  
Prevalence and demographic profiles of betel quid 
chewers vary greatly by region. The Global Adult 
Tobacco Survey in India (2009–2010) shows that 
about 6.2% percent of all adults aged 15 years and 
older (7.5% of males and 4.9% of females) report 
using betel quid with tobacco in India,5 and 24.3% 
of all Bangladeshis aged 15 years and older (23.5% 
of males and 25.2% of females) consume betel 
quid with tobacco.6 The 2009–2010 Asian Betel–
Quid Consortium study found that use of betel quid 
with tobacco among adults aged 15 and older 
ranges widely across several other South-East Asian 
countries:	Prevalence	is	high	in	Nepal	(males,	43.6%;	
females, 34.9%) and among women in Indonesia 
(31.7% among females, compared to 10.4% among 
males). Prevalence is moderate in Malaysia (males, 
6.2%; females, 12.0%), and generally low in Sri Lanka 
(males, 6.4%; females, 3.2%).7 In Myanmar in 2004, 
approximately 16.2% of adults aged 15 years and 
older (males, 27.8%; females, 4.4%) chewed betel 
quid with tobacco.8   
Mode of Absorption  
Oral (chewed, held in mouth)
Use Patterns 
Different regions will use different types of tobacco in 
betel quid, such as sada pata (plain tobacco flakes) 
and zarda (flavored tobacco flakes) in Bangladesh 
and India,1,6 kiwam (tobacco paste) in Pakistan 
and India,1,2 and even half a cigarette in Palau.4,9 In 
Indonesia, Vietnam, and Cambodia, users may use 
tobacco to clean their teeth after chewing betel quid 
rather than inserting it directly in the quid.9,10 Some 
users swallow the juices produced from chewing betel 
quid.2  
Main Ingredients 
Tobacco, areca nut, slaked lime (calcium hydroxide) 
or other alkaline agents, betel leaf, and usually 
catechu (Acacia catechu tree extract). Additional 
ingredients vary regionally according to local 
preference, and can include cardamom, saffron, 




Cottage industry and custom-made: Betel quid 
is prepared by individual vendors for sale or 
assembled at home by individual users. Betel quid 
may be prepared in a variety of ways. Areca nut 
can be raw, boiled, roasted, fermented, or sun-
dried. Tobacco may be used raw, sun-dried, or 
roasted, and then finely chopped or powdered. 
Alternatively, the tobacco may be boiled with 
molasses and made into a paste. The tobacco 
may then be perfumed or flavored. Slaked lime 
and sometimes catechu are smeared on a betel 
leaf, then the betel leaf is folded into a funnel 
shape, and tobacco, areca nut, and any other 
ingredients are added. The top of the funnel is 
folded over, resulting in a quid, which is placed in 
the mouth and chewed.2,9 
Chemical Measurements




2. International Agency for Research on Cancer. Betel-quid and areca-nut chewing and some areca-nut-derived nitrosamines. IARC monographs 
on	the	evaluation	of	carcinogenic	risks	to	humans.	Vol.	85.	Lyon,	France:	World	Health	Organization,	International	Agency	for	Research	on	
Cancer;	2004.	Available	from:	http://monographs.iarc.fr/ENG/Monographs/vol85/mono85.pdf




















For additional information on betel quid (paan), please refer to the following chapters: Chapter 10: Smokeless Tobacco Use in the European Region; 
Chapter 11: Smokeless Tobacco Use in the Eastern Mediterranean Region; Chapter 13: Smokeless Tobacco Use in the South-East Asia Region; and 





Chimó is a tobacco-based paste that was reportedly first used in South America in 
the early days of European colonization. In 
1497, Amerigo Vespucci reported the use of 
a chewing tobacco mixed with ashes in the 
Caribbean.1 According to a popular legend, the 
aboriginal chief Chimauchu was the first to use 
tobacco in the form of a paste, which today is 




El Tovareño, El Tigrito, El Sabroso, El Gran Búfalo, El 
Dragón, El Morichal, San Carleño
Main Geographic Locations  
(WHO Region: Country) 
Region of the Americas: Venezuela, Colombia2
Prevalence and Demographics 
Among adults in Venezuela in 2007, 1.5% of women 
and 6.2% of men were current users, and 3.1% of 
women and 15.4% of men reported ever using 
chimó.3 The Venezuelan Global Youth Tobacco 
Survey (GYTS) was used to estimate tobacco-
specific prevalence of smokeless use among 
students in grades 7–9. GYTS results for Venezuela 
nationally and for eight different states in the years 
2000, 2004, and 2008 found that the prevalence 
of	chimó	use	was	not	uniform	among	the	states:	It	
ranged from 3.8% to 20.7% for boys, and 2.0% to 6.6% 
for girls.2 Prevalence rates of chimó use in Colombia 
are not available. 
Mode of Absorption 
Oral (sucked, held in mouth)
Use Pattern
A small amount of chimó is placed between the lip 
or cheek and the gum and left there for some time, 
usually 30 minutes. The mixture of chimó and saliva is 
spit out.4
Main Ingredients 
Tobacco leaf, baking soda (sodium bicarbonate), 
brown sugar, ashes from the Mamón tree 
(Meliccoca bijuga), and vanilla and anisette 
flavoring. The ingredients vary according to the 
region.4 
Processing/Manufacturing
Cottage industry and commercial: Chimó is usually 
produced by small family-operated factories, but 
commercial, industrial manufacturing of chimó is 
increasing in Venezuela. Tobacco leaves are first 
crushed and boiled for several hours or days, and 
then starch and fibers are removed. The remaining 
concentrated product (10 kilos of tobacco becomes 
one kilo of “basic” chimó paste) is a sticky, heavy, 
black liquid, which can be stored for maturation for 
up to 2 years. For maturation, it is placed in natural 
containers like “taparas” (dried fruit from the Tapara 
tree) or wrapped in banana leaves. The matured 
paste is seasoned with other ingredients (see “Main 
Ingredients”), and then packaged in small tins or 
candy-like wrapped cylinders.4 
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Chemical Measurements
These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type pH
 Total Nicotine Free Nicotine
 mg/g wet wt




6.98–9.40  5.29–30.1 1.32–27.4  310–2,600 318–4,260 14.9–1,330 954–9,390
*Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 

















Creamy snuff is a tobacco-based paste sold in toothpaste-like tubes. It is often advertised 
as being antibacterial and healthy for teeth and 
gums, and it is used primarily by women.1
Photo courtesy of World Health Organization South-East 




IPCO (Asha Industries), Dentobac (Goran Pharma 
LTD), Tona, Ganesh, Charotar, Musa Ka, Rehmat 
Khan, Chad Tara, Dulhan, Suraj, Asif Ka
Main Geographic Location  
(WHO Region: Country) 
South-East Asia Region: India2
Prevalence and Demographics 
Creamy snuff is used primarily by women, but it also 
seems popular among children.1,3 In 2004, one study 
in India reported that the prevalence of creamy 
snuff use among adolescents aged 13 to 15 years 
varied from 2% to 32% across 18 states.4 Although 
no product-specific adult prevalence data are 
available, in 2009–2010 4.7% of all adults (3.3% 
of males and 6.3% of females) in India reported 
applying tobacco products, including creamy snuff, 
mishri, gul, or gudakhu, to their teeth and gums.5 
Mode of Absorption 
Oral (applied to teeth and gums, teeth cleaning)
Use Pattern 
Creamy snuff is used to clean teeth like regular 
toothpaste. Some products’ instructions recommend 
holding the paste in the mouth for a little while 
before rinsing.1,3
Main Ingredients 
Tobacco, clove oil, glycerin, spearmint, menthol, 
camphor, water3
Processing/Manufacturing 
Commercial: Creamy snuff is commercially 
manufactured and is marketed as a teeth cleaner 
(dentifrice).3 Creamy snuff consists of finely ground 
tobacco mixed with aromatic substances, such as 
clove oil, glycerin, spearmint, menthol and camphor, 
salts, water, and other hydrating agents.1,3 Additional 
information on the manufacturing of creamy snuff 
could not be located.
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Chemical Measurements
These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type* pH
 Total Nicotine Free Nicotine
mg/g wet wt
 NNK NNN NNAL Total TSNAs†
ng/g wet wt
Creamy Snuff,  
India
7.51–8.35  5.62–10.0 2.36–3.82  N/A N/A N/A N/A
*All creamy snuff products were commercially manufactured.
†Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram.


















Dissolvable smokeless tobacco products were introduced in the United States in 2001. The first 
products, Ariva and Stonewall, dissolved completely during 
use, with no residual loose tobacco or tobacco-containing 
sachet to discard. In 2009, R.J. Reynolds Tobacco 
Company released Camel Orbs, Strips, and Sticks in a 
variety of formulations and flavors, all of which can fully 
dissolve in the mouth.1 In 2011, Altria began test marketing 
new dissolvable products, Marlboro and Skoal Smokeless 
Tobacco Sticks, which are small toothpick-like sticks coated 
with tobacco, which are discarded after the coating 
dissolves.2 In January 2013, the manufacture and sale of 
Ariva and Stonewall lozenges were discontinued.3 Because 
dissolvables look like candy, there is concern that children 
will accidentally ingest them.4 Photo courtesy of Clifford Watson,  
Centers for Disease Control and Prevention
Type Description Examples
Tablets Tobacco compressed into a lozenge Arriva, Camel Orbs, Stonewall 
Strips Tobacco pressed into a thin wafer-like dissolvable strip (somewhat like a 
breath strip)
Camel Strips
Sticks Tobacco pressed into a long, thin dissolvable stick Camel Sticks
Tobacco Sticks Small toothpick-like stick coated with a semi-hard tobacco-containing 
mixture. All of this product dissolves in the mouth except the toothpick.





Ariva, Stonewall (Star Scientific); Camel Orbs, Camel 
Strips, Camel Sticks (R.J. Reynolds); Marlboro Sticks 
(Philip Morris); Skoal Sticks (U.S. Smokeless Tobacco 
Company)
Main Geographic Location  
(WHO Region: Country) 
Region of the Americas: United States5
Prevalence and Demographics 
A 2010 survey found that less than 1% (0.6%) of 
adults in the United States had tried dissolvables.6 
Dissolvable tobacco products are fairly new to the 
market, and as of 2011–2012, Camel, Marlboro, 
and Skoal dissolvable products were still being test 
marketed in select cities and were not nationally 
available.2,5,7 As these products become more 
widely available, their use may become more 
widespread. 
Mode of Absorption 
Oral (sucked, held in mouth, dissolved)
Use Pattern
These products can dissolve in as few as 3 minutes 
(Camel Orbs) or as much as 30–60 minutes 
(Stonewall).8 Tobacco sticks do not completely 
dissolve because the tobacco is coated onto a 
wooden toothpick that must be thrown away.
Main Ingredients 
Tobacco, humectants, preservatives, flavors9 
B-12
Processing/Manufacturing
Commercial: Dissolvable tobacco is commercially 
manufactured. Limited information is available 
on the specific processes used for manufacturing 
many of these products. To create tobacco tablets, 
tobacco is pasteurized and ground into fine powder, 
and the finely powdered tobacco is combined with 
flavors, such as mint and eucalyptus, and other 
additives that allow the tobacco to be compressed 
into tablet form and dissolved in the mouth.10
Chemical Measurements
These data are for select products and may not represent all products of this type. Data are expressed on 
a per gram basis for products analyzed as received. The amount absorbed will depend on the amount of 
product used.
Product Type* pH
 Total Nicotine Free Nicotine
mg/g wet wt




6.92–8.10  3.03–6.85 0.37–1.65  69–280 61–214 — 536–736
Camel Sticks,  
United States
7.76  3.92 1.45  307 264 — 852
Camel Strips,  
United States
7.88  2.67 1.11  221 152 — 535
*All products were commercially manufactured.
†Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
‡Includes Camel Orbs, Ariva, and Stonewall.
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)- 
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 


















9. Rainey C, Conder P, Goodpaster J. Chemical characterization of dissolvable tobacco products promoted to reduce harm. J Agr Food Chem. 
2011;59(6):2745–51.
10. Philip Morris Products SA. Smokeless dissolvable compressed tobacco product [patent application]. Pub No WO/2010/086010. World Intellectual Property 
Organization.	2010	[cited	2012	Sept	24].	Available	from:	http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2010086010&recNum=1&maxRec=&offi
ce=&prevFilter=&sortOption=&queryString=&tab=PCT+Biblio
11.	Stepanov	I,	Biener	L,	Knezevich	A,	Nyman	AL,	Bliss	R,	Jensen	J,	et	al.	Monitoring	tobacco-specific	N-nitrosamines and nicotine in novel Marlboro and Camel 
smokeless	tobacco	products:	findings	from	Round	1	of	the	New	Product	Watch.	Nicotine	Tob	Res.	2012	Mar;14(3):274–81.	Epub	2011	Oct	29.




Dohra is a wet mixture of tobacco and other ingredients such as areca nut, catechu, 
and flavors. Tobacco is frequently added to 
this mixture in the form of zarda, a smokeless 
tobacco product composed of flavored 
tobacco flakes. Dohra is commonly used in the 
Allahabad District of the Uttar Pradesh state 
in India, and in surrounding districts, such as 
Jaunpur and Pratapgarh.1
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Main Geographic Location  
(WHO Region: Country) 
South-East Asia Region: India (Uttar Pradesh)2
Prevalence and Demographics 
It is estimated that more than 50% of people in 
the Jaunpur area of India use dohra.2 There are 
no available data on nationally representative 
prevalence rates of dohra use in India.
Mode of Absorption 
Oral (chewed)
Use Pattern 
Users may buy the dohra spice mixture packet and 
tobacco packet separately and add the amount of 
tobacco they prefer.1,2
Main Ingredients 
Tobacco, areca nut, and other ingredients such 
as catechu, slaked lime (calcium hydroxide), 
peppermint, cardamom1,2
Processing/Manufacturing 
Custom-made: Dohra is produced by individual 
vendors for sale. It is sold either as a ready-made 
mixed tobacco product or in two packets, one 
containing tobacco (often zarda or surti) that is 
mixed with the contents of the second packet 
(areca nut, catechu, and other flavorings). Dohra 
is normally sold in a plastic bag with a rubber band 













Two types of snuff are manufactured and used	in	the	United	States:	moist	snuff	and	
dry (Scotch) snuff. Moist snuff is by far the most 
widely consumed type in the United States and 
Canada. It contains 20%–60% moisture and often 
is flavored with wintergreen or various fruit flavors. 
In contrast, dry snuff, a finely powdered tobacco 
product produced mainly from Kentucky and 
Tennessee fire-cured tobaccos, has a moisture 
content that is less than 10% by weight.1 This 
factsheet describes only commercial dry snuff. 
Other types of dry snuff are used traditionally 
in many regions around the world (see the 
factsheets Tapkheer and African Traditional Snuff 
Products for more information).
Photo courtesy of Clifford Watson,  






Company); Silver Dollar (Kretek International, Inc.)
Main Geographic Locations  
(WHO Region: Country) 
Region of the Americas: Canada, United States1; 
African Region: South Africa, Nigeria2;  
European Region: Germany1
Prevalence and Demographics 
Use of dry snuff has declined over the last 100 years 
and is rare today. In 2012, the U.S. prevalence of 
smokeless tobacco use (including snuff and chewing 
tobacco) among those aged 12 years and older 
was 3.6% (7.1% of males and 0.4% of females).3 
Although no current prevalence data are available 
specifically for dry snuff use, sales of dry snuff 
comprised only 1.4% of all smokeless tobacco sales 
in the United States in 2009.4 Prevalence data on dry 
snuff use in other countries are not available.
Mode of Absorption 
Oral (sucked, held in mouth); Nasal
Use Pattern 
Dry snuff is usually used orally, but it may also be 
inhaled into the nostrils.1
Main Ingredients 
Tobacco (fire-cured, fermented), often flavored1
Processing/Manufacturing 
Commercial: Dry snuff is commercially 
manufactured. Tobacco is fire-cured and then 
fermented and processed into a dry, powdered 
form; it may also be sweetened. The moisture 
content of the finished product is less than 10% by 




These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type* pH
 Total Nicotine Free Nicotine
mg/g wet wt
 NNK NNN NNAL Total TSNAs†
ng/g wet wt
Dry Snuff (5), 
United States
5.71–6.25  14.9–20.2 0.07–0.30  1,340–14,600 6,120–31,300 47–1,050 10,300–76,500
Dry Snuff (1), 
United States
5.41–7.96  4.70–24.84 0.03–3.13  — — — —
*Dry snuff products were commercially manufactured. 
†Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), N’-nitrosoanatabine and N’-nitrosoanabasine (not shown). 
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)- 
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 
Sources: Lawler et al. 2013 (5); International Agency for Research on Cancer 2007, table 6 (1).
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For additional information on dry snuff, please refer to the following chapters: Chapter 9: Smokeless Tobacco Use in the Region of the Americas, and 




Gudakhu (also spelled gudahku) is a paste-like product that is made from fine tobacco leaf 
dust and molasses (called sheera), red soil, and 
lime.1,2 Gudakhu is predominantly used in India 
in the states of Bihar, Orissa, Uttar Pradesh, and 
Uttaranchal.2 It may be used to clean teeth.3,4
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Main Geographic Location  
(WHO Region: Country) 
South-East Asia Region: India4
Prevalence and Demographics 
No recent information was located specifically on 
the use of gudakhu. Gudakhu is mainly used by 
women. Survey data from the 1970s found that 
1% of men and 16% of women in eastern India 
(Jharkhand) used gudakhu.2,4 In 2009–2010, 4.7% 
of all adults (3.3% of males and 6.3% of females) in 
India reported use of tobacco products that are 
applied to the teeth and gums, including gudakhu, 
snuff, mishri, or gul.5
Mode of Absorption 
Oral (applied to teeth and gums, held in mouth) 
Use Pattern
Gudakhu can be rubbed on the teeth and gums with a 
fingertip and may be left in the mouth. It is an addictive 
substance, with some people using it up to 20 times per 
day.1
Main Ingredients 
Tobacco powder, molasses, red soil, lime, water1,4
Processing/Manufacturing
Commercial and custom-made: Gudakhu is available 
commercially, but can also be made by individuals 
for personal use. It can come in different types of 
packaging (both branded and unbranded) and is 
frequently carried in a metal container.2 Additional 
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Gul is a pyrolysed (burned and decomposed), powdered tobacco product that is 
marketed in small tin cans or sachets under 
several different brand names. It is used as a 
dentifrice in India.1
Photo courtesy of Clifford Watson,  
Centers for Disease Control and Prevention
Common Names  
None
Brand Names 
Shajadi Gul, Mujamal Hussain Musarraf Bahi Shahi 
Eagle, Md. Mustafa Asgar Ali Gul (Bangladesh), 
Chand, Tara Marka, and Gulbadan (India)
Main Geographic Locations 
(WHO Region: Country) 
South-East Asia Region: India, Bangladesh1  
Prevalence and Demographics  
In 2009, 5.3% of adults (5.5% of males and 5.1% 
of females) in Bangladesh reported using gul.2 
In India, gul is popular among women,3,4 and 
in 2004, 2–6% of adolescents in various regions 
of India reported using it.5 There are no recent 
nationally representative statistics on the 
prevalence of gul use in India. In 2009–2010, 4.7% 
of all adults in India (3.3% of males and 6.3% of 
females) reported using oral tobacco, including 
gul, snuff, mishri, or gudakhu.4   
Mode of Absorption  
Oral (teeth cleaning, applied to teeth and gums)
Use Patterns 
Gul is usually used to clean teeth. It is addictive and 
may be used several times a day.1,3
Main Ingredients 
Pyrolysed (burned and decomposed) tobacco 
leaves, molasses, other unknown ingredients3,6 
Processing/Manufacturing 
Commercial:  Gul is commercially manufactured3 
and sold in small tin cans.6 Additional information on 
manufacturing of gul could not be located.
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Chemical Measurements
These data are for select products and may not represent all products of this type. These data are ex-
pressed on a per gram basis for products analyzed as received. The amount absorbed will depend on 
the amount of product used.
Product Type* pH
 Total Nicotine Free Nicotine
mg/g wet wt




8.79–9.22  33.4–34.1 29.1–31.0  1,330–1,370 5,190–8,020 590–630 13,400–17,100
*Gul products were commercially manufactured.
†Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram.
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(Pan Masala with Tobacco)
Gutka, or gutkha, is a dry, granular tobacco thatis a commercially manufactured version of paan 
or betel quid with tobacco.1 Unlike paan, gutka is 
relatively nonperishable and packaged in small single-
use packets that are easy to carry and use “anytime, 
anywhere.”2 Advertising of tobacco products on radio 
and TV has been banned in India since 2004; however, 
pan masala, an identical product without tobacco 
but the same brand names, can be advertised, and 
these ads are often targeted at youth.1 As of October 
2013, almost all states and union territories in India have 
banned gutka, although it is unclear how well these 
bans will be enforced.3,4 
Photo courtesy of World Health Organization South-East 
Asia Regional Office and Dhirendra N. Sinha
Common Names  
Pan masala. (The terms gutka and pan masala are 
sometimes used interchangeably, but gutka usually 
refers to the product with tobacco, and pan masala 
is the same product without tobacco.5)
Brand Names 
Manikchand, Moolchand, Tulsi, Shimla, Sikandar, Pan 
Parag, RMD, Sir, Shikhar, Dandia, Kuber, Wiz, Kesar, 
Club	Class,	Goa,	Shanti	Strong,	Vimal,	Zee,	Mehak	
Silver, Silver, Kanchan
Packaging of some brands of gutka is often identical 
to packaging of pan masala (which does not contain 
tobacco), and companies may be using this identical 
packaging to circumvent India’s 2004 ban on 
tobacco advertising.1
Main Geographic Locations 
(WHO Region: Country) 
South-East Asia Region:	India,	Bangladesh,	Nepal,	
Myanmar, Sri Lanka2,6; Eastern Mediterranean Region: 
Pakistan5
Prevalence and Demographics  
In 2009–2010, 8.2% of all individuals in India aged 
15 years and older (13.1% of males and 2.9% of 
females) reported chewing gutka.5 Use of gutka 
is common among youth and young adults.1,5,7,8 A 
number of surveys conducted in India have shown 
that pan masala and gutka are commonly chewed 
by children and adolescents.5,9 Product-specific 
prevalence data are not available for the other 
countries where gutka is used.
Mode of Absorption  
Oral (chewed, held in mouth)
Use Patterns 
Gutka is held in the mouth and chewed. Saliva is 
generally spit out, but it is also sometimes swallowed.6 
These products are commonly used throughout the 
day.
Main Ingredients 
Tobacco, areca nut, slaked lime (calcium hydroxide), 
catechu, and other condiments, sweeteners, and 
flavorings6
Processing/Manufacturing 
Commercial and cottage industry: Gutka is generally 
commercially manufactured as a dry, relatively 
nonperishable preparation.1 Gutka can also be a 
premade cottage product10 that is packaged in 
nontraditional packaging (i.e., cellophane). Gutka 
is made from powdered tobacco, areca nut, lime, 
and catechu, with other condiments and sweeteners 
added for flavor.2 Manufactured gutka is sold in small, 
brightly colored plastic and paper packets (sachets); 
plastic sachets were banned in India in March 2011.11
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Chemical Measurements
These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on 
the amount of product used.
Product Type pH
 Total Nicotine Free Nicotine
mg/g wet wt




8.20–8.54  0.16–2.08 0.12–1.08  11.6–208 45.4–913 7.02–53.5 83.9–1,560
Gutka,‡
India
8.46–8.88  1.09–2.33 0.86–1.78  57.1–456 167–1,280 23.2–258 370–2,250
Gutka,§ 
India 
7.43–8.61  0.91–4.20 0.19–3.33  7.1–375 154–18,600 10.8–1,030 264–23,900
*Total TSNAs represent the sum of NNK, NNN, and NNAL (shown) and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
†These gutka products were manufactured both commercially and by cottage industry. 
‡These gutka products were commercially manufactured. 
§These gutka products were manufactured by cottage industry.
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 
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5. International Agency for Research on Cancer. Betel-quid and areca-nut chewing and some areca-nut-derived nitrosamines. IARC monographs 
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For additional information on gutka, please refer to the following chapters: Chapter 10: Smokeless Tobacco Use in the European Region, and 
Chapter 13: Smokeless Tobacco Use in the South-East Asia Region.
Gutka
(Pan Masala with Tobacco)
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Iqmik  
Iqmik is a homemade chewing tobacco that consists of tobacco leaves combined with 
ash from burnt tree fungus or wood.1,2,3 Iqmik 
is commonly used by Alaska Native people, 
particularly the Yup’ik and Cup’ik Eskimo people 
in western Alaska.2,4 In contrast to American 
Indian customs, tobacco use does not have 
a spiritual significance for Alaska Natives.1,2 
Rather, it is a relatively recent phenomenon, 
dating back only about 150 years in Alaska, 
although tobacco use among other indigenous 
populations in North America dates back at 
least 2,000 years.2,3 Some people in the Yukon–
Kuskokwim region consider iqmik a healthier 
alternative to smoking tobacco because its 
ingredients are perceived as “natural.”1,2 
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Main Geographic Location  
(WHO Region: Country) 
Region of the Americas: United States (Alaska)5
Prevalence and Demographics 
Iqmik is used by Alaska Natives, including youth of 
all ages.1,2 Iqmik is used in western Alaska, although 
there are reports of similar smokeless tobacco 
mixtures being used by indigenous populations in 
Western Siberia, Yukon, Labrador, British Columbia 
Coast, and Nova Scotia.2,4 Data from the 2004 to 
2007 Behavioral Risk Factor Surveillance System 
(BRFSS) found that iqmik is used by 16% to 22% of 
Alaska Native adults in the western region of the 
state.6,7 It has also been reported that iqmik is often 
used by pregnant women in western Alaska.4  
Mode of Absorption 
Oral (chewed)  
Use Pattern
Users may pre-chew the iqmik and place it in a 
small box for later use by the maker or to share with 
others, including elders, children, and infants. Iqmik is 
believed by some to relieve babies’ teething pain.1,5
Main Ingredients 
Tobacco, tree fungus ash (also known as punk, araq, 
or buluq ash) or other ash derived from burning 
driftwood, alder bush, or willow bush; these woods 
are used because there are few trees along the 
coast of western Alaska.2,4
Processing/Manufacturing
Custom-made: Although the ingredients are 
available at grocery stores and retail outlets, iqmik 
is always prepared by the individual user or a family 
or community member to share. Fire- or air-cured 
tobacco leaves are mixed with punk fungus ash, 
which is generated by burning a woody fungus that 
grows on birch trees, or other woody ash if punk ash 
is unavailable.1,2,5 The mixture can be prepared in 
several	ways:	by	pre-chewing,	stirring	in	a	bowl	with	
water, or even using a modern blender.1,4 Iqmik is 
often stored in a commercial smokeless tobacco box 
or a small plastic container.2,4
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Chemical Measurements
These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for the prepared iqmik. The amount absorbed will depend on the amount of 
product used.
Product Type pH*
 Total Nicotine  Free Nicotine
mg/g wet wt
 NNK NNN NNAL Total TSNAs†
ng/g wet wt
Iqmik with Air-Cured Tobacco,‡  
United States (Alaska)
11.0  38.3 38.3  209 2,995 61 7,238
Iqmik with Fire-Cured Tobacco,‡ 
United States (Alaska)
11.0  38.9 38.9  473 2,400 11 7,191
*pH of the prepared ash/tobacco iqmik mixture; both willow and punk ash are pH 11.0. 
†Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
‡Cured tobacco includes the average of twist and leaf tobacco.
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 





















Khaini (or khoinee in Bangladesh) is a flaky product made of sun-dried tobacco and 
slaked lime. Lime is often added to the tobacco 
just before use.1 Khaini is used in India, Nepal, 
and Bangladesh.2 
Photo courtesy of Clifford Watson,  
Centers for Disease Control and Prevention
Common Names 
Chada, chadha, sada, surti (in Nepal and 
neighboring parts of India)
Brand Names 
Raja, Kuber, Wiz, Buddha Lal, Chaini, Raja Chap, 
Ansul Tobacco, Mirage, Ganesh Tobacco 701, Patta 
Chhap Tej Tobacco
Main Geographic Locations  
(WHO Region: Country) 
South-East Asia Region: India, Bangladesh, Nepal, 
Bhutan2
Prevalence and Demographics 
Among adults in India, khaini is the most commonly 
used type of smokeless tobacco. In 2009–2010, 
11.6% of the Indian population over age 15 (18% of 
males and 4.7% of females) used khaini.3 In 2009, 
in Bangladesh, 1.5% of all adults (1.9% of males 
and 1.2% of females) used khaini.4 Product-specific 
prevalence rates were not available for the other 
countries where khaini is used. 
Mode of Absorption 
Oral (sucked, chewed, held in mouth)
Use Pattern 
People may use khaini from 3 to 30 times a day. A 
regular khaini user may carry a double-ended metal 
container, one side of which is filled with sun-dried 
tobacco and the other slightly moistened slaked 
lime.1,5
Main Ingredients 
Tobacco leaves, slaked lime (calcium hydroxide), 
and sometimes areca nut2,6
Processing/Manufacturing 
Custom-made, cottage industry, and commercial: 
Khaini is usually prepared by the individual user 
from basic ingredients at the time of use, but 
commercially manufactured khaini is also available. 
To prepare khaini, users will use their thumbs to 
vigorously mix a small amount of dried tobacco 
leaves and slaked lime paste in the palm of the 
hand. Areca nut is sometimes added.2 Additional 
information on the commercial manufacturing of 
khaini could not be located.
B-26
Chemical Measurements
These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type pH
 Total Nicotine Free Nicotine
mg/g wet wt




9.65–9.79  2.53–4.79 2.48–4.68  288–502 16,800–17,500 1,350–1,400 21,600–23,500
*Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
†All khaini products were commercially manufactured.
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)- 
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram.
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Available	from:	http://whoindia.org/EN/Section20/Section25_1861.htm








For additional information on khaini, please refer to the following chapters: Chapter 10: Smokeless Tobacco Use in the European Region, and Chapter 13: 




Kiwam (also spelled qiwam, qimam, khiwam, kimam) is a tobacco paste that is made from 
boiled and flavored tobacco leaves. The paste 
may be formed into granules or pellets. Kiwam 
is frequently used as the tobacco ingredient in 
betel quid (paan).1,2,3,4
Photo courtesy of Clifford Watson,  




Avon, Kashmiri, Nauratan, Raj Ratan, Pradip
Main Geographic Locations  
(WHO Region: Country) 
South-East Asia Region: India, Bangladesh, Nepal1,2; 
Eastern Mediterranean Region: Pakistan3
Prevalence and Demographics 
No data are available on the prevalence of kiwam 
use. In 2004, it was reported that kiwam is used 
among upper socioeconomic groups in India and 
Bangladesh.1
Mode of Absorption 
Oral (chewed, held in mouth, chewed in betel quid)
Use Pattern 
Kiwam may be used alone or inserted into a betel 
quid and chewed.2 Additional information on 
patterns of kiwam use could not be located.
Main Ingredients 
Tobacco, spices (cardamom, saffron, and/or 
aniseed), additives such as musk1,2
Processing/Manufacturing 
Commercial: Kiwam is commercially manufactured. 
The stalks, stems, and veins of tobacco leaves are 
removed, and then the remaining leaves are boiled, 
soaked in water, and flavored with powdered 
spices and other additives.1 Once the tobacco has 
softened and broken down, the resulting pulp is 
mashed, strained, and dried into a paste.2 Kiwam 




These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type pH
 Total Nicotine Free Nicotine
mg/g wet wt




—  — —  100–1,030 2,500–8,950 160–1,860 5,430–22,200
*Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
†All kiwam products are commercially manufactured.
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)- 
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 














Three types of chewing tobacco are used in North	America:	loose	leaf,	plug,	and	twist.	
Although loose leaf is the most common form in 
the United States, the use of chewing tobacco 
has declined over the past few decades and is 
now uncommon.1,2
Photo courtesy of Clifford Watson,  
Centers for Disease Control and Prevention
Common Names 
Chew, chaw, chewing tobacco, spit tobacco  
Brand Names 
Red Man, Granger, J.D.’s Blend (Swedish Match 
North America); Levi Garrett, Morgan’s, Taylor’s Pride 
(American Snuff Company); Beech-Nut, Our Pride, 
Stoker (National Tobacco Company); Mail Pouch, 
Chattanooga Chew, Lancaster (Swisher International) 
Main Geographic Location 
(WHO Region: Country) 
Region of the Americas: United States1 
Prevalence and Demographics  
Product-specific prevalence rates are not available 
for any countries where loose leaf chew is used. In the 
United States, chewing tobaccos are primarily used 
by men and are more common in rural areas and the 
South and Midwest.2 In 2012, the U.S. prevalence of 
past-month smokeless tobacco use (including loose 
leaf tobacco, snuff, and other smokeless products) 
for those aged 12 years and older was 3.6% (7.1% of 
males and 0.4% of females).3 Although there are no 
statistics specifically on the prevalence of loose leaf 
tobacco use, sales of loose leaf chew represent 19.7% 
of smokeless tobacco sales in the United States.4  
Mode of Absorption  
Oral (chewed, sucked, held in mouth)
Use Patterns 
A piece of tobacco 0.75 to 1 inch in diameter is either 
chewed or held in place. Saliva is usually spit out, but 
it can also be swallowed.1
Main Ingredients 
Leaf tobacco, sugar, and/or licorice1,5
Processing/Manufacturing 
Commercial: Loose leaf chew is commercially 
manufactured and usually sold in pouches. To 
manufacture loose leaf chew, loose cigar tobacco 
leaves are air-cured, stemmed, and cut or granulated 
to form small strips of shredded tobacco. Most brands 
are sweetened and flavored with sugar and licorice, 
accounting for loose leaf tobacco’s high average 




These data are for select products and may not represent all products of this type. These data are ex-
pressed on a per gram basis for products analyzed as received. The amount absorbed will depend on 
the amount of product used.
Product Type* pH
 Total Nicotine Free Nicotine
mg/g wet wt




5.64–5.98  4.87–7.04 0.03–0.06  238–306 942–2,830 20–90 1,550–4,100
Loose Leaf (1),
United States
5.64–6.76  3.41–8.99 0.02–0.47  — — — —
*All loose leaf products were commercially manufactured.
†Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), N’-nitrosoanatabine and N’-nitrosoanabasine (not shown). 
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram.
Sources: Lawler et al. 2013 (6); International Agency for Research on Cancer 2007, table 5 (1).
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Mainpuri is a mixture of tobacco, finely chopped areca nut, slaked lime, cloves, 
and camphor.1,2,3 It has a short shelf life and is 
mainly sold in the northern part of India in the 
Mainpuri district and nearby areas.1 Mainpuri was 
also sold in neighboring Pakistan, although it was 
banned in 2011. Photo courtesy of Clifford Watson,  
Centers for Disease Control and Prevention




Main Geographic Location 
(WHO Region: Country) 
South-East Asia Region: India (Uttar Pradesh)2 
Prevalence and Demographics  
Mainpuri is a very popular tobacco preparation in 
the Mainpuri district and surrounding areas of Uttar 
Pradesh.5 Recent data on the prevalence of mainpuri 
tobacco use in Uttar Pradesh or in India nationally are 
not available.
Mode of Absorption  
Oral (chewed, chewed in betel quid, held in mouth)
Use Patterns 
No information is available on use patterns.
Main Ingredients 
Tobacco, slaked lime (calcium hydroxide), areca nut, 
camphor, cloves1,2
Processing/Manufacturing  
Cottage industry and custom-made: Mainpuri is 
manufactured by small cottage industries and 
prepared by individual vendors for sale. It is prepared 
by thoroughly mixing together tobacco, slaked lime, 
finely cut areca nut, and powdered camphor and 
cloves.3 Additional information on the preparation of 
mainpuri could not be located. 
B-32
Chemical Measurements
These data are for select products and may not represent all products of this type. These data are  
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend  
on the amount of product used.
Product Type pH
 Total Nicotine Free Nicotine
mg/g wet wt




7.65  1.28 0.38  6.05 106 25.9 219
*Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine;  
NNAL = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram;  
ng/g = nanogram per gram. 















Mawa is a mixture of finely chopped ingredients consisting of areca nut shavings, 
slaked lime, and crushed sun-cured tobacco.1,2 It 
is about 95% areca nut by weight and is used in 
South Asia.1,3
Photo courtesy of Clifford Watson,  





Main Geographic Location  
(WHO Region: Country) 
South-East Asia Region: India1
Prevalence and Demographics 
Mawa is popular among men and young people, 
particularly in Gujarat, India.1,3 Between the 
1970s and the 1990s, mawa chewing increased 
considerably in the Bhavnagar district and adjoining 
areas in Gujarat, particularly among young people. 
One survey in 1998 in this district found that 18.9% 
of men and 0.1% of women used mawa.4 A study 
conducted in 2007–2008 in urban Jamnagar, 
Gujarat, found that approximately 21% of people 
aged 13 and older chewed mawa.5 National data 
on the prevalence of mawa use in India are not 
available.
Mode of Absorption 
Oral (chewed)
Use Pattern 
Mawa is chewed for about 10 to 20 minutes1 and 
may be used as many as 5 to 25 times per day.3
Main Ingredients 
Tobacco, slaked lime, and areca nut1
Processing/Manufacturing 
Cottage industry and custom-made: Mawa is 
prepared by individual vendors for sale or is 
homemade by individual users. The process of 
making mawa consists of sprinkling small pieces of 
sun-cured areca nut with slaked lime and adding 
tobacco flakes. The mixture is rubbed together to 
combine the ingredients. Mawa is about 95% areca 
nut by weight and is sold in cellophane wrappers.3
B-34
Chemical Measurements
These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type pH
 Total Nicotine Free Nicotine
mg/g wet wt




8.31  0.16 0.11  4.47 65.5 3.98 96
*Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
†Data is given for custom-made mawa.
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)- 
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 
Source: Stanfill et al. 2011 (6).
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Mishri (also known as masherior or misheri) is a dry, powdered tobacco product that is 
usually homemade or prepared by a vendor. 
Mishri is commonly believed to clean teeth.1
Photo courtesy of World Health Organization South-East 





Main Geographic Location  
(WHO Region: Country) 
South-East Asia Region: India2,3
Prevalence and Demographics 
Mishri is predominantly used by women and is more 
common among lower socioeconomic groups.4 
Many users begin using mishri as children. While 
there are no national data or recent prevalence 
estimates, various studies of different regions from 
the 1970s to the present have estimated that mishri 
use in India has ranged between 17% and 44% of 
women and between 1% and 23% of men.3,5,6,7 In 
2009–2010, 5% of all individuals aged 15 years and 
over (3.3% of males and 6.3% of females) in India 
consumed oral tobacco including mishri, snuff, gul, 
or gudakhu.8
Mode of Absorption 
Oral (sucked, applied to teeth and gums, teeth 
cleaning)l
Use Pattern 
Mishri is rubbed on the teeth and gums, often for the 
purpose of cleaning the teeth. It is generally used 
twice a day, but users who become addicted may 




Custom-made and cottage industry: Mishri is usually 
prepared at home by individual users, but it can also 
be prepared by vendors for sale and bought in the 
market under various names.5 No other ingredients 
besides tobacco are used in the preparation of 
mishri. Tobacco is baked on a hot metal plate until it 




These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type pH
 Total Nicotine (9) Free Nicotine (9)
mg/g wet wt




6.54  2.73 0.09  4,210 870 — —
*Chemical measurements from both sources are for Shahin mishri.
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 
Sources: Gupta and Sreevidya 2004 (9); Stepanov et al. 2005 (10).
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Moist snuff is a damp, finely ground tobacco product that is more commonly used in 
Western countries than elsewhere. Moist snuff, 
also referred to as dip, is the most common 
form of smokeless tobacco in the United States 
and Canada.1,2 This factsheet only describes 
commercial moist snuff. Other types of moist 
snuff are used in many countries around the 
world.
Common Names 
Dip, spit tobacco (sometimes called “chew,” even 
though it is not chewing tobacco)
Brand Names 
Copenhagen, Skoal, Red Seal, Husky (U.S. Smokeless 
Tobacco Company), Grizzly, Kodiak (American 
Snuff Company), Kayak, Redwood, Gold River, Silver 
Creek, Cooper, Silverado (Swisher International), Red 
Man, Timber Wolf, Longhorn (Swedish Match)
Main Geographic Locations  
(WHO Region: Country) 
Region of the Americas: United States, Canada,1,2 
Mexico3; African Region: South Africa1,4
Prevalence and Demographics 
Moist snuff is the most commonly used form of 
smokeless tobacco in the United States, Canada, 
and Mexico.1,2,3 In the United States, it is primarily 
used by  young adult white men living in the South.5 
Although no statistics specifically on the prevalence 
of moist snuff use are available, sales of moist snuff 
represented 78.2% of U.S. smokeless tobacco sales 
in 2010.6 The prevalence of smokeless tobacco 
use in the United States in 2012 was 3.6% among 
people age 12 and older (7.1% of males and 0.4% 
of females).7 In Canada, smokeless tobacco use 
is low—1% of adult men use any type of smokeless 
tobacco8—and sales of moist snuff make up more 
than 80% of all smokeless tobacco sales.2 
Mode of Absorption 
Oral (held in mouth, sucked)
Use Pattern 
Moist snuff is commonly used loose, but can also 
come in small, ready-to-use pouches. It is usually 
held in the mouth for about 30 minutes. Saliva is 
usually spit out, but it can be swallowed.1
Main Ingredients 
Tobacco, flavorings, inorganic salts, humectants1
Processing/Manufacturing 
Commercial: Moist snuff is commercially 
manufactured. Tobacco leaf, stems, and seeds 
are air- and/or fire-cured, then processed into 
fine particles (“fine cut”) or strips (“long cut”).1 This 
process ferments the tobacco, which produces 
more cancer-causing nitrosamines than snus 
manufacturing9 (snus is often considered a different 
type of moist snuff). Moist snuff has a moisture 
content of roughly 20–60% by weight and is 
available in a variety of flavors, such as mint and fruit 
flavors. The tobacco is usually sold loose, but can 




These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type* pH
 Total Nicotine Free Nicotine
mg/g wet wt
 NNK NNN NNAL Total TSNAs†
ng/g wet wt
Moist Snuff (10), 
United States
5.54–8.62  4.42–25.03 0.01–7.81  382–9,950 2,204–42,554 21–1,412 4,874–90,024
Moist Snuff (1),
United States
5.49–8.38  7.06–24.29 0.03–8.57  — — — —
*Moist snuff products were commercially manufactured.
†Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram.
Sources: Richter et al. 2008 (10); International Agency for Research on Cancer 2007, table 7 (1).
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For additional information on moist snuff, please refer to the following chapters: Chapter 9: Smokeless Tobacco Use in the Region of the Americas, and 





Nass (also known as naswar) is a multinational product made of locally grown tobacco, oil, an alkaline 
modifier such as ash or slaked lime, and other ingredients 
according to regional preference.1,2 Nass/nasway is one 
of the most common types of smokeless tobacco used 
in Pakistan, the United Arab Emirates, Uzbekistan, and 
Kyrgyzstan.1,3 In Uzbekistan and Kyrgyzstan, a product 
known as nasway contains the same main ingredients as 
nass. Although there is insufficient published information 
to determine if nass and nasway are the same product, 
for the purposes of this factsheet, they are assumed to 
be essentially the same.
Photo courtesy of Clifford Watson,  
Centers for Disease Control and Prevention
Common Names 
Naswar (Pakistan); niswar (United Arab Emirates); 
nass (Iran); nasway, nasvay (Kyrgyzstan, Uzbekistan) 
Brand Names 
None
Main Geographic Locations  
(WHO Region: Country) 
Eastern Mediterranean Region: Pakistan, Iran, 
Afghanistan, United Arab Emirates1,4; African Region: 
South Africa1,4; European Region: Turkmenistan, 
Kyrgyzstan, Uzbekistan5,6
Prevalence and Demographics 
In Kyrgyzstan, according to a 2011 World Health 
Organization report, 3.4% of all adults (7.0% of men 
and 0.3% of women) use nasvay.5 In Uzbekistan, 
in a 2002 survey of adults between the ages of 15 
and 60, only 0.4% of women reported ever using 
nasway in their lifetime, compared to 37.9% of 
men. Thus, among men in Uzbekistan, using nasway 
is as common as cigarette smoking.7 Studies in 
Turkmenistan in 1993 reported that 12% of adults 
used nass.6
Mode of Absorption 
Oral (chewed, sucked, held in mouth) 
Use Pattern 
Nass is usually rolled into a ball and placed under 
the tongue or in the cheek.1,4,8 It is held in the mouth 
and sucked for 10 to 15 minutes or may be chewed 
slowly.2
Main Ingredients 
Nass: tobacco, ash, cotton or sesame oil, water, and 
sometimes lime or gum2,9  
Naswar, niswar, nasway: tobacco, slaked lime 
(calcium hydroxide), ash, oil or butter, indigo 
or other coloring agent, water, and sometimes 
flavorings such as cardamom and menthol1,2,4,7,8,9
Processing/Manufacturing 
Cottage industry and custom-made: Nass may be 
made domestically by individual users or prepared 
by local, small-scale cottage manufacturers.4,9 Sun- 
and heat-dried tobacco leaves (often N. rustica), 
slaked lime, ash from tree bark, flavorings (e.g., 
cardamom and menthol), and coloring agents (e.g., 
indigo) are mixed together with a heavy wooden 
mallet. Water is added and the mixture is usually 
rolled into balls.1,4 The product is then packed into 
small polyethylene bags for sale.4 
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Chemical Measurements
These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type pH
 Total Nicotine Free Nicotine
mg/g wet wt




8.76–9.14  10.5–14.2 8.84–13.2  29.4–309 363–545 8.6–104 478–1,380
Nasway,†  
Uzbekistan 
8.43  8.89 6.36  88.3 628 10.5 1,100
*Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown). 
†Naswar/nasway products were produced by cottage industry.
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 
Source: Stanfill et al. 2011 (10).
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For additional information on nass/nasway, please refer to the following chapters: Chapter 10: Smokeless Tobacco Use in the European Region, and 




Plug, one of three types of chewing tobacco sold in North America, is considered the 
oldest form of chewing tobacco. Plug tobacco is 
sweetened with sugar and licorice and pressed 
into a brick shape. It is sold as either “moist” or 
“firm” depending on the amount of moisture in 
the product.1
Photo courtesy of Clifford Watson,  
Centers for Disease Control and Prevention
Common Names 
Chew, chaw, chewing tobacco, spit tobacco  
Brand Names 
Red Man, Days Work, Apple, Brown, Natural Leaf, 
Union Standard, Tinsley, WNT (Swedish Match North 
America), Levi Garrett, Taylors Pride, Cannon Ball 
(American Snuff Company)
Main Geographic Location  
(WHO Region: Country) 
Region of the Americas: United States1
Prevalence and Demographics 
Chewing tobaccos are primarily used by men 
and are more commonly used in rural areas and 
in the Southern and Midwestern United States.2 
Plug use has declined over the past century and 
is rare today in most regions of the United States.1 
Although there are no recent statistics specifically 
on the prevalence of plug use, in 2010 sales of plug 
represented only 0.5% of all smokeless tobacco sales 
in the United States.3
Mode of Absorption 
Oral (chewed, sucked, held in mouth) 
Use Pattern 
A piece of plug is cut off and chewed or held 
between the cheek and gum. Saliva is usually spit 
out, but it can also be swallowed.1
Main Ingredients 
Burley and bright tobacco or cigar tobacco leaves, 
licorice, and sugar1
Processing/Manufacturing 
Commercial: Plug is commercially manufactured. 
Heavier grades of tobacco leaves are picked from 
the top of the plant and stems are removed. The 
tobacco is immersed in a mixture of licorice and 
sugar, pressed into a plug, wrapped in fine tobacco 
leaves, and pressed into bricks or flat blocks. Moist 
plug tobacco has at least 15% moisture by weight, 
whereas firm plug has less than 15% moisture. 
Plug also has a high average sugar content 
(approximately 25% of its weight).1
B-42
Chemical Measurements
These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type* pH
 Total Nicotine Free Nicotine
mg/g wet wt
 NNK NNN NNAL Total TSNAs†
ng/g wet wt
Plug (4),  
United States
5.10–5.95  5.12–15.1 0.01–0.04  340–941 2,920–5,140 11–188 4,090–7,750
Plug (1),
United States
5.07–5.95  6.18–20.43 0.02–0.08  — — — —
*All loose leaf products were commercially manufactured. 
†Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 
Sources: Lawler et al. 2013 (4); International Agency for Research on Cancer 2007, table 5 (1).
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Rapé is a type of dry snuff used in Brazil. Aboriginal groups may mix it with ashes 
from particular trees and use it for medicinal 
purposes.1 Rapé is usually inhaled through the 
nose.
Photo courtesy of Clifford Watson,  




Moeda, Caratinga, Guarany 
Main Geographic Location  
(WHO Region: Country) 
Region of the Americas: Brazil1
Prevalence and Demographics 
Published information on rapé is limited, and data 
on the prevalence of rapé use are not available. 
The 2001 Brazilian Global Adult Tobacco Survey 
found that about 0.4% of adults aged 15 years 
and older use any type of smokeless tobacco.2 
Anecdotal evidence suggests that rapé is primarily 
used in rural areas and small towns, or by aboriginals 
in the Amazon rainforest, where its use has cultural 
significance.
Mode of Absorption 
Nasal 
Use Pattern 
Rapé is inhaled through the nose. Some aboriginal 
groups prepare their own rapé. The Kaxinawás 
Indians from Acre in Brazil prepare a half portion of 
rapé and half portion of ashes from wood, usually 
from the paricá tree (Schizolobium amazonicum). 
They consume rapé by having one person use 
a large “V”-shaped straw to blow the dust into 
their partner’s nose. They may use it for medicinal 
purposes.1
Main Ingredients 
Dried tobacco leaf, flavorings such as tonka bean 
(Dipteryx odorata), clove, cinnamon powder, and 
camphor, and in some cases, ashes from select trees 
Processing/Manufacturing 
Cottage industry and custom-made: Rapé is 
produced locally on small farms, in small tobacco 
industries, or by Indians. The dried tobacco leaf is 
ground and carefully toasted. Rapé is sometimes 
toasted with other ingredients such as spices, herbs, 
and ashes, and the toasted product is then sifted 
into a very fine dust. 
Chemical Measurements
No data available 
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Red toothpowder contains finely powdered tobacco, herbs, flavoring agents, and other 
ingredients.1 It is red in color and is usually used 
in India to clean teeth.1,2 In 1992, India banned 
the use of tobacco as an ingredient in dental 
products.2,3 Brands of red toothpowder have 
stopped listing tobacco as an ingredient, but lab 
results show that some still contain tobacco and 
measureable amounts of nicotine.2,3,4,5
Photo courtesy of World Health Organization South-East 
Asia Regional Office and Dhirendra N. Sinha
Common Names  
Lal dant manjan 
Brand Names 
Dabur, Baidhyanath 
Main Geographic Location 
(WHO Region: Country) 
South-East Asia Region: India1,2 
Prevalence and Demographics  
Red toothpowder is used by men and women 
of all ages, as well as children.2 There are no 
national statistics on the prevalence of use of 
red toothpowder by adults. The 2004 Global 
Youth Tobacco Survey, which surveys school 
students aged 13–15 years, found that reported 
prevalence of red toothpowder use ranged from 
2% to 49% across various regions in India.3 
Mode of Absorption  
Oral (teeth cleaning)
Use Patterns 
Red toothpowder is used to clean teeth (as a 
dentifrice).1,2
Main Ingredients 
Fine red tobacco powder, herbs, flavorings.1 
Additional plant-related ingredients such as ginger, 
pepper, and camphor, among others, may be 
used.6,7
Processing/Manufacturing  
Commercial: Red toothpowder is commercially 
manufactured and is often marketed as an herbal 
dental care product.1 Additional information on the 
manufacturing of red toothpowder is not available.
B-46
Chemical Measurements
These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on 
the amount of product used.
Product Type pH
 Total Nicotine Free Nicotine
mg/g wet wt




5.75–6.71  4.47–5.09 0.03–0.21  — — — —
*Study did not measure NNK, NNN, or NNAL TSNAs. 
†All red toothpowder products were commercially manufactured.
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram.
Source: Gupta and Sreevidya 2004 (5).
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Shammah is a multinational smokeless tobacco product in powder or paste form, which can 
be either greenish-yellow (“white” shammah) or 
brownish-black (“black” shammah). It is made 
from powdered tobacco, slaked lime, ash, and 
black pepper and mainly used in Yemen, Saudi 
Arabia, and Algeria.1 
Photo courtesy of Clifford Watson,  
Centers for Disease Control and Prevention
Common Names 
El-Shama, bajeli, haradi, sharaci, black shammah 




Main Geographic Locations  
(WHO Region: Country) 
Eastern Mediterranean Region: Saudi Arabia, 
Yemen1,2,3; African Region: Algeria1,4
Prevalence and Demographics 
In Yemen in 2003, 10.7% of the population aged 10 
years and older used shammah (15.1% of males and 
6.2% of females).2 Shammah was used by males 
and females of all ages, including adolescents. 
Shammah use increases with age and is more 
common in rural than urban areas.2 In Algeria, 
shammah (or chemma) is commonly consumed 
by men across all social groups.4 Information on 
prevalence of shammah use in Algeria and Saudi 
Arabia is not available.
Mode of Absorption 
Oral (sucked, held in mouth)
Use Pattern 
Shammah is placed between the gum and lower lip 
or cheek.1,2 In Algeria, users may wrap shammah in 
paper before putting it in the mouth.4 
Main Ingredients 
Tobacco, slaked lime, ash, black pepper, oil, 
flavorings, bombosa (sodium carbonate)1,2
Processing/Manufacturing 
Cottage industry and custom-made: Shammah is 
usually prepared by small cottage industries or by 
local individual vendors for sale. The tobacco leaves 
are sun dried, pulverized with bombosa (sodium 
carbonate), and combined with other ingredients 
such as slaked lime, ash, black pepper, oil, and 
other flavorings. Shammah can be sold as a wet 
or dry product. To prepare wet shammah, such as 
black shammah, a water solution of bombosa is 





1. Scheifele C, Nassar A, Reichart PA. Prevalence of oral cancer and potentially malignant lesions among shammah users in Yemen. Oral Oncol. 
2007;43(1):42–50.






For additional information on shammah, please refer to the following chapters: Chapter 11: Smokeless Tobacco Use in the Eastern Mediterranean Region, 




Snus is a traditional Swedish smokeless tobacco product. It is made from moist, finely ground 
tobacco and usually contains lower levels of 
tobacco-specific N-nitrosamines (TSNAs) than 
most oral tobacco products because it is 
pasteurized rather than fermented.1,2 Although 
the use of snus is spreading to other regions of 
the world, in 1992 the sale of snus was banned in 
all countries in the European Union (EU) except 
Sweden.2 Photo courtesy of Clifford Watson,  Centers for Disease Control and Prevention
Common Names  
None
Brand Names 
General, Catch, Ettan, Grovsnus, Göteborgs Rapé, 
Kronan (Swedish Match); Lucky Strike, Pall Mall, 
du Maurier (British American Tobacco); Camel 
(R.J. Reynolds); Marlboro (Philip Morris); Skoal (U.S. 
Smokeless Tobacco Company); Knox, Skruf (Imperial 
Tobacco), Tobaccorette 
Main Geographic Locations 
(WHO Region: Country) 
European Region: Sweden, Norway, Iceland, Finland, 
Denmark3,4; Region of the Americas: United States, 
Canada, Brazil3; African Region: South Africa5   
Prevalence and Demographics  
In Sweden in 2009, the prevalence of daily snus use 
among adults aged 16 years and older was 19% 
for males and 4% for females.6 In Norway, which is 
not a member of the EU and therefore can legally 
sell snus, the prevalence of daily use in 2009 was 
6% among adults aged 16 years and older (11% of 
males and 1% of females).4 In 2010, 5.1% of U.S. adults 
aged 18 years and older had ever tried snus (8.5% of 
males and 2% of females), yet less than 1% currently 
used snus.7 There is little information on prevalence 
of use in most of the other countries where snus is 
available. Although snus has been used in Europe’s 
Nordic region for many years, it was only introduced 
relatively recently into the North American and South 
African markets, and therefore the prevalence of 
snus use may increase in these regions as this product 
becomes more widely available.5,7 
Mode of Absorption  
Oral (held in mouth)
Use Patterns 
Snus can either be packaged into small, ready-to-use 
sachets or sold in loose tobacco form. One portion 
of snus is usually held in the mouth for 30 minutes 
or more and does not require chewing, sucking, or 
spitting. In Sweden the average user keeps snus in 
their mouth for 11 to 14 hours per day.3
Main Ingredients 
Tobacco, moisturizers, sodium carbonate, salt (sodium 
chloride), sweeteners, flavorings3,8
Processing/Manufacturing 
Commercial: Snus is commercially manufactured, but 
processing and manufacturing vary across regions 
and countries. In Sweden, finely ground air-cured 
tobacco is mixed with salts, water, and flavoring. 
Snus is similar to snuff, but snuff is fermented, which 
can increase the formation of TSNAs. Snus goes 
through a heat treatment process that pasteurizes the 
tobacco to kill off bacteria that aid in the formation 
of TSNAs.2 During pre-sale storage, snus is kept cold 
to keep it “fresh” and to prevent more nitrosamines 
from forming.9 However, variations in processing and 
manufacturing can produce variations in TSNAs.3,8,9 
Snus is either sold loose or portion packed in small tea 




These data are for select products and may not represent all products of this type. These data are ex-
pressed on a per gram basis for products analyzed as received. The amount absorbed will depend on 
the amount of product used.
Product Type* pH
 Total Nicotine Free Nicotine
mg/g wet wt




7.55–7.70  8.97–11.3 2.51–3.69  84–146 369–425 20–21 761–884
Swedish Match (8),
Sweden




6.48–7.02  13.4–17.2 0.47–1.19  171–275 925–1,440 18.6–30.4 1,720–2,700
Tobacco-rette (8), 
South Africa
6.56  15.0 0.49  1,340 2,950 84.2 5,850
*All	snus	products	were	commercially	manufactured;	manufacturer	(associated	products):	RJ	Reynolds	(Camel	snus);	Swedish	
Match (General snus; Catch Peppermint snus); and British American Tobacco (Peter Stuyvesant snus; Lucky Strike snus). 
†Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown). 
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 























For additional information on snus, please refer to the following chapters: Chapter 9: Smokeless Tobacco Use in the Region of the Americas; Chapter 




Tapkeer (tapkir) is a form of dry powdered snuff that may be used for teeth cleaning. It is similar to other teeth-cleaning products 





Main Geographic Location  
(WHO Region: Country) 
South-East Asia Region: India1
Prevalence and Demographics 
In Goa, Maharastra, Gujarat, and eastern India, 
tapkeer is widely used by people of lower 
socioeconomic status and is more commonly used 
by women than men.1,2 Although there are no 
national or recent statistics specifically on tapkeer 
use, historical data indicate that 14% of women 
and 1% of men use tapkeer in Gujarat, India.3 In 
2009–2010, 4.7% of adults aged 15 and older (3.3% of 
males and 6.3% of females) reported using at least 
one type of applied oral tobacco product, including 
tapkeer, mishri, or gudakhu.4
Mode of Absorption 
Oral (teeth cleaning, held in mouth), Nasal
Use Pattern 
In India, tapkeer is rubbed on the teeth and gums 
to clean teeth. Because it is addictive, users tend to 




Custom-made: In India, tapkeer is frequently 
prepared by individual users at home by roasting 

















Tobacco Leaf  
Raw dried tobacco leaf may be chewed alone, but it is frequently used in betel quid in 
India, Bangladesh, and Myanmar.1 
Common Names 
Sada pata; chadha (Assam, India)
Brand Names 
None
Main Geographic Locations  
(WHO Region: Country) 
South-East Asia Region: India, Bangladesh, 
Myanmar, Bhutan1,2
Prevalence and Demographics 
In Bangladesh in 2009, 1.8% of adults aged 15 and 
older chewed sada pata (plain tobacco flakes) 
alone (2% of males, 1.6% of females); this figure 
does not include adults who used tobacco leaf in 
betel quid.3 National prevalence data on the use of 
tobacco leaf are not available for other countries. 
In Bangladesh and Myanmar, betel quid chewers of 
low socioeconomic status often put tobacco leaf in 
their quid.1 
Mode of Absorption 
Oral (chewed, chewed in betel quid or other 
custom-made product)
Use Pattern 
In India, a regular user chews about a 15-cm piece 




Custom-made: Raw tobacco leaf is usually dried 
and left unprocessed. It can be powdered, flaked, 
or sold in bundles of several long strands (about 115 
cm long and 5 cm thick). A regular user consumes 
one 15-cm piece of the strand per day.1
B-54
Chemical Measurements
These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type pH
 Total Nicotine Free Nicotine
mg/g wet wt




5.92  19.7 0.15  21.7 165 24.5 574
*Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)- 
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 











For additional information on tobacco leaf, please refer to Chapter 13: Smokeless Tobacco Use in the South-East Asia Region.




Tobacco water (also known as tuibur) is tobacco smoke-infused water that is gargled or sipped. It is commonly used in northeastern 
India, and is called tuibur in Mizoram and hidakpha in Manipur. This 
product has been used since the 19th century.1,2 
Common Names 
Tuibur (Mizoram, India); hidakpha (Manipur, India)
Brand Names 
None
Main Geographic Location  
(WHO Region: Country) 
South-East Asia Region: India3
Prevalence and Demographics 
In 2001, tuibur was used by 7.2% of adults aged 
15 and older in the Aizawl district of Mizoram, and 
by 6.5% of adults in the Churachandpur district of 
Manipur.4 The prevalence of use was similar among 
males and females.1,2,4
Mode of Absorption 
Oral (gargled, held in mouth)
Use Pattern 
Tuibur is either sipped from a bottle or through 
cotton soaked with tobacco water. It is retained in 
the mouth or gargled for 5 to 10 minutes before it is 
spit out. Although people may initially use tuibur to 
clean their teeth, many become addicted and will 




Cottage industry and custom-made: Tuibur is 
produced by passing tobacco smoke through 
water and is sold in glass bottles.1,4 Tuibur may be 
produced by small-scale industry or prepared at 


















Tombol is a mixture of tobacco and flavoring ingredients such as noura, slaked lime, areca 
nut, and catechu. It is used in Yemen and is very 
similar to betel quid (paan), which is used in 
southeast and western Asia.






Main Geographic Location  
(WHO Region: Country) 
Eastern Mediterranean Region: Yemen
Prevalence and Demographics 
No published information on the prevalence of 
tombol use is available.
Mode of Absorption 
Oral (chewed, held in mouth)
Use Pattern 
Tobacco and the other main ingredients are 
wrapped in a tombol leaf (betel leaf), placed in the 
mouth, and sucked and chewed. Powdered khat, 
a plant with psychoactive properties, may also be 
added.
Main Ingredients 
Tobacco, areca nut (fofal), noura, slaked lime 
(calcium hydroxide), catechu (extract from 
the acacia tree), tombol leaf (betel leaf), and 
sometimes powdered khat (Catha edulis) or other 
flavoring ingredients.
Processing/Manufacturing 
Custom-made: Tombol is prepared either by 
a vendor or by the user, who wraps the main 
ingredients (tobacco, areca nut, noura, slake 
lime, catechu) in a tombol leaf. There are three 
types	of	tombol:	(1)	Sweet—a	sweetening	agent,	
usually coconut, is added to the main ingredients; 
(2) bitter—additives like clove oil, cardamom, and 
herbal medicines are used; and (3) mixed with 
tobacco—tombol is often mixed with either dry, thin 
pieces of Yemeni tobacco, called socha (similar to 





Published information on tombol could not be located. 






Toombak is a type of moist tobacco commonly used in Sudan. It is made of sun-dried ground 
tobacco and a solution of baking soda (sodium 
bicarbonate) and water.1 The word toombak 
can also be used to describe the native 
tobacco plant used to manufacture local snuff.2
Photo courtesy of Clifford Watson,  
Centers for Disease Control and Prevention
Common Names 
Sauté, sute, ammari, saood
Brand Names 
El-Sanf (of high quality), Wad Amari (the name of 
the person who introduced toombak to Sudan), 
Sultan El-Khaif (the master which alters the mind)
Main Geographic Locations  
(WHO Region: Country) 
Eastern Mediterranean Region: Sudan1; African 
Region: Chad
Prevalence and Demographics 
No recent information is available on the use of 
toombak. Historically, toombak was commonly used 
by adult Sudanese men, particularly in rural areas. 
The most recent published statistics (1998) found 
that among adults age 18 and older in the northern 
region of Sudan, 34% of Sudanese men and 2.5% of 
women use toombak.3 The prevalence of toombak 
use increases with age for both men and women 
and is more common in rural than urban areas.3 
Mode of Absorption 
Oral (held in mouth, sucked, used as ingredient in 
tombol), Nasal
Use Pattern 
A small portion of the toombak, weighing about 
10 grams, is rolled into a ball called a saffa. It is 
sucked slowly for 10 to 15 minutes, The saliva that 
is produced is then spit out by men or swallowed 
by women, because it is considered socially 
unacceptable for women to use toombak.1,2 Users 
usually rinse their mouths with water after the saffa is 
removed. A regular user may use toombak as many 
as 10 to 20 times per day.2
Main Ingredients 
Tobacco (N. rustica), baking soda (sodium 
bicarbonate, locally called atrun or natron), 
water1,2,4 
Processing/Manufacturing 
Cottage industry and custom-made: Toombak 
tobacco leaves (N. rustica) are harvested and left 
in small heaps in a field to dry for about 45 days 
(sun-curing). The leaves are then tied into bundles, 
sprinkled with water, and stored for a few of weeks 
at 30 to 45º C (85–110º F) to allow fermentation. 
The leaves are then ground into course particles 
by toombak mills and aged for up to a year or 
more in burlap sacks.1,2 Vendors prepare ready-
made toombak by gradually adding baking soda 
(sodium bicarbonate) to the tobacco until the 
mixture is approximately four parts tobacco to one 
part baking soda. The resulting toombak is then 
placed in an airtight container for about 2 hours 
prior to sale.1,2,4 While toombak is not commercially 
manufactured, vendors display commercial names 
at their shops as trademarks.
In addition to selling ready-made toombak, vendors 
may sell dry toombak leaves and baking soda 




These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type pH
 Total Nicotine Free Nicotine
mg/g wet wt




7.38–10.1  9.56–28.2 5.16–10.6  14,700–516,000 115,000–368,000 4,550–6,770 295,000–992,000
*Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)- 
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 
Source: Stanfill et al. 2011 (5).
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Twist, also called roll, is chewing tobacco that is twisted into rope-like strands and braided. 
It was popular in the United States in the late 
1800s, but use of chewing tobacco began to 
decline with the expansion of the cigarette 
industry in 1918.1 Twist is rarely used today, 
and sales of twist make up less than 1.0% of all 
smokeless tobacco sales in the United States.2
Photo courtesy of Clifford Watson,  
Centers for Disease Control and Prevention
Common Names 
Chew, chaw, chewing tobacco
Brand Names 
Moore’s Red Leaf, Cumberland, Mammoth Cave, 
Cotton Boll, Kentucky, Warren County, Rough 
Country (American Snuff Company) 
Main Geographic Location  
(WHO Region: Country) 
Region of the Americas: United States1
Prevalence and Demographics 
Twist use has declined over the past century and 
is rare today. Although statistics specifically on the 
prevalence of twist use are not available, 2009 sales 
of twist made up 0.4% of all smokeless tobacco sales 
in the United States.2 
Mode of Absorption 
Oral (chewed, held in mouth)
Use Pattern 
Users typically cut off a piece, place it in the mouth, 
and chew. Saliva is usually spit out, but it can also 
be swallowed.3
Main Ingredients 
Tobacco, tobacco leaf extract, and sometimes 
sweetener or flavorings1
Processing/Manufacturing 
Commercial: Twist is handmade by commercial 
manufacturers. Air-cured or fire-cured burley 
tobacco leaf is treated with a tar-like tobacco 
leaf extract and sometimes sweeteners and other 
flavorings. The tobacco is then twisted into rope-like 
strands that are dried. The final product is a pliable, 
but dry, rope. Twist is sold by the piece in varying 




These data are for select products and may not represent all products of this type. These data are 
expressed on a per gram basis for products analyzed as received. The amount absorbed will depend on the 
amount of product used.
Product Type pH
 Total Nicotine Free Nicotine
mg/g wet wt




4.73–5.77  21.6–40.1 0.02–0.22  309–556 828–2,460 n.d.‡–104 2,590–4,950
*Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown). 
†Twist products were commercially manufactured.
‡n.d. = not detectable.
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)- 
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 
Source: Lawler et al. 2013 (4).
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Zarda is a flaky mixture of tobacco, lime, spices, and vegetable dyes. It is frequently 
chewed with chopped areca nut or used as an 
ingredient	in	paan.	Zarda	is	commonly	used	in	
South-East Asia and in countries to which people 
from this region have emigrated.1
Photo courtesy of Clifford Watson,  
Centers for Disease Control and Prevention
Common Names  






(Pakistan); Dulal Mishti, Hakim Puri, Bat One Baba, 
Bullet, Surma (Bangladesh)
Main Geographic Locations 
(WHO Region: Country) 
South-East Asia Region: India, Bangladesh, 
Myanmar, Nepal, Bhutan1; Eastern Mediterranean 
Region: Yemen1   
Prevalence and Demographics  
In India, Bangladesh, Myanmar, and Nepal, 
zarda is frequently used as an ingredient in 
paan (betel quid), particularly among middle to 
upper socioeconomic groups.2 Although specific 
prevalence rates for zarda use are not available, 
the prevalence of smokeless tobacco use is 
high in these South-East Asian countries, and 
zarda use is common.1,2 Between 2007 and 2010, 
the adult prevalence rate of current smokeless 
tobacco use ranged from 18.6% to 29.6% in India, 
Bangladesh,3 Myanmar, Nepal, and Bhutan.4  
Mode of Absorption  
Oral (chewed, chewed in paan or tombol)
Use Patterns 
Zarda	may	be	chewed	by	itself,	but	it	is	usually	
chewed with chopped areca nuts and spices. In 
South-East Asia it is often used in paan, and in Yemen 
it is used in tombol.1,2,5,6
Main Ingredients 
Tobacco, lime, spices, vegetable dyes, and 
sometimes areca nut and/or silver flecks1,5 
Processing/Manufacturing  
Commercial:	Zarda	is	commercially	manufactured	but	
is usually used in user- or vendor-made paan.5,6	Zarda	
is processed by boiling broken up tobacco leaves with 
lime and spices until the water evaporates. It is then 
dried and colored with vegetable dyes.1,2	Zarda	is	sold	
in small packets or tins.2 
B-64
Chemical Measurements
These data are for select products and may not represent all products of this type. These data are ex-
pressed on a per gram basis for products analyzed as received. The amount absorbed will depend on 
the amount of product used.
Product Type* pH
 Total Nicotine Free Nicotine
mg/g wet wt




6.51  21.3 0.63  3,840 28,600 3,460 53,700
Zarda	(dry),
Bangladesh
6.28  9.55 0.17  457 4,280 248 9,120
Zarda,	 
India 
5.22  30.43 0.05  829 2,910 390 5,490
*All zarda products were commercially manufactured. 
†Total TSNAs represent the sum of NNK, NNN, and NNAL (shown), and N’-nitrosoanatabine and N’-nitrosoanabasine (not shown).
‡This product contains areca nut.
Abbreviations: NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN = N’-nitrosonornicotine; NNAL = 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; TSNAs = tobacco-specific nitrosamines; mg/g = milligram per gram; ng/g = nanogram per gram. 
Source: Stanfill et al. 2011 (7).
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For additional information on zarda, please refer to the following chapters: Chapter 10: Smokeless Tobacco Use in the European Region, and 














Ad valorem  Tax charged as a percentage of the value of a product. 
Adducts Carcinogenic metabolites bound covalently to DNA. 
Air-curing (of tobacco) Involves placing tobacco stalks on wooden staves that are hung in a well-
ventilated barn. Used to make loose leaf and twist chewing tobaccos and is 
often mixed with fire-cured tobacco to make moist snuff. 
Aldehydes Organic compounds that contain a formyl group (R-CHO). Found in some 
smokeless tobacco products as a result of fire-curing. The International Agency for 
Research on Cancer classifies the aldehyde formaldehyde as carcinogenic in 
humans (Group 1), and by acetaldehyde as a possible carcinogen (Group 2B). 
Alkaline modifiers  Chemicals added to tobacco that include agents such as sodium bicarbonate, 
ammonium bicarbonate, various metallic carbonates (e.g., calcium, magnesium, 
sodium, ammonium), and slaked lime (calcium hydroxide). Addition of alkaline 
agents to tobacco boosts pH and increases the percentage of nicotine present as 
free nicotine. 
Alkaloids Naturally occurring nitrogen compounds that are produced by a large variety of 
organisms, including bacteria, fungi, plants, and animals. Tobacco alkaloids are key 
chemical precursors in the formation of tobacco-specific nitrosamines. 
Anabasine Alkaloid generally found in Nicotiana glauca at higher levels than in other tobacco 
species (N. tabacum or N. rustica). Present in trace amounts in tobacco smoke and 
can be used as an indicator of a person's exposure to tobacco smoke. Thought to 
contribute to the toxicity of N. glauca. 
Anatabine Alkaloid found in Nicotiana tabacum and other tobacco species. Present in 
tobacco products and tobacco smoke and absorbed in the human body after 
tobacco use. 
Areca nut Seed of the areca palm (Areca catechu), which grows in much of the tropical 
Pacific, Asia, and parts of east Africa. Commonly referred to as betel nut, as it is 
often chewed wrapped in betel leaves. Areca nut is classified as a Group 1 
carcinogen to humans by the International Agency for Research on Cancer. 
Arecoline Areca nut alkaloid that is the primary active ingredient responsible for central 
nervous system effects. 
Atherogenesis Formation of atheromatous lesions in the arterial walls. 
Attributable risk  Proportion of a disease that can be attributed to a causal risk factor. 
Betel quid  A custom-made preparation that includes areca nut combined with other 
ingredients, such as tobacco, catechu, alkaline agents, and spices, all wrapped 
in a piper betel leaf. Also known as paan. 
Catechu An extract of Acacia used variously as a food additive, astringent, tannin, and dye. 
Commonly found in smokeless tobacco products from South-East Asia. 
Cessation (of tobacco) Process of quitting tobacco use. 
Chemical additives Chemicals—such as sweeteners, flavor chemicals, whiteners, alkaline agents, 
moisteners, binders, and preservatives—added to products to improve taste, 
enhance appearance, or alter other product characteristics, such as pH, texture, 
or shelf life. 
 
Glossary 





Chemosensory effects Response of senses to chemical stimuli. 
Chewing tobacco A type of smokeless tobacco that presents as long strands of loose leaves, plugs, or 
twists of tobacco. The pieces are chewed or placed between the cheek and gum 
or teeth.  
Conference of Parties The governing body of the Framework Convention on Tobacco Control, World 
Health Organization, comprising all parties to the convention or countries that have 
signed the treaty. 
Cotinine A metabolite of nicotine used as an exposure biomarker of nicotine intake. 
Cottage industry A small-scale industry producing custom-made products at home, in market stalls, 
or in shops for commercial sale. 
Cottage-made products Products that are homemade or are produced by a small-scale industry. These 
products may lack packaging that displays brand name, graphics, and product 
description. 
Cross-price elasticity  The sensitivity of consumers to price or tax changes of a related good. For example, 
an 0.8 cross-price elasticity between cigarettes and smokeless tobacco (ST) means 
that a 10% increase in the price of cigarettes will yield an 8% increase in the 
consumption of ST. 
Current users  People who used any smokeless tobacco product either daily or occasionally in the 
30 days preceding a survey. 
Custom-made smokeless 
tobacco products 
Smokeless tobacco products that are handmade by the user, a relative, or a 
vendor according to user preferences. These products are made of cured tobacco 
or a premade tobacco product (e.g., zarda) combined with one or more 
ingredients, such as ashes, alkaline agents, areca nut, spices, catechu, or other 
plant materials. These products lack commercial packaging and may be placed in 
commonly available materials such as newspaper, cellophane, paper bags, etc., 
after they are made. 
Daily users  People who use smokeless tobacco products on a daily basis. 
Dissolvables Smokeless tobacco that is completely dissolved during use, with no residual loose 
tobacco or sachet to discard. Tobacco-coated toothpicks are considered 
dissolvables because the tobacco portion fully dissolves from the toothpick, which is 
discarded (See Appendix B.) 
Dose–response relationship  Increased risk of a disease with increasing levels of exposure. 
Dual use Use of two or more tobacco products by one person. 
Erythroplakia  Red-colored oral mucosal lesions that have a high risk of developing cancer. 
Ever users  People who have tried smokeless tobacco at least once in their lifetimes. 
Excise tax Similar to sales taxes, internal taxes that can change the price of smokeless 
tobacco (ST) products relative to other consumer goods and can make ST products 
less affordable for the consumer. 
Fermentation A sugar-metabolizing process, facilitated by microorganisms, generally thought to 
enhance product taste. Used to produce products such as moist and dry snuff as 
well as toombak. During fermentation, microbes proliferate, and nitrite is produced 
if nitrite-producing organisms are present. Accumulated nitrite then reacts with 
tobacco alkaloids to produce tobacco-specific nitrosamines. 







Fire-curing method Involves hanging tobacco in a large enclosed area where it is exposed to smoke 
from hardwood fires that continuously burn or smolder. Used in the production of 
plug chewing tobacco, moist and dry snuff, and tobacco used to make iqmik. 
Causes chemical changes in the tobacco leaf, and contaminates the tobacco 
with smoke-related chemicals such as polycyclic aromatic hydrocarbons, phenols, 
and volatile aldehydes. 
Flue-curing method Involves hanging tobacco in an enclosed structure connected to an external heat 
source without exposing it directly to smoke. Used in making chewing tobacco. 
Free nicotine Fraction of the total nicotine that is unprotonated (neutrally charged). This 
uncharged form of nicotine more readily passes through oral membranes and into 
the bloodstream. Free nicotine is calculated using total nicotine and pH values for 
the tobacco product. See also Total nicotine. 
Graduation strategy Theory that the availability of products spanning a wide pH range can make it 
easier for smokeless tobacco users to move on to products delivering increasingly 
higher nicotine levels. 
Gul See the Gul factsheet (Appendix B). 
Gutka See the Gutka factsheet (Appendix B). 
Harm reduction Decreased risks of illness or injury. 
High-income countries Countries with a gross national income per capita, as calculated using the World 
Bank Atlas method, of US$12,616 or more. 
Humectants Chemicals, including glycerol, glycerin, and propylene glycol, added to smokeless 
tobacco products to preserve product moisture content. 
Inferior good  A good that is consumed in decreasing quantities as a consumer’s income 
increases. 
Khaini See the Khaini factsheet (Appendix B). 
Khat A plant (Catha edulis) that contains cathinone, an alkaloid with amphetamine-like 
stimulant properties that are purported to cause euphoria, excitement, and a loss of 
appetite. 
Kiwam See the Kiwam factsheet (Appendix B). 
Leukoplakia White or grayish-white oral mucosal lesions that have the potential to develop 
cancers. 
Low birthweight Infants with a birthweight at the lower extreme of the normal birthweight 
distribution. 
Low-income countries Sometimes referred to as developing economies, with US$1,035 or less gross national 
income per capita. 
Manufactured products Products made in factories or large production facilities for commercial sale. 
Middle-income countries Sometimes referred to as developing economies—lower middle income = 
US$1,036‒$4,085 gross national income (GNI) per capita; upper middle income = 
US$4,086‒$12,615 GNI per capita. 
Mitogenesis Cell proliferation. 
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Modern markets Characterized by the presence of multinational corporations and the 
predominance of standardized, commercially produced smokeless tobacco 
products. 
Moist snuff See the Moist Snuff factsheet (Appendix B). 
Moisture content The percentage of water in a tobacco product. 
Niche Tobacco 
Product Directory 
A website containing a wide variety of tobacco product information. 
Nitrate A nitrogen-containing ion (NO3-) commonly found in soil and fertilizers. These ions  
are absorbed and metabolized by tobacco plants as they grow. When plants are 
harvested, nitrate remains in plant tissues and can subsequently be converted to  
nitrite (NO2-) by certain microbes. The International Agency for Research on Cancer  
has classified nitrate as a Group 2A agent (probable human carcinogen), because 
it can contribute to the formation of nitroso compounds in the human body after 
ingestion. 
Nitrite A nitrogen-containing ion (NO2-) generated by microorganisms capable of  
converting nitrate to nitrite; this process begins once the tobacco leaf begins to dry 
during curing. Once nitrite is produced, it can react with tobacco alkaloids to 
generate tobacco-specific nitrosamines in a chemical process called nitrosation. 
The International Agency for Research on Cancer has classified nitrite as a Group 
2A agent (probable human carcinogen) that can contribute to the formation of 
nitroso compounds in the human body after ingestion. 
Nitrosation Chemical reaction in which nitrite reacts with compounds such as tobacco 
alkaloids and other secondary/tertiary amines to form various nitrosamines. 
Nitroso compounds  Organic compounds containing an N=O group. N-nitroso compounds are of 
concern in tobacco products because several of these compounds are known or 
potential carcinogens. 
Normal good  A good that is consumed in larger quantities as a consumer’s income increases. 
Nornicotine An alkaloid found in the tobacco plant that is a precursor to the carcinogen 
N’-nitrosonornicotine, which is produced during the curing and processing of 
tobacco. 
Odds ratio A measure describing the strength of association or dependence between two 
data values. 
Oral mucosal lesions Abnormality of the oral mucosa that can progress to cancer. 
Oral submucous fibrosis  Progressive disease in which the oral mucosa loses elasticity and develops fibrous 
bands that cause difficulty in opening the mouth. Can progress to cancer and is 
associated with chewing areca nut, which is most often consumed with tobacco. 
Organic compounds Members of a large class of gaseous, liquid, or solid chemical compounds whose 
molecules contain carbon. 
Pan masala  A mixture of areca nut, spices, flavorings, and other ingredients. 
Periodontal disease  A disease affecting one or more of the periodontal (gum) tissues in the mouth. 
pH Measure of the acidity or basicity of a product. It impacts the amount of free 
nicotine in smokeless tobacco products. Higher pH results in a greater percentage 
of nicotine being converted to free nicotine. 







Phenols A class of aromatic organic compound formed when wood or sawdust is burned 
during the fire-curing of tobacco. 
Polycyclic aromatic 
hydrocarbons  
Potent atmospheric pollutants that are produced as byproducts of fuel burning 
(fossil or biomass); ten polycyclic aromatic hydrocarbon compounds found thus far 
in smokeless tobacco have been designated by the International Agency for 
Research on Cancer as carcinogens or potential carcinogens. 
Porronca Smokeless tobacco products used by indigenous Brazilians. 
Portioned pouches Packets of smokeless tobacco containing specific measured amounts—for 
example, snus. 
Prevalence Proportion of a population found to have a condition. Calculated by comparing 
the number of people found to have the condition with the total number of people 
studied or surveyed. 
Protonated nicotine A charged form of nicotine that is more slowly released from tobacco and tends to 
be more slowly absorbed into the bloodstream. This is the predominant form present 
in most unprocessed tobaccos. 
Pyridine-N-glucuronide 
metabolites 
Can be used as biomarkers to provide realistic and direct assessments of a person’s 
exposure to certain tobacco-specific nitrosamines. 
Quit ratio Number of former smokeless tobacco users divided by the number of people who 
have ever used smokeless tobacco daily. 
Sada pata Plain tobacco flakes. 
Slaked lime Calcium hydroxide. Addition of alkaline agents to tobacco boosts pH and increases 
the percentage of nicotine present as free nicotine. 
Smokeless tobacco Includes a large variety of products containing tobacco mixed with chemical, 
plant, and/or other constituents. These products are not smoked, but are used orally 
or nasally. Oral tobacco can be chewed, sucked, applied to the teeth or gums 
(e.g., topical toothpaste or powder), dissolved in the mouth, or gargled. Nasal 
tobacco is finely ground so that it can be inhaled and absorbed through mucus 
membranes. 
Snuff See the Snuff factsheet (Appendix B). 
Snus See the Snus factsheet (Appendix B). 
Sun-curing method Process of drying tobacco leaves in the sun, which is often used in making 
toombak, gutka, maras, khaini, and nass/naswar, and for some tobaccos used in 
betel quid. 
Sweeteners Chemicals added to smokeless tobacco products to make them more palatable. 
Includes honey, molasses, saccharin, brown sugar, sugar, and xylitol. 
Tobacco-specific 
nitrosamines 
Carcinogens that are formed from nicotine and related compounds by nitrosation 
during processes such as curing and fermentation, in which tobacco products are 
made. These compounds are specifically found in tobacco products. 
Tonka bean A seed from Dipteryx odorata that contains a high level of coumarin, a liver 
toxicant. This seed is added to some smokeless tobacco products. 
Total nicotine The amount of nicotine in a product regardless of its ionic form (di-protonated, 
mono-protonated, and unprotonated). 
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Less concentrated markets that trade a large variety of products made under 




Custom-made tobacco products produced by small-scale cottage industries. Can 
also refer to smokeless products that are well established in a particular region. 
Unprotonated nicotine This neutrally charged form of nicotine, commonly referred to as “free” nicotine, is 
usually more quickly released form tobacco during product use than protonated 
nicotine. Free nicotine is also absorbed more quickly into the body tissues for 
distribution throughout the body. 
Verrucous hyperplasia Histopathologically diagnosed abnormality of the oral mucosa. 
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